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Protein–protein interactions (PPIs) are of pivotal importance in the regulation of 
biological systems and are consequently implicated in the development of disease 
states. Here, we investigated two classes of protein, including a transmembrane protein 
(tumor necrosis factor receptor 1 (TNFR1)) and intrinsically disordered proteins (tau and 
huntingtin (HTT)), which are implicated in autoimmune diseases and neurodegenerative 
diseases respectively. Receptor-specific inhibition of TNFR1 signaling is a highly sought 
after strategy for treatment of inflammatory diseases such as rheumatoid arthritis. In this 
study, we investigated the structure-function relationship of TNFR1 by engineering a 
TNFR1 fluorescence resonance energy transfer (FRET) biosensor to monitor the 
structural and conformational changes of the receptor. We have also shown using small-
molecule tool compounds, that the disruption of receptor-receptor interactions 
(competitive inhibition) and perturbation of the receptor conformational dynamics 
(allosteric inhibition) are both feasible approaches to inhibit TNFR1 signaling. We have 
also made a major discovery showing that long-range structural couplings, between 
TNFR1 membrane distal and proximal domains, mediated through the ligand-binding 
loop, determine the conformational states of the receptor that act as a molecular switch 
in receptor function. In addition to deepening the understanding of a novel mechanism in 
TNF receptor activation, we have optimized a lead compound through medicinal 
chemistry by improving its potency by more than sixty-fold to the nanomolar range, 
thereby advancing therapeutic developments in these clinically important targets. The 
heterogeneity of tau and HTT pathology is one of the major challenges that plagues 
current clinical trials, hence impeding the discovery of a cure for Alzheimer’s disease 
(AD) and Huntington’s disease (HD). We have engineered novel FRET biosensors of 
these proteins to target the ensemble of heterogeneous protein oligomers or aggregates 
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in cells. The biosensors are not only capable of monitoring oligomer conformations, but 
can also be used as a high-throughput screening platform. Using these technologies, we 
have discovered small-molecule inhibitors of tau oligomerization or HTT aggregation that 
rescue cell cytotoxicity with nanomolar potency.   
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The work presented in this thesis is divided into two broad sections: 1) the study 
of the structure-function relationship of tumor necrosis factor receptor 1 (TNFR1) and the 
development of new receptor-specific targeting strategies; and 2) the investigation of 
conformational heterogeneity in intrinsically disordered proteins (IDP) including tau and 
huntingtin (HTT), and the development of novel strategy in targeting the ensemble of 
IDP oligomers or aggregates. Chapter 1 describes the implication of TNFR1 and IDPs 
(tau and HTT) in autoimmune diseases and neurodegenerative diseases respectively. 
This chapter also provides a detailed literature review on the current therapeutics and 
their limitations and a description of our proposed targeting strategy.  
From Chapter 2 to 6, the structure-function relationship of TNFR1 is investigated 
using a small-molecule drug discovery approach. In Chapter 2, we developed a TNFR1 
fluorescence resonance energy transfer (FRET) biosensor to monitor the structural and 
conformational change of the receptor. In Chapter 3, we used the FRET biosensor in 
high-throughput screening (HTS) of NIH clinical collection (NCC) library. We identified a 
new small molecule that disrupts TNFR1 receptor-receptor interaction without ablating 
ligand binding and inhibits the receptor function. In Chapter 4, we expanded the scale of 
the HTS and screened a large 50,000-compounds DIVERSet library using the TNFR1 
FRET biosensor. In this study, we discovered a novel small molecule that inhibits 
TNFR1 signaling through an allosteric mechanism by altering the receptor 
conformational states. We also provided the first definitive experimental proof of long-
range allosteric coupling in the extracellular domain of TNFR1 that can be exploited to 
inhibit receptor activation. Building upon the above study, in Chapter 5, we found both 
small molecule activator and inhibitor of TNFR1 from screening of the LOPAC library. 
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We explored both the activation and inhibition mechanism of these small molecules and 
discovered that receptor conformational states can act as a molecular switch in 
determining receptor function. Driven by the motivation to discover potential 
therapeutics, in Chapter 6, we performed medicinal chemistry to establish a structure-
activity relationship (SAR) of a lead compound and improved its potency by more than 
sixty-fold to the nanomolar range, making it a potential drug candidate. 
In the second half of this thesis, we expanded the use of FRET approach in HTS 
to the investigation of heterogeneity in IDPs, including tau (Chapter 7) and HTT (Chapter 
8). We developed novel tau and HTT FRET biosensors that are capable of monitoring 
oligomer or aggregate conformations as well as being a high-throughput screening 
platform. Using these technologies, we discovered small molecules that perturb the 
ensemble of heterogeneous tau oligomers or HTT aggregates and inhibit the self-
association of these proteins, resulting in the rescue of cell cytotoxicity. In our future 
work, we will make use of these technologies as well as develop new technologies to 
further understand the fundamental of these structured proteins and IDPs for more 
effective targeting. In addition, we will advance the small molecules discovered from this 




CHAPTER 1: INTRODUCTION 
1.1 Background on protein-protein interactions 
Protein–protein interactions (PPIs) are highly specific physical contacts 
established between different protein molecules because of biochemical events steered 
by electrostatic forces such as the hydrophobic effect. PPIs are important for protein 
functions, such as protein signaling transduction, and their regulation, in most of the 
structured proteins. Aberrant PPIs, in particular from intrinsically disordered proteins 
(IDPs), are the basis of multiple aggregation-related diseases, such as Alzheimer's 
disease (AD) and Huntington’s disease (HD). PPIs have been studied from different 
perspectives including biochemistry, molecular dynamics, and signal transduction in 
particular. All the garnered information enables the creation of protein interaction 
networks that can elucidate the pathology of diseases, as well as the discovery of 
protein targets of therapeutic interest (1).  
1.1.1. Structured proteins vs. intrinsically disordered proteins 
Structured proteins have a stable tertiary protein structure. They consist of 
various structural domains, such as binding motifs/domain. For example, members of 
the tumor necrosis factor receptor (TNFR) family contain an extracellular domain 
responsible for ligand binding, transmembrane domain that anchors the receptor in the 
cell membrane and an intracellular domain that mediates activation of signaling pathway 
(2). On the other hand, proteins without stable tertiary structure and have a greater 
portion of small and hydrophilic amino acids and proline residues, are known as 
intrinsically disordered proteins. IDPs possess functions that complement functions of 
structured proteins, and are commonly related to recognition, as well as control and 
regulation of various signaling pathways (3). IDPs are usually tightly controlled via ways 
4 
 
such as alternative splicing, controlled expression and degradation, and post-
translational modifications. However, distortions in the regulation and control of IDPs, 
together with aberrant interactivity are commonly associated with various human 
diseases (3). For both types of proteins, they have dynamic behaviors, with ability to 
adopt different conformational states. The transitions between these states typically 
occur on nanoscales, and have been linked to functionally relevant phenomena such as 
allosteric signaling and enzyme catalysis (3). Therefore, studying the protein structural 
dynamics and associated conformational changes are essential for understanding 
protein function, and development of targeting strategies. 
1.2 TNFR receptor 
1.2.1. Background on TNFR1 induced autoimmune diseases  
Tumor necrosis factor receptor 1 (TNFR1) is a characteristic member of the TNF 
receptor superfamily, a family of 27 type I transmembrane receptors (4). TNFR1 binds 
either of its two cognate ligands, tumor necrosis factor (TNF or TNF-) or lymphotoxin-
alpha (LT- or TNF-), via its extracellular domain (5), which leads to the activation of 
two distinct, well-understood signaling pathways. While one pathway results in 
programmed cell death (apoptosis) and programmed necrosis (necroptosis) (6, 7), the 
other leads to an inflammation response (8) and cell survival (9), mainly through the 
activation of the transcription factor NF-κB (10). TNFR1 is most commonly associated 
with its inflammatory pathway (11) (Figure 1.1). Upregulation of both TNF and LT- 
ligand level,has been associated with several autoimmune diseases, such as 
rheumatoid arthritis (RA), juvenile RA, multiple sclerosis, psoriatic arthritis, Crohn’s 
disease, and inflammatory bowel disease (12-16). These diseases have impinged on 
23.5 million people in the United States, affecting up to 8% of the population (17) and 
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incurred over 50 billion dollars in societal costs (18). Therefore, modulation of TNFR is 
important for therapeutics development for disease.  
Figure 1. 1. TNFR1 signaling 
pathways.  
The binding of ligand (TNF-α) with 
TNFR1 causes the recruitment of 
TNFR-associated via death domain 
protein (TRADD), receptor-
interacting serine or threonine-
protein kinase 1 (RIP), and TNFR-
associated factor 2 (TRAF2). These 
molecules form the TNFR1 
signalosome. TRAF2 catalyzes the ubiquitination (Ub) of RIP and recruits the IκB kinase (IKK) 
complex, leading to the phosphorylation (P) of IκBα by IKKβ and the ensuing ubiquitination and 
degradation of IκBα in proteasome. The release of NF-κB p65 and p50 into nucleus results in the 
transcriptional activation of the proinflammatory target genes such as ICAM-1, VCAM-1, and E-
selectin (19).  
1.2.2 Current therapeutics and limitations 
Anti-TNF therapeutics 
Over the past decades, significant work has been done to study the inhibition of 
the TNFR1-induced NF-B pathway to reduce the symptoms of the diseases. Currently, 
the most commonly used treatments are anti-TNF therapeutics such as Etanercept 
(Enbrel®), Infliximab (Remicade®), Adalimumab (Humira®), Certolizumab Pegol 
(Cimzia®) and Golimumab (Simponi®) that work based on sequestration of free ligands  
(14, 16, 20-22) (Figure 1.2A). However, these treatments are expensive and induce 
dangerous side-effects, including reactivation of tuberculosis, development of 
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autoimmune disease and increased susceptibility to infection and lymphoma, mainly due 
to the removal of membrane TNF (memTNF) by the drugs which disrupt the TNFR2 and 
memTNF interaction (23-26). To resolve these problems and reduce the side effects 
arising from non-specific inhibition, new therapeutics that inhibit the undesirable 
signaling cascade resulting from TNFR1 and ligands interactions, while preserving the 
constitutive signaling from the TNFR2 and memTNF interaction need to be developed. 
Two novel approaches for specific targeting of the inflammatory effects from TNFR1 and 
ligands interaction have been developed that include the exclusive inhibition of soluble 
TNF and the direct blocking of TNFR1 signaling by anti-TNFR1 monoclonal antibodies 
(14, 27, 28). For exclusive inhibition of soluble TNF, researchers have developed 
signaling-incompetent dominant-negative TNF derivatives (29) such as XPro1595 (30) 
that specifically inhibit soluble TNF, hence preserving signaling via memTNF. In addition, 
a small-molecule inhibitor that promotes subunit disassembly of trimeric TNF has been 




Small molecule inhibitors 
potentially targeting PLAD
 
Figure 1. 2. Current therapeutics and the proposed PLAD targeting strategy.  
(A) Inhibition by anti-TNF and anti-TNFR monoclonal antibodies, and mimic of soluble TNFR. (B) 
TNF-TNFR oligomer signaling held together by PLAD. (C) New concept of TNF-TNFR inhibition 
by potentially targeting the pre-ligand assembly domain (PLAD) by soluble PLAD and small 
molecules (32). 
 
Blocking of ligand binding  
For direct blocking and inhibition of TNFR1 signaling, antagonists specific to 
TNFR1 can be used to neutralize the pro-inflammatory activity of TNF. Examples of 
TNFR1-specific antagonists and antibodies include R1antTNF (33), DMS5540 (34), and 
ATROSAB (35). Small molecules that competitively block receptor-ligand interaction 
between TNFR1 and TNF have also been identified (36, 37). The ligand binding affinity 
of TNFα to TNFR1 is very high (38), so small molecules that work by competitively 
eliminating ligand binding may not be effective. Additionally, it has been suggested that 
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TNFR1 antagonists that block ligand binding reduce the TNFα neutralizing capacity of 
soluble TNFR1, as the circulating forms of the receptor may function as decoys for the 
ligand, and their concentrations may reflect long-term exposure to this proinflammatory 
cytokine (39-41). At low concentrations, soluble TNFR1 enhances the actions of TNFα, 
but at higher concentrations the effects of TNFα are abrogated (42). Furthermore, cell-
autonomous interaction between TNFα and TNFR1 is critical for cell survival, 
maintenance and function as well as neuroprotective (43, 44). As such, approaches that 
do not involve eliminating ligand binding are highly attractive, though have proved 
elusive.  
1.2.3. Potential or novel targeting strategy  
PLAD targeting strategy 
Despite the advancement of these approaches, there is still tremendous interest 
in disrupting the protein-protein interaction (45, 46), particularly at the interface between 
the pre-ligand associated receptors known as the pre-ligand assembly domain (PLAD) to 
directly inhibit TNFR1 activation (47), and reduce off-target side-effects. An inhibition 
model has been proposed where targeting the TNFR1 pre-ligand assembly domain 
(PLAD) disrupts the pre-ligand associated receptors (47, 48). The PLAD is a portion of 
the extracellular region of TNFR1 that contains the noncovalent interactions responsible 
for the TNFR1 pre-ligand associated dimer, which has been shown via crystallography 
(49, 50). This association may further results in an oligomeric network structure formed 
by the receptor and ligand upon activation (Figure 1.2B). It is crucial in mediating 
receptor-chain association essential for signaling and hence an important therapeutic 
target (47, 48). A provisional model has been proposed where soluble PLAD binds to 
TNFR1, causing a disruption of pre-ligand associated receptors and blocking the 
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biochemical effect of ligand in vitro (51), which potently inhibits arthritis in animal models 
(52-54). This motivates the discovery of small-molecule inhibitors that could potentially 
target TNFR1 PLAD to modulate receptor-receptor and/or receptor-ligand interactions, 
thereby inhibiting downstream signaling and reducing inflammatory responses (Figure 
1.2C). Competitively eliminating the PLAD-PLAD interaction is an attractive alternative to 
blocking ligand binding because the monomer-monomer interaction (low micromolar) is 
weaker than the ligand-receptor affinity (55, 56).  
Allosteric modulation by targeting receptor conformational dynamics 
Ligand binding induces TNFR1 trimerization, leading to trimerization of cytosolic 
death domains and concomitant recruitment of downstream signaling machinery (21, 
57). This model is primarily based off the original crystal structure of a ligand-bound, 
trimeric receptor complex, in which there are no direct receptor-receptor interactions 
(57). However, it has been found that TNFR1 is actually pre-assembled as high-affinity 
receptor dimers in the plasma membrane (55, 58, 59), where there is no overlap 
between its ligand-binding and self-assembly domains. Crystal structure and subsequent 
mutagenesis studies (55, 58-60) show that pre-ligand dimerization is driven by well-
defined monomer-monomer interactions across the pre-ligand assembly domains 
(PLAD), located within the N-terminal cysteine-rich domain (CRD1) and far from the 
ligand binding loop. Critically, there is no evidence to suggest that these dimer structures 
dissociate on ligand binding, despite the lack of receptor-receptor interactions in the 
trimeric structure. Instead, it would form an extended hexagonal network in which the 
vertices are formed by ligand/receptor complexes and edges are formed by receptor 
dimers (59). This model was advocated for TNFR1 (61-63). Crosslinking experiments 
confirmed the formation of high-molecular weight oligomeric complexes of TNFR1 upon 
ligand binding (58), and confocal microscopy have visualized clustering for TNFR1 (64, 
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65). Hence the trimerization model is incomplete as it lacks the explanation on the 
importance of receptor self-interaction or ligand/receptor network formation. It is possible 
that the pre-assembled dimer remains intact upon ligand binding, and undergo a 
conformational change that propagates from the extracellular domain (ECD) to the 
cytosol without dimer dissociation, and this receptor conformational dynamics can serve 
as a potential target for inhibitory small molecules.  
1.3. Intrinsically disordered proteins 
1.3.1 Heterogeneity in intrinsically disordered proteins  
Intrinsically disordered proteins such as tau or huntingtin (HTT) are characterized 
by the exceptional spatiotemporal heterogeneity, where different parts of a protein are 
ordered or disordered to a different degree, and this distribution is constantly changing 
over time (66). IDPs have a very complex structural organization that includes foldons 
(independently foldable units of a protein), inducible foldons (disordered regions that can 
fold at least in part due to their interaction with binding partners), non-foldons (non-
foldable protein regions), semi-foldons (regions that are always in a semi-folded form), 
and unfoldons (ordered regions that have to undergo an order-to-disorder transition to 
become functional) (67). Since these differently disordered structural elements might 
have well-defined and specific functions, an IDP can be multifunctional, being involved in 
interaction with or regulation of, and can be controlled by a multitude of structurally 
unrelated partners. Consequently, the nature of IDP’s heterogeneity also limits the 
identification of specific targets that can modulate its behaviors.  
1.3.2 Tau protein 
Tau is an intrinsically disordered protein that plays an important role in the 
regulation of microtubule stability and axonal transport (68). Tau has been implicated in 
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a group of neurodegenerative disorders, or tauopathies, such as AD, where it is 
characterized by the presence of tau inclusions in affected brain regions (69). Under 
pathological conditions, tau exhibits aberrant behavior where it becomes 
hyperphosphorylated and detaches from microtubules, thereby accumulating in the 
cytosol (70). This has been correlated with upstream mitochondrial dysfunctions such as 
in the electron transport system or Krebs cycle, oxidative stress (71, 72), as well as 
neuron morphology and axonal transport defects (73). Unbound tau has a tendency to 
misfold and undergo conformational changes starting with the formation of tau oligomers 
that subsequently nucleate into paired helical filaments (PHFs), and eventually into 
intracellular NFTs (74) (Figure. 1.3). NFTs have been the regarded as the primary 
causative of tauopathies, where their presence in the brain show significant correlation 
with the degree of cognitive impairment (75). However, recent studies suggest that 
soluble oligomeric tau promote cytotoxicity in vitro, and are linked to cognitive 
phenotypes in vivo (76-82), thereby contributing a major role to the induction of 
neurodegeneration (78, 83). As a result, the focus in therapeutic development has begun 
to shift from targeting large NFTs to inhibiting or disrupting the formation of toxic soluble 
tau oligomers (83-86). Tau oligomers exist as an ensemble of distinct assemblies 
including both toxic and non-toxic, on- and off-pathway species along the fibrillogenesis 
cascade (87-93). However, no specific toxic tau oligomer species has been isolated or 
identified to date (86, 94, 95). Despite decades of rigorous and focused research, there 
are currently no significant disease modifying therapies for tauopathies (96). 
Furthermore, there is a dearth of compounds that target tau, with only five out of the 105 
small molecules currently in clinical trials being tau-focused (97, 98). Hence, there is 
desperate need for technologies that enable the identification of tau-focused disease-




Figure 1. 3. Tau fibrillogenesis cascade.  
The intrinsically disordered tau monomer is capable of misfolding into spontaneously formed 
oligomers, producing toxic assemblies implicated in AD (I-II). While oligomers are metastable and 
difficult to monitor with high precision and accuracy, the large assemblies (paired helical filaments 
(PHFs) and neurofibrillary tangles (NFTs) form irreversibly with -sheet structures (III-IV) (101). 
The fibrillar species can be excreted via exosomes leading to a prion-like cell-to-cell propagation 
of pathology and may induce seeded oligomerization. NFTs may be neuroprotective by 
sequestering toxic oligomers and disruption of NFTs may induce toxicity from elevated 
concentrations of toxic oligomers.  
 
1.3.3 Huntingtin protein 
Huntington’s disease (HD) is an inherited neurodegenerative disorder caused by 
expansion of a CAG repeat in the exon 1 of huntingtin (HTT) gene, which translates into 
an abnormal polyglutamine (polyQ) in HTT protein (102, 103). It has the highest 
prevalence in United States and European countries, with a prevalence of 100 cases per 
million (104). HTT is an IDPs that regulates fast axonal trafficking, vesicle transport 
(including transport of brain-derived neurotrophic factor (BDNF)) and synaptic 
transmission (105). It also plays an important role in neurons in the brain and is essential 
for normal fetal development (106). HD is caused by an abnormal expansion of CAG 
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repeats at the exon 1 of the IT15 gene of HTT protein, encoding a polyQ stretch in 
various proteins (107) (Figure 1.4A). The wild type protein contains 35 glutamine 
repeats or less (≤Q35, no pathology) while in the mutant forms the expanded glutamines 
are more than 35 repeats (Q36-39, late onset; ≥Q40, observed pathology) (108) (Figure 
1.4B). Importantly, the length of the polyQ stretch and the age of disease onset are 
inversely correlated, with longer stretches resulting in earlier onset and increased 
severity of the disease(108-110). In addition, it has been shown that N-terminal HTT with 
polyQ tracts in the pathological range (>Q35), but not with polyQ tracts in the normal 
range (≤Q35), form high molecular weight protein aggregates with a -sheet fibril 
morphology (Figure 1.4C-D) (111).  
Altered HTT clump together and trap other useful and important molecules. These “clumps” are called protein aggregates and they 




Figure 1. 4. HTT pathophysiology.  
(A and B) HD is caused by an abnormal expansion of CAG repeats at the exon 1 of the IT15 
gene of HTT protein (112, 113). (C) Aggregated proteins forms -sheet fibrils (114). (D) 





(Scheuing et al, 2014)
Mutant HTT protein disrupts multiple physiological processes leading to 
homeostasis of apoptotic molecules imbalance, transcriptional dysregulation, autophagy 
deficits, mitochondrial abnormalities, axonal transport impairment, reduced cellular 
BDNF support, and glutamate excitotoxicity (116) (Figure 1.5).  
Figure 1. 5. Mutant HTT affects a 
plethora of cell functions  
Consequences of non-specific 
interaction between HTT and other 
proteins include cell survival, 
mitochondrial abnormalities and 
axonal transport impairments (117). 
 
While aggregate formation is 
regarded as the hallmark of HD 
(111, 118), its effect on toxicity remains debatable. It has been shown that the prominent 
inclusion bodies (IBs) have been shown to decrease mutant HTT levels elsewhere in the 
neuron, prolonging cell survival (119), suggesting that  large contained aggregates may 
have a neuro-protective response. Instead, there has been strong evidence for the 
toxicity of monomeric and small oligomeric species of mutant HTT with specific 
conformational states (120-130), but the true toxic species remains unknown (121, 131-
133). To date, there are still no cures or significant disease modifying therapies available 
for HD (103). While there has been clinical trials of potential compounds acting through 
indirect mechanism (not directly targeting HTT), there is no ongoing clinical trial of small 
molecules acting through direct disruption of HTT aggregation, which remains an 
important area for targeting (134-136).  
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1.3.4. Current therapeutics and limitations  
There are numerous recent efforts to discover small molecules that target toxic 
tau oligomers, with some yielding efficacious compounds (137-143). These include 
curcumin (Kd=3.3 M; fibrillization IC50=10.6 M) (140), heparin-like oligosaccharides 
(Kd=140-350 nM; cell cytotoxicity rescued at 10 M) (141), phenothiazines such as 
methylene blue (MB) and its derivatives Azure A, Azure B and Azure C (Kd=100 nM-3.4 
M; fibrillization IC50=1-10 M; Azure C rescues cell cytotoxicity at 5 M) (137, 138, 
142), and polyphenols such as epigallocatechin gallate (EGCG) (cell cytotoxicity and 
fibrillization inhibited at 12.5 M)(139). However, only MB has reached phase III clinical 
trials, although there was no significant improvement in patient cognition reported (144). 
However, all the compounds were were protective only in the low micromolar range 
(137-143). A possible limitation with these studies could be due to poor recapitulation of 
the cellular environment, where only purified proteins were used, instead of also 
including numerous chaperone proteins that may be required to produce the ensemble 
of tau oligomers that populate the fibrillogenesis cascade.  Moreover, purified protein 
assays are only capable of identifying hits that directly perturb tau and unable to 
elucidate any indirect mechanisms of action.  
For HTT, three major classes of screening campaigns - targeted phenotype of 
aggregation, enhanced clearance and inhibition of cell death have been reported (145), 
including recent efforts in indirect HTT targeting mechanisms (146) using antibodies 
fragments (147), antisense oligonucleotides (148), and small molecules (149). Screens 
that discovers small molecules directly targeting HTT aggregation identified MB 
(inhibition of protein aggregation by targeting monomer, oligomer and aggregates tested 
at 1-100 M; inhibition of cell cytotoxicity tested at 100 nM) (150), C2-8 (inhibition of 
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protein aggregation IC50=25 M; inhibition of cell cytotoxicity tested with IC50=50 nM) 
(151), epigallocatechin gallate (EGCG) inhibition of protein aggregation (perturb 
oligomer conformation with IC50=~1 M; inhibition of toxicity tested in yeast model of HD 
(at 500 M) and HD transgenic flies (at 0.1–100 M)) (152, 153), leflunomide and 
teriflunomide (inhibition of HTT-Q72-Luc protein aggregation reporter assay with IC50=1–
3 M; inhibition of HTT protein aggregation tested at 100 M) (154), PGL-135 and PGL-
137 (inhibition of HTT aggregation with IC50=40 M (PGL-135) and IC50=100 M (PGL-
137); reduction of inclusion bodies in cells tested at 25 M (PGL-135) and 50 M (PGL-
137)) (155), congo red (inhibition of HTT aggregation with IC50=0.3 M) (129, 156), 
thioflavin-S (inhibition of HTT aggregation with IC50=20 M) (156), and xyloketal 
derivatives (inhibition of HTT aggregation tested in Caenorhabditis elegans model of HD 
at 100 M) (157). However, none of these compounds has successfully advanced to 
become an effective therapeutic, and the small molecules MB and EGCG have also 
been reported in tau screens and are hence promiscuous compounds. All the molecules 
were initially identified through direct measurements of HTT aggregation and 
disaggregation, and lack the monitoring of and information on the HTT conformational 
changes or dynamics. The targeting of HTT conformations has only recently been 
proposed, and efforts have focused on repurposing some of the previously identified 
small molecules such as MB (150), EGCG (152) and congo red (129). Similar to the tau 
screens, most of the studies were also performed using in vitro purified protein assays, 
which do not reliably represent the cellular environment, and faces similar limitations of 
identifying hits that only directly perturb HTT protein, but not able to distinguish indirect 
mechanisms of action, affecting other pathologically relevant cellular processes. Hence, 
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a cellular approach that monitors HTT aggregation holds promise as a novel HTS 
platform to discover more effective therapeutics. 
1.4. Proposed targeting strategy  
1.4.1 Small molecule drug discovery through high-throughput screening (HTS)  
HTS of small-molecule compounds to identify modulators of molecular targets is 
a mainstay of pharmaceutical development. Increasingly, HTS is being used to identify 
chemical probes of signaling pathways and cell functions, with the ultimate goal of 
establishing the relationship between chemical structures and biological activities. The 
majority of the conventional assays capable of quantifying intermediate signal 
transduction events are limited to biochemical assays, immunoassays, and complex 
image-based assays (158). However, these technologies generally suffer from the lack 
of biological relevance, excessive hands-on time, and lack of adequate signal-to-noise 
and reproducibility required for HTS applications (158). Therefore, there is a need for 
new methods of HTS to produce rich data sets that can be immediately mined for 
reliable biological activities, thereby providing a platform for chemical genomics and 
accelerating the identification of leads for drug discovery (159). Examples of TNFR1-
related HTS include the development of two homogenous TNF-α assays based on 
homogenous time resolved fluorescence and AlphaLISA (160). In addition, a high-
throughput NF-κB b-lactamase reporter gene assay has been used to identify nineteen 
drugs that inhibit NF-κB activation possibly through inhibition of TNFR1-activated 
pathway (161). Bioluminescence resonance energy transfer (BRET) is also a method 
associated with HTS. To study the interaction between two proteins by BRET, the first 
protein is genetically fused to energy donor, and the second protein is fused to an 
energy acceptor. The two proteins are then co-expressed in cells, and the BRET signal 
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is measured as a readout of molecular proximity. While BRET can detect PPIs in all 
cellular compartments, it does not experimentally distinguish between dimeric or 
multimeric interactions and cannot provide information on subcellular sites of interaction 
(162). Time-resolved fluorescence resonance energy transfer (TR-FRET) has also been 
proposed to study PPIs, and offers advantages such as high resolution conformational 
sensitivity and high-throughput recording (163). Hence, TR-FRET may be a good tool for 
the detection of TNFR1 receptor-receptor interactions and conformational dynamics as 
well as IDP self-association.  
1.4.2 Structure based drug design through medicinal chemistry 
From high-throughput screening of a library containing of thousands of small 
molecules, hundreds of hits are potentially expected (164). The hits have to undergo an 
inherently multi-objective optimization process to develop a drug that satisfies the key 
objectives of safety and efficacy. Their structures are listed, analyzed and clustered to 
obtain a molecular scaffold, which is a fixed part of a molecule where functional groups 
are substituted or exchanged. There are many proposed ways to generate a SAR 
library, such as using NMR spectroscopy, computer-aided drug design (CADD) or 
medicinal chemistry structure-based drug design (SBDD). NMR spectroscopy is limited 
by constraints on the molecular size of the protein and the requirement for multiple 
isotopic labeling and uncertainty in the identity or location of protein or ligand atoms.  
Crystallization (for X-ray structure determination) may change the structure of the ligand-
protein interaction (165). CADD techniques uses prototypical ligand based approaches 
(LBDD) including quantitative structure−activity relationships models or pharmacophore 
based models and use physicochemical properties and conformational preferences to 
explain the variation in SARs. However, ligand-based approaches can only be used 
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when sufficient activity data are available, and their utility for pose prediction depends on 
the availability of the bioactive conformations of one or more active compounds. For 
example, a receptor may have more than a single active site and may adapt to different 
ligands, and multiple pharmacophores may be possible for a single site. Furthermore, 
selecting a model that reflects the biochemical reality is a difficult issue, as selection 
criteria that use statistical significance alone might lead to erroneous model prioritization 
from a pool of possible models. Overall, CADD is limited in the case of scoring functions, 
such as incorporating molecular flexibility and solvent effects, targeting receptors with 
little to no structural information, increasing computational efficiency and limited 
accuracy in virtual screening (166).  
Determination of the molecular scaffold is more cost-effective if done earlier in the drug 
discovery process because it drastically affects the SAR. However, the main challenge is 
to understand how to choose a suitable scaffold, because there is no direct or obvious 
set of criteria for scaffold identification.  Nonetheless, there are still general frameworks 
that can be adopted to better identify the scaffold, such as Maximum Common 
Substructure clustering method (167), Murcko Framework (168), and Scaffold Tree 
(169), which are robust and effective (170). Once the scaffold is determined, the 
functional groups around the scaffold can be substituted or exchanged by ways of hit 
evolution, bio-isosteric replacements and hit fragmentation (171) to determine the SAR. 
Examples of TNFR1-related SAR studies include a series of N-alkyl 5-arylidene-2-
thioxo-1,3-thiazolidin-4-ones which are antagonists of TNF-α binding to TNFR1 (36) and 
a series of coumarin-based TNF-α inhibitors (172). Therefore, medicinal chemistry 
based SAR is essential for structure-based drug design.  
20 
 
CHAPTER 2: FLUORESCENCE BASED TNFR1 BIOSENSOR FOR 
MONITORING OF RECEPTOR STRUCTURAL AND 
CONFORMATIONAL DYNAMICS AND DISCOVERY OF SMALL 
MOLECULE MODULATORS 
Chih Hung Lo1, Tory M. Schaaf2, David D. Thomas2,3 and Jonathan N. Sachs1* 
Manuscript to be submitted to Methods in Molecular Biology 
1Department of Biomedical Engineering, 2Department of Biochemistry, Molecular Biology 
and Biophysics, University of Minnesota, Minneapolis, Minnesota 55455 
3Photonic Pharma LLC, Minneapolis, MN 55410 
Author contributions: C.H.L. wrote the manuscript. T.M.S, D.D.T and J.N.S. provided 
comments and edits to the manuscript. 
2.1 Summary 
Inhibition of tumor necrosis factor receptor 1 (TNFR1) is a billion dollar industry 
for treatment of autoimmune and inflammatory diseases. As current therapeutics of anti-
TNF leads to dangerous side effects due to global inhibition of the ligand, receptor-
specific inhibition of TNFR1 signaling is a highly sought after strategy. To directly 
monitor the receptor structural and conformational changes, we engineered a 
fluorescence resonance energy transfer (FRET) biosensor by fusing green and red 
fluorescent proteins to TNFR1. Expression of the FRET biosensor in living cells allows 
for detection of receptor-receptor interactions and receptor conformational dynamics. 
Using the TNFR1 FRET biosensor, in conjunction with a high-precision and high-
throughput fluorescent lifetime detection technology, we developed a time-resolved 
FRET-based high-throughput screening platform to discover small molecules that 
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directly target and modulate TNFR1 functions. Using this method in screening multiple 
pharmaceutical libraries, we have discovered a competitive inhibitor that disrupts 
receptor-receptor interactions and allosteric inhibitors that alter the conformational states 
of the receptor. This enables scientists to conduct high-throughput screening through a 
biophysical approach with relevance to compound perturbation of receptor structure and 
conformations, for the discovery of novel lead compounds with high specificity for 
inhibition of TNFR1 signaling.  
2.2 Introduction 
 Tumor necrosis factor receptor 1 (TNFR1) is a membrane receptor in which its 
activation is most commonly associated with the signal transduction to induce 
inflammation (5). Upon ligand stimulation by tumor necrosis factor-alpha (TNF) or 
lymphotoxin-alpha (LTα), the downstream signaling complex inclusive of receptor 
interacting protein-1 (RIP1), TNF receptor-associated death domain (TRADD) and 
TRAF2 is recruited and further led to the degradation of the inhibitor of nuclear factor Bα 
(IκBα) and the activation of nuclear factor κB (NF-κB) (11). Over-activation of TNFR1 
results in excessive NF-B activation which has been associated with several 
autoimmune diseases such as rheumatoid arthritis (173). Therapeutic targeting of 
TNFR1 signaling is a billion-dollar industry (17). Current therapeutics include anti-TNF 
which are antibodies that sequester free ligand (15, 21). However, global inhibition of 
ligand can cause severe side effects such as reactivation of tuberculosis, increased risk 
of inflammation or lymphoma (15, 25, 174). This is primarily due to the off-target 
inhibition of TNFR2, which mediates immune modulatory functions (175). Hence, there is 
a need for TNFR1-selective inhibitors that specifically block TNFR1 signaling without 
interfering other receptors (39).  
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 To achieve this, novel therapeutics that bind and target TNFR1 directly are 
needed in order to exert the receptor-specific effects. Previous reports include small 
molecules that bind the receptor and prevent ligand binding (35-37, 176). In addition, the 
isolated soluble pre-ligand assembly domain (PLAD) of TNFR1 was shown to inhibit 
TNF- induced inflammatory signaling in vitro and to ameliorate arthritis in a mouse 
model and the proposed mechanism is that the PLAD protein disrupted receptor-
receptor interactions (52). However, this study showed the soluble GST-tagged PLAD 
protein ablated ligand binding, making it unclear whether the small protein was targeting 
the PLAD and disrupting the pre-ligand receptor dimer (52). Furthermore, it has been 
suggested that a non-competitive targeting strategy may be more effective in inhibiting 
protein or receptor function (177-179). To make progress in these therapeutic windows, 
it requires the field to exploit the understanding of the structure and dynamics of the 
receptor for therapeutic developments (62, 180-184). A small molecule (F002), which 
was discovered by computational design, binds to a cavity distal to the ligand binding 
loop and perturbs the ligand binding residue of tryptophan 107 (W107), leading to 
allosteric inhibition of TNFR1 signaling (38). Even though the F002 does not directly 
prevent ligand binding to the receptor, the movement of the ligand binding residue 
induced by the small molecule results in weakened ligand affinity for the receptor and 
reduced effective ligand stimulated signaling. Moreover, the functional efficacy of F002 is 
sixty-fold weaker than its binding affinity, suggesting that this small molecule perhaps 
competes with ligand binding and may not be truly allosteric. Hence, there is still 
potential to discover more effective allosteric small molecules that inhibit TNFR1 
signaling by neither ablating ligand binding nor disrupting receptor-receptor interactions. 
 While the crystal structures of TNFR1 have been available for the past two 
decades (57, 59), there is a lack of effort towards targeting the receptor, based on 
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information for its structure and dynamics. Here, we engineered a TNFR1 FRET 
biosensor that detects compounds that directly alter the structure or the conformational 
status of the receptor by measuring the distance between the receptor monomers 
(Figure 2.1A). Here we present a FRET-based high-throughput screening (HTS) assay, 
using the TNFR1 FRET biosensor in conjunction with a fluorescence lifetime detection 
technology, the probability of finding novel chemical structures that directly perturb the 
receptor for lead development rather than any indirect effect on the inhibition of NF-κB 
activation is drastically increased.  
 The FRET-based HTS assay to discover receptor-specific small molecules 
targeting TNFR1 is enabled by high density well plates (384 or 1536 wells) containing 
the TNFR1 FRET biosensor in conjunction with fluorescence lifetime readout using a 
direct waveform recording method incorporated in a fluorescence lifetime plate-reader 
(FLT-PR) (185). This nanosecond time-resolved fluorescence spectrometer acquires 
fluorescence decay waveforms from each well of a 384-well microplate in 3 minutes with 
signal-to-noise exceeding 400 (186). In addition, lifetime measurements are 5- to 30-fold 
more precise than the simultaneously acquired intensity measurements (163, 186). 
Furthermore, waveforms acquired in 0.1 seconds, by 1000 laser pulses with the FLT-PR 
instrument were of sufficient precision to analyze two samples having different lifetimes, 
resolving minor components with high accuracy with respect to both lifetime 
(nanosecond decay rate of the fluorescent molecule) and mole fraction (existence of 
multiple species with different lifetime that depict multiple structural states of the TNFR1 
biosensor) (187). Concurrent to the lifetime measurements, we also record a complete 
high-quality fluorescence emission spectrum on a well-by-well basis using a spectral 
unmixing plate reader (SUPR). While SUPR can give an accurate quantitation of FRET 
of an intramolecular FRET system (fluorophores attached to the same protein), its 
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application on an intermolecular system (fluorophores attached to the separate protein) 
requires further testing (188, 189). Hence, we have primarily used the new SUPR 
technology to filter fluorescence compounds in the screening libraries for this 
intermolecular FRET biosensor.  
 In this FRET assay, changes in FRET (either increase or decrease) correspond 
to structural or conformational changes of TNFR1, induced by the compounds. However, 
it does not give a functional readout of the effect of the compounds on receptor 
signaling. Hence, the FRET assay has to be coupled with other functional assays such 
as NF-κB activation luciferase assay, as well as other biochemical and biophysical 
assays to validate the functional and mechanistic effects of the hit compounds. Using 
this approach, we have screened multiple chemical libraries including the NIH clinical 
collection (NCC), library of pharmaceutically active compounds (LOPAC) and 
ChemBridge DIVERSet. We have discovered compounds that inhibit TNFR1 signaling 
by disrupting receptor-receptor interactions (zafirlukast) (190) or altering the 
conformational states of the receptor (e.g. DS42) (191). Interestingly, we have also 
found a small molecule activator that perturbs the receptor conformational dynamics 
(unpublished results). Putting these findings together, we have suggested that the 
conformational states of TNFR1 can act as a molecular switch in determining receptor 
function and the TNFR1 FRET biosensor is a useful and important technology to study 


























Figure 2. 1. Schematic representation of the TNFR1 FRET biosensor.  
(A) FRET is observed when the receptor dimerizes or adopts a close conformation and the 
fluorophores are in close proximity to each other. Treatment with small molecule inhibitors lead to 
either disruption of receptor-receptor interactions (yellow compound) or perturbation of the 
receptor conformational states (orange compound) and both result in reduced FRET as the 
receptor monomers are further apart. (B) Plasmids encoding the TNFR1 gene of interest fused to 





2.3. Materials  
2.3.1. Scientific Equipment 
1. Fluorescence lifetime plate-reader (Fluorescence Innovations, Minneapolis, MN, 
USA). 
2. Spectral unmixing plate-reader (Fluorescence Innovations, Minneapolis, MN, USA). 
3. EVOS-FL cell imaging system (Thermo Fisher Scientific, Waltham, MA, USA). 
4. FACSAria II flow cytometry equipment (BD Biosciences, San Jose, CA, USA). 
5. Olympus IX2 inverted confocal fluorescence microscope equipped with a FluoView 
FV1000 laser scanning confocal head and 60× (1.42NA) oil immersion objective 
lenses (Olympus, Waltham, MA, USA). 
6. Mosquito HV liquid handler (TTP Labtech Ltd., Hertfordshire, UK).  
7. Multidrop Combi reagent dispenser (Thermo Fisher Scientific, Waltham, MA, USA). 
8. Echo Acoustic Liquid Dispenser (Labcyte, San Jose, CA, USA)  
2.3.2. Plasmid DNA, Cell Culture, Transfection, and Small-Molecule Treatments 
1. Plasmid DNA: The TNFR1ΔCD-GFP plasmid was cloned in a custom expression 
vector (pRH132 vector) with EF-1 alpha promoter and puromycin mammalian 
selection marker and the TNFR1ΔCD-RFP was cloned in pRFP vector with CMV 
promoter and neomycin mammalian selection marker (Figure 2.1B) (see Note 1). 
2. Plasmids preparation: Following the manufacturer’s protocol from plasmid maxiprep 
kit. Resuspend plasmid DNA in autoclaved and 0.2 m filterd water at a 




3. HEK293.2sus cells (ATCC): Maintain and culture in an incubator at 37 °C in 5% CO2, 
and routinely passage with sterile technique in a cell culture biosafety hood (see 
Note 2). 
4. Complete Dulbecco's Modified Eagle Medium (DMEM) cell culture media: phenol 
red-free DMEM supplemented with heat-inactivated 10% fetal bovine serum (FBS), 2 
mM L-glutamine, 100 U/ml penicillin and 100 g/ml streptomycin. (see Note 3). 
5. Mammalian cell antibiotic selection: Aliquoted stocks of puromycin (10 mg/mL) and 
geneticin (50 mg/mL) can be store up to a year at −20 °C. Puromycin (0.5 g/mL for 
selection and 0.25 g/mL for maintenance) and geneticin (500 g/mL for selection 
and 250 g/mL for maintenance) are freshly diluted in complete DMEM media prior 
to use. 
6. Lipofectamine 3000™. 
7. Serum-free Opti-MEM™ media. 
8. TrypLE™ Express. 
9. Cell culture centrifuge. 
10. Sterile phosphate buffered saline (PBS). 
11. Trypan blue solution (0.2 m filtered). 
12. Sterile cell strainer with 70 μm nylon mesh. 
13. Cell counter with function to check cell viability (e.g. automated cell counter 
(Countess, Invitrogen). 
14. Sterile dimethyl sulfoxide (DMSO). 
15. Drug plates containing libraries of chemical compounds such as from NIH clinical 
collection (NCC), library of pharmaceutically active compounds (LOPAC) or 
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ChemBridge DIVERSet 50,000 compounds. (see Note 4). These drug plates are 
frozen at -20 °C prior to screening.  
2.4. Methods 
2.4.1. Generation of stable cell lines expressing TNFR1-GFP only or TNFR1-
GFP/RFP (TNFR1 FRET biosensor) 
 This section describes a method for generating a stably expressing TNFR1 
FRET biosensor that can be expanded and directly used for FRET measurements by 
acquiring the fluorescence lifetime. We describe the use of adapted HEK293.2sus cells 
and transfection with the Lipofectamine 3000™ reagent, but other cell lines and 
analogous approaches for introducing plasmids into mammalian cells should work 
equally well. Co-transfection of the FRET biosensor plasmids with orthogonal antibiotic 
selection allows for high stringency in selecting high TNFR1-GFP and TNFR1-RFP co-
expressing cells. 
1. Start with a healthy and low passage adapted HEK293.2sus cell culture. Split one 
million cells per well in a 6-well or 35 mm plate. 
2. After 24 h, confirm that HEK293.2sus cells have attached and are evenly distributed 
in the 6-well plate under bright field of a light microscope. Transfect these cells with 
Lipofectamine 3000™, following manufacturer’s protocol (see Note 5).  
For the transfection, we prepare two 1.5 mL tubes prefill with serum-free Opti-
MEM™ media. To one tube, we mix the TNFR1-GFP only or TNFR1-GFP/RFP (1:6 
ratio) (total DNA is 2.5 μg) and 5 L of P reagent (2 L/g of DNA used) from the 
transfection kit to the Opti-MEM™ media. To the other tube of Opti-MEM™ media, 
we add 7.5 L of the Lipofectamine 3000™ (3 L/g of DNA used). We then mix 
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both tubes, vortex gently and incubate at room temperature for 15 min. After the 
incubation, add this mixture dropwise to the HEK293.2sus cells in the 6-well plate. 
3. After 6 h, gently remove media on cells and replace with fresh growth media. 
4. Allow cells to express the TNFR1-GFP only control or the TNFR1 FRET biosensor 
from the transfected plasmids for 48 h. Confirm this expression and a >90% 
transfection efficiency with fluorescent microscopy using EVOS-FL cell imaging 
system. Successful transfection should show fluorescent signal in both the green and 
red channel as well as the merged channel (Figure 2.2A). Very gently transport the 
plate to and from the incubator, as the cells are liable to detach very easily at this 
stage. (see Note 6) 
5. Trypsinize and count HEK293.2sus cells from a healthy transfected culture. Mix 1 × 
103 cells with 20 mL of fresh growth media supplemented with puromycin and 
geneticin. Plate these cells into a 96-well plate with 5-10 cells per well in 200 L 
volume with 0.5 g/mL puromycin and 500 g/mL genecitin for selection. Multiple 96-
well plates can be used. As a control, an untransfected 6-well plate of cells is also 
split into growth media containing puromycin and geneticin. The cells in this control 
should not survive the puromycin selection because they are not transfected, and in 
contrast the transfected cells should fluoresce green and proliferate under the same 
puromycin selection conditions. (see Note 7). 
6. Check cells undergoing puromycin selection daily. If there are many unhealthy or 
unattached cells in the culture, gently wash away the debris from attached growing 
cells by removing the media and replacing with fresh growth media containing 
puromycin and geneticin. 
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7. Cell lines should be expanded and grown under puromycin and geneticin selection 
for a minimum of 1–2 weeks. The resulting stable cell lines should also be evaluated 
by flow cytometry to confirm a high population of cells expressing the TNFR1 FRET 
biosensor (Figure 2.2B) as well as their proper folding and trafficking to the cell 
membrane (Figure 2.2C) (see Note 8). At this point, cells can be frozen in 10% 
DMSO in FBS as freezer stocks for storage at −80 °C overnight and in liquid nitrogen 




















Figure 2. 2. Characterization of the TNFR1 FRET biosensor.  
(A) Fluorescence microscopy images of HEK293.2sus cells stably expressing the TNFR1 FRET 
biosensor with co-localization of both TNFR1-GFP and TNFR1-RFP. (B) Flow cytometry analysis 
of the stable cells expressing the TNFR1 FRET biosensor shows that nearly all cells contain both 
TNFR1-GFP and TNFR1-RFP. (C) Confocal microscopy images showing the GFP, RFP, DIC and 
merged channel of the stable cells expressing TNFR1 FRET biosensor indicates the co-
localization of TNFR1-GFP and TNFR1-RFP at the cell membrane. 
2.4.2. Preparation of the FRET biosensor for HTS 
1. Four days prior to each screening, vials containing the frozen stock of the stable 
TNFR1ΔCD-GFP (donor-only control) or TNFR1-GFP/RFP (TNFR1 FRET 
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biosensor) cells are thawed and plated in two 225 cm2 flasks to ensure the same 
passage of cells are used in screening (see Note 10). 
2. After 24 h, the cells are expanded into six 225 cm2 flasks to obtain sufficient number 
of cells for screening.  
3. The cells are lifted from the 225 cm2 flasks by incubating with 6 mL of TrypLETM 
Express for 5-10 min followed by neutralization with 6 mL of complete DMEM media 
and harvested in 50 mL conical. 
4. The cells are then washed three times in PBS by centrifugation at 300 g and 
resuspending in 20 mL of PBS 
5. Each tube of cells in PBS is filtered using 70 µm cell strainers into a glass flask.  
6. Cell viability was assessed using trypan blue assay with viability above 95%.  
7. A small aliquot of the cells goes through flow cytometry measurement to confirm that 
the expression of TNFR1ΔCD-GFP and TNFR1-GFP/RFP (TNFR1ΔCD-FRET pair) 
in stable cells is above 95%. 
8. The cells are counted and diluted to one million cells/mL using an automated cell 
counter. 
9. After resuspension and dilution in PBS, the stable cells were constantly and gently 
stirred using a magnetic stir bar at room temperature, keeping the cells in 
suspension and evenly distributed to avoid clumping. 
2.4.3. High-throughput screening in 384-well or 1536-well plates 
1. The fluorescence lifetime plate-reader utilizes a 473 nm microchip laser for excitation 
of the GFP fluorescence and a 488 nm long pass filter, as well as a 517/20 nm band 
pass to filter the emission. The 473-nm passively Q-switched microchip laser 
(Concepts Research Corporation, Italy) delivers highly reproducible and high-energy 
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pulses (~1 µJ) at a 5-kHz repetition rate. A full fluorescence decay waveform was 
detected in response to each laser pulse over a 128-ns time window, using a 
photomultiplier module from Hamamatsu (Bridgewater, NJ; cat. H10720-210) and a 
proprietary transient digitizer from Fluorescence Innovations (Minneapolis, MN). A 
488-nm long-pass filter from Semrock (Rochester, NY) and 517/20 bandpass 
emission filter were used, ensuring that only emission from the GFP donor was 
detected. A 488-nm dichroic mirror directed fluorescence signal toward the PMT 
(lifetime mode) or spectrograph (spectral mode) using a fiber-optic cable (see Notes 
11 and 12). 
2. The instrument response function (IRF), acquired by recording scatter from 0.31-µm 
latex microsphere suspensions (Thermo Fisher Scientific).(see Note 13) 
3. The spectral unmixing plate-reader provides direct high-throughput detection of the 
complete fluorescence emission spectrum (emission vs. wavelength), with excitation 
provided by a 473-nm continuous wave laser. Spectra are recorded using a grating-
based fiber-optic input spectrograph equipped with linear-array CCD detector (Sony 
ILX511B; Sony, Tokyo, Japan). The recorded wavelength range in these 
experiments spanned the entire visible spectrum, but only the 500- to 700-nm range 
was used in the data analysis. 
4. On the day of screening, the compound plates were equilibrated for 30 minutes at 
room temperature (25 °C).  
5. The fluorescence measurement of a 384 well plate containing only the TNFR1 FRET 
biosensor without any compounds is conducted before any drug treatment. This is to 
ensure that the signal intensity (Figure 2.3A), coefficient of variation (Figure 2.3B) 
and the lifetime of the biosensor giving the basal FRET level (Figure 2.3C) is 
excellent for HTS. 
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6. Cells (50 μl/well at one million cells per mL concentration) were dispensed by a 
Multidrop Combi Reagent Dispenser into the 384-well assay plates containing the 
compounds. 
7. Once the drug plates are equilibrated to room temperature (25 °C), cells are 
dispensed over the drug plates for incubation. 
8. The cells and compounds are incubated at room temperature for 2 hours before 
readings were taken by the fluorescence lifetime and spectral unmixing plate-reader 


























Intensity CV = 14%
Lifetime CV = 0.7%
 
Figure 2. 3. FRET measurements of TNFR1 biosensor using fluorescence lifetime 
technology.  
(A) The fluorescence decay waveforms from a 384-well plate containing the stable cells 
expressing TNFR1 FRET biosensor. Very little variations between the fluorescence decay 
waveforms are observed. (B) A comparison between the coefficient of variation (CV) between the 
intensity vs. the lifetime based FRET measurements. The CV of the lifetime measurement is 20 
times less than the intensity measurements, making it an excellent approach for high-throughput 
screening assay and allowing better selection of hits. (C) Fluorescence lifetime measurement for 
the stable cells expressing TNFR1 FRET biosensor and the calculated FRET obtained from the 
measurement.  
2.4.4. Data analysis and selection of hits 
1. Time-resolved fluorescence waveforms for each well are fitted to single-exponential 
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decays using least-squares minimization global analysis software (Fluorescence 
Innovations, Inc.) to give donor lifetime (τD) and donor-acceptor lifetime (τDA).  
2. FRET efficiency (E) was then calculated based on Equation 1. 
𝐸 = 1 − (
𝜏𝐷𝐴
𝜏𝐷
)              𝐸𝑞. 1 
3. Fluorescent compounds are flagged as potential false positives due to interference 
from compound fluorescence by the spectral recording method based on the 
assessment of the similarity index of each well from the screening plates obtained 
from the spectral unmixing waveforms (188). 
4. Once the data are fitted using a custom MATLAB analysis software or Fluorescence 
Innovation Data analysis software. This software trasnforms the lifetime and spectral 
data into a easy to use excel spreadsheet which is generated with columns including 
index, row and column number, compound ID, lifetime, FRET, spectral ratio and 
similarity index. 
5. After removal of fluorescent compounds, a histogram of the average FRET 
distribution from all compounds in the screens was processed and fitted to a 
Gaussian curve to obtain a mean and standard deviation (SD). 
6. A hit was defined as a compound that changed the average FRET efficiency by more 
than three times the standard deviation (3SD) relative to the mean (see Note 15). 
7. Assay quality was determined with hit compounds as positive controls and DMSO as 
negative controls and calculated based on Equation 2 (192).  
𝑍′ =  1 −
3(𝜎𝑝 + 𝜎𝑛)
|𝜇𝑝 − 𝜇𝑛|
             𝐸𝑞. 2 
where σp and σn are the standard deviations (SD) of the observed τDA values, and µp 
and µn are the mean τDA values of the positive and negative controls. To make this 
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metric less sensitive to strong outliers, we utilized the normalized median absolute 
deviation (1.4826*MAD) and median in place of the standard deviation and mean, 
respectively (193). (see Note 16).  
Table 2. 1. Reference compounds and their FRET EC50 values, Z’ and functional NF-κB 
activation IC50 values obtained from NCC and DIVERSet HTS using the TNFR1 FRET 
biosensor in the 384-well format. 
Compound FRET EC50 
(μM) 
Z’ (200 μM) NF-κB activation 
absolute IC50 (μM) 
References 
Zafirlukast 18.2 0.76±0.02 48.0 (190) 
DS42 101.7 0.63±0.03 49.8 (191) 
 
2.5. Notes 
1. We describe the fusion of TNFR1 with truncated cytosolic domain (TNFR1ΔCD) to 
GFP and RFP but other fluorophores such as the red-shifted orange and maroon 
fluorescent proteins (OFP and MFP) FRET pair can be used too with adjustment to 
the respective lasers and filters required to measure the fluorescence waveforms of 
these proteins (185). Alternatively, chemical dyes (Alexa Fluor 488 or 562) can also 
be used to label the receptor at region of interactions (e.g. PLAD) for fluorescence 
lifetime measurements. 
2. We describe the use of HEK293.2sus cells which are suspension cells. In our study, 
we titrated FBS to the cells to allow them to become adapted cells that adhere to the 
surface of the cell culture plates or flasks for ease of transfection (194). Other 
suspension or adherent cell lines may be used with some optimization required to 
obtain a good FRET signal.  
3. Phenol-red free media is used for cell culture as it avoids the risk of fluorescence 
interference of the lifetime measurements. Unwashed media will not interfere with 
the fluorescence reading. Phenol red media can still be used but the user has to 
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make sure that the cells are washed thoroughly with PBS and there is no 
interference in the reading by any leftover media. 
4. The chemical libraries (NCC, LOPAC, ChemBridge DIVERSet, etc.) was purchased 
and formatted into 96-well mother plates using a FX liquid dispenser, and 
subsequently formatted across 384 well plates at 50 nl or 1536 well plates at 5 nl (10 
µM final concentration per well) using an Echo liquid dispenser. DMSO (matching 
%v/v) was loaded as in-plate no-compound controls as well as in column 1, 2, 23 
and 24 of the 384 well plates or column 1, 2, 23, 24, 25, 26, 47 and 48 of the 1536 
well plates (negative controls). The flat, black-bottom polypropylene plates (384w: 
PN 781209, Greiner Bio-One) were selected as the assay plates for their low auto-
fluorescence, and low inter-well cross-talk. The plates were sealed and stored at −20 
°C until use.  
5. We describe transfection with the Lipofectamine 3000™ reagent, but analogous 
approaches such as using calcium phosphate, electroporation or lentivirus for 
introducing plasmids into mammalian cells work equally well.  These protocols 
should be optimized by the FRET efficiency observed when different method of 
transfection is adopted.  
6. The lifetime measurements of the TNFR1-GFP donor-only cell line is required to act 
as a control in determining the lifetime of the GFP fluorophore when it is not in close 
proximity to an acceptor fluorophore (e.g. RFP) or when there is no energy transfer. 
The lifetime of both the donor-only and the donor-acceptor samples are needed in 
the calculation of FRET using Equation 1. 
7. We describe creation of stable cell line using the dilution method but other methods 
of creating stable cell line such as using lentivirus can also be used. Characterization 
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of the stable cell line has to be performed to ensure the quality of the TNFR1 FRET 
biosensor. 
8. Western blotting can also be performed to ensure the gene of interest and the 
fluorophores are expressed. Western blot should indicate the correct molecular 
weight of the receptor and that there is no protein degradation due to attachment of 
the fluorescent proteins. 
9. Our frozen stock of the FRET biosensor has been made more than 4 years ago. We 
thaw the frozen stock to check on the expression of the FRET biosensor at least 
once a year and ensure that they are still functional. We suggest users to do the 
same routine check at least once a year. When a drift in the expression of the FRET 
biosensor is observed, exposure of the cells to respective antibiotic may restore the 
expression. Alternatively, fluorescence-activated cell sorting (FACS) on the cell line 
can be performed to select the cells with co-expression of TNFR1-GFP and TNFR1-
RFP for further growth and expansion. 
10. During large scale screening, more than six T225 cm2 flasks of cells may be required 
(typically 30-35 flasks of cells are required), fresh frozen stock of the cell lines have 
to be thawed a week in advance. After 24 h of thawing, split the cells into six T225 
cm2 flasks for 3 days and further split each of the six flasks into six more flasks, 
making a total of 36 flasks for screening. On the other hand, much less cells are 
required for screening in 1536 well plates with 5 L of cells per well at one million 
cells per mL (185). 
11. Fluorescence lifetime plate-reader enables high-throughput fluorescence lifetime 
detection at high precision by utilizing a unique direct waveform recording 
technology.(195) The performance of this fluorescence lifetime plate-reader has 
been previously demonstrated with FRET-based HTS that targets both structured 
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proteins (e.g. SERCA and ryanodine receptor) (163, 188, 196-198) and intrinsically 
disordered proteins (e.g. tau) (199).  
12. We have developed fluorescence resonance energy transfer (FRET) biosensors with 
red-shifted fluorescent proteins, yielding improved characteristics for time-resolved 
(lifetime) fluorescence measurements. In comparison to biosensors with green and 
red FRET pairs (GFP/RFP), FPs that emit at longer wavelengths (orange and 
maroon, OFP/MFP) increased the FRET efficiency, dynamic range, and signal-to-
background of high-throughput screening (HTS) (185). There is also a big reduction 
in compounds that exhibit fluorescent interference. 
13. The instrument response function (IRF) needs to be acquired to remove 
background contributions from the FLT-PR laser and detection equipment. It is 
convolved with an exponential to measure the lifetime of the samples. The decay 
found from the instrument itself is removed by convolution of the samples. This 
convolution is performed in an iterative process using MATLAB or Fluorescence 
Innovations data analysis software. 
14. Different incubation timings such as 20 min, 1 h or anytime up to 4 h can be 
monitored for kinetics measurements. The FRET signal has been determined to be 
stable for up to 4 h (unpublished results).  
15. In determining the hits, a minimum of 3SD should be used for statistical significance. 
User can increase the stringency of the hit selection by adopting a higher SD cut off 
(e.g. 4SD, 5SD, etc.) with the purpose to limit the hit rate to 0.5-1% for ease of 
subsequent testing of the hits. Each FRET biosensor will behave differently, so 
threshold should be defined on a screen by screen basis. 
16. For control inhibitor compounds during HTS, the user can choose from several 
well-characterized small molecules that disrupt receptor-receptor interaction or 
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perturb receptor conformational dynamics leading to inhibition of TNFR1-induced 
NF-κB activation (see Table 2.1).   
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3.1 Summary 
Tumor necrosis factor receptor 1 (TNFR1) is a transmembrane receptor that 
binds tumor necrosis factor or lymphotoxin-alpha and plays a critical role in regulating 
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the inflammatory response. Upregulation of these ligands is associated with 
inflammatory and autoimmune diseases. Current treatments reduce symptoms by 
sequestering free ligands, but this can cause adverse side effects by unintentionally 
inhibiting ligand binding to off-target receptors. Hence, there is a need for new small 
molecules that specifically target the receptors, rather than the ligands. Here, we 
developed a TNFR1 FRET biosensor expressed in living cells to screen compounds 
from the NIH Clinical Collection. We used an innovative high-throughput fluorescence 
lifetime screening platform that has exquisite spatial and temporal resolution to identify 
two small-molecule compounds, zafirlukast and triclabendazole,that inhibit the TNFR1-
induced IB degradation and NF-B activation. Biochemical and computational docking 
methods were used to show that zafirlukast disrupts the interactions between TNFR1 
pre-ligand assembly domain (PLAD), whereas triclabendazole acts allosterically. 
Importantly, neither compound inhibits ligand binding, proving for the first time that it is 
possible to inhibit receptor activation by targeting TNF receptor-receptor interactions. 
This strategy should be generally applicable to other members of the TNFR superfamily, 
as well as to oligomeric receptors in general. 
3.2 Introduction 
Tumor necrosis factor receptor 1 (TNFR1) is a transmembrane receptor that regulates 
the inflammatory pathways (5). Binding of tumor necrosis factor (TNF-) or lymphotoxin-
alpha (LT-) to the extracellular domain of TNFR1 leads to IB degradation and NF-B 
activation (11). Upregulation of these ligands has been associated with several 
inflammatory and autoimmune diseases, including rheumatoid arthritis (RA), juvenile RA, 
multiple sclerosis, Crohn’s disease, and inflammatory bowel disease (200). Therapeutic 
targeting of TNFR1 signaling is a billion-dollar industry. Current treatments involve 
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monoclonal antibodies (e.g. infliximab, golimumab and adalimumab) that function by 
sequestering and blocking ligand binding (15). Unfortunately, these anti-TNF drugs also 
inhibit ligand binding to related TNF receptors that are not involved in the disease 
condition. As such, current treatments can induce dangerous side-effects such as lupus-
like disease and increased incidence of lymphoma (25, 174). In order to overcome these 
limitations, there is a desperate need to develop new receptor-specific treatments that 
take advantage of recent breakthroughs regarding the structure and dynamics of the 
receptor itself (62, 201).  
TNFR1 exists as ligand-independent, homophilic dimers that are stabilized by the 
extracellular pre-ligand assembly domain (PLAD) (49, 202). The PLAD is structurally 
distinct from the ligand-binding domain, and mutational analysis of the PLAD has shown 
the importance of receptor pre-assembly in signaling (202, 203). As a consequence, 
competitively blocking pre-ligand receptor dimerization via the PLAD has been 
considered a potential therapeutic target. Suggestively, the isolated, soluble PLAD of 
TNFR1 was shown to inhibit TNF- induced inflammatory signaling in vitro and to 
ameliorate arthritis in a mouse model (52). In that study, the PLAD molecule (which was 
GST-tagged) ablated ligand binding, making it impossible to determine whether the 
small protein was targeting its intended site and, in fact, disrupting the dimer. Therefore, 
there remains no direct or unambiguous evidence in the literature that inhibition of 
receptor-receptor interactions is a viable targeting strategy for TNFR inhibition.   
In the current study, our goal was to establish a small-molecule approach that 
ablates receptor-receptor interactions, or alters receptor conformational dynamics, 
without interrupting ligand binding (Figure 3.1). We used an innovative time-resolved 
FRET (TR-FRET) based strategy, which combines fluorescent biosensor engineering 
and fluorescence lifetime measurements in a high-throughput screening (HTS) platform 
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to identify small-molecule inhibitors of TNFR1 signaling. The screen was enabled by the 
first truly high-throughput fluorescence lifetime plate-reader, which increases the speed 
of lifetime detection by a factor of 105 and the precision of FRET-based screening by a 
factor of thirty (163). This extra precision, enabling reliable detection of protein structural 
changes of 1Å, is particularly powerful for the detection of allosteric regulation of 
receptors by small molecules. By using this strategy, we found two small-molecule 
compounds that inhibit TNFR1-induced IB degradation and NF-B activation. As 
such, the results of our study should not only impact TNFR research, but should also 

















Figure 3. 1. Inhibition of TNFR1 signaling by small molecules targeting receptor-receptor 
interactions.   
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Small molecules could inhibit ligand-induced NF-B activation by targeting TNFR1 pre-ligand 
assembly domain (PLAD) and disrupting the receptor-receptor interactions without affecting 
ligand binding. 
3.3. Materials and Methods 
3.3.1. Molecular biology 
To generate TNFR1ΔCD-GFP and TNFR1ΔCD-RFP, cDNAs encoding truncated 
TNFR1ΔCD (amino acids 1-242) were fused to the N-terminus of the EGFP and 
TagRFP vectors using standard cloning techniques. For photobleaching FRET assays, 
TNFR1ΔCD was inserted at the N-terminus of the pEYFP-N1 and pECFP-N1 vectors. All 
mutations were introduced by Quikchange mutagenesis and sequenced for confirmation. 
All vectors contain the monomeric mutation A206K to the fluorescent proteins preventing 
constitutive fluorophore clustering (204). EGFP, TagRFP, pEYFP-N1, pECFP-N1 and 
GFP-linker-RFP vectors were a kind gift from David D Thomas.  
3.3.2. Cell culture and generation of stable cell lines 
Human embryonic kidney cells 293 (HEK293) were cultured in phenol red-free 
DMEM (Gibco) supplemented with 2 mM L-Glutamine (Invitrogen), heat-inactivated 10% 
fetal bovine serum (FBS HI, Gibco), 100 U/mL penicillin and 100 g/mL streptomycin 
(HyClone). Cell cultures were maintained in an incubator with 5% CO2 (Forma Series II 
Water Jacket CO2 Incubator, Thermo Scientific) at 37 ºC. To generate TNFR1ΔCD-
FRET pair stable cell line, HEK293 cells were transiently transfected using 
Lipofectamine 3000 (Invitrogen) with TNFR1ΔCD-GFP only or with both TNFR1ΔCD-
GFP and TNFR1ΔCD-RFP (1:6 ratio). Transiently transfected cells were treated with two 
antibiotics, G418 (Enzo Life Sciences) and puromycin (Gibco) to eliminate non-
expressing cells. Stable cell lines expressing TNFR1-GFP or TNFR1-GFP/RFP 
(TNFR1ΔCD-FRET pair or TNFR1 biosensor) with the largest population of expressing 
45 
 
cells were selected by flow cytometry and fluorescence microscopy. Aliquots of the 
stable cell lines have been monitored continuously for over a year with expression 
maintaining above 95% characterized by flow cytometry.  
3.3.3. Flow cytometry 
Homogeneous expression of the TNFR1ΔCD-FRET pair stable cells was 
determined by flow cytometry performed with FACSAria II (BD Biosciences) with GFP 
laser (488 nm) at 250V and RFP laser (561 nm) at 500V. HEK293 cells stably 
expressing TNFR1ΔCD-FRET pair were harvested from a 6-well plate by detaching cells 
with TrypLE (Invitrogen) and washing three times with phosphate buffer solution (PBS, 
Thermo Scientific). Next, cells were passed through a polystyrene round-bottom tube 
with cell-strainer cap (BD Falcon). Data were analyzed by using FlowJo (Company 
Name) software. 
3.3.4. Fluorescence microscopy 
Localization of the TNFR1ΔCD-FRET pair on plasma membrane of stable cells 
was determined by confocal fluorescence microscopy (ATCC, Manassas, VA). Images 
were taken in a glass-bottom chambered coverslips (Matek Corporation, Ashland, MA) 
using an Olympus IX2 inverted confocal fluorescence microscope equipped with a 
FluoView FV1000 laser scanning confocal head and 60X (1.42NA) oil immersion 
objective lenses. Excitation was accomplished with laser illumination at 488 nm for GFP 
and 561 nm for RFP.   
3.3.5. Preparation of cells for FRET measurements and specificity of TNFR1 
biosensor  
TNFR1ΔCD-FRET pair stable cells were cultured in 225 cm2 flask (Corning). On 
the day of measurement, cells were harvested by incubating with TrypLE (Invitrogen) for 
5 min, washed three times with PBS by centrifugation at 300 g, filtered using 70 µm cell 
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strainers (BD Falcon) and resuspended in PBS at a concentration of one million cells/ml 
using an automated cell counter (Countess, Invitrogen). For lifetime measurements, cells 
were dispensed (50 μl/well) into a 384 well-plate (PN 781209, Greiner Bio-One) by a 
Multidrop Combi Reagent Dispenser (Thermo Scientific). Binding specificity of the 
TNFR1ΔCD-FRET pair was tested by transiently transfecting (Invitrogen Lipofectamine 
3000 ) stable cells with full length unlabeled Death Receptor 5 (DR5) (440 amino acids) 
and full length unlabeled TNFR1 (455 amino acids). Two days after transfection, cells 
were harvested and prepared as above for fluorescence lifetime measurements. For 
comparison between the control and the treated samples, an unpaired t-test was used to 
validate statistical differences. 
3.3.6. Fluorescence data acquisition 
Fluorescence lifetime measurements were carried out by a prototype 
fluorescence lifetime plate-reader (Fluorescence Innovations, Inc., Minneapolis, MN) 
(163, 188, 196, 197). GFP fluorescence was excited with a 473 nm microchip laser from 
Concepts Research Corporation (Belgium, WI) and emission was filtered with 488 nm 
long pass and 517/20 nm band pass filters (Semrock, Rochester, NY) (163, 186). This 
instrument enables high-throughput fluorescence lifetime detection at high precision by 
utilizing a unique direct waveform recording technology (195). The performance of this 
fluorescence lifetime plate-reader has been previously demonstrated with FRET-based 
HTS that targets SERCA and ryanodine receptor (163, 188, 196, 197).  
3.3.7. Pilot screening with NIH Clinical Collection library  
The NIH Clinical Collection (NCC) library containing 446 compounds was 
purchased from Evotec, formatted into 96-well mother plates using a FX liquid 
dispenser, and subsequently formatted across two 384 well plates at 50 nl (10 µM final 
concentration per well) using an Echo liquid dispenser. DMSO (matching %v/v) was 
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loaded as in-plate no-compound controls as well as in column 1, 2, 23 and 24 (negative 
controls). The 384 well flat, black-bottom polypropylene plates (PN 781209, Greiner Bio-
One) were selected as the assay plates for their low auto-fluorescence, and low inter-
well cross-talk. The plates were sealed and stored at −20 °C until use.  
Three days prior to screening, stable TNFR1ΔCD-GFP (donor only control) or 
TNFR1-GFP/RFP (TNFR1ΔCD-FRET pair) cells were expanded in five 225 cm2 flasks 
(Corning). On each day of screening, the compound plates were equilibrated to room 
temperature (25 °C). The cells were harvested from the 225 cm2 flasks by incubating 
with TrypLE (Invitrogen) for 5 min, washed three times in PBS by centrifugation at 300 g 
and filtered using 70 µm cell strainers (BD Falcon). Cell viability was assessed using 
trypan blue assay with viability above 95% and diluted to 1 million cells/ml using an 
automated cell counter (Countess, Invitrogen). Expression of TNFR1ΔCD-GFP and 
TNFR1-GFP/RFP (TNFR1ΔCD-FRET pair) in stable cells was confirmed by flow 
cytometry to be above 95% prior to each screen. After resuspension and dilution in PBS, 
the stable cells were constantly and gently stirred using a magnetic stir bar at room 
temperature, keeping the cells in suspension and evenly distributed to avoid clumping. 
During screening, cells (50 μl/well) were dispensed by a Multidrop Combi Reagent 
Dispenser (Thermo Scientific) into the 384-well assay plates containing the compounds 
and allowed to incubate at room temperature for 20 min before readings were taken by 
the fluorescence lifetime plate-reader (Fluorescence Innovations, Inc.).  
3.3.8. HTS data analysis 
Time-resolved fluorescence waveforms for each well were fitted to single-
exponential decays using least-squares minimization global analysis software 
(Fluorescence Innovations, Inc.) to give donor lifetime (τD) and donor-acceptor lifetime 
(τDA). FRET efficiency (E) was then calculated based on Equation 1. 
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𝐸 = 1 − (
𝜏𝐷𝐴
𝜏𝐷
)              𝐸𝑞. 1 
Assay quality was determined with NCC hits as positive controls and DMSO as negative 
controls and calculated based on Equation 2.(192)  
𝑍′ =  1 −
3(𝜎𝑝 + 𝜎𝑛)
(𝜇𝑝 − 𝜇𝑛)
             𝐸𝑞. 2 
where σp and σn are the standard deviations and µp and µn are the means of the positive 
and negative controls, respectively. 
FRET data from four independent NCC screens were collected and averaged. 
Fluorescent compounds were flagged as potential false positives due to interference 
from compound fluorescence by the spectral recording method based on the 
assessment of the similarity index of each well from the pilot NCC screens (188). T-test 
was performed on the data and the left and right 5% tails were classified as outliers and 
removed. After removal of fluorescent compounds, histogram of the average FRET 
distribution from all compounds in the screens was plotted and fitted to a Gaussian curve 
to obtain a mean and standard deviation (SD). A hit was defined as a compound that 
changed the average FRET efficiency by more than four times the standard deviation 
(4SD) relative to the mean.  
3.3.9. FRET dose-response assay 
The hit compounds, triclabendazole (PubChem CID: 50248) and zafirlukast 
(PubChem CID: 5717), were purchased from (AK Scientific, Inc.). These drug 
compounds were dissolved in DMSO to make10 mM stock solution anddiluted into 50X 
concentrations which were then subsequently serially diluted in 96 well mother plates. 
Hits were screened at nine different concentrations (0.1 to 200 μM). Compounds (1 μL) 
were transferred from the mother plates into assay plates using a Mosquito HV liquid 
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handler (TTP Labtech Ltd, UK). The same procedure of cell culture and dispensing as 
the pilot screening was applied in the FRET dose response assays.  
3.3.10. IB degradation assay 
HEK293 cells were cultured in a 150 cm2 flask (Corning) for three days and 
dispensed into two 6 well plates at 1.5 million cells/well and incubated overnight before 
treating with drugs. Next day, cells were treated with DMSO (negative control) and 
respective doses of drug compounds (0.1 to 200 M) for 2 hours followed by 30 min of 
LT- (100 ng/ml) or TNF- (1 ng/ml) (210-TA-005, R&D Systems) treatment at 37 °C. 
Cells were lysed for 30 min on ice with RIPA lysis buffer (Pierce RIPA buffer, Thermo 
Scientific) containing 1% of protease inhibitor (Clontech) and centrifuged at 15,000 g at 4 
°C for 30 minutes. Total protein concentration of lysates was determined by BCA assay 
(Pierce) and equal amounts of total protein (60 μg) were mixed with 4X Bio-Rad sample 
buffer and boiled for 3-5 minutes, and loaded on 4-15% Tris-glycine SDS-PAGE gels 
(Bio-Rad). Proteins were transferred to nitrocellulose membrane and probed using 
antibodies against IB (44D4, Cell Signaling Technology) and β-actin (ab8227, 
Abcam). Blots were quantified on the Odyssey scanner and densitometric analysis was 
carried by the Image Studio (LI-COR Biosciences).  
3.3.11. NF-B luciferase reporter gene assay  
HEK293 cells were transfected with the NF-B-luciferase reporter gene in a 100 
mm plate with Lipofectamine 3000. On the following day, cells were lifted with TrypLE 
and resuspended in phenol red-free DMEM (Gibco). These cells were dispensed in 96-
well (30000 cells/well) white solid bottom plates (Greiner Bio-One North America) and 
incubated with drugs (0.1 to 200 M) or DMSO (negative control) in the presence (100 
ng/ml) and absence of LT- for 18 hours at 37 °C. After incubation, 50 l of Dual-Glo 
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Luciferase Reagent (Promega) was added, incubated at room temperature for 15 min, 
and measured firefly luminescence using a Cytation 3 Cell Imaging Multi-Mode Reader 
luminometer (BioTek). Next, 50 l of Dual-Glo Stop & Glo Reagent (Promega) was 
added, incubated at room temperature for 15 min, and measured Renilla luminescence 
using luminometer. 
3.3.12. Overexpression and Purification of Recombinant Proteins 
The N-terminal FLAG-tagged LT- and FLAG-tagged TNFR1 PLAD (residues 
30-82) were overexpressed using the pT7-FLAG-1 inducible expression system in 
Escherichia coli (E. coli) and purified by anti-FLAG affinity column (M2 anti-FLAG affinity 
agarose resin, Sigma-Aldrich). Purity of the proteins was assessed by 4-15% SDS-
PAGE gels (Bio-Rad) under reducing conditions followed by Coomassie staining. Protein 
concentrations were measured using BCA assay (Thermo Fisher Scientific). 
3.3.13. Co-immunoprecipitation 
Anti-FLAG magnetic beads were mixed with soluble FLAG-tagged LT-α and 
incubated for 2-4 hours at 4 °C. The unbound FLAG-tagged LT-α were then removed by 
washing the beads with wash buffer (150 mM NaCl, 50 mM Tris, 10% Glycerol, pH 7.5). 
HEK293 and transiently transfected cells were washed three times with ice-cold PBS 
before lysis with immunoprecipitation (IP) buffer (20 mM Tris-HCl, 1 mM EDTA, 100 mM 
NaCl, pH 7.5 and 0.5% NP-40) containing complete protease inhibitors cocktail (Roche). 
Subsequently, cells were sonicated for 30 seconds, incubated for 15 minutes on ice, and 
centrifuged at 16,000 g for 30 min at 4 °C. Next, the supernatant was transferred to a 
tube containing magnetic beads coated with anti-FLAG antibody bound to FLAG-tagged 
LT-α. The tube was rotated for 4 hours at 4 °C, followed by three washes with IP buffer. 
Immunoprecipitate samples and whole-cell lysates were resolved using 4-15% SDS-
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PAGE gels and subjected to Western blotting using FLAG (2044S, Cell Signaling 
Technology) and TNFR1 (Ab19139, Abcam) antibodies. 
3.3.14. Analytical SEC and native characterization of proteins 
Analytical size exclusion chromatography (SEC) was used to detect the 
oligomeric states of soluble PLAD. SEC experiments were performed using BioLogic 
DuoFlow Chromatography System (Bio-Rad) with a Superose-12 10/300 GL column (GE 
LifeSciences) with detection at 280 nm and 0.5 mL/min flow rate. SEC column was 
calibrated with protein standard mix (69385, Sigma-Aldrich). Purified soluble PLAD and 
LT-α was accessed by Native-PAGE gels (Bio-Rad) in the absence and presence of 
DMSO and hit compounds (200 M) under non-reducing conditions followed by 
Coomassie staining. 
3.3.15. Photobleaching FRET assay 
HEK293 cells were transiently transfected using the calcium phosphate method 
with 0.5 μg pECFP-TNFR1ΔCD and 1.5 μg pEYFP-TNFR1ΔCD in a 12-well plate. The 
following day, cells were lifted with TrypLE, resuspended in phenol red-free DMEM, and 
plated on poly-D-Lysine coated plates. Cells were allowed to settle at room temperature 
for 1 hour before imaging. Live-cell FRET imaging was performed on a Nikon Eclipse 
TE200 inverted microscope and a 20x objective configured as in our previous study with 
minor modifications detailed here.(181) Cells were imaged in the EYFP and ECFP 
channels every 15 s for 5 min. Between image captures, acceptor was bleached by 
continuous exposure through the EYFP excitation channel. Image analysis was carried 
out in ImageJ. FRET efficiency was calculated as the intercept of the linear fit of 
normalized EYFP fluorescence plotted against normalized ECFP enhancement with 
typical R2 values of around 0.90. The FRET efficiencies measured from individual cells 
were plotted against EYFP intensity for qualitative analysis.  
52 
 
3.3.16. Molecular dynamics and computational docking 
For analysis of the TNFR1 dimer interface residues, Visual Molecular Dynamics 
(VMD) was used. For computational docking, the structure preparation of TNFR1 
monomers, dimers and NCC compounds was done in MOE 2015.1001 (Chemical 
Computing Group, Inc.). TNFR1 monomer: The protein structure of TNFR1 was 
downloaded from the Protein Data Bank (PDB: 1NCF) (49). The water molecules and 
chain B were removed before the chain A was prepared using Structure Preparation 
application of MOE. TNFR1 dimer: The same procedure was followed to prepare the 
dimer except that only the water molecules were removed. NCC compounds: The 446 
compounds from the NCC were downloaded (Evotec), and the compounds were 
prepared by Database Wash program in MOE. Subsequently, the compounds were 
subjected to energy minimization using Energy Minimize application of MOE with 
MMFF94s force field until the gradient of 0.05 rms kcal/(mol.Å2) was met.  
The molecular docking simulation was done using Dock application of MOE. Docking on 
chain A: The PLAD residues (i.e. residues 12-53 in 1NCF) were specified as the docking 
site. NCC compounds were docked individually into the PLAD region of 1NCF chain A 
using the rigid receptor protocol of MOE Dock (205, 206). Initially, 10,000 poses were 
generated by the Triangle Matcher method and scored by London dG. The top 1,000 
docked poses from the initial scoring moved on to the next refinement stage where 
poses were scored and ranked using GBVI/WSA (205), a forcefield-based scoring 
function which estimates the free energy of binding of the ligand from a given pose. It 
should be noted that lower/more negative scores indicate more favorable poses. Only 
the top 100 poses were considered in the subsequent statistical analysis. Docking on 
dimer: The same docking procedure was followed except: (i) The prepared TNFR1 dimer 
was used; (ii) The PLAD residues on both chains were specified as the docking site.  
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 For statistical analysis, a Matlab (MathWorks, Inc.) script was written to calculate the 
Boltzmann-weighted scores by multiplying the probability of contacting a given residue 
by the mean Boltzmann-weighted predicted free energy for each pose contacting that 
residue: 𝑃 ⟨𝑒
−∆𝐺
𝑘𝐵𝑇⟩, where P is the probability of contacting either a specific residue, or the 
interface, ∆𝐺 is the predicted free energy of binding from the docking simulation, and T is 
the temperature (300 K), and the brackets represent the average weighted value for all 
scores where either a specific residue, or the interface is contacted. Structural analysis 
of the hit compounds was carried by MarvinSketch (ChemAxon Ltd.).  
3.4. Results 
3.4.1. TNFR1ΔCD FRET biosensor and fluorescence lifetime technology as HTS 
platform  
To develop a HTS platform that can detect small-molecule modulation of TNFR1 
receptor-receptor interactions, we engineered a TNFR1ΔCD FRET biosensor expressed 
in living cells. We used HEK293 cells stably expressing TNFR1ΔCD fused to green 
(GFP) or red (RFP) fluorescent proteins (TNFR1ΔCD-FRET pair) (Figure 3.2A) to 
identify small molecules that inhibit the endogenous TNFR1-TNFR1 interaction. 
Homogeneity of the TNFR1ΔCD-FRET pair on the plasma membrane was determined 
by flow cytometry and confocal microscopy. Flow cytometry analysis showed extremely 
low background with a 97% induction of TNFR1ΔCD-FRET pair, which suggested that 
most of the stable cells were capable for high-throughput screening to identify 
compounds that modulate TNFR1 interactions (Figure 3.2B). Confocal images showed 
that the receptors were evenly distributed on the cell membrane (Figure 3.2C). We then 
tested the functionality of TNFR1ΔCD-FRET pair by measuring FRET efficiency. Lifetime 
measurements showed a substantial decrease in the donor fluorescence lifetime in the 
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presence of the acceptor compared with the donor only, which indicated efficient FRET 
(Figure 3.2D), and recapitulates the known ligand-independent association of TNFR1 
receptors (49). As there is no known positive control that targets TNFR1 receptor-
receptor interactions, we transfected the stable cells with either unlabeled-TNFR1 or 
DR5 (negative control) to confirm that the measured FRET was specific to TNFR1-
TNFR1 interactions and could be modulated. DR5 caused no significant FRET change, 
but TNFR1 showed a significant decrease in FRET, indicating that TNFR1 interactions 
were specific and not affected by other superfamily members (Figure 3.2E). This 
established the lifetime-based FRET detection with TNFR1ΔCD-FRET pair stable cells 
























Figure 3. 2. TNFR1ΔCD FRET biosensor and fluorescence lifetime technology as high-
throughput screening (HTS) platform.  
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(A) Schematics and principles of TNFR1ΔCD-FRET pair biosensor in identifying small-molecule 
compounds that modulate receptor-receptor interactions and inhibit receptor signaling. Pre-ligand 
assembled TNFR1 dimers exhibit FRET which will be reduced upon disruption of receptor-
receptor interaction by small-molecule inhibitors. (B) Flow cytometry analysis of the TNFR1ΔCD-
FRET pair stable cells show that nearly all of the stably dual transfected cells contain both 
TNFR1ΔCD-GFP and TNFR1ΔCD-RFP. (C) Confocal microscopy images i) GFP channel, ii) RFP 
channel, iii) differential interference contrast (DIC) and iv) merged channel of the dual GFP and 
RFP-tagged stable cells indicate the presence of both TNFR1ΔCD-GFP and TNFR1ΔCD-RFP 
co-localized at the cell membrane. (D) Fluorescence lifetime measurements with TNFR1ΔCD-
FRET pair stable cells show FRET, indicating ligand-independent association of TNFR1 
receptors. Values are mean ± S.D. (n=384). (E) Specificity of TNFR1ΔCD-FRET pair was 
confirmed by transfecting the stable cells with unlabeled-TNFR1 or DR5 (another TNF 
superfamily receptor as control). Cells transfected with DR5 show no significant FRET change 
and with unlabeled-TNFR1 show a significant decrease in FRET. Values are mean ± SD 
***P<0.0001 (n=32) for treated vs control group.  
 
3.4.2. High-throughput screening of NCC library to identify compounds that 
modulate TNFR1 receptor-receptor interactions    
Using the TNFR1ΔCD-FRET pair stable cells, we performed high-throughput 
screening of NIH Clinical Collection (NCC: 446 bioactive compounds) to identify 
compounds that disrupt endogenous TNFR1 receptor-receptor interactions. The NCC 
library is a collection of small molecules that have been previously tested in clinical trials, 
and therefore have known safety profiles. These compounds can provide excellent 
starting points for medicinal chemistry optimization and may even be appropriate for 
direct human use in new disease areas. After an initial quality control check of the stable 
cell lines expressing the TNFR1 biosensor on each day of screening (signal level and 
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coefficient of variance), the cells were dispensed into the drug plates and incubated with 
the compounds or DMSO control wells. A single-exponential fit was used to obtain the 
lifetime from cell line expressing TNFR1ΔCD-FRET pair (τDA) and from the TNFR1ΔCD-
GFP donor-only control cell line (τD) to determine FRET efficiency (Eq. 1). The 
fluorescence lifetime measurement is prone to interference from fluorescent compounds, 
so a stringent fluorescent compound filter was used to flag 26 compounds as potential 
false-positives due to interference from compound fluorescence (188). This filter did not 
change significantly the mean or standard deviation of the histogram (Figures 3.3A and 
3.3B). FRET efficiency from all compounds that passed the fluorescent compound filter 
were averaged from four independent NCC screens. Histogram of the average FRET 
distribution from these compounds was plotted and fitted to a Gaussian curve to obtain a 
mean and standard deviation (SD) (Figures 3.3A and 3.3B). Two hits from the library, 
zafirlukast (PubChem CID: 5717) and triclabendazole (PubChem CID: 50248), were 
identified to decrease the average FRET by more than 4SD greater than the mean of 
control cells (Figure 3.3A). In addition, each NCC screen was analyzed independently 
with two to eight hits being identified. zafirlukast and triclabendazole were discovered to 
be reproducible hits in three or more screens (Figure 3.3C). Both compounds decreased 
FRET efficiency in a dose-dependent manner (Figure 3.3D), with half-maximal effects at 
relative EC50values of 15 μM (triclabendazole) and 18 μM (zafirlukast). To calculate Z´ 
(Eq. 2) for this assay, these two hits with maximum changes of FRET of 0.038 
(triclabendazole) and 0.055 (zafirlukast) were used as positive controls and DMSO as 
negative controls. Using the latter value from zafirlukast in the Z´ calculation (Eq. 2), we 
obtain a value of Z´ = 0.5210.014, which indicates excellent assay quality. This value of 
Z´ is likely to increase, indicating even better assay quality, once a larger library is 
screened, since better positive controls are likely to be discovered, increasing the signal 
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window, (µp - µn) in Eq. 2 (192). Remarkably, both of these compounds—which were 
blindly identified in our screen—have been shown to play a role in NF-B inhibition 
through the TNFR1-induced pathway (161), but no molecular mechanisms to explain 
their impacts have been explored. Zafirlukast is a FDA-approved inflammatory mediator 
that has been used for the treatment of asthma in adults (207), In addition, zafirlukast is 
effective as an anti-inflammatory agent in the treatment of adults with cystic fibrosis 
(208)—a disease in which TNF- has been implicated (209)—as well as in patients with 
autoimmune chronic urticarial (210). On the other hand, triclabendazole is a member of 
the benzimidazole family of anthelmintics which displays high efficacy against 
helminthiasis in both immature and adult live flukes especially related to hermaphroditic 
trematondes known as clonorchis sinensis (211). Clonorchis sinensis can cause an 









Figure 3. 3. Time-resolved FRET-based high-throughput screening of NCC library for 
compounds that inhibit TNFR1 receptor-receptor interactions.  
(A) Pilot screening with NCC library containing 446 compounds. Applied threshold at a change in 
FRET efficiency of 0.028 (4SD) is shown by the black lines. Two hits with reproducible FRET 
change were identified from the pilot screens (blue). (B) Histogram plots of all compounds from 
NCC screen after removal of fluorescent compounds show an average FRET efficiency of 0.119 
± 0.0069. (C) Reproducibility of the two hits across four independent screens with 0.028 threshold 
of FRET change (4SD) shown in black line. (D) The two reproducible FRET hits identified were 
dispensed into 384 well-plates at nine different concentrations from 0.1 to 200 μM and both 
produce a dose-dependent FRET change. 
3.4.3. Cell-based assays to determine the biological activity and efficacy of hit 
compounds 
The effect of triclabendazole and zafirlukast on ligand-induced IB degradation 
and NF-B activation was determined by immunoblotting and cell-based assays. 
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Potency measurements showed an absolute inhibitory concentration (absolute IC50) of 
67 μM (triclabendazole) and 114 μM (zafirlukast) for inhibiting LT-α mediated IB 
degradation in HEK293 cells (Figures 3.4A and 3.4B). Similarly, both compounds 
inhibited LT-α mediated NF-B activation in a dose-dependent manner, with absolute 
IC50 of 55 μM (triclabendazole) and 50 μM (zafirlukast) (Figure 3.4C). The partial 
inhibition by zafirlukast could be due to NF-B activation being further downstream in the 
signaling pathway, as well as influence from biological crosstalk (213). Similar results 
were observed from IB degradation assay with TNF-α treated cells (Figure 3.4D), 
indicating that triclabendazole and zafirlukast are inhibiting TNFR1 function. For the 
functional assays, we calculated Z´ (Eq. 2) by using the maximum inhibition of the two 
hits as positive controls and DMSO as a negative control in each assay. The Z´ values 







TNF-α (1 ng/mL) - +      - +       +       +     
 
Figure 3. 4. Hit compounds inhibit ligand-induced IB degradation and NF-B activation 
in HEK293 cells.  
(A) Effect of triclabendazole and zafirlukast on LT- induced IB degradation was analyzed by 
Western blot. HEK293 cells with endogenous TNFR1 receptors were treated with DMSO and the 
two hit compounds in a dose dependent manner from 0.1 to 200 μM for 2 hours followed by the 
addition of LT- (100 ng/ml) for 30 min and Western blotting analysis. Qualitative dose dependent 
inhibition of IB degradation was observed from the increase in the intensity of the IB protein 
bands. (B) Densitometric analysis of Western blots (n=3) to quantify the effects of hit compounds 
on IB degradation. (C) NF-B activation luciferase assay with HEK293 cells treated with 
triclabendazole and zafirlukast followed by the addition of LT-α (100 ng/ml) (n=3). Both 
compounds inhibited IB degradation and NF-B activation in a dose dependent manner. (D) 
Effect of hit compounds on TNF-α induced IκBα degradation. HEK293 cells were treated with the 
two hit compounds (200 μM) followed by the addition of TNF-α (1 ng/ml). Cell lysates were 




3.4.4. Mode of inhibition of TNFR1 signaling by zafirlukast and triclabendazole 
Fundamental to our stated goal, we then determined whether the inhibitory 
effects of these drugs are due to perturbations in ligand-receptor and/or receptor-
receptor interactions. We monitored ligand-receptor binding in the presence and 
absence of drugs using co-immunoprecipitation. Western blot results illustrated that 
neither drug inhibited ligand-receptor binding (Figure 3.5A). In addition, we confirmed 
that the drugs had no effect on ligand-ligand interactions (Figure S3.1A). We then tested 
the effect of drugs on fluorophores with cells expressing GFP-linker-RFP (linker contains 
32 amino acids). FRET measurements showed no change in the FRET efficiency in the 
presence and absence of drug compounds (Figure S3.1B), which confirmed that the 
small molecules were not acting through disrupting interactions between the cytosolic 
fluorophores. Thus, by elimination, the two compounds were causing a change in FRET 
through interactions with either the extracellular or transmembrane (TM) domain.  
In order to investigate the hypothesis that these compounds are acting directly on 
PLAD-PLAD assembly, or through another indirect/allosteric mechanism, we tested their 
effects on soluble FLAG-tagged PLAD. Size exclusion chromatography showed that 
soluble PLAD existed as a dimer in the native condition (Figure 3.5B). Next, we tested 
the effect of zafirlukast and triclabendazole on the dimerization of PLAD. We treated 
soluble PLAD with zafirlukast or triclabendazole and compared with the untreated 
protein on a native gel. These results clearly showed that zafirlukast disrupted the 
dimerization of PLAD (Figure 3.5C). However, triclabendazole did not disrupt the 
isolated PLAD-PLAD dimer, which implied that it might be binding to the 
conformationally active regions of the receptor that are important for its function. 
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3.4.5. Virtual screening by computational docking of the NCC library to both 
monomeric and dimeric TNFR1 PLAD 
To further explore the relative potency of zafirlukast in disrupting PLAD-PLAD 
interactions, we carried out a virtual screen by computational docking of the NCC library 
to both monomeric and dimeric PLAD (Protein Data Bank (PDB): 1NCF) (49), zafirlukast 
ranked sixth among 446 compounds (Figures S3.2A and S3.2B). Importantly, 
zafirlukast scored substantially better than triclabendazole. This was especially so when 
considering interactions with key residues at the dimer interface (Figures 3.5D, S3.2C 
and S3.2D), including those previously identified (e.g. K19, K32, and Q48, amongst 
others) (202). We then experimentally tested the impact of mutating a subset of 
interfacial residues (Q17, K19, H34 and Q48) that potentially stabilize the receptor 
chains. Photobleaching FRET assay showed that K19, H34 and Q48 were crucial for 
stabilizing the affinity of receptor monomers (Figures S3.3A and S3.3B), but individually 
do not eliminate ligand binding (Figure S3.3C). Thus, the most likely mode of binding for 
zafirlukast is at the PLAD interface, although it remains possible that the binding is 
elsewhere within the PLAD and that the impact on dimerization is non-
competitive/allosteric. Triclabendazole, which is a more potent compound than 
zafirlukast (Figure 3.4), does not biochemically disrupt the isolated PLAD-PLAD dimer. 
Structural analysis of the two compounds has shown that zafirlukast is a more polar 
molecule than triclabendazole. Under physiology conditions, zafirlukast has a charge of -
1, with 2 hydrogen bond donors and 6 hydrogen bond acceptors, suggesting that it 
should interact with charged and polar amino acid residues at the dimer interface 
(Figure 3.5D).  On the other hand, triclabendazole is less polar with no charge and has 
only 1 hydrogen bond donor and 3 hydrogen bond acceptors, suggesting that 
triclabendazole should not binding to the polar dimer interface but rather to a less polar 
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region. In addition, we have recently shown that the other regions of TNFR1, including 
the cysteine rich domain that connects to the TM domain (CRD4), and the TM domain 
itself, are conformationally active (62). Triclabendazole’s relative potency, which bears 
future investigation, is therefore consistent with the notion that non-competitive inhibitors 








Figure 3. 5. Mode of inhibition of TNFR1 signaling by zafirlukast and triclabendazole.  
(A) Effect of zafirlukast and triclabendazole (200 μM) on TNFR1-LT interaction was determined 
by co-immunoprecipitation with anti-FLAG–conjugated agarose beads. (B) Oligomeric states of 
PLAD were determined by analytical size-exclusion chromatography. Dimer peak is indicated. 
Open triangle indicates non-specific protein. (C) Effect of zafirlukast and triclabendazole on 
PLAD-PLAD interactions was determined by Native-PAGE. Open circle indicates nonspecific 
band. (D) Docking scores for zafirlukast and triclabendazole on TNFR1 chain B (PDB: 1NCF) 
interfacial residues. Boltzmann-weighted scores were calculated by multiplying the probability of 
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contacting a given residue by the mean Boltzmann-weighted predicted free energy for each pose 
contacting that residue. 
3.5. Discussion 
New receptor-specific approaches are needed to treat diseases associated with 
over-activation of TNFR1 as conventional therapeutics of anti-TNF cause dangerous 
side effects due to off-target inhibition of related TNF receptors (25, 174). Here, we 
sought to inhibit TNFR1 signaling by altering the oligomeric assembly of the receptors 
without disrupting ligand binding. Our results suggest two distinct modes of action in 
targeting receptor assembly. The first mode, which we anticipated in our experimental 
design (Figure 3.1), was to competitively target PLAD-PLAD interactions and in so-
doing disrupt oligomerization of endogenous TNFR1. We proved the viability of this 
approach in targeting TNFR1 with zafirlukast. The second mode, which emerged as 
something of a surprise, is to target the receptor with small molecules that act non-
competitively: triclabendazole does not compete with ligand or with PLAD-PLAD 
assembly.  
One obvious limitation of these two small molecules isolated from the relatively 
small NCC library is the micromolar concentrations needed for inhibition. Moving forward 
in optimizing the small molecule approach, it is provocative that triclabendazole is a 
slightly more potent compound than zafirlukast (Figure 3.4). In general, small-molecule 
inhibitors that do not directly compete with protein-protein interactions may be the most 
effective for the simple fact that they are unencumbered by competition (214-216). In the 
specific case of triclabendazole, we can safely assume that the binding of the small 
molecule is to either the ECD or TM domain of TNFR1, because the intracellular 
domains in our FRET constructs are replaced with fluorescent tags, which were shown 
to have no interaction with the small-molecule compounds (Figure S3.1B). Therefore, 
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triclabendazole may act allosterically to disrupt receptor oligomerization; or, based on 
more recent discussions of small-molecule strategies for targeting receptor-receptor 
interactions (214, 216). it may bind to conformationally active sites of the receptor and 
disrupt the propagation of the downstream signaling. In this vein, recent work has 
fundamentally altered the view of TNFR activation. Older models involved ligand-
induced receptor oligomerization absent any backbone conformational changes in the 
participating monomers. However, it is now believed that pre-assembled oligomers serve 
as conformational switching stations that are activated when ligand binds (62, 180, 181, 
217, 218). In the context of this new dynamic model of activation, then, it is intriguing to 
think that small molecules that perturb TNFR dynamics, rather than preventing 
oligomerization, could be the most effective.  
Regardless of the specific mechanism, our novel therapeutic strategy using small 
molecules that target receptor-receptor interactions holds great promise for ongoing 
efforts to develop more effective anti-TNFR drugs. The TNFR1ΔCD-FRET pair (TNFR1 
biosensor) can be improved by increasing the FRET efficiency through optimization of 
donor and acceptor ratio and using other fluorescent proteins that have increased 
brightness, photostability, and ability to detect larger distances of separation between 
their fluorophores. In addition, the stable cells expressing TNFR1 biosensor will be 
further used in large-scale screening to identify potent compounds that reduce FRET to 
a greater extent. Increasing the dynamic range of the biosensor as well as identifying 
compounds that are more potent will result in a higher Z´ value and enhance the assay 
quality. This strategy, using our TR-FRET based high-throughput screening approach, 




3.6. Supplemental figures 
 
Supplemental Figure 3. 1. Effect of Triclabendazole and Zafirlukast on the oligomeric 
assembly of ligand and the cytosolic fluorophores.  
(A) Coomassie-stained Native-PAGE gel of LT- with two hit compounds. (B) Effect of both drugs 




Supplemental Figure 3. 2. Analysis of molecular docking of NCC library and hit 
compounds.  
(A) Weighted docking scores for each compound contacting interfacial residues. (B) Weighted 
docking scores for each compound when not in contact with interfacial residues. (C) Weighted 
scores for Zafirlukast and Triclabendazole docking to the TNFR1 dimer interface residues. (D) 
Weighted scores for Zafirlukast and Triclabendazole docking to the dimer non-interface residues. 
 
Supplemental Figure 3. 3. Mutational analysis of the TNFR1 dimer interface residues.  
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(A) Rationally selected residues (Q17, K19, H34 and Q48) for mutation and their interaction 
partners in the TNFR1 PLAD (PDB: 1NCF). (B) Qualitative FRET analysis shows a higher 
concentration of acceptor required to reach saturation for K19A, H34A and Q48A compared to 
wild type, which indicates that these residues play significant roles in pre-ligand association of 
TNFR1. (C) Co-immunoprecipitation of TNFR1 mutants with FLAG-tagged LT-α indicates that the 
mutations do not eliminate ligand binding. CHAPTER 4: NONCOMPETITIVE 
INHIBITORS OF TNFR1 PROBE CONFORMATIONAL 
ACTIVATION STATES 
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4.1. Summary  
Tumor necrosis factor receptor 1 (TNFR1) is a central mediator of the 
inflammatory pathway and is associated with several autoimmune diseases such as 
rheumatoid arthritis. A revision to the canonical model of TNFR1 activation suggests that 
activation involves conformational rearrangements of pre-assembled receptor dimers. 
Herein, we identified small molecule allosteric inhibitors of TNFR1 activation and probed 
receptor dimerization and function. Specifically, we used a fluorescence lifetime-based 
high-throughput screening and biochemical, biophysical and cellular assays to identify 
small molecules that non-competitively inhibit the receptor without reducing ligand 
affinity or disrupting receptor dimerization. We also found that residues in the ligand 
binding loop critical to the dynamic coupling between the extracellular and the 
transmembrane domains, played a key gatekeeper role in the conformational dynamics 
associated with signal propagation. Finally, using a simple structure-activity relationship 
analysis we demonstrated that these newly discovered molecules were further 
optimizable for improved potency and specificity. Together these data solidify and 




Tumor necrosis factor receptor 1 (TNFR1) plays a key role in the transduction of 
inflammatory signals (5). Binding of its native ligands, tumor necrosis factor-alpha 
(TNFα) and lymphotoxin-alpha (LTα), to TNFR1 stimulates IBα degradation and NF-B 
activation, which has been associated with several autoimmune diseases such as 
rheumatoid arthritis (5, 11, 173). Therapeutic targeting of TNFR1 signaling is a billion-
dollar industry (17). Unfortunately, and despite the availability of crystal structures for 
over two decades (57, 59), currently available anti-TNF therapeutics do not directly or 
specifically target the receptors, and as a consequence induce dangerous side-effects 
(21, 23-25). Thus, there is an urgent need to develop a new approach to inhibition of 
TNFRs. The most promising approach will be to take advantage of the available 
structures to deepen our understanding of the structure-function relationship of TNFR1, 
with the goal of rationally maximizing the efficiency of inhibitors. 
Ligand binding induces TNFR1 trimerization, which promotes trimerization of 
cytosolic death domains and concomitant recruitment of downstream signaling 
machinery (21, 57). This model is primarily based on the original crystal structure of a 
ligand-bound, trimeric receptor complex, in which there are no direct receptor-receptor 
interactions (57). However, this model is confounded by the fact that TNFR1 is pre-
assembled as high-affinity receptor dimers in the plasma membrane (55, 58, 59). Based 
on the crystal structure, and on subsequent mutagenesis studies (55, 58-60), pre-ligand 
dimerization is driven by well-defined monomer-monomer interactions across the pre-
ligand assembly domains (PLAD), located within the N-terminal cysteine-rich domain 
(CRD1) and far from the ligand binding loop. Critically, there is no evidence to suggest 
that these dimer structures dissociate on ligand binding, despite the lack of receptor-
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receptor interactions in the trimeric structure. Thus, reconciling this apparent 
inconsistency in the dimer and trimer structures is a long-standing goal within the field 
(182).  
Using TNFR1 and Death Receptor 5 (DR5), another member of the TNFR 
superfamily, we have provided evidence for a revision to the accepted model of TNFR 
activation that reconciles both structural states (60, 62, 180, 181, 219, 220). We and 
others speculate that TNF receptor dimers may form the nexus for larger scale networks 
of ligand-bound TNFR trimers (181, 221-223), and we show this to be the case in one of 
two alternatively spliced isoforms of DR5 (181). Based on the crystal structures of 
TNFR1 (57, 59), we build a structural model of this oligomeric network, which in its 
minimal, active state consists of a dimer of ligand-bound trimers (Figure 4.1A) (62). This 
minimal size has been supported by super-resolution techniques (183). In this model, 
the pre-assembled dimer remains intact upon ligand binding, and is predicted to undergo 
a conformational change that propagates from the extracellular domain (ECD) to the 
cytosol without dimer dissociation. Our focus here is the further exploration of 
conformational dynamics as central to TNFR1 inhibition, and as a potential target for 
inhibitory small molecules. While we have focused on the idea that dimer itself is the 
functional signaling unit, the receptor trimer complex (non-interacting receptor 
monomers stabilized by ligand binding) may still be functional (though perhaps less so). 
Regardless of this open controversy, the idea that activation is accompanied by 
conformational changes, be they in the dimer or trimer, now has solid support (62, 224). 
In particular, fluorescence resonance energy transfer (FRET) data suggest, without 
delineating a clear mechanism, that ligand binding causes a conformational change in 
the pre-assembled TNFR1 complex (61, 224). In addition, we use FRET to show that a 
constitutively active, disease-related mutant (R92Q) is, like wild-type, pre-assembled as 
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a dimer (62). Importantly, the FRET measurements show that this active R92Q dimer is 
conformationally distinct from wild-type, the first direct evidence of a correlation between 
the backbone structure of the pre-assembled TNFR1 dimer and receptor activity. As 
further support, our computational normal mode analysis of an elastic network model of 
the TNFR1 crystal structures suggests a long-range, anti-correlated motion near the 
ligand binding loop that propagates a conformational change through the backbone of 
the ECD (62).   
Collectively, these findings strongly suggest that TNFR1 activation is 
accompanied by backbone conformational changes. However, whether the backbone 
conformational state of TNFR1 is critical to its activation and whether altering the native 
conformation of the pre-assembled dimer is a viable strategy for inhibition, remain open 
and provocative questions. To address this, we used small molecule discovery driven by 
time-resolved FRET (TR-FRET) measurements of inter-monomeric spacing as a means 
to probe previously undetected conformational states of the pre-assembled TNFR1 
dimer. We discovered a class of small molecules that perturb the conformation of 
TNFR1 and, critically, that do so without altering either ligand binding affinity or receptor 
pre-assembly. In so doing, we provided experimental proof of long-range allosteric 
coupling in the extracellular domain of TNFR1, which could be exploited to inhibit 
activation. In addition to providing further evidence for a new model of TNFR1 activation, 
we showed that these new molecules could be optimized for binding affinity, potency 




4.3 Materials and methods 
4.3.1. Molecular biology 
The DNAs (TNFR1ΔCD-GFP and TNFR1ΔCD-RFP) used in the engineering of 
the TNFR1 FRET biosensor was generated in our previous work (190). Briefly, cDNAs 
encoding truncated TNFR1ΔCD (amino acids 1-242) were fused to the N-terminus of the 
EGFP and TagRFP vectors using standard cloning techniques. The mutations of the key 
ligand binding residues (Q107A, S108A, QS107/108AA and M80A) and the control 
mutant (V90A) in the TNFR1ΔCD-GFP and TNFR1ΔCD-RFP plasmids were introduced 
by Quikchange mutagenesis (Agilent Technologies) and sequenced for confirmation. To 
prevent constitutive fluorophore clustering, all vectors contain the monomeric mutation 
A206K to the fluorescent proteins (204).  
4.3.2. Cell culture and generation of stable cell lines 
Human embryonic kidney cells 293 (HEK293, ATCC) were cultured in phenol 
red-free Dulbecco's Modified Eagle Medium (DMEM, Gibco) supplemented with 2 mM L-
Glutamine (Invitrogen), heat-inactivated 10% fetal bovine serum (FBS HI, Gibco), 100 
U/ml penicillin and 100 g/ml streptomycin (Gibco). HAP1 wild-type and TNFR1 
knockout cells (Horizon) were cultured in Iscove's Modified Dulbecco's Medium (IMDM, 
Gibco) supplemented with 10% FBS (Gibco), 100 U/ml penicillin and 100 g/ml 
streptomycin (Gibco). Cell cultures were maintained in an incubator with 5% CO2 (Forma 
Series II Water Jacket CO2 Incubator, Thermo Scientific) at 37 ºC. The HAP1 TNFR1 
knockout cell line was edited by CRISPR/Cas to contain a 70 base pair (bp) insertion in 
a coding exon of TNFRSF1A. Sanger sequencing was performed as a quality control to 
confirm the knockout. The TNFR1ΔCD-FRET pair stable cell line was generated as 
described in our previous work and have been monitored continuously for over three 
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years with expression maintaining above 95% characterized by flow cytometry (190). 
The high expression of the TNFR1ΔCD-FRET pair in the stable cell line indicates that 
they are functional and applicable in high-throughput screening. The mutant forms of the 
TNFR1 FRET biosensor (Q107A, S108A, QS107/108AA, M80A and V90A) were 
generated by transiently transfecting HEK293 cells using Lipofectamine 3000 
(Invitrogen) with TNFR1ΔCD-GFP and TNFR1ΔCD-RFP DNAs containing the respective 
mutations. 
4.3.3. Large-scale high-throughput screening with ChemBridge DIVERSet library 
The DIVERSet library containing 50,000 compounds was purchased from 
ChemBridge Corp., formatted into 96-well mother plates using a FX liquid dispenser, and 
subsequently formatted across 157 plates of the 384-well plate at 50 nl (10 µM final 
concentration per well) using an Echo liquid dispenser. Dimethyl sulfoxide (DMSO) was 
loaded in matching %v/v as in-plate no-compound controls as well as in column 1, 2, 23 
and 24 (negative controls). The 384-well flat, black-bottom polypropylene plates (PN 
781209, Greiner Bio-One) were chosen as the assay plates for their low auto-
fluorescence and low inter-well cross-talk. The plates were sealed and stored at −20 °C 
until use. The screening was carried out across five days with ~10,000 compounds (~32 
compound plates) screened each day. A week prior to screening, a fresh vial of 
TNFR1ΔCD-GFP/RFP (TNFR1ΔCD-FRET pair) cells were thawed, plated in a 225 cm2 
flask (Corning) and checked for expression. The cells were then expanded into six 225 
cm2 flasks for three days and further expanded into 36 flasks for another three days. 
Prior to each day of screening, the stable cells expressing the TNFR1 FRET biosensor 
were harvested to check for expression and response variation in fluorescent intensity. 
Stable cells were then dispensed into the drug plates (50,000 cells/well) and incubated 
with the compounds or DMSO as a negative control followed by fluorescence lifetime 
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measurements. The fluorescence waveforms were acquired by a prototype fluorescence 
lifetime plate-reader (Fluorescence Innovations, Inc.) as described (190).  
4.3.4. HTS data analysis 
Time-resolved fluorescence waveforms obtained for each well were fitted to 
single-exponential decays using least-squares minimization global analysis software 
(Fluorescence Innovations, Inc.) to give donor-acceptor lifetime (τDA) from the 
TNFR1ΔCD-GFP/RFP (FRET pair) cell line and donor lifetime (τD) from a TNFR1ΔCD-
GFP donor-only control cell line. FRET efficiency (E) was then calculated based on 
Equation 1. 
𝐸 = 1 − (
𝜏𝐷𝐴
𝜏𝐷
)              𝐸𝑞. 1 
The Z-factor, a HTS assay quality indicator, was determined with zafirlukast as a positive 
control and DMSO as a negative control and calculated based on Equation 2 (192).  
𝑍′ =  1 −
3(𝜎𝑝 + 𝜎𝑛)
|𝜇𝑝 − 𝜇𝑛|
             𝐸𝑞. 2 
where σp and σn are the standard deviations of the observed τDA values, and µp and µn 
are the mean τDA values of the positive and negative controls, respectively. To make this 
metric less sensitive to strong outliers, we utilized the normalized median absolute 
deviation (1.4826*MAD) and median in place of the standard deviation and mean, 
respectively (225). The Z-factor obtained was 0.76±0.02, indicating excellent assay 
quality. 
Fluorescent compounds were flagged as potential false positives due to 
interference from compound fluorescence by a set of stringent fluorescent compound 
filters based on analysis of the spectral waveforms of each well from the DIVERSet 
screen (226). After removal of fluorescent compounds, histogram of the FRET 
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distribution from all compounds in the screen was plotted and fitted to a Gaussian curve 
to obtain a mean and standard deviation (SD). A hit was defined as a compound that 
decreased the FRET efficiency by more than three times the standard deviation (3SD) 
relative to the mean.  
4.3.5. FRET dose-response assay 
The hit compounds, DS41 (ID 19298144), DS42 (ID 43812755), DS43 (ID 
23420063), DS44 (ID 95020298), DS45 (ID 45055796), DS50 (ID 33619467) and DS51 
(ID 74188632) were purchased from ChemBridge Corp. A negative control compound 
(ID 65311687) was also purchased. These drug compounds were dissolved in DMSO to 
make 10 mM stock solution which were then subsequently serially diluted in 96-well 
mother plates to obtain eight doses at 50X concentrations. Hits were screened at eight 
different concentrations (0.1 to 200 μM). Compounds (1 μl) were transferred from the 
mother plates into assay plates using a Mosquito HV liquid handler (TTP Labtech Ltd.). 
The cell preparation of the wild-type TNFR1 FRET biosensor in the FRET dose-
response assays were carried out through the same way as the high-throughput 
screening.  
4.3.6. Functional assays (IB degradation assay and NF-B activation assay) 
IB degradation assay and NF-B activation assay with HEK293 cells were 
carried out as described (190). Densitometry of the Western blots was performed using 
Image Studio (LI-COR Biosciences) and data are normalized to the β-actin loading 
control and the amount of IκBα in the control cells in the absence of ligand. For TRADD-
induced NF-B activation in HEK293 cells, cells (1 x 106) in a 6-well plate were 
transfected with 1 g of NF-B firefly luciferase reporter genes, 0.1 g of Renilla 
luciferase reporter genes, 1 g of TRADD plasmid and 0.4 g of control plasmid to give 
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2.5 g of total DNA. In the control cells, the TRADD plasmid was replaced with control 
plasmid. After 3 hours of transfection, cells were harvested and plated (30,000 cells/well, 
total volume 50 l) into 96-well white solid bottom assay plates (Greiner Bio-One North 
America). Drug treatments (0.1 to 200 M) or DMSO (negative control) was performed 5 
hours after cell plating. Luciferase activities were determined 24 hours after treatments. 
Briefly, 50 l of Dual-Glo Luciferase Reagent (Promega) was added, incubated at room 
temperature for 15 min, and measured firefly luminescence using a Cytation 3 Cell 
Imaging Multi-Mode Reader luminometer (BioTek). Next, 50 l of Dual-Glo Stop & Glo 
Reagent (Promega) was added, incubated at room temperature for 15 min, and 
measured Renilla luminescence using luminometer. The luciferase activities were 
normalized on the basis of Renilla expression levels.  
For NF-B activation luciferase assay with HAP1 wild-type and TNFR1 knockout 
cells, the cells were transfected with the NF-B-luciferase reporter genes (10 g of firefly 
luciferase genes and  1 g of Renilla luciferase genes) in a 100 mm plate with 
Lipofectamine 3000 (Invitrogen). On the following day, cells were lifted with TrypLE and 
resuspended in phenol red-free DMEM (Gibco). These cells were dispensed into 96-well 
assay plates (30000 cells/well, total volume 50 l) and incubated with drugs (0.1 to 200 
M) or DMSO (negative control) in the presence (0.1 g/ml) and absence of LT for 18 
hours at 37 °C. Readings for luciferase activities were acquired as described above. All 
data from NF-B activation assays were normalized to luciferase activity of cells in the 
presence of ligand or TRADD overexpression. 
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4.3.7. Mechanistic assays (co-immunoprecipitation and native gel 
characterization) 
Co-immunoprecipitation between endogenous TNFR1 and ligand LT in the 
presence and absence of hit compounds was performed as described previously (190). 
The overexpression and purification of the N-terminal FLAG-tagged LT and FLAG-
tagged TNFR1 PLAD (residues 30-82) were carried out as described previously and the 
soluble PLAD protein was shown to exist as dimers under native conditions (190). The 
recombinant human TNFR1 extracellular domain (ECD) was purchased from Abcam. 
The purity of the proteins was assessed by 4%–15% SDS-PAGE gels (Bio-Rad) under 
reducing conditions, followed by Coomassie staining. Protein concentrations were 
measured using the BCA assay (Thermo Fisher Scientific). To test the disruption of 
receptor-receptor or ligand-ligand interactions, purified soluble TNFR1 PLAD or ECD 
and LTα (5 µg) were assessed by Native-PAGE gels (Bio-Rad) in the absence and 
presence of hit compounds (200 M) under non-reducing conditions followed by 
Coomassie staining. Native-PAGE gel of soluble PLAD was also characterized by 
Western blot with TNFR1-specific antibody (H-5) (sc-8436, Santa Cruz Biotechnology) 
that targets the extracellular domain of the receptor. Competition assay between the hit 
compounds and zafirlukast was performed by the co-treatment of both the hit 
compounds (200 or 1000 M) and zafirlukast (200 M) at the same time to soluble 
PLAD and observed the extent of disruption of PLAD-PLAD interactions.  
4.3.8. Surface plasmon resonance (SPR) binding assay 
Binding affinity between TNFR1 ECD and compounds or ligand was determined 
by SPR analysis using BIAcore S200. Recombinant human TNFR1 ECD (Abcam) was 
immobilized on the CM5 sensor chip (Biacore, GE Healthcare) by amine coupling. 
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Briefly, the dextran surface was activated with a 1:1 mixture of 0.4 M 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride and 0.1 M N-hydroxysuccinimide. 
TNFR1 ECD (20 μg/ml) in 10 mM sodium acetate at pH 5 was flowed past a working 
surface before blocking the remaining activated carboxymethyl groups with 1 M 
ethanolamine at pH 8.5 to achieve a level of 2500 RU suitable for binding analysis. The 
reference surface was activated and reacted with only ethanolamine. 
For direct binding assays between the receptor and the small molecules, the hit 
compounds and the analogues at eight different concentrations (0.1-200 μM) as well as 
DMSO-only controls were prepared in HEPES-EP containing a total of 2% DMSO. For 
competition assays between ligand and small molecules, ligand at eight different 
concentrations (LTα = 0.1-200 nM) was prepared in HEPES-EP in the presence of 
saturated dose of compounds (200 μM) or DMSO containing a total of 2% DMSO. For 
other competition assays, samples containing small molecules and/or antibody were 
prepared in HEPES-EP buffer. The samples were injected over both the reference and 
ECD immobilized surfaces at 10 μl/min for 90 seconds and dissociated in glycine-HCl pH 
2.5. All of the samples, along with blanks from buffer and DMSO-only controls were 
measured on a 96-well microplate (Biacore, GE Healthcare) at 25 °C. Reflectivity 
response data points were extracted from response curves at 5 seconds prior to the end 
of the injection to determine steady-state binding. All the data were double referenced 
with blanks using standard procedures with Biacore S200 Evaluation Software v1.0.  
4.3.9. Computational analysis of crystal structure 
For analysis of the TNFR1 crystal structure, visual molecular dynamics (VMD) 
was used. The crystal structure of the pre-ligand dimer of TNFR1 ECD was downloaded 
from the Protein Data Bank (PDB: 1NCF) (59) and the structure preparation was done in 
CHARMM-GUI. The distance measurement of the TNFR1 ECD was performed in VMD. 
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The hydrogen bonds between the residues in the ligand binding loop were determined 
by VMD with distance cutoff of <3.2Å and angle cutoff of <60o. 
4.3.10. Structure-activity relationship (SAR) analysis 
The analogues of the lead compound (DS41) were identified through a search of 
the company’s database (ChemBridge) that share more than 90% similarity (based on 
the chemical functionality and scaffolding as determined by the company’s similarity 
search engine) to the lead compound. A total of 19 analogues of DS41 (compound IDs 
in table S1) were purchased from ChemBridge Corp. The analogues were dissolved in 
DMSO to make 10 mM stock solution which were then subsequently serially diluted in 96 
well mother plates at eight different doses (0.1 to 200 μM) at 50X concentration. FRET 
measurements were performed using the wild-type TNFR1 FRET biosensor at a 
compound concentration of 50 µM. The inhibition of IB degradation of the analogue 
was tested at a compound concentration of 200 µM and the inhibition of NF-κB activation 
was determined in a dose-dependent manner to obtain the IC50 values and percent 
inhibition listed in table S1. SPR binding assays, specificity tests and mechanistic assays 
were conducted with methods and materials as described above.  
4.3.11. Statistical analysis 
Data are presented as mean ± standard deviation unless stated otherwise. To 
determine statistical significance for all experiments, data analysis was performed by a 
two-tailed unpaired t test (Student’s t test) with P values determined by using GraphPad 
Software. Values of P < 0.05 were considered statistically significant. GraphPad style in 
using asterisks to denote P values in figures was used (*P < 0.05, **P < 0.01, ***P < 




4.4.1. Discovery of small molecules that modulate conformational states of pre-
assembled dimeric TNFR1 
We performed high-throughput screening of the 50,000 compound ChemBridge 
DIVERSet library to identify small molecules that modulate TNFR1 conformational 
states. To detect changes in the cytosolic spacing between receptor monomers, we 
used our previously engineered stable cell lines expressing a TNFR1ΔCD-FRET pair 
construct, in which either a green or red fluorescent protein (GFP or RFP) is fused to the 
C-terminus of TNFR1 with a truncated cytosolic domain (ΔCD) (TNFR1ΔCD-GFP as 
donor and TNFR1ΔCD-RFP as acceptor) (Figure 4.1B). We show that these truncated 
receptor constructs are properly trafficked to the plasma membrane where they maintain 
their pre-assembled dimeric assembly (62), and are validated for high-throughput 
screening on a smaller library in the absence of ligand (190). As will be clarified below, 
changes in FRET could represent either: 1) dissociation of the TNFR1 dimer; or 2) as is 
our focus in this study, a change in the backbone conformation of the receptor that 
results in small changes in inter-monomeric spacing without inhibiting dimerization. The 
screen was enabled by a high-throughput fluorescence lifetime plate-reader technology 
that has an increased precision of TR-FRET based screening by a factor of thirty (163), 
which allows for reliable detection of subtle protein structural changes and is capable of 
monitoring allosteric regulation of receptors by small molecules. 
The FRET efficiency for all of the compounds, after removing the potential false 
negatives, was plotted (Figure 4.1C) and the distribution of efficiencies was fitted to a 
Gaussian distribution to obtain a mean and standard deviation (SD). The top forty 
compounds, each of which decreased the average FRET by more than 3SD greater than 
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the mean of control cells, were selected and purchased from ChemBridge Corp. For 
simplicity we have limited our search to compounds that reduce FRET, though others 
that increase FRET may also be of interest in future studies. The compounds were then 
tested for dose-dependent FRET change to confirm their specific interactions with the 
biosensor as well as to measure the potency and the extent of receptor perturbation by 
the compounds. Seven of the forty hit compounds had a dose-dependent decrease in 
FRET efficiency (Figure 4.1D) with half-maximal effects (relative EC50) ranging between 
20-110 M, with DS43 having the lowest EC50. No FRET change was observed with a 
negative control compound (fig. S3.1A). We note that from our previous study the EC50 
of the dimer-breaking compound zafirlukast was at the lower end of this spectrum (18 
M) (Figure 4.1D). The structures of these seven novel compounds identified from the 
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Figure 4. 1. Discovery of small molecules that perturb conformational states of pre-
assembled TNFR1 dimer.  
(A) Schematic of ligand-induced oligomerization of TNFR1 trimers held together by the pre-ligand 
assembly domain (PLAD). (B) Schematic of the TNFR1ΔCD-FRET biosensor engineered by 
fusing the green or red fluorescent proteins (GFP or RFP) to the C-terminus of TNFR1 with 
truncated cytosolic domain. Ligand-independent association of the fluorophore-tagged receptors 
through PLAD-PLAD interactions results in fluorescence resonance energy transfer (FRET). The 
FRET biosensor is capable of detecting changes in the cytosolic spacing between receptor 
monomers. (C) High-throughput screening of ChemBridge DIVERSet 50,000 compound library 
using the TNFR1 FRET biosensor expressed in HEK293 cells. Compounds that reduced the 
FRET efficiency below the applied threshold (red line) were selected for further characterization. 
Data are representative of one experiment. (D) Secondary FRET analysis of the dose response 
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of the seven hit compounds and zafirlukast (known TNFR1 inhibitor). Data are means ± SD from 
three independent experiments. 
4.4.2. Cell-based assays to determine the biological activity and efficacy of hit 
compounds 
The dose-dependent effect of hit compounds on ligand-induced IB degradation 
was determined by immunoblotting (Figure 4.2A). After LT treatment, IB was 
degraded to 20% of the basal levels in HEK293 cells (Figure 4.2B). IB degradation 
was inhibited in a dose-dependent manner with treatment of each of the seven hit 
compounds, and potency measurements showed relative inhibitory concentrations 
(relative IC50) between 30 μM and 111 μM (Figure 4.2C). To test inhibition of NF-B 
activation, a luciferase assay was performed in the presence of LT (Figure 4.2D). Hit 
compounds again inhibited ligand-induced NF-B activation in a dose-dependent 
manner, with relative IC50 of the compounds between 14 μM and 90 μM (Figure 4.2E). 
We note that both functional assays produced IC50 values that roughly correspond to the 
FRET results, although important differences do exist that reflect differences in the 
specificity of the individual compounds for the receptor. This important nuance will be 
addressed below with studies using TNFR1 knockout cell line. Additionally, we note from 
the luciferase assay that a basal NF-B activation (20% relative luciferase activity) was 
observed in HEK293 cells in the absence of exogenous ligands. This has been 
suggested to be due to constitutive signaling of cytokine receptors in the ligand-free 
state including TNFR1 (227, 228). Specific inhibition of TNFR1 such as through 
upregulation of silencer of death domain (SODD) has been shown to be able to reduce 
this constitutive signaling (228). 
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Figure 4. 2. Hit compounds inhibit TNFR1-stimulated NF-κB activation.  
(A to C) Western blot analysis of IκBα abundance in lysates of HEK293 cells treated with LT and 
the hit compounds at the indicated doses. Western blots (A) are representative of three 
independent experiments. Quantified band intensity values (B and C) are means ± SD from all 
experiments. ****P < 0.0001 versus control by two-tailed unpaired t test. (D and E) Luciferase 
assay of NF-κB activation in HEK293 cells transfected with reporter plasmids and treated with 
LT and DMSO control (D) or LT and increasing concentrations of hit compounds (E). Data are 
means ± SD of three independent experiments. ****P < 0.0001 versus control by two-tailed 
unpaired t test. 
4.4.3. A subset of hit compounds are receptor-specific in blocking TNFR1-induced 
NF-B activation 
To determine which, if any, of the seven hit compounds are acting directly on 
TNFR1, we first performed measurements with surface plasmon resonance (SPR). 
Purified TNFR1 extracellular domain (ECD) was immobilized onto the SPR chip, which 
was followed by flowing the compounds through the chip to allow for binding. All hit 
86 
 
compounds showed dose-dependent binding to the TNFR1 ECD with binding affinities 
(Kd) between 31 and 81 M, as compared to 86 M for zafirlukast (Figure 4.3A and fig. 
S4.2, A to H). 
Next, we aimed to establish whether the functional effects of the hit compounds 
(Figure 4.2E) are specifically due to binding the receptor and alteration of the receptor 
conformation, rather than through the inhibition of proteins in alternate signaling 
pathways. To do so, we first used a TNFR1 knockout (KO) HAP1 cell line established by 
CRISPR. We treated both parental wild-type (WT) and TNFR1 KO HAP1 cells with 
increasing doses of LTα. As expected, WT HAP1 cells showed a dose-dependent 
increase in luciferase activity which was not observed in the TNFR1 KO cells, confirming 
that the TNFR1 KO cells were not functionally sensitive to TNFR1 stimulation (Figure 
4.3B). A ligand concentration of 0.1 g/ml was chosen for treatment of both WT and 
TNFR1 KO HAP1 cells as maximum NF-B activation measured by luciferase activity 
was obtained at this concentration in the WT cells while the TNFR1 KO cells remained 
non-functional (Figure 4.3C).  
As in the case of the HEK293 cells (Figure 4.2D), the KO cells showed basal 
activation of the NF-B pathway (approximately 20% relative luciferase activity). 
Importantly, this basal activity was unchanged in the presence of ligand. This feature 
makes these cell lines useful as a first control to ensure that the functional effects we 
observed in the HEK293 cells were due to direct interactions with TNFR1 and not due to 
the compounds indirectly acting on other proteins on alternate NF-B pathways. As 
expected, all compounds reduced ligand-induced NF-B activation in the WT HAP1 cells 
to very a similar extent as was observed in the HEK293 cells (Figure 4.3D and fig. 
S4.3A). Then, the TNFR1 specificity of the compounds was determined by monitoring 
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whether and to what extent they altered the basal level of NF-B activation in the TNFR1 
KO cells. Our expectation was that the truly specific compounds should have no impact 
on this basal activity. To show the effectiveness of this approach, DS44 and DS50 
reduced the basal level of NF-B activation in the TNFR1 KO cells at similar IC50 to the 
WT cells (fig. S4.3B), clearly demonstrating a non-specific interaction with other proteins 
in the cells and ruling these two compounds out as specific inhibitors of TNFR1. We 
noted that DS44 was the compound with the highest binding affinity for TNFR1, as 
measured by SPR, highlighting the importance of this specificity test. DS41, DS43, DS45 
and DS51 are all specific at the range near their IC50, but each of these compounds do 
show some non-specificity at higher concentrations (Figure 4.3E and fig. S4.3B). DS42, 
on the other hand, together with zafirlukast, emerged as the most specific of the newly 
discovered inhibitors, showing almost no effect on basal levels in the TNFR1 KO cells 
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Compound concentration (M)  
Figure 4. 3. Hit compounds bind TNFR1 and require the receptor for their effects.  
(A) Direct binding of the hit compounds to the TNFR1 extracellular domain (ECD) was 
characterized by surface plasmon resonance (SPR). Data are means ± SD from three 
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independent experiments. (B) Dose-dependent ligand-induced NF-κB activation in both wild-type 
(WT) and TNFR1 knockout (KO) HAP1 cells. Data are means ± SD of three independent 
experiments. ****P < 0.0001 versus control by two-tailed unpaired t test and n.s. indicates not 
significant. (C) NF-κB activation in WT and TNFR1 KO HAP1 cells with the optimized LTα 
concentration of 0.1 μg/ml. Data are means ± SD of three independent experiments. ****P < 
0.0001 versus control by two-tailed unpaired t test and n.s. indicates not significant. (D and E) 
NF-κB activation in WT HAP1 cells (D) and TNFR1 KO HAP1 cells (E) treated with LT and 
increasing concentration of compounds (DS41, DS42 and zafirlukast) to test the specificity of the 
compounds to TNFR1. Data are means ± SD of three independent experiments. 
As a second control to further determine the specificity of the compounds, we 
tested their effect on TNFR1-associated death domain (TRADD)-induced NF-B 
activation, independent of ligand activation of TNFR1. Because TRADD is the first 
cytosolic protein in the TNFR1 cascade, testing the effect of the compounds after 
stimulating TRADDwithout involving TFNR1represents the most complete control for 
specificity. Overexpression of TRADD significantly increased the NF-B activation in 
HEK293 cells (fig. S4.4A), which was shown previously (229). Both DS42 (fig. S4.4B) 
and zafirlukast (fig. S4.4C) had little effect on TRADD-induced NF-B activation, even at 
relatively high concentrations; DS42 did show partial inhibition at 200 M, though this is 
well above its IC50. In contrast, DS41, which showed some non-specificity in inhibiting 
basal NF-B activity in the TNFR1 KO HAP1 cells, also inhibited TRADD-induced NF-B 
activation at a similar IC50 to its inhibition of the TNFR1-induced NF-B activation (fig. 
S4.4D). These results further confirmed the high specificity of DS42 and zafirlukast in 
targeting TNFR1.  
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4.4.4. Small-molecule inhibitors do not change binding affinity of ligand to TNFR1 
After determining the specificity of each of the compounds, we then aimed to 
parse whether the mechanisms of action of these compounds is to perturb ligand-
receptor interactions, receptor-receptor interactions such as dimerization, or a new 
mechanism: alteration of conformational states of the receptor. We note that DS42 had 
only a small, though significant, effect on FRET. If we were able to show that the 
compound does not prevent ligand binding or dimerization, this would highlight the 
possibility that subtle changes in conformation of the pre-assembled dimer may be 
enough to inhibit the receptor in the ligand-bound, fully assembled state.  
First, to test whether the compounds act by blocking ligand binding, we 
monitored ligand-receptor binding in the absence and presence of the compounds using 
co-immunoprecipitation (co-IP) and SPR. Co-IP experiments qualitatively confirmed that 
none of the hit compounds eliminate ligand-receptor interactions (Figure 4.4A). To 
quantitatively confirm the non-competitive nature of the compounds, we performed SPR 
measurements in the presence of both the ligand and the compounds. Both LTα (50 nM) 
and the compounds (DS42 and zafirlukast at 200 μM) were passed through the TNFR1 
ECD immobilized surface for SPR measurements with individual treatment of ligand-only 
or compound-only as controls. For both DS42 and zafirlukast, the response from co-
treatment of ligand and compounds was equal to the sum of the individual response 
from ligand-only or compound-only binding, indicating simultaneous binding of the ligand 
and the small-molecule inhibitors to the receptor (Figure 4.4B). We then investigated the 
dose-dependence of ligand binding to TNFR1 in the presence of the compounds to 
determine if either had any effect on ligand binding affinity (Kd). We found that in the 
absence of compounds, the Kd of LTα is 37 nM (Figure 4.4C and fig. S4.5A), as 
expected (230). In the presence of saturating concentrations of the compounds, DS42 
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(200 μM) or zafirlukast (200 μM), LTα binding affinity was essentially unchanged (within 
error of the measurements) (Figure 4.4, D to F and fig. S4.5, B and C).  
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Figure 4. 4. Small-molecule inhibitors do not block ligand-receptor interactions.  
(A) Co-immunoprecipitation between TNFR1 and ligand LTα with treatment of hit compounds at 
saturation dose of 200 M. Equal amount of LTα is shown as pull-down controls. Western blots 
are representative of three independent experiments. (B) Non-competitive binding assay of LTα 
(50 nM) and compounds (DS42 or zafirlukast at 200 μM) to TNFR1 ECD was performed by SPR. 
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Data are means ± SD of three independent experiments. (C) Dose-dependent binding of LTα to 
TNFR1 ECD with increasing concentration of ligand. Data are means ± SD of three independent 
experiments. (D and E) Dose-dependent binding of LTα in the presence of compounds, DS42 (D) 
or zafirlukast (E), at saturated compound concentration of 200 μM. Data are means ± SD of three 
independent experiments. (F) Comparison of the binding affinity of LTα to TNFR1 in the absence 
and presence of compounds (DS42 or zafirlukast). Data are means ± SD of three independent 
experiments and n.s. indicates not significant by two-tailed unpaired t test. 
4.4.5. Small-molecule inhibitors also do not change dimerization of the TNFR1 
PLAD or ECD 
Having shown that the new compounds do not act by disrupting ligand binding, 
we next investigated whether, like zafirlukast, they act by disrupting the dimerization of 
TNFR1 extracellular domains through the PLAD. We illustrate that purified soluble 
TNFR1 PLAD exists as dimers under native conditions which can be disrupted to form a 
monomer band by small molecules that disrupt receptor-receptor interaction such as 
zafirlukast (190). Following this biochemical approach (190), we first tested each of the 
compounds’ ability to disrupt soluble PLAD dimers under native conditions. The results 
show that none of the new hit compounds, except zafirlukast, disrupted the PLAD dimer 
(Figure 4.5A). We used antibody staining to show that the higher molecular weight 
bands in the native gel of soluble PLAD are aggregates of PLAD protein, and that these 
were not altered by the compounds (fig. S3.6A). To test if the compounds could be 
binding elsewhere on the ECD of the receptor and causing PLAD dissociation by 
inducing long-range allosteric coupling, we tested their ability to disrupt dimers of 
purified, full-length TNFR1 ECD proteins under native conditions. The results again 
showed that none of the compounds other than zafirlukast disrupted the TNFR1 ECD 
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dimer (Figure 4.5B). In addition, we confirmed that none of the hit compounds had any 
effect on ligand-ligand interactions (fig. S4.6B).  
Collectively, these findings clearly distinguish the new compounds discovered 
here from zafirlukast and from previous small molecules targeting TNFR1 by blocking 
the ligand binding (36-38). It is important to pause in clarifying the nature of zafirlukast 
as a competitive inhibitor, as it is not competitive in the most traditional sense of 
preventing ligand binding. Instead, zafirlukast competes with monomer-monomer 
binding, without disrupting ligand binding, and diminishes function by reducing 
dimerization (Figure 4.5C). We have here shown that the new compounds, on the other 
hand, act non-competitively, blocking neither ligand binding or TNFR1 monomer-
monomer interactions. Instead, the TNFR1 specific compounds are exerting their 
inhibitory effect by altering the conformational state of the pre-assembled dimer (as 
observed from the FRET changes), and somehow do so in a way that does not prevent 
ligand binding or dimerization (Figure 4.5D). From the perspective of understanding the 
mechanism of TNFR1 activation, this demonstrates that TNFR1 can be inactive, even if 




















Figure 4. 5. Small-molecule inhibitors do not disrupt receptor-receptor interactions.  
(A) Native gel characterization of soluble pre-ligand assembly domain (PLAD) of TNFR1 with 
treatment of DMSO control, zafirlukast and hit compounds (200 μM). Gels are representative of 
three independent experiments. (B) Native gel characterization of soluble extracellular domain 
(ECD) of TNFR1 with treatment of DMSO control, zafirlukast and hit compounds (200 μM). Gels 
are representative of three independent experiments. (C) Schematics illustrating the mechanism 
of competitive inhibition by zafirlukast in disrupting receptor-receptor interactions. (D) Schematics 
illustrating the mechanism of non-competitive inhibition by the new hit compounds in stabilizing 
the non-functional conformational states of TNFR1 without disrupting receptor-receptor 
interactions. 
4.4.6. New non-competitive inhibitors are more efficient than zafirlukast, a 
competitive inhibitor 
We next compared the efficiency of inhibition of DS42, a non-competitive 
inhibitor, and zafirlukast, a competitive inhibitor. In theory, given equal affinity for its 
binding site on the receptor, a non-competitive compound should be more efficient than 
a competitive one. Indeed, using inhibition of NF-B activation as a metric for this, we 
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observed that DS42 achieves a far better percent inhibition (93%) as compared to 
zafirlukast (55%) (Figure 4.6A). By comparing the binding and inhibitory profiles of 
DS42 and zafirlukast, we found that both compounds have very similar binding affinity 
(Kd) and absolute IC50 (Figure 4.6B). This indicates that the increase in inhibition by 
DS42 is due to more efficient allosteric inhibition unencumbered by competition and not 
due to increased binding. The inability to obtain maximum inhibition by zafirlukast could 
be attributed to its competition with native receptor monomers, which are in dynamic 
equilibrium with the dimeric form, making it difficult for zafirlukast to achieve maximum 
inhibition with the low binding affinity.  
A B
Zafirlukast DS42
Kd (μM) 86.3±5.5 81.2±7.0 (n.s.)
Abs IC50 (μM) 48.0±5.2 49.8±3.8 (n.s.)
% inhibition 55.1±2.4 92.6±2.5 (****)
      (HEK293 cells)
DS42 (Abs IC50 = 49.8 M)
Zafirlukast (Abs IC50 = 48.0 M)
        












































Figure 4. 6. Non-competitive inhibitors are more efficient than competitive inhibitor.  
(A) NF-κB activation in HEK293 cells treated with LT and increasing concentration of 
compounds (DS42 and zafirlukast) to compare the inhibition efficiency between non-competitive 
and competitive inhibitors. Data are means ± SD of three independent experiments. (B) 
Comparison of the binding affinity, the absolute IC50 and the percent inhibition of NF-κB activation 
between DS42 and zafirlukast. Data are means ± SD of three independent experiments. ****P < 
0.0001 for DS42 versus zafirlukast by two-tailed unpaired t test and n.s. indicates not significant. 
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4.4.7. Long-range perturbation of TNFR1 conformational dynamics by non-
competitive inhibitors is mediated by residues in the ligand binding loop 
Next, we asked whether we could use the small molecules to elucidate any 
details regarding the changes in conformational states in the pre-assembled dimer. We 
show that the constitutively active, dimeric R92Q mutant adopts an altered, active 
conformation compared to wild-type (62). We also use computational normal mode 
analysis of the available TNFR1 crystal structures and predict the implicit capacity of the 
receptor (in both the pre-ligand and ligand-bound states) to undergo an anti-correlated 
motion that couples conformational changes across the ECD (62). In particular, even in 
the absence of ligand we highlight conformational coupling between residues in the 
ligand binding loop (residues: 77-81 and 107−113) and the membrane proximal domain. 
We then predict a hinge that connects the domains and hence serves a critical role in 
propagating activating conformational changes. Here, by further examining the residues 
in the ligand binding loop in the crystal structure of the pre-ligand dimer (PDB: 1NCF), 
we found that the key ligand binding residues W107, S108 and M80 form four hydrogen 
pairs, W107-Q113, W107-L111, S108-L111 and M80-C114 in this hinge region (Figure 
4.7, A and B). This led us to ask whether these critical residues and this same coupling 
might also be important in propagating the long-range conformational changes induced 
by our new small molecules, despite the fact that the inhibited conformation state is by 
definition distinct from the active state.  
To test this hypothesis experimentally, we made single and double mutants of 
these three critical residues (W107A, S108A, WS107/108AA and M80A) in the FRET 
biosensor as well as a control mutant (V90A) located far from the ligand binding loop. To 
be clear, while these residues are essential in ligand binding (62, 231, 232), here we are 
interrogating the conformations in the absence of ligand to further elucidate the details of 
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our FRET results and understand the mechanism of inhibition by the small molecules. If 
these residues form a critical region in the conformational network within the ECD, then 
by breaking these hydrogen bonds we hypothesized that we would de-couple the 
domains and reduce the ability of the small molecules to cause the inhibitory 
conformational change. To start, the mutations did not have an effect on the basal FRET 
observed from pre-ligand receptor dimers (fig. S3.7A). While the compounds did still 
reduce FRET in the mutants (fig S3.7B), the magnitude of the effect was significantly 
diminished with each of the compounds (except DS50), thus supporting the hypothesis 
of a loss in conformational coupling between the loop and the remainder of the ECD 
(Figure 4.7C). We note that the biggest effect of the mutations was on DS41 which is, 
quite interestingly, a compound that showed one of the largest FRET changes in the 
wild-type receptor (Figure 4.1E). As a negative control, the extent of FRET change 
induced by all compounds in the control mutant (V90A) is similar to that of the WT FRET 
biosensor (Figure 4.7C).   
We also asked whether we could use zafirlukast to probe, at low resolution, the 
potential binding regions for the small molecules. In particular, as the hit compounds 
bind TNFR1 ECD with higher affinity than zafirlukast (Figure 4.3A) but do not disrupt the 
PLAD-PLAD interaction (Figure 4.5A), we hypothesized that compounds that compete 
with zafirlukast and prevent its disruption of PLAD-PLAD interaction might be binding in 
the PLAD. Co-treatment of soluble dimeric PLAD with the hit compounds and zafirlukast 
revealed that some compounds, in particular DS41, DS42 and DS43, were competitive 
to zafirlukast in binding to PLAD and prevented disruption of PLAD dimerization (Figure 
4.7D and fig. S4.8, A and B). Compounds that have little or no effect in competing with 
zafirlukast may be binding to the part of CRD2 that is not responsible for ligand binding 
which is close to the PLAD or CRD4 nearer to the region of perturbation. In addition, we 
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quantitatively showed that co-treatment of DS42 and zafirlukast reduced the binding 
affinity of DS42 (Kd from 73 M to 112 M) to TNFR1 ECD (fig. S4.8C) and decreased 
its potency in inhibiting TNFR1-induced NF-B activation (IC50 from 52 M to 142 M) 
(fig. S4.8D) as compared to DS42-only treatment. However, whether these compounds 
are directly competing with zafirlukast or allosterically changing the conformation of 
receptor such that it cannot bind zafirlukast remains to be investigated. It is also 
important to note that there are both the dimer binding interface and non-binding 
interface in the PLAD and our results do not distinguish between these two surfaces; 
however, this result can suggest that some compounds interact directly with the PLAD.  
To further probe the specific mechanisms of DS42 and zafirlukast, we tested the 
effects of these small molecules in the presence of H398 human TNFR1-specific 
antibody. The binding epitope of the H398 antibody has been shown to be in regions of 
the CRD1 and CRD2 of TNFR1, and inhibits receptor function by blocking ligand binding 
(35). We hypothesized that DS42 and zafirlukast, which did not ablate ligand binding, 
would not be competitive to H398 binding and function. SPR binding indicated that 
indeed DS42 and zafirlukast (200 M) do not compete with H398 (at its Kd of 1.0 nM 
(35)) for binding TNFR1 (fig. 4.S9A). Furthermore, H398 antibody inhibited TNFR1-
induced NF-B activation with an IC50 of 1.2 nM (fig. S4.9B), similar to a previous report 
(35). Consistent with our hypothesis, the IC50 values for DS42 and zafirlukast inhibition 
of NF-B are unchanged by the presence of H398, illustrating that neither compound 
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Figure 4. 7. Long-range perturbation of TNFR1 conformational dynamics by non-
competitive inhibitors is mediated by residues in the ligand binding loop.  
(A) Crystal structure of TNFR1 ECD indicates the distance between the membrane distal domain, 
including PLAD, and the membrane proximal domain is estimated to be 73.6 Å, which suggests a 
potential long-range signal propagation between non-competitive inhibitors binding at the PLAD 
or the ECD and the perturbation of the membrane proximal domain as shown by FRET change. 
Four different cysteine rich domains (CRD 1 to 4) are colored in blue, gray, red and orange 
respectively. (B) Surface representation showing the coupling motions between residues in the 
ligand binding loop and the membrane proximal domain. The key ligand binding residues, W107, 
S108 and M80 form four hydrogen bonds with L111, Q113 and C114 which stabilize the 
conformation of the region to behave like a hinge in aiding the opening of the receptor. Abolishing 
the hydrogen bonds may de-couple the domains and prevent conformational change acting 
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through the hinge. (C) Comparison of the amount of FRET decreased between HEK293 cells 
expressing WT and mutant TNFR1 FRET biosensors (W107A, S108A, WS107/108AA, M80A and 
V90A) treated with non-competitive inhibitors (200 µM) in the absence of ligand. Data are means 
± SD of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 for WT versus mutant 
biosensors by two-tailed unpaired t test and n.s. indicates not significant. (D) Native gel 
characterization of soluble PLAD with co-treatment of DMSO control or hit compounds (1000 µM) 
and zafirlukast (200 µM) to test the competition between the hit compounds and zafirlukast in 
interacting with PLAD. Gels are representative of three independent experiments.  
4.4.8. Preliminary SAR of a representative hit compound 
The best compounds identified from screening the 50,000 compound DIVERSet 
library have absolute IC50 values (inhibition of NF-B activation) around 50M, similar to 
the value we obtain for zafirlukast (50 M) (190). In order to test whether we could 
improve on this, we performed a preliminary structure-activity relationship (SAR) 
analysis of the hit compounds to optimize the small molecules for improved potency and 
specificity. We chose DS41 as our main focus for SAR analysis for several reasons. 
First, DS41 showed the biggest effect in the mutant study (Figure 4.7C), suggesting that 
chemical aspects of this compound, if harnessed, may be most efficient in targeting the 
novel allosteric mechanism of action described in this study. Second, however, DS41 
has non-specific effects as shown in two assays (Figure 4.3E and fig. S4.4D). Thus, we 
wanted to know if we could optimize the compound by both eliminating this non-
specificity and by increasing binding affinity, thereby improving the potency such that the 
compound is specific at its effective concentration (IC50). We obtained 19 analogues 
from ChemBridge (table S4.1) to probe the SAR. One analogue, DSA114, showed a 
strong increase in binding affinity to the TNFR1 ECD (Figure 4.8A and fig. S4.10A), 
strong inhibition of IBα degradation (fig. S4.10, B and C), and a 3-fold increase in the 
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potency of inhibiting NF-B activation as compared to the lead compound, DS41 (Figure 
4.8B and fig. S4.10D). Most importantly, DSA114 is substantially more specific than 
DS41 (Figure 4.8C) especially at its IC50 (fig. S4.10, D and E), and maintained its core 
mechanistic features (does not block ligand-receptor interactions (Figure 4.8D and fig. 
S4.10, F to H), does not disrupt PLAD-PLAD interactions (Figure 4.8E), and prevents 
zafirlukast from disrupting the PLAD-PLAD interactions (fig. S4.10I)). Additionally, 
DSA114 decreased FRET in the WT TNFR1 biosensor more significantly than DS41 at 
the same compound concentration (Figure 4.8F). 
In terms of the chemical structure, DS41 contains a 4-piperidinyl-1H-pyrazol-5-yl 
core with 2-methyl-3-phenyl-2-propen-1-yl (R1) attached to the nitrogen of the piperidine 
and cyclopentanecarboxamide (R2) to the pyrazole (table S4.1, Cpd 1). Our preliminary 
SAR analysis of DS41 has illustrated that both its R1 and R2 groups play important roles 
in determining compound binding affinity and potency. In particular, the R1 group is 
preferred in order to maintain potent activity (IC50 and percent inhibition) inhibition as 
deviation from the current 2-methyl-3-phenyl-2-propen-1-yl group resulted in a 
substantial decreased percent inhibition (table S4.1, Cpd 2 to 14). However, modification 
of R1 did modulate the potency in terms of IC50 and hydrophobic groups were better 
tolerated than substituents containing polar moieties. Interestingly, simplification of the 2-
methyl-3-phenyl-2-propen-1-yl substituent by reduction of the olefin and removal of the 
phenyl ring substantially enhanced potency at the expense of percent inhibition (table 
S4.1, Cpd 8). Our data suggest that the 2-methyl and 3-phenyl groups on the 2-propene 
of the R1 of DS41 may be important for increasing the percent inhibition and a flexible 
carbon chain (changing propene to propane) may favor binding and increase potency 
(table S4.1, Cpd 2 vs 5). On the other hand, the R2 group was much more tolerant to 
modification and five of the six derivatives containing benzyl, substituted phenyl and 3-
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phenylpropyl groups maintained or exceeded the percent inhibition of the initial hit while 
varying in potency from 26 to 115 µM (table S4.1, Cpd 15 to 20). One cannot extrapolate 
too much from this limited series, but it is clear this position offers more opportunity to 
modulate potency and drug disposition properties while maintaining high percent 
inhibition. A comparison between the structures of DS41 and DSA114, and other hit 
compounds such as DS42 indicates moderate structural similarity as all contain a 
substituted piperidine core (fig. S4.1B). This preliminary SAR, together with the 
comparison with other hit compounds, suggests that some of these structurally similar 
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Figure 4. 8. Lead compounds are optimizable for binding affinity, potency and specificity. 
(A) SPR characterization of binding affinity of hit compound (DS41) or its analogue (DSA114) to 
TNFR1 ECD. Data are means ± SD of three independent experiments. (B and C) NF-κB 
activation in WT HAP1 cells (B) and TNFR1 KO HAP1 cells (C) treated with LT and increasing 
concentration of hit compound (DS41) or its analogue (DSA114) to test the improvements in the 
potency and specificity of the analogue. Data are means ± SD of three independent experiments. 
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(D) Non-competitive binding test of LTα (50 nM) and DSA114 (200 μM) to TNFR1 ECD was 
performed by SPR. Data are means ± SD of three independent experiments. (E) Native gel 
characterization of soluble PLAD with treatment of DMSO control, zafirlukast, DS41 or DS114 
(200 μM) to test the disruption of PLAD dimerization by the compounds. Gels are representative 
of three independent experiments. (F) FRET measurements using HEK293 cells expressing WT 
TNFR1 FRET biosensor treated with DMSO control, DS41 (50 μM) and DSA114 (50 μM) in the 
absence of ligand to compare the extent of receptor perturbation by the hit compound and its 
analogue. Data are means ± SD of three independent experiments. *P < 0.05 and ****P < 0.0001 
versus control by two-tailed unpaired t test. 
4.5. Discussion 
There are currently five FDA-approved biologic agents including monoclonal 
antibodies (infliximab, adalimumab, certolizumab pegol, golimumab) and soluble TNF 
receptor (etanercept) that target TNFα for treatment of TNFR1-related inflammatory 
diseases (21, 233-235). Despite high potency, these therapeutics result in global TNFα 
blockade, which has several negative consequences: low rates of disease remission; the 
development of fatal side effects such as lupus-like symptoms and lymphomas; and the 
generation of antibodies against biologic TNFα inhibitors (235, 236). In addition, 
compared to small molecules, antibodies are expensive and often fail to cross the blood-
brain barrier, and can also lead to injection site reactions or infusion reactions (21, 237, 
238).  
To overcome these limitations, the therapeutic paradigm in this field has shifted 
from targeting TNFα to developing inhibitors that directly target TNFR1. Largely TNFR1 
receptor-specific inhibitors are antibodies (33, 35, 176, 239) or small molecules that 
competitively block ligand-receptor interactions (36, 37). One notes that the ligand 
binding affinity of TNFα to TNFR1 is very high (Kd=0.38 nM) (38), and so small 
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molecules that work by competitively eliminating ligand binding have a very steep hill to 
climb. Additionally, it has been suggested that TNFR1 antagonists that block ligand 
binding reduce the TNFα neutralizing capacity of soluble TNFR1 as the circulating forms 
of the receptor may function as decoys for the ligand and their concentrations may 
reflect long-term exposure to this proinflammatory cytokine (39-41). At low 
concentrations, soluble TNFR1 enhances the actions of TNFα, but at higher 
concentrations the effects of TNFα are abrogated (42). Furthermore, cell-autonomous 
interaction between TNFα and TNFR1 is critical for cell survival, maintenance and 
function as well as neuroprotective (43, 44).  
As such, approaches that do not involve eliminating ligand binding are highly 
attractive, though have proved elusive. One approach has been to block the pre-
assembly of TNFR1 dimers by targeting the pre-ligand assembly domain (PLAD). 
Competitively eliminating the PLAD-PLAD interaction is an attractive alternative to 
blocking ligand binding because the monomer-monomer interaction (low micromolar) is 
weaker than the ligand-receptor affinity (55, 56). In a seminal study, it was suggested 
that soluble TNFR1 PLAD was able to disrupt TNFR1 receptor-receptor interaction and 
inhibit TNFα-induced inflammatory signaling in vitro as well as to ameliorate arthritis in a 
mouse model (52). However, in that study, the glutathione S transferase (GST)-tagged 
PLAD protein ablated ligand binding, making it unclear whether the effect of inhibition 
was, in fact, due to disruption of the receptor dimer (52). In our previous high-throughput 
screening study, we showed for the first time that a small molecule (zafirlukast) is 
capable of disrupting the dimeric PLAD-PLAD interaction without blocking ligand binding, 
inhibiting ligand-induced NF-κB activation with a potency of 50 M (absolute IC50) (190). 
To our knowledge, this was the only small-molecule inhibitor that had been 
demonstrated to inhibit TNFR1 without blocking ligand binding, before the current study. 
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However, zafirlukast has relatively low affinity and only partially inhibits activation. 
Besides the need to compete with the PLAD-PLAD interaction that has a much higher 
homotypic affinity than the zafirlukast-PLAD affinity, we speculate that the inability of 
zafirlukast to completely inhibit TNFR1 could be due to preservation of a functionally 
inefficient ligand-bound trimeric structure, despite elimination of the dimer  (223).  
Nonetheless, the relatively low affinity and inhibition efficiency of zafirlukast and 
related compounds suggested a pressing need for a non-competitive targeting strategy 
for more effective inhibition of TNF receptors. To make progress in this way has required 
that the field exploit developments in understanding the structure and dynamics of the 
receptors (62, 180-184). We are aware of one important study that utilized computational 
design to discover a small molecule (called F002) that binds to a cavity distal to the 
ligand binding loop and inhibits TNFR1 allosterically (38). Even though the binding cavity 
of the small molecule is located away from the ligand interaction site and the binding of 
the small molecule may not directly prevent ligand binding to the receptor, there was no 
evidence given to rule out the possibility of reduced or eliminated ligand-binding. 
Importantly, the functional efficacy of F002 was determined to be sixty-fold weaker than 
its binding affinity, strongly suggesting that this small molecule was competing with some 
other process, perhaps ligand-binding.  
In theory, small molecules that act at allosteric sites but cause conformational 
changes that reduce ligand binding suffer the same competitive disadvantage of 
orthosteric modulators that directly eliminate ligand binding (240). Allosteric small-
molecule inhibitors that do not influence ligand binding or require outcompeting receptor-
receptor interactions may be more efficient for the simple fact that they are 
unencumbered by competition (either ligand-receptor or receptor-receptor) (177-
179). But by what mechanism could such a small molecule operate? Here, we have 
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demonstrated one approach to receptor inhibition by small molecules acting non-
competitively on the receptor: stabilization of non-functional conformational states of the 
receptor that is independent of ligand binding or receptor dimerization. Not only are 
these molecules more efficient in inhibiting TNFR1 signaling, small modifications to the 
chemical structures allow us to easily increase the potency of the lead compounds. 
These scaffolds may be further optimized by medicinal chemistry for potential 
therapeutic developments. 
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Supplemental Figure 4. 1. Negative control compound does not cause a FRET change and 
chemical structures of novel small molecules that perturb the conformational states of the 
pre-assembled TNFR1 dimer.  
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(A) No FRET change was observed with a negative control compound. Data are means ± SD of 
three independent experiments and n.s. indicates not significant by two-tailed unpaired t test. (B) 
The chemical structures and the ChemBridge IDs of the seven previously unidentified small 
molecules, discovered from high-throughput screening of the ChemBridge DIVERSet 50,000 
compound library, that perturb the conformational states of the pre-assembled TNFR1 dimer.  
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Supplemental Figure 4. 2. The seven hit compounds and zafirlukast bind TNFR1 ECD as 
characterized by SPR measurements.  
SPR raw binding curves for (A) DS41, (B) DS42, (C) DS43, (D) DS44, (E) DS45, (F) DS50, (G) 
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Supplemental Figure 4. 3. Some hit compounds illustrate non-specificity to TNFR1 in the 
inhibition of NF-κB activation.  
(A and B) NF-κB activation in WT HAP1 cells (A) and TNFR1 KO HAP1 cells (B) treated with LTα 
and increasing concentration of hit compounds (DS43, DS44, DS45, DS50 and DS51) to test the 
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Supplemental Figure 4. 4. DS42 and zafirlukast do not inhibit TRADD-induced NF-κB 
activation in HEK293 cells but DS41 does.  
(A) NF-κB activation in HEK293 cells expressed with reporter plasmids as well as overexpression 
of control plasmids (no TRADD) or TRADD plasmids, and treated with DMSO control. Data are 
means ± SD of three independent experiments and ****P < 0.0001 versus control by two-tailed 
unpaired t test. (B to D) TRADD-induced NF-κB activation from (A) with HEK293 cells treated with 
increasing concentration of compounds (DS42 (B), zafirlukast (C) and DS41 (D)). Data are 












































































































Supplemental Figure 4. 5. Small-molecule inhibitors do not disrupt ligand-receptor 
interactions as characterized by SPR measurements. 
SPR raw binding curves for (A) LTα and DMSO, (B) LTα and DS42, and (C) LTα and zafirlukast. 
Binding curves are representative of three independent experiments. 
LTα trimer





Supplemental Figure 4. 6. Hit compounds do not disrupt both TNFR1 PLAD dimer and LTα 
trimer.  
(A) Western blot analysis of soluble TNFR1 PLAD with treatment of DMSO control, DS42 and 
zafirlukast. Western blots are representative of three independent experiments. (B) Native gel 
characterization of LTα with treatments of DMSO control and hit compounds. Gels are 




 DS41 (200 M)
 DS42 (200 M)
 DS43 (200 M)
 DS44 (200 M)
 DS45 (200 M)
 DS50 (200 M)
 DS51 (200 M)




























































































WT Q107A S108A W107A
S108A
M80A V90A WT Q107A S108A W107A
S108A
M80A V90A
Supplemental Figure 4. 7. Hit compounds reduce FRET in the TNFR1 mutant biosensors.  
(A) TNFR1 mutant FRET biosensors were created with mutations at the ligand binding loop and 
the conformationally active region of the receptor (W107A, S108A, WS107/108AA and M80A). A 
control mutant (V90A) which is located far from the ligand binding loop was also created. FRET 
was measured by the fluorescence lifetime plate-reader and the basal FRET calculated for all the 
biosensors are shown. Data are means ± SD of three independent experiments and n.s. indicates 
not significant by two-tailed unpaired t test. (B) All of the hit compounds (200 μM) reduced FRET 
significantly in the TNFR1 mutant biosensors. Data are means ± SD of three independent 
experiments and *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by two-tailed unpaired t test. 
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Supplemental Figure 4. 8. Hit compounds are competitive to zafirlukast in binding to the 
TNFR1 pre-ligand assembly domain (PLAD) and in NF-κB activation functional assay.  
(A) Native gel characterization of soluble TNFR1 PLAD with co-treatment of the hit compounds 
(200 µM) and zafirlukast (200 µM). Gels are representative of three independent experiments. (B) 
Native gel characterizations of soluble TNFR1 PLAD with co-treatment of increasing 
concentration of DS41 (0.1 to 1000 µM) and a single dose of zafirlukast (200 µM). Gels are 
representative of three independent experiments. (C) SPR competition assay between increasing 
concentration of DS42 and a single dose of zafirlukast (100 µM). Data are means ± SD of three 
independent experiments. (D) NF-κB activation in HEK293 cells treated with LTα, increasing 
concentration of DS42 and a single dose of zafirlukast (100 µM) to test the competition of DS42 
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Supplemental Figure 4. 9. Hit compounds are not competitive to H398 antibody modulation 
of TNFR1 signaling.  
(A) Non-competitive binding assay of H398 antibody (1 nM) and compounds (DS42 or zafirlukast 
at 200 μM) to TNFR1 ECD was performed by SPR. Data are means ± SD of three independent 
experiments. (B) NF-κB activation in HEK293 cells treated with LTα and increasing concentration 
of H398 antibody to test the functional inhibition effects of the antibody. Data are means ± SD of 
three independent experiments. (C and D) NF-κB activation in HEK293 cells treated with LTα and 
increasing concentration of compounds (DS42 and zafirlukast) in the absent (C) and present of 
H398 antibody (1 nM) (D) to test the competition in functional effects between the compounds 
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Supplemental Figure 4. 10. DSA114, an analogue of DS41, illustrates improved potency 
and specificity by acting through the same non-competitive inhibition mechanism.  
(A) Surface plasmon resonance (SPR) raw curves for the binding of DSA114 to TNFR1 ECD. 
Binding curves are representative of three independent experiments. (B and C) Western blot 
analysis of IκBα abundance in lysates of HEK293 cells treated with LT and the hit compound 
(DS41) and its analogue (DSA114) at 200 µM. Western blots (B) are representative of three 
independent experiments. Quantified band intensity values (C) are means ± SD from all 
experiments. ****P < 0.0001 versus control by two-tailed unpaired t test. (D) NF-κB activation in 
HEK293 cells treated with LT and increasing concentration of hit compound (DS41) or its 
analogue (DSA114) to test the improvements in the potency of the analogue. Data are means ± 
SD of three independent experiments. (E) TRADD-induced NF-κB activation in HEK293 cells 
treated with increasing concentration of DSA114. Data are means ± SD of three independent 
experiments. (F) Co-immunoprecipitation between TNFR1 and ligand LTα with treatment of 
DMSO control, hit compound (DS41) and its analogue (DSA114) at saturation dose of 200 M. 
Equal amount of LTα is shown as pull-down controls. Western blots are representative of three 
independent experiments. (G) Dose-dependent binding of LTα in the presence of DSA114 at 
saturated compound concentration of 200 μM. Data are means ± SD of three independent 
experiments. (H) SPR raw curves of the dose-dependent binding of LTα to TNFR1 ECD in the 
presence of DSA114 (200 M). Binding curves are representative of three independent 
experiments. (I) Native gel characterization of soluble TNFR1 PLAD with co-treatment of DS41 or 
DSA114 (1000 µM) and zafirlukast (200 µM). Gels are representative of three independent 
experiments.  
 
Supplemental Table 4. 1. Functional characterization of DS41 and its analogues.  
NF-κB activation in HEK293 cells treated with LT and lead compound (DS41) or its analogues in 
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5.1. Summary 
Tumor necrosis factor receptor 1 (TNFR1) is a transmembrane receptor which 
plays a key role in the regulation of the inflammatory pathway. While inhibition of TNFR1 
has been the focus of many studies for treatment of autoimmune diseases such as 
rheumatoid arthritis, intervened activation of the receptor is important for treatment of 
immunodeficiency diseases such as HIV or neurodegenerative diseases such as 
Alzheimer’s disease that required a boost in the proliferation or immune signaling. In 
addition, activation of other TNF receptors such as death receptor 5 or FAS receptor is 
important for cancer therapy. Here, we used TNFR1 as a model to investigate the 
conformational rearrangement of the pre-ligand assembled receptor dimers that 
corresponds to the active states of the receptor. Specifically, we used a previously 
established TNFR1 FRET biosensor together with a fluorescence lifetime technology as 
a high-throughput screening platform to identify a novel small molecule that activates the 
TNFR1 by altering the receptor conformational dynamics independent of ligand 
stimulation. By probing the interaction between the receptor and its downstream 
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signaling molecule, we suggest that the conformational states of TNFR1 could act as a 
molecular switch in determining receptor functions. 
5.2. Introduction 
The receptors and ligands in the tumor necrosis factor (TNF) superfamily have 
unique structural attributes that couple them directly to signaling pathways that are 
responsible for a wide-range of cellular activities such as cell proliferation, differentiation 
or death (4, 241). Within this superfamily, tumor necrosis factor receptor 1 (TNFR1) is a 
characteristic member and a central mediator in the signal transduction of the 
inflammatory pathway (5). Stimulation by the native ligands of TNFR1, tumor necrosis 
factor-alpha (TNFα) and lymphotoxin-alpha (LTα), leads to the recruitment of TNFR1 
associated death domain (TRADD) followed by IBα degradation and NF-B activation 
(11). While over-activation of TNFR1 results in excessive NF-B activation which has 
been associated with several autoimmune diseases such as rheumatoid arthritis (5, 11, 
173), lack of NF-B activation has been implicated in diseases related to immune 
deficiency and cell death such as HIV, neurodegeneration and tissue degeneration (242-
245). Hence, there is a need for increased activation of TNFR1 beyond its native 
activation to promote NF-κB activation for treatment of these diseases (246-251). In 
addition, activation of other TNF receptors such as death receptor 5 or FAS receptor is 
important for cancer therapy (252-255). 
Current methods of TNFR1 activation include ligand mimics such as 
staphylococcus aureus protein A which has been shown to act as a ligand and mimic 
TNFα in order to activate TNFR1 (256). Burkholderia cenocepacia BC7 also has been 
shown to bind to and activate TNFR1 (257). Another way to increase the activation of 
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TNFR1 is by increasing the expression of TNFR1 in cells (258), though the presence of 
native ligand is still required for the receptor activation. The limitation for proteins that 
mimic the ligand is that they compete with native ligand binding, diminishing the potential 
elevated effects in activating TNFR1. Hence, the most effective way in activating of 
TNFR1 would be a receptor-specific approach that activates the receptor regardless of 
ligand stimulation or amplifies the effect of ligand stimulation by making use of the 
receptor structures and conformations. 
Recent evidences have provided a revision to the accepted model of TNFR 
activation that the pre-assembled dimer remains intact upon ligand binding, potentially 
forming the nexus for larger scale networks of ligand-bound TNFR trimers (181, 221-
223). This reconciles the controversy between the two crystal structures of TNFR1 
trimerization induced by ligand binding without direct receptor-receptor interactions (57) 
and that TNFR1 forms pre-ligand assembled dimers held together by the pre-ligand 
assembly domain (PLAD) (55, 58, 59). Several works have been done on directly 
targeting the receptor dimer to alter its function based on this revised model. In our 
previous work, we have shown that disruption of receptor-receptor interactions by 
zafirlukast, a small molecule, without ablating ligand binding inhibits TNFR1 signaling, 
supporting the oligomeric network model (190). In addition, we have also shown that 
small molecule allosteric inhibitors (e.g. DS42) exert their inhibitory effect by altering the 
conformational state of the pre-assembled dimer without blocking ligand binding or 
dimerization, demonstrating that TNFR1 can be inactive, even if ligand is bound and the 
receptor dimer is intact (191). This suggests that the possibility to further activate the 
receptor from its native signaling complex potentially through perturbation of receptor 
conformational dynamics. This possibility is supported by a study showing that ligand 
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binding causes a conformational change in the pre-assembled TNFR1 complex as 
measured by fluorescence resonance energy transfer (FRET) but the exact activation 
mechanism was not delineated (61, 224). In addition, we used FRET to show that a 
disease-related mutant (R92Q), which is constitutively active, also forms a pre-ligand 
assembled dimer (62). Importantly, the FRET measurements show that this active R92Q 
dimer is conformationally distinct from wild-type, suggesting the correlation between the 
TNFR1 conformational states and receptor activity. Furthermore, our recent 
computational and experimental results suggest that long-range perturbation of TNFR1 
conformational dynamics mediated by the ligand binding loop with signal propagation 
through the backbone of the ECD is feasible approach to control receptor function (62, 
191).   
To investigate whether multiple conformational states corresponding to receptor 
activation or inhibition exist in TNFR1, we used the previously established TNFR1 FRET 
biosensor to perform high-throughput screening (HTS) on the library of 
pharmacologically active compounds (LOPAC) to discover small molecules that perturb 
the pre-ligand assembled TNFR1 dimer. We considered compounds that altered FRET 
in the biosensor in search for activators. We discovered a small molecule, SB-200646 
hydrochloride (SBH), which binds TNFR1, reduces FRET of the biosensor and 
importantly, increases NF-κB activation by the same fold change both in the presence 
and absence of the ligand. In addition, the activating effect of SBH was diminished in the 
TNFR1 knockout cells, indicating its specificity to TNFR1. Furthermore, we showed that 
this small molecule is exerting the activating signal propagation through the 
conformationally active region of the ligand binding loop of the receptor. Probing the 
interaction between the receptor and its downstream signaling molecule, we suggest 
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that the ensemble of TNFR1 conformational states can be stabilized by small molecules 
for its activation, hence acting like a molecular switch. 
5.3. Materials and methods 
5.3.1. Molecular biology 
In our previous work we generated the DNAs (TNFR1ΔCD-GFP and 
TNFR1ΔCD-RFP) used in the engineering of the TNFR1 FRET biosensor (190). Briefly, 
standard cloning techniques were used to fuse cDNAs encoding truncated TNFR1ΔCD 
(amino acids 1-242) with the N-terminus of the EGFP and TagRFP vectors. Quikchange 
mutagenesis (Agilent Technologies) was used to introduce the mutations of the key 
ligand binding residues (Q107A, S108A, QS107/108AA and M80A) and the control 
mutant (V90A) in the TNFR1ΔCD-GFP and TNFR1ΔCD-RFP plasmids. This was then 
sequenced for confirmation. All vectors contain the monomeric mutation A206K to the 
fluorescent proteins in order to prevent constitutive fluorophore clustering, (204).  
5.3.2. Cell culture and generation of stable cell lines 
Human embryonic kidney cells 293 (HEK293, ATCC) were cultured in phenol 
red-free Dulbecco's Modified Eagle Medium (DMEM, Gibco). These were supplemented 
with 2 mM L-Glutamine (Invitrogen), heat-inactivated 10% fetal bovine serum (FBS HI, 
Gibco), 100 U/ml penicillin and 100 g/ml streptomycin (Gibco). HAP1 wild-type and 
TNFR1 knockout cells (Horizon) were cultured in Iscove's Modified Dulbecco's Medium 
(IMDM, Gibco). These were supplemented with 10% FBS (Gibco), 100 U/ml penicillin 
and 100 g/ml streptomycin (Gibco). An incubator with 5% CO2 (Forma Series II Water 
Jacket CO2 Incubator, Thermo Scientific) at 37 ºC was used to maintain the cell cultures. 
CRISPR/Cas technology was used to generate the HAP1 TNFR1 knockout cell line 
containing a 70 base pair (bp) insertion in a coding exon of TNFRSF1A. To confirm the 
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knockout in the cells, Sanger sequencing was performed as a quality control. Our 
previous work describes how the TNFR1ΔCD-FRET pair stable cell line was generated 
(190). It also describes how they have been monitored continuously for over four years 
while maintaining expression above 95% characterized by flow cytometry (190). The 
TNFR1ΔCD-FRET pair shows high expression in the stable cell line which indicates that 
they are functional and applicable in high-throughput screening. HEK293 cells were 
transiently transfected using Lipofectamine 3000 (Invitrogen) with TNFR1ΔCD-GFP and 
TNFR1ΔCD-RFP DNAs containing the respective mutations (Q107A, S108A, 
QS107/108AA, M80A and V90A) in order to generate the mutant forms of the TNFR1 
FRET biosensor. 
5.3.3. High-throughput screening with LOPAC library 
The LOPAC library containing 1280 compounds was purchased from 
ChemBridge Corp. and a FX liquid dispenser was used to format the compounds into 
96-well mother plates. An Echo liquid dispenser was used to subsequently format across 
4 plates of the 384-well plate at 50 nl (10 µM final concentration per well). Dimethyl 
sulfoxide (DMSO) was loaded in columns 1, 2, 23 and 24 (negative controls) as well as 
matching %v/v as in-plate no-compound controls. The assay plates chosen were the 
384-well flat, black-bottom polypropylene plates (PN 781209, Greiner Bio-One) because 
of their low auto-fluorescence and low inter-well cross-talk. Until the plates were used, 
they were sealed and stored at −20 °C. Over three different days the triplicate screens 
were performed with a library screened each day. A fresh vial of TNFR1ΔCD-GFP/RFP 
(TNFR1ΔCD-FRET pair) cells were thawed, plated in a 225 cm2 flask (Corning) and 
checked for expression a week prior to screening. The cells were then expanded into six 
225 cm2 flasks for three days. The stable cells expressing the TNFR1 FRET biosensor 
were harvested to check for expression and response variation in fluorescent intensity 
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prior to each day of screening. The stable cells were then dispensed into the drug plates 
(50,000 cells/well) and incubated with the compounds or DMSO as a negative control. 
Fluorescence lifetime measurements were then performed on the plates. A prototype 
fluorescence lifetime plate-reader (Fluorescence Innovations, Inc.) was used to record 
the fluorescence waveforms as described (190).  
5.3.4. HTS data analysis 
Using least-squares minimization global analysis software (Fluorescence 
Innovations, Inc.), time-resolved fluorescence waveforms obtained from each well were 
fitted to single-exponential decays. This was done to obtain donor-acceptor lifetime (τDA) 
from the TNFR1ΔCD-GFP/RFP (FRET pair) cell line and donor lifetime (τD) from a 
TNFR1ΔCD-GFP donor-only control cell line. Equation 1 was used to calculate FRET 
efficiency (E). 
𝐸 = 1 − (
𝜏𝐷𝐴
𝜏𝐷
)              𝐸𝑞. 1 
Using SBH as a positive control and DMSO as a negative control, the Z-factor, a 
HTS assay quality indicator, was calculated based on Equation 2 (192).  
𝑍′ =  1 −
3(𝜎𝑝 + 𝜎𝑛)
|𝜇𝑝 − 𝜇𝑛|
             𝐸𝑞. 2 
Where σp and σn are the standard deviations of the observed τDA values, and µp 
and µn are the mean τDA values of the positive and negative controls, respectively. We 
utilized the normalized median absolute deviation (1.4826*MAD) and median in place of 
the standard deviation and mean, respectively (225). This was done to make this metric 
less sensitive to strong outliers (225). The Z-factor obtained was 0.55±0.02 using SBH 




Based on analysis of the spectral waveforms of each well from the LOPAC 
screen, fluorescent compounds were determined to be potential false positives due to 
interference from compound fluorescence by a set of stringent fluorescent compound 
filters (226). After the fluorescent compounds were removed, a histogram of the FRET 
distribution from all compounds in the screen was plotted. This histogram was fitted to a 
Gaussian curve to obtain a mean and standard deviation (SD). A compound that 
changed the FRET efficiency by more than four times the standard deviation (4SD) 
relative to the mean was defined as a hit.  
5.3.5. FRET dose-response assay 
The three hit compounds, SB200646 hydrochloride (SBH) (S0568), candesartan 
cilexetil (CC) (SML0245), palmitoyl-DL-carnitine chloride (PDLCC) (P4509) were 
purchased from Millipore Sigma. Each drug compound was dissolved in DMSO to make 
10 mM stock solution. Each solution was then serially diluted in 96-well mother plates to 
obtain eight doses at 50X concentrations. Hits were screened at eight different 
concentrations (0.1 to 200 μM). Using a Mosquito HV liquid handler (TTP Labtech Ltd.), 
1 μl of compounds were transferred from the mother plates into assay plates. The same 
high-throughput screening methods were used on the cell preparation of the wild-type 
TNFR1 FRET biosensor in the FRET dose-response assays. 
5.3.6. Functional assays (IB degradation assay and NF-B activation assay) 
IB degradation assay with HEK293 cells were performed with Western blots as 
described (190). Densitometry of the Western blots was performed using ImageJ. The 
data was normalized to the β-actin loading control and the amount of IκBα in the control 
cells in the absence of ligand. For the NF-B activation luciferase assay with HEK293, 
HAP1 wild-type and TNFR1 knockout cells, the cells were transfected with the NF-B-
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luciferase reporter genes (10 g of firefly luciferase genes and 1 g of Renilla luciferase 
genes) in a 100 mm plate with Lipofectamine 3000 (Invitrogen). The cells were lifted with 
TrypLE and resuspended in phenol red-free DMEM (Gibco) the next day. These cells 
were dispensed into 96-well assay plates (30000 cells/well, total volume 50 l) and 
incubated with SBH (0.1 to 200 M) or DMSO (negative control) in both the presence 
(0.1 g/ml) and absence of LT for 18 hours at 37 °C. Readings for luciferase activities 
were recorded after 24 hours. Briefly, 50 l of Dual-Glo Luciferase Reagent (Promega) 
was added, incubated at room temperature for 15 min, and firefly luminescence was 
measured using a Cytation 3 Cell Imaging Multi-Mode Reader luminometer (BioTek). 
Next, 50 l of Dual-Glo Stop & Glo Reagent (Promega) was added, incubated at room 
temperature for 15 min, and Renilla luminescence was measured using a luminometer. 
The luciferase activities were normalized based on Renilla expression levels. Luciferase 
activity of cells in the absence of ligand was used to normalize all of the data from the 
NF-B activation assays. 
5.3.7. Mechanistic assays (co-immunoprecipitation and native gel 
characterization) 
Co-immunoprecipitation between endogenous TNFR1 and ligand LT in the 
presence and absence of SBH was carried out as described previously (190). Briefly, 
lysates of HEK293 cells containing endogenous TNFR1 were prepared. Anti-FLAG 
magnetic beads were also coated with FLAG-tagged LTα. The cell lysates containing 
TNFR1 and LTα coated magnetic beads were incubated in the presence of DMSO 
(control) or SBH (activator, 200 M). After 24 hours, the proteins were eluted from the 
magnetic beads using glycine pH 2.5 and Western blots were performed using FLAG 
(2368S, Cell Signaling Technology) and TNFR1 (sc-8436, Santa Cruz Biotechnology) 
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antibodies. The overexpression and purification of the N-terminal FLAG-tagged LT and 
FLAG-tagged TNFR1 PLAD (residues 30-82) were performed as described previously. 
Under normal conditions, the soluble PLAD protein was shown to exist as dimers (190). 
The recombinant human TNFR1 extracellular domain (ECD) was purchased from 
Abcam. 4%–15% SDS-PAGE gels (Bio-Rad) were used to assess the purity of proteins 
under reducing conditions. Coomassie staining was then performed. The BCA assay 
(Thermo Fisher Scientific) were used to measure protein concentrations. To test the 
disruption of receptor-receptor, purified soluble TNFR1 PLAD (5 µg) were assessed by 
Native-PAGE gels (Bio-Rad) in the absence and presence of SBH (200 M) or 
zafirlukast (200 M) under non-reducing conditions. This was followed by Coomassie 
staining. The extent of disruption of PLAD-PLAD interactions were then observed.  
5.3.8. Surface plasmon resonance (SPR) binding assay 
A BIAcore S200 was used to perform SPR analysis to determine the binding 
affinity between TNFR1 ECD and compounds or ligand. Using amine coupling, the 
recombinant human TNFR1 ECD (Abcam) was immobilized on the CM5 sensor chip 
(Biacore, GE Healthcare). Briefly, the dextran surface was activated with a 1:1 mixture of 
0.4 M 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and 0.1 M N-
hydroxysuccinimide. TNFR1 ECD (20 μg/ml) in 10 mM sodium acetate at pH 5 was 
flowed past a working surface before preventing the remaining activated carboxymethyl 
groups with 1 M ethanolamine at pH 8.5 to reach a level of 2500 RU suitable for binding 
analysis. The reference surface was activated and only ethanolamine was able to react 




Compound SBH at eight different concentrations (0.1-200 μM) as well as DMSO-
only controls were prepared in HEPES-EP containing a total of 2% DMSO for the direct 
binding assays between the receptor and the small molecules. Ligand at 50 nM was 
prepared in HEPES-EP in the presence of saturated dose of SBH (200 μM) or DMSO 
containing a total of 2% DMSO for the competition assays between ligand and small 
molecules. The samples were injected over both the reference and ECD immobilized 
surfaces at 10 μl/min for 90 seconds. They were then dissociated in glycine-HCl with a 
pH of 2.5. Along with blanks from buffer and DMSO-only controls, all the samples were 
measured on a 96-well microplate (Biacore, GE Healthcare) at 25 °C. Reflectivity 
response data points were taken from response curves 5 seconds prior to the end of the 
injection. This was done to determine steady-state binding. All the data was double 
referenced with blanks using standard procedures with Biacore S200 Evaluation 
Software v1.0.  
5.3.9. TRADD recruitment co-immunoprecipitation assay 
HEK293 cells were cultured in 100 mm plates at 5 million cells per plate. 
Respective SBH (100 M) and ligand treatments (0.1 g/mL) were then performed and 
incubated for 24 hours. The cells were then harvested and lysed. Anti-FLAG magnetic 
beads were pre-coated with FLAG-tagged LTα for 24 hours. After 24 hours, the LTα 
bound beads were washed with PBS for three times and further incubated with the 
supernatant of the cell lysates for another 24 hours for pulled down of TNFR1 and 
TRADD (which was recruited to the receptor). After incubation, the beads were washed 
with PBS for three times and the bound proteins were eluted using 30 L of glycine pH 
2.5. The protein samples were then mixed with the 4X loading dye with -
mercaptoethanol reducing agent and Western blots were performed using FLAG 
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(2368S, Cell Signaling Technology), TNFR1 (sc-8426, Santa Cruz Biotechnology) and 
TRADD (3684S, Cell Signaling Technology) antibodies. The Western blots were then 
stained with respective secondary antibodies and images were acquired using the 
ChemiDocTM MP Imaging System (BIO-RAD). Images were quantified by ImageJ for 
densitometry analysis. 
5.3.10. Statistical analysis 
Data are shown as mean ± standard deviation unless stated otherwise. To 
determine the statistical significance for all experiments, data analysis was carried out by 
a two-tailed unpaired t test (Student’s t test) with P values determined using GraphPad 
Software. Values of P < 0.05 were classified as statistically significant. P values were 
denoted in figures using asterisks following the GraphPad style (*P < 0.05, **P < 0.01, 
***P < 0.001 and ****P < 0.0001). 
5.4. Results 
5.4.1 Discovery of small molecules that probe conformational states of pre-ligand 
assembled TNFR1 dimer  
To identify small molecules that modulate TNFR1 conformational states, we 
performed high-throughput screening of the library of pharmaceutically active 
compounds (LOPAC) containing 1280 compounds using our previously established 
stable cell lines expressing a TNFR1 FRET biosensor (TNFR1ΔCD-FRET pair 
construct). The TNFR1 FRET biosensor was engineered by fusing a green or red 
fluorescent protein (GFP or RFP) to the C-terminus of TNFR1 with a truncated cytosolic 
domain (ΔCD) (TNFR1ΔCD-GFP as donor and TNFR1ΔCD-RFP as acceptor) and was 
expressed in living HEK293 cells (Fig. 5.1A). The FRET biosensor was validated for its 
capability to detect changes in cytosolic spacing between the pre-ligand receptor 
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monomers in response to a change in the backbone conformation of the receptor 
induced by non-competitive small molecule functional effectors (190, 191) (Fig. 5.1A). 
The coupling between fluorescent biosensor engineering and a high-throughput 
fluorescence lifetime plate-reader technology allows for increased precision and 
sensitivity as well as reliable detection of subtle changes in protein structures or 
conformational states induced by allosteric small molecule effectors (163).  
The FRET efficiency for all of the compounds, after removing the fluorescence 
interfering compounds, was plotted (Fig. 5.1B) and the distribution of efficiency was 
fitted to a Gaussian distribution to obtain a mean and standard deviation (SD) (Fig. 
5.1C). We also performed a donor-only screen as a control to further remove 
compounds that affect the fluorophores rather than the receptor. We found three 
compounds that showed up as hits in both donor-only screen and FRET screen which 
were removed as false positives (Supplementary Fig. S5.1A-B, highlighted in 
pentagon). We then selected three reproducible hits that decreased the average FRET 
by more than 4SD greater than the mean of control cells for further investigation (Fig. 
5.1B, highlighted in red). To confirm their specific interactions with the biosensor as well 
as to measure the potency and the extent of receptor perturbation by the hit compounds, 
they were tested for dose-dependent FRET change. All three hit compounds, SB200646 
hydrochloride (SBH), candesartan cilexetil (CC) and palmitoyl-DL-carnitine chloride 
(PDLCC), had a dose-dependent change in FRET efficiency (Fig. 5.1D) with half-























 Mean = 0.120



















 SBH (EC50 = 6.63 M)
 CC (EC50 = 17.8 M)
 PDLCC (EC50 = 19.9 M)












Figure 5. 1. Small molecules probe conformational states of pre-ligand assembled TNFR1 
dimer. 
(A) Schematic of the TNFR1ΔCD-FRET biosensor engineered by fusing the green or red 
fluorescent proteins (GFP or RFP) to the C-terminus of TNFR1 with truncated cytosolic domain. 
Ligand-independent association of the fluorophore-tagged receptors through PLAD-PLAD 
interactions results in fluorescence resonance energy transfer (FRET). The FRET biosensor is 
capable of detecting changes in the cytosolic spacing between receptor monomers. Small 
molecules targeting the receptor will induce a FRET change in the biosensor. (B) High-throughput 
screening of library of pharmaceutically active compounds (LOPAC) using the TNFR1 FRET 
biosensor expressed in HEK293 cells. Potential false positives were removed from the screening 
plot. Three reproducible hits that decreased FRET below the 4SD applied threshold (black line) 
were selected for further characterization. Data are representative of three independent 
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experiments. (C) Histogram plot of all compounds from the LOPAC screen after removal of false 
positives to obtain the average FRET efficiency and the standard deviation (SD) of the screen. 
(D) Secondary FRET analysis of the dose response of the three hit compounds. Data are means 
± SD from three independent experiments. 
 
5.4.2. Small molecule activator (SBH) stimulates TNFR1-induced NF-κB signaling 
pathway 
The functional effect of hit compounds was first determined by ligand-induced 
IB degradation using by immunoblotting (Fig. 5.2A). The amount of IB was 
degraded to 6-fold of the basal levels in HEK293 cells upon LT treatment (Fig. 5.2B). 
From all the hit compounds, we found that CC and PDLCC inhibit IB degradation 
(data not shown), which is not the focus of this study. On the other hand, SBH showed a 
further degradation of IB with an EC50 of 38 μM, indicating enhanced receptor 
activation (Fig. 5.2C). We then chose SBH for further investigation. We tested SBH in 
ligand-induced NF-B activation (Fig. 5.2D). SBH further stimulated ligand-induced NF-
B activation in a dose-dependent manner, with a relative EC50 value of 5.2 M (Fig. 
5.2E). In addition, SBH also activated NF-B activation in the absence of ligand with a 
relative EC50 values of 6.8 μM (Fig. 5.2F). We note that the effective concentrations of 
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Figure 5. 2. Effect of small molecule activator (SBH) on TNFR1-stimulated NF-κB 
activation. 
(A to C) Western blot analysis of IκBα abundance in lysates of HEK293 cells treated with LT 
and SBH at the indicated doses. Western blots (A) are representative of three independent 
experiments. Quantified band intensity values (B-C) are means ± SD from all experiments. ****P 
< 0.0001 versus control by two-tailed unpaired t test. (D and E) Luciferase assay of NF-κB 
activation in HEK293 cells transfected with reporter plasmids and treated with (D) LT and 
DMSO control or (E) LT and increasing concentrations of SBH. (F) Treatment of SBH to the NF-
κB activation luciferase assay in the absence of LTα. Data are means ± SD of three independent 
experiments. ****P < 0.0001 versus control by two-tailed unpaired t test. 
 
5.4.3. SBH binds TNFR1 and is a receptor-specific activator  
To determine if SBH directly binds and acts on TNFR1, we first performed affinity 
measurements using surface plasmon resonance (SPR). Purified TNFR1 extracellular 
domain (ECD) was immobilized onto the SPR chip and SBH was flowed through the chip 
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to allow for binding. SBH showed dose-dependent binding to the TNFR1 ECD with 
binding affinities (Kd) of 75 M (Fig. 5.3A and Supplementary Fig. S5.2). 
Next, we used both parental wild-type (WT) and TNFR1 KO HAP1 cell lines 
(established by CRISPR) to determine whether the receptor is required for the functional 
effects of the hit compounds or they may be acting through the inhibition of proteins in 
alternate signaling pathways. In our previous work, we have established that the basal 
activation of the NF-B pathway (approximately 20% relative luciferase activity) in the 
TNFR1 KO HAP1 cells allows them as a first control to ensure that the functional effects 
we observed in the HEK293 cells were due to direct interactions with TNFR1 and not 
due to the compounds indirectly acting on other proteins on alternate NF-B pathways 
(191). We have again showed that the TNFR1 KO HAP1 cells illustrate a basal 
activation of the NF-B pathway and were not functionally sensitive to ligand stimulation 
of TNFR1 (Fig. 5.3B). As expected, SBH further stimulated NF-B activation in both in 
the presence and absence of the ligand in the WT HAP1 cells to very a similar extent as 
was observed in the HEK293 cells (EC50 values are 8.7–9 M)  (Fig. 5.3C-D). On the 
other hand, SBH increased the basal level of NF-B activation in the TNFR1 KO cells 
both in the presence and absence of ligand with EC50 values of 124–138 M which is 
more than 10-fold of its EC50 values in the WT cells (Figs. 5.3E-F), making SBH a 
specific activator of TNFR1 at its effective concentration.   
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         HAP1 TNFR1 KO cells (No LT)
 SBH (EC50 = 138.1 M)
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Figure 5. 3. SBH binds TNFR1 and requires the receptor for its functional effect. 
(A) Direct binding of SBH to the TNFR1 extracellular domain (ECD) was characterized by surface 
plasmon resonance (SPR). Data are means ± SD from three independent experiments. (B) NF-
κB activation in WT and TNFR1 KO HAP1 cells with the optimized LTα concentration of 0.1 
μg/ml. Data are means ± SD of three independent experiments. ****P < 0.0001 versus control by 
two-tailed unpaired t test and n.s. indicates not significant. (C and D) NF-κB activation in HAP1 
WT cells treated with LT and increasing concentration of (C) SBH as well as (D) SBH in the 
absence of ligand. (E and F) NF-κB activation in HAP1 TNFR1 KO cells treated with LT and 
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increasing concentration of (E) SBH as well as (F) SBH in the absence of ligand to test the 
specificity of the compounds to TNFR1. Data are means ± SD of three independent experiments.  
 
5.4.4. SBH perturbs TNFR1 conformational dynamics 
After determining the specificity of SBH, we then aimed to delineate the 
mechanisms of action of SBH to test whether it is perturbing ligand-receptor interactions, 
disrupting receptor-receptor interactions, or altering conformational states of the 
receptor. We first monitored the ligand-receptor interactions in the absence and 
presence of SBH using co-immunoprecipitation (co-IP) and SPR. Co-IP experiments 
qualitatively confirmed that SBH does not eliminate ligand-receptor interactions (Fig. 
5.4A). To quantitatively confirm the non-competitive nature of SBH, we performed SPR 
measurements in the presence of both the ligand and SBH. Both LTα (50 nM) and SBH 
(200 μM) were passed through the TNFR1 ECD immobilized surface for SPR 
measurements with individual treatment of ligand-only or compound-only as controls. 
The response from co-treatment of ligand and SBH was equal to the sum of the 
individual response from ligand-only or compound-only binding, indicating simultaneous 
binding of the ligand and the small-molecule activator to the receptor (Fig. 5.4B). In 
addition, we investigated the ability of each compound to disrupt soluble PLAD dimers 
under native conditions by running native gels of soluble PLAD in the absence and 
presence of SBH. The result shows that SBH did not disrupt PLAD-PLAD interactions 
but a previously known inhibitor (zafirlukast) did (Fig. 5.4C).  
Furthermore, we tested if SBH perturbs TNFR1 receptor conformational 
dynamics. To do this, we used the previously engineered TNFR1 FRET biosensors with 
mutations at the ligand binding loop (Q107A, S108A, QS107/108AA, M80A and V90A 
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(control)) which has been shown to be the conformationally active region of the receptor. 
We have established that these residues form a critical region in the conformational 
network within the ECD important in mediating signal propagation from the membrane 
distal domain to the membrane proximal domain of the receptor and breaking the 
hydrogen bonds by mutations de-coupled the domains and reduced the ability of the 
small molecules to cause the conformational change (191). We first observed significant 
FRET reduction in the mutant FRET biosensors upon SBH treatment (Fig. 5.4D). 
Interestingly, there was a significant decrease in the magnitude of the FRET change with 
treatment of SBH in the mutant biosensors, supporting that the ligand binding loop is 
mediating signal propagation between the membrane distal and the membrane proximal 
domains (Fig. 5.4E). In addition, the extent of FRET change in V90A (a negative control) 
















































































Figure 5. 4. SBH perturbs TNFR1 conformational dynamics. 
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(A) Co-immunoprecipitation between TNFR1 and ligand LTα with treatment of SBH at saturation 
dose of 200 M. Equal amount of LTα is shown as pull-down controls. Western blots are 
representative of three independent experiments. (B) Non-competitive binding assay of LTα (50 
nM) and SBH (200 μM) to TNFR1 ECD was performed by SPR. Data are means ± SD of three 
independent experiments. (C) Native gel characterization of soluble pre-ligand assembly domain 
(PLAD) of TNFR1 with treatment of DMSO control, SBH (200 M) and zafirlukast (200 μM). Gels 
are representative of three independent experiments. (D) SBH (200 M) reduced FRET 
significantly in the TNFR1 mutant biosensors (W107A, S108A, WS107/108AA, M80A and V90A 
(control)). (E) Comparison of the amount of FRET decreased between HEK293 cells expressing 
WT and mutant TNFR1 FRET biosensors (W107A, S108A, WS107/108AA, M80A and V90A) 
treated with SBH (200 µM) in the absence of ligand. Data are means ± SD of three independent 
experiments. *P < 0.05, **P < 0.01, ***P < 0.001 and n.s. indicates not significant by two-tailed 
unpaired t test.  
 
5.4.5. Conformational states of TNFR1 as a molecular switch in receptor function 
SBH reduced FRET in the TNFR1 biosensor, corresponding to receptor adopting 
an open conformation, and stimulated NF-κB activation. On the other hand, a previously 
identified small molecule, DS42, also reduced FRET in the TNFR1 biosensor but 
inhibited receptor signaling (191).  This suggests that the two dimensional orientation of 
the receptor is insufficient in determining its function and the three dimensional 
orientation of the receptor may be important in its signaling mechanism such as the 
recruitment of the downstream signaling molecules. To test this, we performed another 
co-IP experiment to determine the interactions between TNFR1 and the downstream 
signaling molecule TNFR1 associated death domain (TRADD) with treatment of SBH. 
The co-IP results indicated that significantly more TRADD was pulled down with 
treatment of SBH both in the absence or presence of the ligand given the same amount 
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of TNFR1 in the samples (Fig. 5.5A-B). This suggests that receptor conformational 
states, either two or three dimensional orientation, could affect the recruitment of 
downstream signaling molecules and correspond to either receptor activation or 
inhibition, hence behaving like a molecular switch (Fig. 5.5C). This new hypothesis 
would also require higher resolution microscopic or biophysical techniques in studying 



































































Figure 5. 5. Conformational states of TNFR1 as a molecular switch for receptor function. 
(A) Co-immunoprecipitation (co-IP) between LTα, TNFR1 and TRADD with and without treatment 
of SBH (100 M) and in the absence and presence of the ligand (0.1 g/mL). Equal amount of 
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FLAG-tagged LTα coated on the magnetic beads with FLAG antibody is shown as pull-down 
controls. Western blots are representative of three independent experiments. (B) Quantification of 
the Western blot for co-IP in (A). (C) Proposed model of conformational states of TNFR1 as a 
molecular switch for receptor function. Receptor function can be controlled by altering receptor 
dynamics with a need to take into account the three dimensional orientation of the receptor for its 
recruitment of the downstream signaling molecules upon ligand stimulation and the determination 
of receptor activation or inhibition. 
 
5.5. Discussion 
Being a major contributor to the NF-κB activation pathway, TNFR1 activation can 
significantly lead to increased NF-κB activation for treatment of immune deficiency and 
neurodegenerative diseases (259, 260). To the best of our knowledge, SBH is not only 
the first small molecule activator of TNFR1, it also acts through a novel mechanism of 
perturbing receptor conformational states to sensitize the receptor for activation in the 
absence of ligand or increased activation in addition to ligand stimulation without 
competing for binding site with the ligand. This receptor-specific mechanism is distinctly 
different from the existing activators for other TNF receptors that either sensitize 
receptors to ligand activation or mimic ligand in which the activation efficiency is limited 
by the need to compete for ligand binding. Some of these examples include small 
molecules that sensitize FAS receptor to its agonist antibody for killing of cancer cells 
(252), small molecule mimic of Smac that potentiates TRAIL and TNFα mediated deaths 
in cancer cells (253), another small molecule (bioymifi) that can act as a single agent to 
induce DR5 clustering and aggregation, leading to apoptosis, similar to TRAIL mimics 
targeting DR5 for cancer therapy (254) and compounds that block OX40-OX40L 
interactions but acting as OX40 agonist/ligand (255). Here, we would like to clarify that 
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SBH works differently from these small molecules in that even though it activates TNFR1 
in the absence of ligand, it does not behave as ligand mimic as its effect is not additive 
to ligand stimulation but instead acts in multiplicity and it does not compete with cognate 
ligand binding. This suggests that SBH has an amplifying effect in TNFR1 signaling with 
an estimate of two-fold change regardless of ligand stimulation.  
SBH is a known selective inhibitor of 5-HT2C/2B serotonin receptor, though it 
also inhibits 5-HT2A to some extent (261). We note that 5-HT2A serotonin receptor 
activation has been shown to potently suppresses TNFα induced inflammation in cells 
and animal models (262, 263). This suggests that the effect of SBH in activating TNFR1 
may partially due to its inhibition of 5-HT2A receptor, leading to the lifting of the 
suppression of TNFα effect. However, these effects were restricted to 5-HT2A receptors, 
as 5-HT2B and 5-HT2C receptor-selective agonists were ineffective in suppressing 
TNFα-induced inflammation (264). In addition, it has been shown that HEK293 cells 
contain little or no 5-HT2A/2B/2C receptors (265-268). Furthermore, we have shown in 
the current study that TNFR1 is required for the activating effect of SBH. All these 
suggest that SBH possesses a relatively high specificity to targeting TNFR1.  
An obvious benefit of receptor-specific activation by perturbing receptor 
conformational states is that the effect of activation may be in multiple instead of mere 
additive. For example, regardless of receptor constitutive signaling in the absence of 
ligand or ligand stimulation, the receptor activation is estimated increased by two-fold 
such as the relative luciferase activity changed from 1 to 2 (in the absence of ligand) or 6 
to 12 (in the presence of ligand). This indicates that the receptor is adopting an active 
conformation that sensitizes the receptor to broadly transduce twice the activation 
signals. In addition, the non-competitive nature of the small molecule allows for 
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constitutive signaling by the cognate ligand of the receptor in addition to the activation 
effect of the small molecule, enhancing the overall activation effect. SBH exerts its 
activation effect by altering the conformational state of the pre-assembled dimer to adopt 
an open and active conformation. This is consistent with our previous computational 
study showing that ligand activation of TNFR1 adopts an opening conformation (62). 
This is further supported by other studies on TNF receptors have also shown that 
opening conformations were adopted and preferred for receptor activation (180, 219). 
From the perspective of understanding the mechanism of TNFR1 activation, this 
demonstrates that TNFR1 can be both increasingly active when the ligand is bound and 
the receptor dimer is intact. This suggests that the ensemble of TNFR1 conformational 
states can be stabilized by small molecules for its activation or inhibition, acting like a 
molecular switch.  
5.6. Supplemental figures 
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Supplemental Figure 5. 1. Donor-only control screen to remove false positives.  
(A) Representative donor-only control screen with LOPAC library using HEK293 cells expressing 
only TNFR1ΔCD-GFP which do not show FRET signal so the lifetime plot is shown. Applied 
threshold at a change in lifetime of 3SD is shown by the black lines. Three reproducible hits from 
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the donor-only screen are the same as that obtained from the FRET screen and they are 
removed as false positives. (B) Histogram plot of all compounds from the LOPAC donor-only 




































Supplemental Figure 5. 2. The binding of SBH to TNFR1 ECD as characterized by SPR 
measurements. 
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6.1. Summary 
A series of 5-amino-3benzyl-1H-indole was synthesized based on a scaffold of 
zafirlukast obtained from a FRET-based HTS to discover inhibitors that disrupt TNFR1 
receptor-receptor interaction. The SAR shows the sulfonamide moiety of the molecule 
plays a critical role in the inhibition mechanism and the extent of inhibition while the 
carbamate domain of the molecule is important for the binding affinity and potency of the 
molecule. In addition, both the sulfonamide and the carbamate functional groups are 
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required for compound specificity for TNFR1 as truncation of either or both groups 
resulted in decrease in specificity. The analogue with 4-(trifluoromethyl)benzene 
sulfonamide and isopropyl carbamate (40) emerged as one of the most promising 
analogues with an improved inhibition of NF-κB activation (absolute IC50) of the initial hit 
by more than 60-fold with a half maximum inhibitory concentration at around 800 nM and 
full inhibition. In addition, compound 40 illustrates similar inhibition mechanism in 
disruption of receptor-receptor interactions with better potency in the FRET assay as 
well as high specificity to TNFR1. Future work includes synthesizing additional 
analogues with variation in the 3-benzylindole core and determining the binding affinity 
of the compounds using SPR.  
6.2. Introduction 
Tumor necrosis factor receptor 1 (TNFR1) plays a pivotal role in the signal 
transduction of the inflammatory pathway (5). Binding of cognate ligands, tumor necrosis 
factor (TNF) or lymphotoxin-alpha (LT-), to the extracellular domain of TNFR1 leads to 
IB degradation and NF-B activation (11). Upregulation of ligand level has been 
associated with several inflammatory and autoimmune diseases, including rheumatoid 
arthritis (RA), multiple sclerosis, inflammatory bowel disease and Crohn’s disease (200). 
The prevalence of these autoimmune diseases affected up to 23.5 million in the USA, 
based on 24 autoimmune diseases with available epidemiologic studies (17). However, 
the American Autoimmune Related Diseases Association predicts, considering all 
autoimmune diseases, that there are up to 50 million people in the USA affected by an 
autoimmune disease (269). Hence, TNFR1 is a high-value target and therapeutic 
intervention of the receptor signaling is a billion-dollar industry and of high interest to 
pharmaceutical companies.  
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Current treatments involve anti-TNF biologic agents including monoclonal 
antibodies (infliximab, adalimumab, certolizumab pegol, golimumab) and soluble TNF 
receptor (etanercept) that function by sequestering ligands and blocking their binding to 
the receptor (21, 233-235). Despite high potency, these therapeutics have several 
negative consequences as a result of global ligand blockade. These limitations include 
the development of fatal side effects such as lupus-like symptoms and lymphomas; low 
rates of disease remission; and the generation of antibodies against biologic anti-TNF 
(235, 236). In addition, compared to small molecules, administration of antibodies result 
in injection site reactions or infusion reactions and they are expensive and often fail to 
cross the blood-brain barrier (21, 237, 238). In order to overcome these limitations, there 
is a desperate need to develop new receptor-specific treatments that directly target 
TNFR1 rather than the ligands. 
Most of the current TNFR1 receptor-specific inhibitors are small molecules (36, 
37) or antibodies (33, 35, 176, 239) that competitively block receptor-ligand interactions. 
Due to the very high affinity for ligand binding to TNFR1 (Kd=0.38 nM) (38), the small 
molecules that work by competitively eliminating ligand binding may not be effective 
(177). In addition, circulating forms of soluble TNFR1 may function as native decoys for 
the ligand and their TNF neutralizing capacity may be reduced by TNFR1 antagonists 
that block ligand binding (39-41). As such, approaches that do not involve eliminating 
ligand binding are highly attractive. An approach is to disrupt the pre-assembly of 
TNFR1 dimers by targeting the pre-ligand assembly domain (PLAD) which is an 
attractive alternative to blocking ligand binding because the monomer-monomer 
interaction is weaker than the receptor-ligand affinity (55, 56). While it has been 
suggested that soluble TNFR1 PLAD was able to disrupt TNFR1 receptor-receptor 
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interaction and inhibit receptor signaling in vitro as well as in a mouse model, the soluble 
PLAD protein blocked ligand binding, making it inconclusive whether the inhibition 
mechanism of the small protein was, in fact, disrupting the receptor dimer (52).  
Recently, we showed for the first time, in a fluorescence resonance energy 
transfer (FRET) based high-throughput screening study using NIH clinical collection 
library, that a small molecule lead compound, zafirlukast, is capable of disrupting 
receptor-receptor interaction and inhibiting ligand-induced NF-κB activation without 
blocking ligand binding (190). However, zafirlukast has relatively weak potency (relative 
IC50 = 26 M; absolute IC50 = 51 M), low binding affinity to the receptor (86 M) and 
only partially inhibits activation (56% inhibition) (190, 270). To our knowledge, this was 
the first and only small-molecule inhibitor that had been demonstrated to inhibit TNFR1 
without blocking ligand binding. We were intrigued by the potential of the zafirlukast 
scaffold (Fig. 5.1A) to be repurposed to target TNFR1 based on it being a FDA-
approved drug targeting leukotriene receptor with potent anti-inflammatory activity for 
treatment of asthma, known safety profiles, clearly defined structure–activity 
relationships and chemical tractability for analogue synthesis (271-273). In this study, we 
describe a systematic and comprehensive SAR analysis of the zafirlukast scaffold that 
resulted in compounds with improved activity profiles on receptor-specific inhibition of 
TNFR1 signaling. 
6.3. Materials and methods 
6.3.1. General procedures (compounds not listed are in progress to be included 
and some characterizations are currently in process) 
General Procedure A for the synthesis of 3-benzylindole (adopted from CHL-I-031) 
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To a suspension of nitroindole (8.3 g, 51 mmol, 1.7 equiv) in dry dioxane (30 mL) at 25 
°C was added zinc bromide (5.3 g, 20 mmol, 0.66 equiv) and N,N-diisopropylethylamine 
(6.58 g, 51 mmol, 1.7 equiv). The mixture was stirred for 20 min, then benzyl bromide 
(7.9 g, 31 mmol, 1.0 equiv) was added and the reaction was stirred at 25 °C for 40 h. 
The mixture was concentrated in vacuo and the crude residue was redissolved in 
CH2Cl2 (50 mL) and washed with H2O (50 mL). The aqueous layer was extracted with 
CH2Cl2 (3 × 50 mL). The combined organic fractions were dried over Na2SO4, filtered 
and concentrated in vacuo. The residue was purified by flash column chromatography 
(hexanes/EtOAc) on silica gel. 
Methyl 3-methoxy-4-(5-nitroindol-3-ylmethyl)benzoate (1) (CHL-I-031).   
The title compound was synthesized from 5-nitroindole (8.3 g, 51 mmol) and methyl 4-
(bromomethyl)-3-methoxybenzoate (7.9 g, 31 mmol) using the General Procedure A to 
afford a yellow solid (yield: 52%): Rf = 0.19 (80:20 hexanes/EtOAc); 1H NMR (400 MHz, 
CDCl3) 𝛿 3.90 (s, 3H), 3.95 (s, 3H), 4.15 (s, 2H), 7.11 (s, 1H), 7.16 (d, J = 7.9 Hz, 1H), 
7.37 (d, J = 9.0 Hz, 1H), 7.55–7.56 (m, 2H), 8.08-8.11 (m, 1H), 8.40 (s, 1H), 8.59 (s, 1H); 
13C NMR (400 MHz, CDCl3) 𝛿 information TBD; HRMS (ESI+) calcd for C18H17N2O5 
[M+H]+ 341.1132, found XXX.XXXX (error X.X ppm). 
Methyl 4-((5-nitro-1H-indol-3-yl)methyl)benzoate (45) (CHL-II-004) 
The title compound was synthesized from 5-nitroindole (5.1 g, 0.032 mmol) and methyl 
4-(bromomethyl)benzoate (4.6 g, 0.019 mmol) using the General Procedure A to afford a 
yellow solid (yield: 61%): Rf = 0.17 (70:30 hexanes/EtOAc); 1H NMR (400 MHz, CD3OD) 
𝛿 3.87 (s, 2H), 4.23 (s, 2H), 7.28 (s, 1H), 7.41 (d, J = 8.9 Hz, 2H), 7.46 (d, J = 9.3 Hz, 
1H), 7.94 (d, J = 7.8 Hz, 2H), 8.02 (d, J = 9.2 Hz, 1H), 8.38 (s, 1H); 13C NMR (400 MHz, 
CD3OD) 𝛿 information TBD; HRMS (ESI+) calcd for C17H15N2O4 [M+H]+ 311.1026, found 
XXX.XXXX (error X.X ppm). 
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General Procedure B for the methylation of 3-benzylindole (adopted from CHL-I-
032) 
To a suspension of methyl nitroindolebenzoate (2.75 g, 8.09 mmol, 1.00 equiv) in dry 
THF (57.3 mL) at 25 °C was added sodium hydride (0.327 g, 8.17 mmol, 1.01 equiv) and 
iodomethane (2.36 g, 16.7 mmol, 2.06 equiv). The mixture was concentrated in vacuo 
and the crude residue was redissolved in CH2Cl2 (50 mL) and washed with H2O (50 mL). 
The aqueous layer was extracted with CH2Cl2 (3 × 50 mL). The combined organic 
fractions were dried over Na2SO4, filtered and concentrated in vacuo. The residue was 
purified by flash column chromatography (hexanes/EtOAc) on silica gel. 
Methyl 3-methoxy-4-((1-methyl-5-nitro-1H-indol-3-yl)methyl)benzoate (2) (CHL-I-
032)  
The title compound was synthesized from methyl 3-methoxy-4-(5-nitroindol-3-
ylmethyl)benzoate (1) (CHL-I-031) (2.75 g, 8.09 mmol) using the General Procedure B 
(yield: 75%): Rf = 0.28 (70:30 hexanes/EtOAc); 1H NMR (400 MHz, CDCl3) 𝛿 3.79 (s, 
3H), 3.90 (s, 3H), 3.96 (s, 3H), 4.13 (s, 2H), 6.92 (s, 1H), 7.17 (d, J = 8.1 Hz, 1H), 7.28 
(d, J = 9.1 Hz, 1H), 7.54–7.56 (m, 2H), 8.10-8.13 (m, 1H), 8.59 (d, J = 2.2 Hz, 1H); 13C 
NMR (400 MHz, CDCl3) 𝛿 information TBD; HRMS (ESI+) calcd for C19H19N2O5 [M+H]+ 
355.1288, found XXX.XXXX (error X.X ppm). 
Methyl 4-((1-methyl-5-nitro-1H-indol-3-yl)methyl)benzoate (44) (CHL-II-021) 
The title compound was synthesized from methyl 4-((5-nitro-1H-indol-3-
yl)methyl)benzoate (45) (CHL-II-004) (0.780 g, 2.52 mmol) using the General Procedure 
B (Yield: 81%): Rf = 0.19 (70:30 hexanes/EtOAc); 1H NMR (400 MHz, CDCl3) 𝛿 3.78 (s, 
3H), 3.88 (s, 3H), 4.14 (s, 2H), 6.90 (s, 1H), 7.27 (d, J = 9.1 Hz, 1H), 7.32 (d, J = 7.9 Hz, 
2H), 7.96 (d, J = 7.9 Hz, 2H), 8.06-8.09 (m, 1H), 8.41 (s, 1H); 13C NMR (400 MHz, 
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CDCl3) 𝛿 information TBD; HRMS (ESI+) calcd for C18H17N2O4 [M+H]+ 325.1183, found 
XXX.XXXX (error X.X ppm). 
General Procedure C for the reduction of nitroindole (adopted from CHL-I-070) 
To a suspension of nitroindole (0.44 g, 1.2 mmol, 1.0 equiv) in dry THF (10 mL) at 25 °C 
was added palladium (0.66 g, 0.62 mmol, 0.50 equiv). The mixture was stirred at 25 °C 
for 24 h. The mixture was passed through celite to remove the palladium followed by 
washing with methanol and ethyl acetate to elute the compound. The residue was 
purified by flash column chromatography (hexanes/EtOAc) on silica gel. 
Methyl 4-((5-amino-1-methyl-1H-indol-3-yl)methyl)-3-methoxybenzoate (3) (CHL-I-
070) 
The title compound was synthesized from methyl 3-methoxy-4-((1-methyl-5-nitro-1H-
indol-3-yl)methyl)benzoate (2) (CHL-I-032) (0.44 g, 1.2 mmol) using the General 
Procedure C (yield: 89%): Rf = 0.25 (70:30 hexanes/EtOAc); 1H NMR (400 MHz, CDCl3) 
𝛿 3.66-3.67 (m, 3H), 3.93 (s, 3H), 3.96 (s, 3H), 4.07 (s, 2H), 6.68-6.71 (m, 1H), 6.73 (s, 
1H), 6.81 (s, 1H), 7.11 (d, J = 8.5 Hz, 1H), 7.18 (d, J = 7.8 Hz, 1H), 7.56–7.58 (m, 1H), 
7.60 (s, 1H); 13C NMR (400 MHz, CDCl3) 𝛿 25.2, 32.6, 52.0, 55.5, 104.1, 109.7, 110.7, 
110.9, 112.5, 127.0, 127.9, 128.7, 128.9, 129.6, 132.2, 135.7, 139.0, 157.1, 167.2; 
HRMS (ESI+) calcd for C19H21N2O3 [M+H]+ 325.1547, found XXX.XXXX (error X.X ppm). 
4-((5-amino-1-methyl-1H-indol-3-yl)methyl)-N-((4-
(trifluoromethyl)phenyl)sulfonyl)benzamide (47) (CHL-II-026) 
The title compound was synthesized from 4-((1-methyl-5-nitro-1H-indol-3-yl)methyl)-N-
((4-(trifluoromethyl)phenyl)sulfonyl)benzamide (50) (CHL-II-024) (0.100 g, 0.193 mmol) 
using the General Procedure C (Yield: TBD): Rf = 0.22 (0:100 hexanes/EtOAc); 1H NMR 
(400 MHz, CDCl3) 𝛿 3.88 (s, 3H), 3.94 (s, 3H), 4.14 (s, 2H), 7.09 (s, 1H), 7.15 (d, J = 7.9 
Hz, 1H), 7.36 (d, J = 9.0 Hz, 1H), 7.52–7.54 (m, 2H), 8.08 (d, J = 8.9 Hz, 1H), 8.38 (s, 
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1H), 8.57 (s, 1H); 13C NMR (400 MHz, CDCl3) 𝛿 information TBD; HRMS (ESI+) calcd for 
C24H21F3N3O3S [M+H]+ 488.1250, found XXX.XXXX (error X.X ppm). 
 
General Procedure D for addition of carbamate (adopted from CHL-I-071) 
To a suspension of aminoindole (0.21 g, 0.64 mmol, 1.0 equiv) in DCM (10 mL) at 25 °C 
was added chloroformate (0.47 g, 3.2 mmol, 5.0 equiv) and triethylamine (0.32 g, 3.2 
mmol, 5.0 equiv). The mixture was stirred at 4 °C for 24 h. The mixture was 
concentrated in vacuo and the crude residue was redissolved in CH2Cl2 (50 mL) and 
washed with H2O (50 mL). The aqueous layer was extracted with CH2Cl2 (3 × 50 mL). 
The combined organic fractions were dried over Na2SO4, filtered and concentrated in 
vacuo. The residue was purified by flash column chromatography (hexanes/EtOAc) on 
silica gel. 
Methyl 4-((5-(((cyclopentyloxy)carbonyl)amino)-1-methyl-1H-indol-3-yl)methyl)-3-
methoxybenzoate (4) (CHL-I-071) 
The title compound was synthesized from methyl 4-((5-amino-1-methyl-1H-indol-3-
yl)methyl)-3-methoxybenzoate (3) (CHL-I-070) (0.21 g, 0.64 mmol) and 
cyclopentylchloroformate (0.47 g, 3.2 mmol) using the General Procedure D (yield: 
82%): Rf = 0.23 (70:30 hexanes/EtOAc); 1H NMR (400 MHz, CDCl3) 𝛿 1.24-1.53 (m, 
8H0, 3.30 (s, 3H), 3.54 (s, 3H), 3.56 (s, 3H), 3.72 (s, 2H), 4.85-4.88 (m, 1H), 6.39 (s, 
1H), 6.48 (s, 1H), 6.78-6.85 (m, 3H), 7.17-7.20 (m, 2H); 13C NMR (400 MHz, CDCl3) 𝛿 
14.2, 21.0, 23.3, 23.7, 25.2, 32.6, 32.8, 35.5, 52.0, 55.5, 60.4, 73.9, 109.3, 110.8, 112.3, 
122.0, 128.0, 128.1, 128.9, 129.6, 130.1, 134.1, 135.5, 157.0, 167.2; HRMS (ESI+) 





yl)carbamate (36) (CHL-II-108) 
The title compound was synthesized from 4-((5-amino-1-methyl-1H-indol-3-yl)methyl)-3-
methoxy-N-((4-(trifluoromethyl)phenyl)sulfonyl)benzamide (10 mg, 0.019 mmol) and 
cyclobutyl carbonchloridate (13 mg, 0.097 mmol) using the General Procedure D (yield: 
TBD): Rf = 0.13 (0:100 hexanes/EtOAc); 1H NMR (400 MHz, CD3OD) 𝛿 2.01-2.34 (m, 
6H), 3.70 (s, 2H), 3.89 (s, 1H), 3.99 (s, 1H), 5.34 (s, 1H), 6.84 (s, 1H), 7.03 (s, 1H), 7.15 
(s, 1H), 7.20 (s, 1H), 7.43-7.46 (m, 2H), 7.60 (s, 1H), 7.76 (s, 2H), 8.14 (d, J = 8.2 Hz, 
2H); 13C NMR (400 MHz, CD3OD) 𝛿 information TBD; HRMS (ESI+) calcd for 
C31H31F3N3O6S [M+H]+ 630.1880, found XXX.XXXX (error X.X ppm). 
Tetrahydrofuran-3-yl (3-(2-methoxy-4-(((4-
(trifluoromethyl)phenyl)sulfonyl)carbamoyl)benzyl)-1-methyl-1H-indol-5-
yl)carbamate (43) (CHL-II-019) 
The title compound was synthesized from 4-((5-amino-1-methyl-1H-indol-3-yl)methyl)-3-
methoxy-N-((4-(trifluoromethyl)phenyl)sulfonyl)benzamide (32 mg, 0.062 mmol) and 
oxylan-3-yl chloroformate (47 mg, 0.31 mmol) using the General Procedure D (yield: 
TBD): Rf = 0.13 (0:100 hexanes/EtOAc); 1H NMR (400 MHz, CD3OD) 𝛿 1.96-2.20 (m, 
6H), 3.71 (s, 3H), 3.90 (s, 3H), 3.99 (s, 2H), 5.28 (s, 1H), 6.85 (s, 1H), 7.03 (d, J = 8.0 
Hz, 1H), 7.16 (s, 1H), 7.22 (d, J = 8.6 Hz, 1H), 7.43–7.45 (m, 1H), 7.50 (s, 1H), 7.60 (s, 
1H), 7.76 (d, J = 8.1 Hz, 2H), 8.14 (d, J = 8.1 Hz, 2H); 13C NMR (400 MHz, CD3OD) 𝛿 
information TBD; HRMS (ESI+) calcd for C30H29F3N3O7S [M+H]+ 632.1673, found 
XXX.XXXX (error X.X ppm). 
Methyl (3-(2-methoxy-4-(((4-(trifluoromethyl)phenyl)sulfonyl)carbamoyl)benzyl)-1-
methyl-1H-indol-5-yl)carbamate (38) (CHL-II-018) 
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The title compound was synthesized from 4-((5-amino-1-methyl-1H-indol-3-yl)methyl)-3-
methoxy-N-((4-(trifluoromethyl)phenyl)sulfonyl)benzamide (32 mg, 0.062 mmol) and 
methyl chloroformate (29 mg, 0.31 mmol) using the General Procedure D (yield: TBD): 
Rf = 0.21 (0:100 hexanes/EtOAc); 1H NMR (400 MHz, CD3OD) 𝛿 3.48-3.71 (m, 6H), 3.90 
(s, 3H), 3.99 (s, 2H), 6.84 (s, 1H), 7.04 (d, J = 7.9 Hz, 1H), 7.17 (s, 1H), 7.22 (d, J = 8.6 
Hz, 1H), 7.43 (d, J = 7.8 Hz, 1H), 7.48 (s, 1H), 7.58 (s, 1H), 7.76 (d, J = 8.1 Hz, 2H), 
8.14 (d, J = 8.1 Hz, 2H); 13C NMR (400 MHz, CD3OD) 𝛿 information TBD; HRMS (ESI+) 
calcd for C27H25F3N3O6S [M+H]+ 576.1411, found XXX.XXXX (error X.X ppm). 
isopropyl (3-(2-methoxy-4-(((4-(trifluoromethyl)phenyl)sulfonyl)carbamoyl)benzyl)-
1-methyl-1H-indol-5-yl)carbamate (40) (CHL-I-125) 
The title compound was synthesized from 4-((5-amino-1-methyl-1H-indol-3-yl)methyl)-3-
methoxy-N-((4-(trifluoromethyl)phenyl)sulfonyl)benzamide (CHL-I-106) (13 mg, 0.025 
mmol) and isopropyl chloroformate (16 mg, 0.13 mmol) using the General Procedure D 
(yield: TBD): Rf = 0.07 (50:50 hexanes/EtOAc); 1H NMR (400 MHz, CD3OD) 𝛿 1.28 (d, J 
= 7.7 Hz, 6H), 3.70 (s, 3H), 3.89 (s, 3H), 3.99 (s, 2H), 6.83 (s, 1H), 7.04 (d, J = 8.0 Hz, 
1H), 7.15 (s, 1H) 7.21 (d, J = 8.2 Hz, 1H), 7.44 (d, J = 8.0 Hz, 1H), 7.49 (s, 1H), 7.59 (s, 
1H), 7.76 (d, J = 8.0 Hz, 1H), 8.13-8.15 (m, 2H) ;13C NMR (400 MHz, CD3OD) 𝛿 
information TBD; HRMS (ESI+) calcd for C29H29F3N3O6S [M+H]+ 604.1724, found 




yl)carbamate (37) (CHL-II-017) 
The title compound was synthesized from 4-((5-amino-1-methyl-1H-indol-3-yl)methyl)-3-
methoxy-N-((4-(trifluoromethyl)phenyl)sulfonyl)benzamide (CHL-II-016) (20 mg, 0.040 
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mmol) and cyclohexyl chloroformate (33 mg, 0.20 mmol) using the General Procedure D 
(yield: TBD): Rf = 0.13 (50:50 hexanes/EtOAc); 1H NMR (400 MHz, CD3OD) 𝛿 1.78-2.03 
(m, 10H), 3.71 (s, 3H), 3.89 (s, 3H), 3.99 (s, 2H), 4.58 (s, 1H), 6.83 (s, 1H), 7.03 (d, J = 
7.8 Hz, 1H), 7.15 (s, 1H), 7.22 (d, J = 8.8 Hz, 1H), 7.44 (d, J = 7.9 Hz, 1H), 7.47 (s, 1H), 
7.60 (s, 1H), 7.75 (d, J = 8.2 Hz, 1H), 8.14 (d, J =8.1 Hz, 2H); 13C NMR (400 MHz, 
CD3OD) 𝛿 information TBD; HRMS (ESI+) calcd for C32H33F3N3O6S[M+H]+ 644.2037, 
found XXX.XXXX (error X.X ppm). 
General Procedure E for saponification of methyl benzoate (adopted from CHL-I-
072) 
To a suspension of methyl benzoate (0.17 g, 0.39 mmol, 1.0 equiv) in THF (10 mL) and 
water (5 mL) was added lithium hydroxide (56 mg, 2.3 mmol, 6.0 equiv) and the reaction 
was stirred at 25 °C for 20 h. The reaction was acidified and kept in cold, and the titled 
compound precipitated.  
4-((5-(((cyclopentyloxy)carbonyl)amino)-1-methyl-1H-indol-3-yl)methyl)-3-
methoxybenzoic acid (24) (CHL-I-072) 
The title compound was synthesized from methyl 4-((5-
(((cyclopentyloxy)carbonyl)amino)-1-methyl-1H-indol-3-yl)methyl)-3-methoxybenzoate 
(4) (CHL-I-071) (0.17 g, 0.39 mmol, 1.0 equiv) using the General Procedure E (yield: 
88%): Rf = 0.21 (95:5 DCM/MeOH); 1H NMR (400 MHz, CD3OD) 𝛿 1.55-1.81 (m, 8H), 
3.56 (s, 3H), 3.84 (s, 3H), 3.97 (s, 2H), 5.08 (s, 1H), 6.75 (s, 1H), 7.07-7.13 (m, 3H), 
7.45-7.48 (m, 1H), 7.53 (s, 1H), 7.56 (s, 1H); 13C NMR (400 MHz, CD3OD) 𝛿14.1, 20.1, 
24.6, 26.0, 29.8, 30.7, 32.6, 33.7, 55.9, 78.6, 110.1, 110.9, 111.9, 113.4, 116.4, 123.1, 
129.2, 130.6, 131.6, 135.6, 137.0, 156.7, 158.4, 170.6; HRMS (ESI+) calcd for 
C24H27N2O5 [M+H]+ 423.1914, found XXX.XXXX (error X.X ppm). 
4-((1-methyl-5-nitro-1H-indol-3-yl)methyl)benzoic acid (47) (CHL-II-022) 
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The title compound was synthesized from methyl 4-((1-methyl-5-nitro-1H-indol-3-
yl)methyl)benzoate (44) (CHL-II-021) (0.50 g, 1.5 mmol) using the General Procedure E 
(yield: 85%): Rf = 0.23 (95:5 DCM/Methanol); 1H NMR (400 MHz, CD3OD) 𝛿 3.84 (s, 3H), 
4.21 (s, 2H), 7.21 (s, 1H), 7.39 (d, J = 8.0 Hz, 2H), 7.48 (d, J = 9.1 Hz, 1H), 7.94 (d, J = 
8.0 Hz, 2H), 8.06–8.09 (m, 1H), 8.41 (d, J = 2.3 Hz, 1H); 13C NMR (400 MHz, CD3OD) 𝛿 
information TBD; HRMS (ESI+) calcd for C17H15N2O4 [M+H]+ 311.1026, found XXX.XXXX 
(error X.X ppm). 
General Procedure F for addition of sulfonamide (adopted from CHL-I-073) 
To a suspension of benzoic acid (15.0 mg, 0.0355 mmol, 1.00 equiv) in DCM (10 mL) at 
25 °C was added sulfonamide (6.38 mg, 0.0373 mmol, 1.05 equiv), DMAP (4.56 mg, 
0.0373 mmol, 1.05 equiv) and EDC (7.15 mg, 0.0373 mmol, 1.05 equiv) and the reaction 
was stirred for 24 h. The mixture was acidified using 1N HCl and the aqueous layer was 
extracted with CH2Cl2 (3 × 50 mL). The combined organic fractions were dried over 
Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash column 
chromatography (hexanes/EtOAc or DCM/MeOH) on silica gel. 
Cyclopentyl (3-(2-methoxy-4-((m-tolylsulfonyl)carbamoyl)benzyl)-1-methyl-1H-
indol-5-yl)carbamate (25) (CHL-I-073)   
The title compound was synthesized from 4-((5-(((cyclopentyloxy)carbonyl)amino)-1-
methyl-1H-indol-3-yl)methyl)-3-methoxybenzoic acid (24) (CHL-I-072) (15.0 mg, 0.0355 
mmol) and 3-methylbenzene sulfonamide (6.38 mg, 0.0373 mmol) using the General 
Procedure F (yield: TBD): Rf = 0.19 (95:5 DCM/MeOH); 1H NMR (400 MHz, CD3OD) 𝛿 
1.61-1.87 (m, 8H), 2.39 (s, 3H), 3.70 (s, 3H), 3.88 (s, 3H), 4.00 (s, 2H), 5.09-5.12 (m, 
1H),  6.85 (s, 1H), 7.06 (d, J = 7.7 Hz, 1H), 7.10-7.12 (m, 1H), 7.21 (d, J = 8.7 Hz, 1H), 
7.36 (d, J = 4.6 Hz, 2H), 7.42 (d, J = 7.6 Hz, 1H), 7.15 (d, J = 7.9 Hz, 1H), 7.36 (d, J = 
9.0 Hz, 1H), 7.52–7.54 (m, 2H), 7.79-7.18 (m, 1H), 7.84 (s, 1H); 13C NMR (400 MHz, 
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CD3OD) 𝛿 14.5, 20.9, 21.3, 23.7, 24.6, 26.0, 30.5, 30.7, 32.7, 33.1, 33.7, 33.8, 55.9, 
61.5, 78.6, 110.1, 111.3, 113.7, 122.0, 125.5, 128.7, 129.3, 129.5, 130.4, 134.0, 135.7, 
135.9, 139.9, 143.5, 156.8, 158.3; HRMS (ESI+) calcd for C31H34N3O6S [M+H]+ 
576.2163, found XXX.XXXX (error X.X ppm). 
Cyclopentyl (3-(2-methoxy-4-(tosylcarbamoyl)benzyl)-1-methyl-1H-indol-5-
yl)carbamate (26) (CHL-I-074)   
The title compound was synthesized from 4-((5-(((cyclopentyloxy)carbonyl)amino)-1-
methyl-1H-indol-3-yl)methyl)-3-methoxybenzoic acid (24) (CHL-I-072) (15.0 mg, 0.0355 
mmol) and 4-methylbenzene sulfonamide (6.38 mg, 0.0373 mmol) using the General 
Procedure F (yield: TBD): Rf = 0.13 (95:5 DCM/MeOH); 1H NMR (400 MHz, CD3OD) 𝛿 
1.61- 1.87 (m, 8H), 2.41 (s, 3H), 3.70 (s, 3H), 3.90 (s, 3H), 4.01 (s, 2H), 5.09-5.12 (m, 
1H), 6.87 (s, 1H), 7.09 (d, J = 7.9 Hz, 2H), 7.22 (d, J = 8.7 Hz, 1H), 7.34 (d, J = 8.0 Hz, 
3H), 7.44 (s, 1H), 7.51 (s, 1H), 7.92 (d, J = 8.1 Hz, 2H); 13C NMR (400 MHz, CD3OD) 𝛿 
9.2, 14.5, 19.4, 20.9, 21.3, 21.5, 24.6, 28.0, 30.3, 30.8, 32.7, 33.8, 56.0, 61.5, 78.6, 
110.1, 111.0, 113.5, 116.4, 121.7, 129.0, 129.3, 129.4, 130.2, 130.6, 131.7, 135.7, 
136.5, 145.0, 156.8, 158.5; HRMS (ESI+) calcd for C31H34N3O6S  [M+H]+ 576.2163, 
found XXX.XXXX (error X.X ppm). 
Cyclopentyl (3-(4-(((4-chlorophenyl)sulfonyl)carbamoyl)-2-methoxybenzyl)-1-
methyl-1H-indol-5-yl)carbamate (27) (CHL-I-075)   
The title compound was synthesized from 4-((5-(((cyclopentyloxy)carbonyl)amino)-1-
methyl-1H-indol-3-yl)methyl)-3-methoxybenzoic acid (24) (CHL-I-072) (15.0 mg, 0.0355 
mmol) and 4-chlorobenzene sulfonamide (7.15 mg, 0.0373 mmol) using the General 
Procedure F (yield: TBD): Rf = 0.22 (95:5 DCM/MeOH); 1H NMR (400 MHz, CD3OD) 𝛿 
1.61-1.86 (m, 8H), 3.69 (s, 3H), 3.88 (s, 3H), 4.00 (s, 2H), 5.08-5.11 (m, 1H), 6.86 (s, 
1H), 7.07-7.11 (m, 2H), 7.20-7.22 (m, 1H), 7.37 (d, J = 7.8 Hz, 1H), 7.48-7.53 (m, 4H), 
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7.99-8.00 (m, 2H); 13C NMR (400 MHz, CD3OD) 𝛿 14.5, 20.9, 24.6, 26.0, 30.8, 31.8, 
32.7, 33.8, 55.9, 61.5, 78.6, 110.1, 111.0, 111.3, 113.6, 116.4, 122.0, 129.3, 129.4, 
129.8, 130.3, 130.5, 131.6, 135.0, 135.7, 136.2, 139.6, 142.2, 156.8, 158.4; HRMS 
(ESI+) calcd for C30H31ClN3O6S [M+H]+ 596.1617, found XXX.XXXX (error X.X ppm). 
Cyclopentyl (3-(4-(((1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl)carbamoyl)-2-
methoxybenzyl)-1-methyl-1H-indol-5-yl)carbamate (33) (CHL-I-076)   
The title compound was synthesized from 4-((5-(((cyclopentyloxy)carbonyl)amino)-1-
methyl-1H-indol-3-yl)methyl)-3-methoxybenzoic acid (24) (CHL-I-072) (15.0 mg, 0.0355 
mmol) and 1,3,-dimethyl-1H-pyrazole-4sulfonamide (6.54 mg, 0.0373 mmol) using the 
General Procedure F (yield: TBD): Rf = 0.18 (95:5 DCM/MeOH); 1H NMR (400 MHz, 
CD3OD) 𝛿 1.62-1.88 (m, 8H), 2.40 (s, 3H), 3.71 (s, 3H), 3.83 (s, 3H), 3.92 (s, 3H), 4.01 
(s, 2H), 5.11 (s, 1H), 6.87 (s, 1H), 7.07-7.13 (m, 2H), 7.22 (d, J = 8.6 Hz, 1H), 7.38 (d, J 
= 7.9 Hz, 1H), 7.51 (s, 2H), 8.03 (s, 1H); 13C NMR (400 MHz, CD3OD) 𝛿 12.4, 14.5, 20.9, 
24.6, 26.0, 32.7, 33.8, 39.2, 56.0, 61.5, 78.6, 110.2, 110.7, 113.3, 116.4, 119.8, 121.4, 
129.2, 129.5, 130.8, 132.3, 135.7, 137.3, 137.5, 149.7, 156.8, 158.7, 168.1, 173.0; 
HRMS (ESI+) calcd for C29H34N5O6S  [M+H]+ 580.2224, found XXX.XXXX (error X.X 
ppm). 
Cyclopentyl (3-(4-(((4-cyanophenyl)sulfonyl)carbamoyl)-2-methoxybenzyl)-1-
methyl-1H-indol-5-yl)carbamate (29) (CHL-I-077)   
The title compound was synthesized from 4-((5-(((cyclopentyloxy)carbonyl)amino)-1-
methyl-1H-indol-3-yl)methyl)-3-methoxybenzoic acid (24) (CHL-I-072) (15.0 mg, 0.0355 
mmol) and 4-cyanobenzene sulfonamide (6.80 mg, 0.0373 mmol) using the General 
Procedure F (yield: TBD): Rf = 0.10 (95:5 DCM/MeOH); 1H NMR (400 MHz, CD3OD) 𝛿 
1.61-1.86 (m, 8H), 3.69 (s, 3H), 3.89 (s, 3H), 4.00 (s, 2H), 5.08-5.11 (m, 1H), 6.87 (s, 
1H), 7.10 (d, J = 7.6 Hz, 2H), 7.21 (d, J = 8.7 Hz, 1H), 7.32-7.35 (m, 1H), 7.43 (s, 1H), 
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7.52 (s, 1H), 7.88-7.90 (m, 2H); 13C NMR (400 MHz, CD3OD) 𝛿 14.1, 20.2, 24.6, 26.0, 
30.7, 32.7, 32.8, 33.8, 33.9, 56.0, 78.6, 110.2, 111.0, 113.4, 116.4, 117.5, 118.5, 121.8, 
129.2, 129.4, 129.8, 130.7, 131.7, 133.2, 133.8, 135.7, 137.1, 146.4, 156.8, 158.6, 




yl)carbamate (28) (CHL-I-078)   
The title compound was synthesized from 4-((5-(((cyclopentyloxy)carbonyl)amino)-1-
methyl-1H-indol-3-yl)methyl)-3-methoxybenzoic acid (24) (CHL-I-072) (15.0 mg, 0.0355 
mmol) and 4-(trifluoromethyl)benzenesulfonamide (8.40 mg, 0.0373 mmol) using the 
General Procedure F (yield: TBD): Rf = 0.10 (95:5 DCM/MeOH); 1H NMR (400 MHz, 
CD3OD) 𝛿 1.61-1.86 (m, 8H), 3.69 (s, 3H), 3.90 (s, 3H), 4.01 (s, 2H), 5.08-5.11 (m, 1H), 
6.88 (s, 1H), 7.08-7.12 (m, 2H), 7.21 (d, J = 8.6 Hz, 1H), 7.33 (d, J = 7.9 Hz, 1H), 7.42 
(s, 1H), 7.52 (s, 1H), 7.87 (d, J = 8.1 Hz, 2H), 8.23 (d, J = 8.1 Hz, 2H); 13C NMR (400 
MHz, CD3OD) 𝛿 14.5, 20.9, 24.6, 26.0, 32.7, 33.8, 56.0, 61.5, 78.6, 110.1, 111.0, 113.4, 
116.4, 121.8, 124.0, 125.8, 126.9, 129.2, 129.4, 129.8, 130.7, 131.7, 133.5, 135.1, 
135.3, 135.7, 136.9, 146.2, 156.8, 158.5, 170.0; HRMS (ESI+) calcd for C31H31F3N3O6S 
[M+H]+ 630.1880, found XXX.XXXX (error X.X ppm). 
Cyclopentyl (3-(2-methoxy-4-((morpholinosulfonyl)carbamoyl)benzyl)-1-methyl-1H-
indol-5-yl)carbamate (34) (CHL-I-079)   
The title compound was synthesized from 4-((5-(((cyclopentyloxy)carbonyl)amino)-1-
methyl-1H-indol-3-yl)methyl)-3-methoxybenzoic acid (24) (CHL-I-072) (18.0 mg, 
0.0426mmol) and morpholine-4-sulfonamide (7.44 mg, 0.0477 mmol) using the General 
Procedure F (yield: TBD): Rf = 0.13 (50:50 hexanes/EtOAc); 1H NMR (400 MHz, CD3OD) 
159 
 
𝛿 1.62-1.88 (m, 8H), 3.35-3.37 (m, 4H), 3.70-3.72 (m, 7H), 3.95 (s, 3H), 4.05 (s, 2H), 
6.91 (s, 1H), 7.09-7.15 (m, 2H), 7.23 (d, J = 8.8 Hz, 1H), 7.37-7.39 (m, 1H), 7.50-7.54 
(m, 2H); 13C NMR (400 MHz, CD3OD) 𝛿 11.4, 14.5, 19.4, 23.7, 24.6, 25.0, 26.0, 28.1, 
30.5, 30.6, 30.8, 31.6, 32.7, 33.1, 33.8, 40.2, 56.0, 67.6, 69.1, 78.6, 110.1, 111.2, 121.8, 
129.3, 129.9, 130.5, 132.4, 158.4; HRMS (ESI+) calcd for C28H35N4O7S  [M+H]+ 
571.2221, found XXX.XXXX (error X.X ppm). 
Cyclopentyl (3-(2-methoxy-4-((pyridine-4-ylsulfonyl)carbamoyl)benzyl)-1-methyl-
1H-indol-5-yl)carbamate (32) (CHL-I-080)   
The title compound was synthesized from 4-((5-(((cyclopentyloxy)carbonyl)amino)-1-
methyl-1H-indol-3-yl)methyl)-3-methoxybenzoic acid (24) (CHL-I-072) (18.0 mg, 0.0426 
mmol) and pyridine-4-sulfonamide (7.08 mg, 0.0477 mmol) using the General Procedure 
F (yield: TBD): Rf = 0.11 (90:10 DCM/MeOH); 1H NMR (400 MHz, CD3OD) 𝛿 1.62-1.87 
(m, 8H), 3.70 (s, 3H), 3.89 (s, 3H), 4.00 (s, 2H), 5.11 (s, 1H), 6.84 (s, 1H), 7.04 (d, J = 
7.9 Hz, 1H), 7.11-7.13 (m, 1H), 7.22 (d, J = 8.7 Hz, 1H), 7.49 (d, J = 8.3 Hz, 2H), 7.63 (s, 
1H), 7.90-7.92 (m, 2H), 8.67 (d, J = 5.1 Hz, 2H); 13C NMR (400 MHz, CD3OD) 𝛿 24.2, 
24.6, 28.0, 30.7, 30.8, 32.7, 33.8, 55.9, 78.6, 101.2, 110.1, 111.2, 111.7, 114.0, 116.4, 
122.3, 122.4, 129.3, 130.2, 131.6, 135.0, 135.7, 137.5, 150.7, 154.5, 156.8, 158.2, 
175.6, 210.1; HRMS (ESI+) calcd for C29H31N4O6S  [M+H]+ 563.1959, found XXX.XXXX 
(error X.X ppm). 
Cyclopentyl (3-(2-methoxy-4-(((4-(pentafluoro-𝝀𝟔-
sulfaneyl)phenyl)sulfonyl)carbamoyl)benzyl)-1-methyl-1H-indol-5-yl)carbamate 
(30) (CHL-I-084)   
The title compound was synthesized from 4-((5-(((cyclopentyloxy)carbonyl)amino)-1-
methyl-1H-indol-3-yl)methyl)-3-methoxybenzoic acid (24) (CHL-I-072) (23.4 mg, 0.0554 
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mmol) and 4-(pentafluoro-sulfanyl)benzenesulfonamide (16.5 mg, 0.0582 mmol) using 
the General Procedure F (yield: TBD): Rf = 0.19 (80:20 hexanes/EtOAc); 1H NMR (400 
MHz, CD3OD) 𝛿 1.61-1.87 (m, 8H), 3.71 (s, 3H), 3.92 (s, 3H), 4.02 (s, 2H), 5.09-5.12 (m, 
1H), 6.90 (s, 1H), 7.08-7.14 (m, 2H), 7.22 (d, J = 8.7 Hz, 1H), 7.30-7.33 (m, 1H), 7.40 (s, 
1H), 7.51 (s, 1H), 8.05-8.07 (m, 2H), 8.24 (d, J = 8.5 Hz, 2H); 13C NMR (400 MHz, 
CD3OD) 𝛿 14.4, 15.4, 24.6, 26.0, 30.8, 32.7, 33.8, 56.0, 78.7, 96.0 ,99.5, 110.1, 111.0, 
111.4, 113.4, 116.4, 121.8, 127.7, 129.3, 129.4, 130.0, 130.7, 131.7, 133.4, 135.7, 
136.9, 145.9, 156.8, 158.6, 169.9; HRMS (ESI+) calcd for C30H31F5N3O6S2 [M+H]+ 
688.1569, found XXX.XXXX (error X.X ppm). 
Cyclopentyl (3-(4-(((4-(tert-butyl)phenyl)sulfonyl)carbamoyl)-2-methoxybenzyl)-1-
methyl-1H-indol-5-yl)carbamate (31) (CHL-I-095)   
The title compound was synthesized from 4-((5-(((cyclopentyloxy)carbonyl)amino)-1-
methyl-1H-indol-3-yl)methyl)-3-methoxybenzoic acid (24) (CHL-I-072) (15.0 mg, 0.0355 
mmol) and tertbutylsulfonamide (7.95 mg, 0.0373 mmol) using the General Procedure F 
(yield: TBD): Rf = 0.16 (80:20 hexanes/EtOAc); 1H NMR (400 MHz, CD3OD) 𝛿 1.33 (s, 
9H), 1.62-1.88 (m, 8H), 3.70 (s, 3H), 3.90 (s, 3H), 3.99 (s, 2H), 5.10-5.11 (m, 1H), 5.33-
5.36 (s, 1H), 6.83 (s, 1H), 7.02 (d, J = 7.9 Hz, 1H), 7.15 (s, 1H), 7.21 (d, J = 8.6 Hz, 1H), 
7.42-7.45 (m, 1H), 7.48-7.50 (m, 2H), 7.59 (s, 1H), 7.89-7.91 (m, 2H), 7.36 (d, J = 9.0 
Hz, 1H), 7.52–7.54 (m, 2H), 8.08 (d, J = 8.9 Hz, 1H), 8.38 (s, 1H), 8.57 (s, 1H); 13C NMR 
(400 MHz, CD3OD) 𝛿 14.4, 14.5, 23.7, 24.6, 25.9, 26.9, 28.1, 28.9, 30.3, 30.5, 30.7, 
31.6, 32.7, 33.1, 33.8, 35.8, 36.5, 55.9, 62.1, 78.6, 110.0, 111.6, 122.0, 126.1, 128.2, 
129.3, 130.1, 130.8, 134.4, 138.1, 142.5, 155.6, 158.1, 170.2; HRMS (ESI+) calcd for 
C34H40N3O6S [M+H]+ 618.2632, found XXX.XXXX (error X.X ppm). 
4-((1-methyl-5-nitro-1H-indol-3-yl)methyl)-N-((4-
(trifluoromethyl)phenyl)sulfonyl)benzamide (50) (CHL-II-024)   
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The title compound was synthesized from 4-((1-methyl-5-nitro-1H-indol-3-
yl)methyl)benzoic acid (47) (CHL-II-022) (0.500 g, 1.62 mmol) and 4-
(trifluoromethyl)benzenesulfonamide (0.383 g, 1.70 mmol) using the General Procedure 
F (yield: 40%): Rf = 0.50 (50:50 hexanes/EtOAc); 1H NMR (400 MHz, CD3OD) 𝛿 3.75-
3.78 (m, 3H), 7.13 (d, J = 6.5 Hz, 1H), 7.27-7.30 (m, 2H), 7.37-7.42 (m, 1H), 7.76-7.79 
(m, 2H), 7.87 (d, J = 7.7 Hz, 2H), 7.97–8.02 (m, 1H), 8.17 (d, J = 8.2 Hz, 2H), 8.29-8.31 
(m, 1H); 13C NMR (400 MHz, CD3OD) 𝛿 information TBD; HRMS (ESI+) calcd for 
C24H19F3N3O5S [M+H]+ 518.0992, found XXX.XXXX (error X.X ppm). 
Ethyl (3-(2-methoxy-4-(((4-(trifluoromethyl)phenyl)sulfonyl)carbamoyl)benzyl)-1-
methyl-1H-indol-5-yl)carbamate (39) (CHL-I-114) 
The title compound was synthesized from 4-((5-((ethoxycarbonyl)amino)-1-methyl-1H-
indol-3-yl)methyl)-3-methoxybenzoic acid (CHL-I-037) (12.3 mg, 0.0322 mmol) and 4-
(trifluoromethyl)benzene sulfonamide (7.61 mg, 0.0338 mmol) using the General 
Procedure F (yield: TBD): Rf = 0.13 (50:50 hexanes/EtOAc); 1H NMR (400 MHz, CD3OD) 
𝛿 1.30 (s, 5H), 3.70 (s, 3H), 3.89 (s, 2H), 3.99 (s, 2H), 6.84 (s, 1H), 7.03 (d, J = 7.8 Hz, 
1H), 7.16 (s, 1H), 7.22 (d, J = 8.0 Hz, 1H), 7.44 (d, J = 8.4 Hz, 1H), 7.49 (s, 1H), 7.59 (s, 
1H), 7.76 (d, J = 7.8 Hz, 2H), 8.14 (d, J = 8.1 Hz, 2H); 13C NMR (400 MHz, CD3OD) 𝛿 
information TBD; HRMS (ESI+) calcd for C28H27F3N3O6S [M+H]+ 590.1567, found 
XXX.XXXX (error X.X ppm). 
Tert-butyl (3-(2-methoxy-4-(((4-(trifluoromethyl)phenyl)sulfonyl)carbamoyl)benzyl)-
1-methyl-1H-indol-5-yl)carbamate (41) (CHL-I-115) 
The title compound was synthesized from 4-((5-((tert-butoxycarbonyl)amino)-1-methyl-
1H-indol-3-yl)methyl)-3-methoxybenzoic acid (CHL-I-113) (20.4 mg, 0.0497 mmol) and 
4-(trifluoromethyl)benzene sulfonamide (11.8 mg, 0.0522 mmol) using the General 
Procedure F (yield: TBD): Rf = 0.23 (50:50 hexanes/EtOAc); 1H NMR (400 MHz, CD3OD) 
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𝛿 1.45-1.53 (m, 9H), 3.70 (s, 3H), 3.90 (s, 3H), 3.99 (s, 2H), 6.8 (s, 1H), 7.03 (d, J = 7.8 
Hz, 1H), 7.11 (d, J = 9.1 Hz, 1H), 7.20 (d, J = 8.7 Hz, 1H), 7.43-7.45 (m, 1H), 7.46 (s, 
1H), 7.60 (s, 1H), 7.75 (d, J = 8.0 Hz, 2H), 8.14 (d, J = 8.0 Hz, 2H); 13C NMR (400 MHz, 
CD3OD) 𝛿 information TBD; HRMS (ESI+) calcd for C30H31F3N3O6S [M+H]+ 618.1880, 
found XXX.XXXX (error X.X ppm). 
2-methoxyethyl (3-(2-methoxy-4-(((4-
(trifluoromethyl)phenyl)sulfonyl)carbamoyl)benzyl)-1-methyl-1H-indol-5-
yl)carbamate (42) (CHL-I-124) 
The title compound was synthesized from 3-methoxy-4-((5-(((2-
methoxyethoxy)carbonyl)amino)-1-methyl-1H-indol-3-yl)methyl)benzoic acid (CHL-I-119) 
(12.8 mg, 0.0310 mmol) and 4-(trifluoromethyl)benzene sulfonamide (7.34 mg, 0.0326 
mmol) using the General Procedure F (yield: TBD): Rf = 0.08 (50:50 hexanes/EtOAc); 1H 
NMR (400 MHz, CD3OD) 𝛿 3.38 (s, 3H), 3.63 (s, 2H), 3.7 (s, 3H), 3.89 (s, 3H), 4.00 (s, 
2H), 4.22-4.25 (m, 2H), 6.85 (s, 1H), 7.05 (d, J = 7.7 Hz, 1H), 7.14-7.16 (m, 1H), 7.22 (d, 
J = 8.4 Hz, 1H), 7.42 (d, J = 7.8 Hz, 1H), 7.50 (s, 1H), 7.56 (s, 1H), 7.78 (d, J = 8.0 Hz, 
2H), 8.16 (d, J = 8.0 Hz, 2H); 13C NMR (400 MHz, CD3OD) 𝛿 information TBD; HRMS 
(ESI+) calcd for C29H29F3N3O7S  [M+H]+ 620.1673, found XXX.XXXX (error X.X ppm). 
6.3.2. Cell culture  
Human embryonic kidney cells 293 (HEK293, ATCC) were cultured in phenol 
red-free Dulbecco's Modified Eagle Medium (DMEM, Gibco) supplemented with 2 mM L-
Glutamine (Invitrogen), heat-inactivated 10% fetal bovine serum (FBS HI, Gibco), 100 
U/ml penicillin and 100 g/ml streptomycin (Gibco). HAP1 wild-type and TNFR1 
knockout cells (Horizon) were cultured in Iscove's Modified Dulbecco's Medium (IMDM, 
Gibco) supplemented with 10% FBS (Gibco), 100 U/ml penicillin and 100 g/ml 
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streptomycin (Gibco). Cell cultures were maintained in an incubator with 5% CO2 (Forma 
Series II Water Jacket CO2 Incubator, Thermo Scientific) at 37 ºC. The HAP1 TNFR1 
knockout cell line was edited by CRISPR/Cas to contain a 70 base pair (bp) insertion in 
a coding exon of TNFRSF1A. Sanger sequencing was performed as a quality control to 
confirm the knockout. The TNFR1ΔCD-FRET pair stable cell line was generated as 
described in our previous work and have been monitored continuously for over three 
years with expression maintaining above 95% characterized by flow cytometry (190).  
6.3.3. NF-B activation functional assay 
Ligand stimulated or TRADD induced NF-B activation assay with HEK293 cells 
and HAP1 cells (WT and TNFR1 KO) were carried out as described (190, 270). Briefly, 
the cells were transfected with firefly luciferase reporter genes and Renilla luciferase 
reporter genes for 48 hours. These cells were then dispensed into 96-well assay plates 
(30000 cells/well, total volume 50 l) and incubated with drugs or DMSO (negative 
control) in the presence (0.1 g/ml) and absence of LT for 18 hours at 37 °C. Readings 
for luciferase activities were acquired as described in the dual glo luciferase kit protocol 
(Promega).  
For TRADD-induced NF-B activation in HEK293 cells, cells (1 x 106) in a 6-well 
plate were transfected with NF-B firefly luciferase reporter genes, Renilla luciferase 
reporter genes, TRADD plasmid and control plasmid to give the same total DNA. In the 
control cells, the TRADD plasmid was replaced with control plasmid. After 3 hours of 
transfection, cells were harvested and plated (30,000 cells/well, total volume 50 l) into 
96-well white solid bottom assay plates (Greiner Bio-One North America). Drug 
treatments or DMSO (negative control) was performed 5 hours after cell plating. 




6.3.4. Native gel characterization 
To test the disruption of receptor-receptor interactions, purified soluble TNFR1 
PLAD was assessed by Native-PAGE gels (Bio-Rad) in the absence and presence of hit 
compounds (200 M) under non-reducing conditions followed by Coomassie staining. 
The overexpression and purification of the N-terminal FLAG-tagged TNFR1 PLAD 
(residues 30-82) were carried out as described previously and the soluble PLAD protein 
was shown to exist as dimers under native conditions (190).  
6.3.5. FRET dose-response assay 
These synthesized analogues were dissolved in DMSO to make 10 mM stock 
solution which were then subsequently serially diluted in 96-well mother plates to obtain 
eight doses at 50X concentrations. Hits were screened at eight different concentrations 
(0.01 to 100 M or 0.1 to 200 μM). Compounds (1 μl) were transferred from the mother 
plates into assay plates using a Mosquito HV liquid handler (TTP Labtech Ltd.). On the 
day of conducting the assay, the stable cells expressing the TNFR1 FRET biosensor 
were harvested to check for expression. Stable cells were then dispensed into the drug 
plates containing the analogues (50,000 cells/well) and incubated with the compounds or 
DMSO as a negative control followed by fluorescence lifetime measurements. The 
fluorescence waveforms were acquired by a prototype fluorescence lifetime plate-reader 





The lead structure of zafirlukast can be split into three parts for SAR analysis: the 
central 3-benzylindole core and an aryl-sulfonamide moiety coupled to the acyl 
substitution on the benzyl group as well as a cyclopentyl carbamate domain at C-5 of the 
indole respectively (Fig. 6.1B). Based on the previous SAR studies conducted on 
zafirlukast, majority of the changes in the activity of the molecule primarily lies in the 
variation of the substituents of the sulfonamide and carbamate region of the molecule 
(274-279). With this, we elected to initially prepare two series of analogues with the 
replacement of aryl sulfonamide with methyl ester (R1) or the replacement of the alicyclic 
carbamate (R2) with nitro group to establish the importance of each domain in the 





X = H or Me
Y = H or OMe
R3 = Table 3
R4 = Table 4
Relative IC50 = 26 μM
Abs IC50 = 51 μM
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Kd = 86 μM
Disrupted receptor PLAD dimer
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Figure 6. 1. Optimization of zafirlukast, a hit obtained from a FRET-based HTS.  
(A) Structure of zafirlukast. (B) Zafirlukast scaffold for synthesis of analogues. 
Following the synthesis steps from previous studies on zafirlukast (274-279), the 
indole nitrogen underwent alkylation in the presence of zinc bromide (1) followed by 
methylation to give (2). The nitro group was reduced to amine (3) and acylated to give 
the target carbamate compounds without the sulfonamide moiety (4-11) (R1 in Scheme 
6.1). On the other hand, the methyl ester of (2) was hydrolyzed to give the 
corresponding carboxylic acid (12) followed by reactions with sulfonamide with various 
substituents to give the target sulfonamide compounds without the carbamate domain 
(13-23) (R2 in Scheme 6.2). In the above two series, we kept the truncated portion of the 
molecule stable by capping them with methyl ester and nitro group, though we note that 
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there is liability such as toxicity that associated with the nitro group (280). However, we 
clarify here that our primary goal is to examine if the carbamate domain is required for its 
inhibition mechanism and not directly for therapeutic purposes. We made analogues of 
the truncated series to assess preliminarily if the side group has a flat SAR (which may 
indicate that they are not worth further pursuing in designing subsequent analogues) or if 
they are indeed contributing to the inhibitory effects. 
 
Scheme 6. 1. Variation of R1 and R3 groups of the initial zafirlukast structure.  
Reagents and conditions: (a) ZnBr2, DIPEA, dioxane, RT, 40 hr, (b) NaH, MeI, THF, RT, 2 hr, (c) 
Pd/C, H2, THF, RT, 16 hr, (d) Various chloroformates (R1), Et3N, DCM, 4C, 24 hr, (e) LiOH, 
THF/H2O, RT, 20 hr, (f) Various sulfonamides (R3), DMAP, EDC, DCM, RT, 24 hr. 
As a result of the reduced percent inhibition and lack of inhibition mechanism of 
the sulfonamide truncated derivatives (4-11), we moved on to explore the importance of 
this sulfonamide moiety. We maintained the original cyclopentyl carbamate of zafirlukast 
(4) while the methyl benzoate was hydrolyzed to benzoic acid (24) and coupled with 
various sulfonamide substituents to provide the desired analogues (25-34) (R3 in 
Scheme 6.1). We have adopted the strategy to probe the steric involvement of the aryl 
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sulfonamide by manipulating the position of methyl substituent on the phenyl along with 
increasing steric bulk as well as the electronegativity of the substituent at the para 
position. In addition, we tested the carbon tolerance of the compounds by increasing the 
size of the molecule. Furthermore, we also tested other heterocycles as compared to 
phenyl with the aim to reduce lipophilicity of the molecule.  
On the other hand, carbamate truncated derivatives displayed weakened affinity, 
leading to our investigation on the significance of the carbamate domain while fixing the 
most potent 4-(trifluoromethyl)benezene sulfonamide (28). Analogue 28 underwent 
reduction to give amine (35) followed by coupling with carbamates with various 
substituents to afford 36-43 (R4 in Scheme 6.2).  We initially varied the size of the 
alicyclic ring between four to six members. We then built alkyl substituents with 
increasing branching from methyl to tert-butyl. Finally, we added oxygen to two of the 
derivatives, again with the goal to reduce the lipophilicity.  
 
Scheme 6. 2. Variation of the R2 and R4 groups of the initial zafirlukast structure.  
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Reagents and conditions: (a) ZnBr2, DIPEA, dioxane, RT, 40 hr, (b) NaH, MeI, THF, RT, 2 hr, (c) 
LiOH, THF/H2O, RT, 20 hr, (d) Various sulfonamides (R2), DMAP, EDC, DCM, RT, 24 hr, (e) 
Pd/C, H2, THF, RT, 16 hr, (f) Various chloroformates (R4), Et3N, DCM, 4C, 24 hr. 
Currently, we are examining the importance of the substituents on the indole core as 
well as on the 3-benzyl group. Different intermediates (44-54) will be prepared with 
either methyl substituted on the nitrogen or free indole together with either methoxy 
substituted or free benzyl to couple with the optimized 4-(trifluoromethyl)benezene 
sulfonamide and the isopropyl carbamate to give the target compounds (55-57) 
(Scheme 6.2). 
6.4.2. Cellular and biochemical assays to determine the biological activity of 
analogues 
Compounds were evaluated for their potential to inhibit ligand stimulated TNFR1 
induced NF-κB activation, both their half maximal effective concentration (IC50) and 
percent inhibition, in HEK293 cells expressing endogenous TNFR1 which is a validated 
platform in testing the compounds (190). In addition, in order to determine if the 
compounds are specifically binding the receptor and exerting their functional effects, 
rather than inhibiting other proteins in the signaling pathways non-specifically, we also 
used a TNFR1 knockout (KO) HAP1 cell line established by CRISPR, together with the 
control HAP1 wild-type (WT) cell line (270). Furthermore, we tested the effect of 
compounds in TNFR1-associated death domain (TRADD)-induced NF-B activation, 
independent of ligand activation of TNFR1, in HEK293 cells to eliminate non-specific 
effect in the intracellular signaling directly downstream of TNFR1 (229, 270). Once 
confirming the biological activity of the compounds, we then investigated their 
mechanism of action in disruption of receptor-receptor interactions by performing native 
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gels of PLAD with treatments of compounds (Supplementary Fig. 6.1) as well as testing 
their effect on the TNFR1 FRET biosensor (190, 270). 
Replacement of the aryl sulfonamide in zafirlukast with methyl ester (4) 
significantly decreased percent inhibition and completely abolished the ability of the 
compounds in disrupting PLAD-PLAD interactions (Table 6.1). In addition, all other 
compounds in this R1 series, which lack the sulfonamide domain (5-11) (Table 6.1), also 
did not show disruption of the dimeric PLAD, directly highlighting the importance of 
sulfonamide moiety in the inhibition mechanism of the compounds. Keeping the 
compounds as methyl benzoate, we then varied the carbamate domain to see if we can 
regain activity. We first switched cyclopentyl to phenyl derivatives (5-6) and both the 
potency and the percent inhibition were weakened. From phenyl, we included a 
methylene spacer to reduce rigidity by switching the molecule to contain a benzyl 
carbamate (7), which greatly increased the potency and the percent inhibition. However, 
this molecule did not tolerate larger substituents on the benzyl such as the nitro (8) or 
9h-fluoren-9-ylmethyl (FMOC) group (9) as these molecules had very weak or no 
activity. Since a large substituent was not favorable, we further reduced the molecule 
size while keeping the flexibility in alkyl region by synthesizing the ethyl carbamate (10) 
which indeed illustrated the best activity in this series with both improved potency and 
activity. Finally, we tested a larger alkyl group with a tert-butyl carbamte (11) and the 
activity was reduced, suggesting that a small group is highly favorable at this position. 
However, we noted that the specificity of the molecule was significantly decreased with 
the removal of the sulfonamide domain, as shown through the inhibition of the basal NF-
κB activation in the HAP1 TNFR1 KO cells, further confirming the importance of the 
sulfonamide group for TNFR1 specific targeting. Interestingly, the hydrolysis of 4 to 
benzoic acid (24) results in a strong TNFR1 specific activator (Table 6.1). This suggests 
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that the acid element, which contains a negative charge in physiologically condition, 
rather than the ester, is important for specificity. More importantly, the sulfonamide 
moiety behaves like a molecular switch in controlling receptor activation (when the 
molecule does not contain sulfonamide) or inhibition (when it contains a sulfonamide 
group that results in disruption of receptor-receptor interaction). 



































4 Cyclopentyl  14 28 22 20 12 26 - - No 
5 4-Methylphenyl 145 14 - - 18 25 - - No 
6 4-Chlorophenyl  148 47 - - 125 45 - - No 
7 Benzyl  8.2 66 - - 6.8 60 - - No 
8 4-Nitrobenzyl  127 21 - - >200 14 - - No 
9 9H-Fluoren-9-
ylmethyl 
>200 0 - - >200 25 - - No 
10 Ethyl 6.5 60 7.9 75 9.3 57 - - No 
11 Tert-butyl 35 38 - - 24 44 - - No 




% act  EC50 
(M) 
% act  EC50 
(M) 
% act  EC50 
(M) 
% act  Yes/No 
24 Cyclopentyl 52 93 56 112 >200 0 - - No 
 
The other portion of zafirlukast contains a cyclopentyl carbamate connected at 
the C-5 of the indole. Replacement of cyclopentyl carbamate with a nitro group (13) 
(Table 6.2) resulted in more than four-fold decrease in potency, as shown through the 
increase in IC50 from 25 to 114 M while the percent inhibition remained similar and the 
molecule was still able to disrupt the dimeric PLAD. This provides a strong evidence that 
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the carbamate moiety is highly important in controlling the affinity and potency of the 
molecule. We followed by testing the effect of varying the sulfonamide domains in this 
carbamate truncated series (14-23) (Table 6.2). The compounds were synthesized with 
the sulfonamide domain containing 1) electron-withdrawing and donating substituents at 
the ortho, meta, and para positions, 2) varying sizes of substituents (from methyl to 
naphthyl), 3) different aromatic systems or heterocycles, and 4) N-alkylation of the 
sulfonamide. Removal of the ortho substituted methyl group or changing it to the meta or 
para position (13-16) resulted in nearly twice increase in the percent inhibition to near full 
inhibition, while the weak potency remained similar. This suggests that the ortho position 
may be subject to steric hindrance and hence preventing the inhibition capacity. 
Changing the para position to from methyl to chloro group (17) significantly increased 
the potency, indicating the need for large electronegative group at this position and the 
possibility in further improving the potency through changing the para substituent on the 
phenyl too. However, a larger naphthyl group (18) greatly reduced the potency while 
maintaining relatively high percent inhibition. Deviation from the phenyl group on the 
sulfonamide (19-22) with other heterocycles interestingly resulted in no disruption of 
PLAD-PLAD interactions and greatly reduced potency and percent inhibition, indicating 
that the phenyl group or the aromatic ring is highly responsible for the inhibition 
mechanism and compound activity. Finally, N-alkylation of the sulfonamide (23) 
completely abolished the compound activity, suggesting that the amino group of the 
sulfonamide is a bioisostere of the carboxylic acid and potentially mimic the negative 
charge. The compounds in this R2 series, though illustrating some non-specificity, were 
in general relatively more specific than the compounds in the R1 series, potentially due to 
the presence of the sulfonamide domain. 




































13 2-Methylphenyl 114 55 115 51 No 58 - - Yes 
14 3-Methylphenyl 11 91.6 - - 131 42 - - Yes 
15 4-Methylphenyl 175 96 - - No 0 - - Yes 
16 Phenyl  12 95 - - No 0 - - Yes 
17 4-Chlorophenyl  86 94 102 90 No 73 - - Yes 
18 2-Naphthyl  105 87 - - No 53 - - Yes 
19 2-Thiophenyl  124 81 - - No 36 - - No 
20 Methyl  >200 0 - - No 55 - - No 
21 2-Pyridyl  >200 0 - - 185 30 - - No 
22 Cyclopropyl  111 41.4 - - 159 41 - - No 
23 N,2-
dimethylbenzenesulfonamide 
176 25 - - No 0 - - No 
 
From the both truncated series, we observed both the importance of sulfonamide 
moiety in the inhibition activity and mechanism and the key role of the carbamate 
domain in determining the affinity of the molecule. Both groups are also important in 
compound specificity as the removal of either (Table 6.1 or 6.2) or both groups 
(Supplementary Table 6.1) greatly reduced the specificity of compound to TNFR1. With 
this, we synthesized two more series of analogues, first with variation in the sulfonamide 
group while keeping the cyclopentyl carbamate (R3, 25-34) (Table 6.3) followed by 
keeping the optimized sulfonamide side group with the best potency and activity and 
further changing the carbamate group to improve on the affinity and potency (R4, 36-43) 
(Table 6.4). Finally, we sought to combine the knowledge from both series and make 
further changes to the indole and/or the benzyl group (R5, 55-57) (Table 6.5) to 
potentially yield the best molecule.  



































25 3-Methylphenyl  95 90 - - >100 30 >100 0 Yes 
26 4-Methylphenyl  30 93 - - >50 65 >100 0 Yes 
27 4-Chlorophenyl  14 96 - - 36 54 >100 0 Yes 
28 4-Trifluoromethylphenyl 5.2 95 4.9 92 >100 24 >100 38 Yes 
29 4-Nitrilephenyl  81 94 - - >100 29 >100 0 Yes 
30 4-Pentafluorosulfanyl  61 96 - - >100 53 >100 13 Yes 
31 4-Tertbutylphenyl  120 55 - - >50 40 >100 0 Yes 
32 4-Pyridyl  135 77 - - >50 55 >50 31 No 
33 1,3-Dimethyl-1H-
pyrazole 
149 62 - - >100 0 >100 0 No 
34 Morpholinyl 155 54 - - >100 0 >100 0 No 
 
In the R3 series of the sulfonamide analogues, we prepared a systematic set of 
sulfonamide analogues with only a single change from zafirlukast by keeping the 
cyclopentyl unchanged (Table 6.3). As suggested from the R2 truncated series of 
compounds, we first changed the methyl substituent from the ortho to the mata position 
(25) which resulted in an expected increase in the percent inhibition (to full inhibition) at 
the expense of the potency (55 to 95 M). Interestingly, further changing of the methyl 
substituent from meta to the para position (26) allowed the molecule to regain its 
potency (95 to 30 M) while maintaining at full inhibition. As informed by the truncated 
series that an electronegative substitution such chloro group helps in improving the 
potency. Indeed, the 4-chlorobenzene group (27) further enhanced the potency by two-
fold to 14.0 M. We then further increased the electronegativity of the phenyl 
substituents by synthesizing a trifluoromethyl group at the para position (28) which 
resulted in another three-fold increase in the potency to 5.2 M while still maintaining the 
full inhibition. We then tested the carbon tolerance of the molecule by expanding the size 
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of the molecule (29-31) which interestingly reduced the potency as well as the percent 
inhibition of the molecule, indicating that an optimized carbon number was achieved in 
28. To confirm the importance the phenyl group or aromatic ring on the sulfonamide 
domain in disrupting PLAD-PLAD interactions, we synthesized other heterocycles with 
pyridyl (32), pyrazole (33) and morpholinyl (34) groups attached to the sulfonamide and 
indeed they did not disrupt the dimeric PLAD and illustrated substantial decreased 
potency and activity. From this series, we obtained a 4-trifluoromethylphenyl group on 
the sulfonamide domain (28) with a five-fold improvement in the relative IC50 (26 to 5.2 
M) and a ten-fold improvement in the absolute IC50 (51 to 5.2 M) with maximum 
percent inhibition. In addition, the electronegative substituent of trifluoromethyl made the 
negative charge on the amino group of the sulfonamide more negative charged. In terms 
of specificity, compound 28 is highly specific to TNFR1 as shown through the HAP1 
TNFR1 KO cells. However, it appeared that the increase in potency comes at the 
expense of some non-specificity in the intracellular signaling pathway, though at high 
concentration (ten-fold greater than the IC50) in the inhibition of TRADD-induced NF-κB 
activation. This suggests the need to further optimize the cyclopentyl carbamate portion 
of 28 to obtain better potency and specificity. 
Table 6. 4. Alteration of R4 carbamates on the initial zafirlukast structure. 
 

































36 Cyclobutyl  41 85 52 82 >100 0 >100 0 Yes 
37 Cyclohexyl  36 95 22 88 >100 15 >100 0 Yes 
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38 Methyl  0.75 54 0.93 60 >100 0 >100 0 No 
39 Ethyl  1.6 42 0.96 65 >100 0 >100 0 No 
40 Isopropyl  0.86 92 0.72 94 >100 0 >100 0 Yes 
41 Tert-butyl  4.5 37 3.4 38 >100 0 >100 0 No 
42 Methoxyethyl  3.3 40 3.1 58 >100 0 >100 0 No 
43 Tetrahydrofuran-3-yl 4.7 43 4.5 32 >100 0 >100 0 No 
 
In order to further improve the potency and specificity of the molecule, we 
synthesized analogues with the optimized 4-trifluoromethylphenyl substituent on the 
sulfonamide moiety with varying carbamate domain (R4, 36-43) (Table 6.4). We first 
varied alicyclic substituent from cyclopentyl  to cyclobutyl (36) or cyclohexyl (37). Both 
36 and 37 showed a reduction in the potency or IC50 of the molecule while maintaining 
near full inhibition and disrupting dimeric PLAD. As suggested by the R1 truncated 
series, an alkyl group may potentially help in improving the potency. We then 
synthesized four alkyl carbamates with increased branching, consisting of methyl (38), 
ethyl (39), isopropyl (40) and tert-butyl (41) substituents. Strikingly, we observed a 
significant improvement in the IC50 of the molecule from single-digit micromolar to 
submicromolar potency in 38-40. However, 38 and 39 only exhibited partial inhibition 
(40-60% inhibition), potentially due to their lack of ability in disrupting PLAD-PLAD 
interactions. Compound 40 appeared as the best molecule with IC50 between the range 
of 0.72-0.86 M and exhibited full inhibition with disruption of dimeric PLAD (Fig. 6.2A). 
Further increase in the size of the molecule to tert-butyl carbamate (41) reduced the 
potency back to single-digit micromolar and abolished the ability of the compound to 
disrupt dimeric PLAD, leading to partial inhibition. We also tested the addition of more 
polar oxygen atom to the compounds such as the methoxyethyl carbamate (42) or the 
tetrahydrofuran-3-yl carbamate (43) to reduce the lipophilicity of the compound but they 
resulted in weakened potency and percent inhibition respectively. In addition, all the 
analogues in this R4 series, including 40, illustrated very high specificity to TNFR1 as 
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there is no inhibition in both the basal level of NF-κB activation in the HAP1 TNFR1 KO 
cells (Fig. 6.2B) as well as the TRADD-induced NF-κB activation (Fig. 6.2C).  
Table 6. 5. Alteration of R5 3-benzylindole core on the initial zafirlukast structure. 
 
















Cpd X Y IC50 
(M) 
% red  IC50 
(M) 
% red  IC50 
(M) 
% red  IC50 
(M) 
% red  Yes/No 
55 H OMe TBD TBD TBD TBD TBD TBD TBD TBD TBD 
56 Me H TBD TBD TBD TBD TBD TBD TBD TBD TBD 
57 H H TBD TBD TBD TBD TBD TBD TBD TBD TBD 
 
To further confirm the inhibition mechanism quantitatively, we tested the potency 
of the analogues in disrupting receptor-receptor interactions by performing the 
fluorescence resonance energy transfer (FRET) experiments with the previously 
established TNFR1 FRET biosensor treated with compound 28 and 40 as well as 
zafirlukast. The FRET results showed that all compounds reduced FRET in the 
biosensor, confirming the disruption of receptor-receptor interactions. Importantly, both 
analogues 28 and 40 reduced FRET to a greater extent and with a better potency of 15 
and 4.2 M respectively as compared to 17 M for zafirlukast (Fig. 6.2D). This 
observation is consistent with the functional effects of the compounds, thus confirming 
that these analogues are novel receptor-specific inhibitors of TNFR1 with enhanced 
potency and biological activity.  
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Figure 6. 2. Biological characterization of the best analogues (cpd 40 and 28) and 
zafirlukast.  
Effect of compounds on NF-κB activation in (A) HAP1 WT cells, (B) HAP1 TNFR1 KO cells, (C) 
HEK293 cells with TRADD overexpression and (D) FRET measurements with TNFR1 FRET 
biosensors. 
6.5. Conclusion 
We synthesized a systematic series of 5-amino-3benzyl-1H-indole analogues 
based on a scaffold of zafirlukast obtained from a FRET-based HTS to discover 
inhibitors that disrupt TNFR1 receptor-receptor interaction. The SAR demonstrates that 
the carbamate moiety at C-5 of the indole plays a critical role in the binding affinity and 
the potency of the molecule. On the other hand, the sulfonamide domain coupled to the 
benzoic acid is important in the inhibition mechanism and the extent of inhibition. In 
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addition, both functional groups are required for compound specificity for TNFR1. We 
obtained an analogue with 4-(trifluoromethyl)benzene sulfonamide and isopropyl 
carbamate (40) that strongly inhibits ligand induced NF-κB activation with more than 60-
fold improved potency (absolute IC50) than the initial hit. In addition, compound 40 
disrupts receptor-receptor interactions and reduces FRET in the FRET assay with 
enhanced potency as well as having high specificity to TNFR1. Synthesis of additional 
analogues with variation in the 3-benzylindole core (as proposed in R5) may further 
improve the potency and efficacy of the molecule. We note here that the 4-
(trifluoromethyl)benzene sulfonamide and isopropyl carbamate of our current best 
compound are novel structure (not found in existing literatures that study SAR of 
zafirlukast), making 40 a novel potent receptor-specific inhibitor of TNFR1 signaling. This 
new scaffold can increase the compound specificity to TNFR1 and further differentiating 
inhibitors between TNFR1 and other proteins (e.g. leukotriene receptor).  
In addition, there is potential, though outside the scope of this study, to examine 
those compounds that did not act through disruption of PLAD-PLAD interactions (e.g. 38 
and 39). Some of these compounds that inhibited TNFR1 stimulated NF-κB activation 
may be allosteric inhibitors and further investigation may be able to understand the 
interplay between allostery and receptor dimerization. Furthermore, the identification of a 
receptor-specific activator (24) from subtle change in the initial hit suggests the potential 
in using these analogues as probe to understand TNFR1 activation in general, in 
addition to finding potent inhibitors. Further efforts will be required to test the 
pharmacological properties, metabolic stability and effects of the compounds in animal 
models of inflammation prior to pre-clinical assessment of this class of compounds.  
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Supplemental Figure 6. 1. Native gel characterization of analogues.  
Characterization of the ability of analogues R1 (4-11 and 24), R2 (13-23), R3 (25-34) and R4 (36-
43) as well as Rx and Ry (1-3, 12 and 58-60) in disrupting TNFR1 PLAD-PLAD interactions.  
Supplemental Table 6. 1. Alteration of side groups on the 3-benzylindole without the 
carbamate or sulfonamide domains. 
 



































2 NO2 Me Me 52 59 - - 39 53 - - No 
3 NH2 Me Me 120 62 - - >200 22 - - No 
12 NO2 H Me >200 33 - - >200 0 - - No 
1 NO2 Me H 20 91 - - 16 78 - - No 
58 NH2 Me H 149 86 - - >150 43 - - No 
59 NO2 H H 130 29 - - >200 39 - - No 
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7.1. Summary 
Understanding the heterogeneous pathology in Alzheimer’s disease (AD) and 
related tauopathies is one of the most urgent and fundamental challenges facing the 
discovery of novel disease modifying therapies. Through monitoring ensembles of toxic 
and non-toxic tau oligomers spontaneously formed in cells, our biosensor technology 
can identify tool compounds that modulate tau oligomer structure and toxicity, providing 
much needed insight into the nature and properties of toxic tau oligomers.  
Background: 
Tauopathies are a group of neurodegenerative disorders characterized by 
pathological aggregation of the microtubule binding protein tau. Recent studies suggest 
that tau oligomers are the primary toxic species in tauopathies. 
New/Updated Hypothesis: 
We hypothesize that tau biosensors capable of monitoring tau oligomer 
conformation are able to identify tool compounds that modulate the structure and 
conformation of these tau assemblies, providing key insight into the unique structural 
fingerprints of toxic tau oligomers. These fingerprints will provide gravely needed 
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biomarker profiles to improve staging of early tauopathy pathology as well as generate 
lead compounds for potential new therapeutics. Our time-resolved FRET (TR-FRET) 
biosensors provide us an exquisitely sensitive technique to monitor minute structural 
changes in monomer and oligomer conformation. In this proof-of-concept study, we 
identified a novel tool compound, MK-886, which directly binds tau, perturbs the 
conformation of toxic tau oligomers, and rescues tau induced cytotoxicity. Furthermore, 
we show that MK-886 alters the conformation of tau monomer at the proline-rich and 
microtubule binding regions, stabilizing an on-pathway oligomer. 
Major Challenges for the Hypothesis: 
Our approach monitors changes in the ensemble of assemblies that are 
spontaneously formed in cells but does not specifically isolate or enrich unique toxic tau 
species. However, TR-FRET does not provide high-resolution, atomic scale information, 
requiring additional experimental techniques to resolve the structural features stabilized 
by different tool compounds.  
Linkage to Other Major Theories: 
Our biosensor technology is broadly applicable to other areas of tauopathy 
therapeutic development. These biosensors can be readily modified for different 
isoforms of tau, specific post-translational modifications, as well as familial AD 
associated mutations. We are eager to explore tau interactions with chaperone proteins, 
monitor cross-reactivity with other intrinsically disordered proteins, and target seeded 
oligomer pathology.  
Objective 
This paper emphasizes the need for targeting the heterogeneous ensemble of 
toxic tau oligomers in Alzheimer’s disease (AD) and other tauopathies based on 
emerging biosensor technology. We report on two novel cellular fluorescence resonance 
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energy transfer (FRET) biosensors that monitor tau oligomer and monomer 
conformations and can be used as a high-throughput screening (HTS) platform to 
identify novel tool compounds that modulate tau oligomer conformations, thereby 
attenuating their toxicity. With our biosensors and HTS platform we are poised to (1) 
study the conformational ensemble of tau oligomers; (2) identify novel tool compounds 
capable of targeting tau species, both monomer and oligomer, to disrupt oligomer 
formation or stabilize different tau conformations; (3) develop a biophysical fingerprint 
that delineates toxic and non-toxic oligomers, allowing us to better stage tau pathology, 
improve biomarker development, and reduce the heterogeneity present in clinical trials; 
and (4) provide a novel therapeutic pipeline to identify lead compounds that target 




Tauopathies, including AD, are a group of neurodegenerative disorders 
characterized by the presence of tau inclusions in affected brain regions (69). Despite 
decades of rigorous and focused research, there are currently no significant disease 
modifying therapies for AD or related tauopathies (96). Furthermore, there is a dearth of 
compounds that target tau, with only five out of the 105 small molecules currently in 
clinical trials being tau-focused (97, 98). Hence, there is desperate need for technologies 
that enable the identification of tau-focused disease-modifying therapies (98-100). 
Tau is an intrinsically disordered protein (IDP) that plays an important role in the 
regulation of microtubule stability and axonal transport (68). Under pathological 
conditions, tau is hyperphosphorylated and detaches from microtubules, accumulating in 
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the cytosol (70). These pathological conditions have been correlated with upstream 
mitochondrial dysfunctions in the Krebs cycle and/or the electron transport system, 
oxidative stress (71, 72), as well as defects in neuron morphology and axonal transport 
(73). Unbound tau can misfold, initiating the tau fibrillogenesis cascade with an initial 
formation of tau oligomers that subsequently nucleate into paired helical filaments 
(PHFs), and eventually intracellular NFTs (Fig. 7.1) (74). NFTs have been the primary 
histopathological hallmark of tauopathies, with their presence in the brain showing 
significant correlation with the degree of cognitive impairment (75). However, recent 
studies suggest that these large insoluble NFTs are not the principle toxic species, 
implicating soluble oligomeric tau—intermediate tau assemblies formed prior to PHFs—
in the induction of neurodegeneration (78, 83). Tau oligomers promote cytotoxicity in 
vitro and are linked to neurodegeneration and cognitive phenotypes in vivo (76-82). They 
exist as an ensemble of distinct assemblies which include both toxic and non-toxic, on- 
and off-pathway species along the fibrillogenesis cascade (Fig. 7.1) (87-93). Critically, 
no specific toxic tau oligomer species has been isolated or identified to date (86, 94, 95). 
Rationale 
Recent efforts to target toxic tau oligomers have yielded compounds with low 
micromolar IC50 (137-143). Of these small molecules, only methylene blue advanced to 
phase III clinical trials, albeit with unsuccessful results (144). One commonality among 
these molecules is that they were initially identified using in vitro purified protein assays 
(137-143). These systems do not recapitulate the cellular environment, lacking the 
numerous chaperone proteins that may be required to produce the ensemble of tau 
oligomers that populate the fibrillogenesis cascade. Additionally, purified protein assays 
are only capable of identifying hits that directly perturb tau and are wholly naive against 
indirect mechanism of action (MOA). Furthermore, many of the small molecules 
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discovered in purified protein assays disrupted both fibrils and tau oligomers, the former 
having recently been suggested to be potentially inert and neuroprotective (281). 
Therapeutic development for tauopathies has thus begun to shift from targeting large 
fibrillar aggregates to inhibiting or disrupting the formation of these toxic tau oligomers 
(83-86). The complex heterogeneity of tau oligomers likely requires the cellular 
environment (e.g. post-translational modifications (PTM) and chaperone proteins) to 
produce the ensemble of toxic and non-toxic tau assemblies. Hence, a cellular biosensor 
approach capable of monitoring this ensemble holds promise as a novel HTS platform to 
discover more effective therapeutics. 
Building upon the groundbreaking biosensors developed by the Diamond group 
(which were engineered to detect pathogenic species in patient biofluids as a biomarker 
for AD diagnosis) (282), we have developed a technology platform that directly monitors 
spontaneous tau oligomerization in cells, enabling therapeutic targeting of early-stage 
tau pathology. Our robust assay can be easily modified to accommodate additional 
tauopathy cell models and new pathological phenotypes as they continue to be 
elucidated. Through our approach we will develop two unique classes of tool 
compounds, direct tau binders and indirect tau effectors (modifying tau oligomers 
through orthogonal pathways). The interplay between direct and indirect MOA and 
corresponding changes to tau oligomer conformations and toxicity will provide much 
needed insight into tau pathology. 
We engineered two distinct FRET biosensors to monitor tau oligomerization. 
These biosensors were used for HTS of the NIH Clinical Collection (NCC) library using 
our state-of-the-art fluorescence lifetime plate reader (FLT-PR) (283). Fluorescence 
lifetime (FLT) detection increases the precision of FRET-based screening by a factor of 
30 compared with conventional fluorescence intensity detection (284), and provides 
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exquisite sensitivity to resolve minute structural changes within protein ensembles. This 
sensitivity allows direct detection of conformational changes within an ensemble of 
oligomers (e.g. conversion from toxic to non-toxic oligomers), the dissociation of 
oligomers, or even changes in monomer conformations (190, 226, 270). The FRET 
biosensors express full-length 2N4R wild-type (WT) tau and fluorescent protein fusion 
constructs in living cells, allowing us to monitor inter-molecular or intra-molecular tau 
interactions. Using full-length 2N4R WT tau ensures the targeting of spontaneously 
formed ensembles of tau oligomers, not fibrils, as the 2N4R isoform of WT tau does not 
fibrillize without seeding (285-288).  
After first establishing that the new technology platform specifically monitors tau 
oligomer formation (using known tau aggregators), we identified a small molecule, MK-
886, that directly binds tau and strongly attenuates FRET with an EC50 of 1.40 μM in our 
HTS HEK293 cells (and a FRET EC50 of 1.06 μM in SH-SY5Y cells). The compound 
rescues tau induced cell cytotoxicity with an IC50 of 0.523 μM. To elucidate the MOA, we 
used an advanced single-molecule FRET (smFRET) technique to show that MK-886 
perturbs the folding of purified, monomeric tau in the proline-rich and microtubule-
binding regions. This effect is recapitulated in our cellular intra-molecular FRET 
biosensor and indicates an unfolding of the two termini of tau. 
To further explore MK-886’s MOA we employed a heparin induced thioflavin-T 
(ThT) aggregation assay with purified tau. MK-886 reduces the lag phase of tau 
fibrillization and is unable to nucleate tau fibrillization without the presence of heparin. It 
has been shown that overexpression of P301L tau does not induce fibril formation in SH-
SY5Y cells (288), suggesting that P301L tau induced toxicity is due to toxic oligomer. 
Because MK-886 rescues tau induced cytotoxicity while not fully ablating tau oligomer 
associated FRET, we hypothesize that the rescue of P301L tau induced cytotoxicity by 
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MK-886 is through conversion of toxic tau oligomers into non-toxic oligomers. Whether 
these new oligomers are on- or off-pathway species is difficult to determine in our 
cellular system, without the use of inducers. Thus, the rescue of P301L tau induced 
toxicity could be through an accelerated conversion of toxic tau oligomers into 
neuroprotective fibrils. Nevertheless, our new technology is well suited to identify novel 























Figure 7. 1. Tau fibrillogenesis cascade for tauopathies and Alzheimer’s disease (AD).  
The intrinsically disordered tau monomer is capable of misfolding into spontaneously formed 
oligomers, producing toxic assemblies implicated in AD (arrows a1 and a2). While oligomers are 
metastable and difficult to monitor with high precision and accuracy, the large assemblies (paired 
helical filaments (PHFs) and neurofibrillary tangles (NFTs), arrows b1 and b2) form irreversibly 
with β-sheet structures. The fibrillar species can be excreted via exosomes leading to a prion-like 
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cell-to-cell propagation of pathology and may induce seeded oligomerization. NFTs may be 
neuroprotective by sequestering toxic oligomers and disruption of NFTs may induce toxicity from 
elevated concentrations of toxic oligomers. Our cellular time-resolved fluorescence resonance 
energy transfer (FRET) biosensors target reversible spontaneous oligomerization (a1 and a2), 
while also monitoring seeded aggregation and downstream processes such as fibrillization (b1 
and b2) with high sensitivity. 
 
New or updated hypothesis 
Updated hypothesis: We hypothesize that the spontaneously formed ensemble 
of tau oligomers includes early-stage toxic tau species and by resolving conformational 
differences between toxic and non-toxic oligomers, we can target toxic tau assemblies, 
thereby rescuing tau induced pathology. Small-molecule modulation of tau 
conformations can be correlated with changes in the FRET signal as well as tau induced 
cytotoxicity. Lastly, through investigating tau oligomerization in the cellular environment, 
we include other protein machineries (e.g. chaperone proteins) which may play 
significant roles in tau pathogenesis. 
7.3. Materials and methods 
7.3.1. Molecular biology 
To generate tau-GFP and tau-RFP, cDNA encoding full-length 2N4R tau (441 
amino acids) was fused to the N-terminus of EGFP and TagRFP vectors. The P301L 
mutation was introduced by QuikChange mutagenesis (Agilent Technologies, Santa 
Clara, CA) and sequenced for confirmation. The GFP-tau-RFP was generated by fusing 
the N-terminal of tau to the C-terminus of GFP and the C-terminus of tau to the N-
terminus of RFP. All constructs contain the monomeric mutation A206K to prevent 
constitutive fluorophore clustering (204).  
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7.3.2. Cell culture and generation of stable cell lines 
HEK293 and SH-SY5Y cells (ATCC) were cultured in phenol red-free Dulbecco's 
Modified Eagle Medium (DMEM, Gibco) supplemented with 2 mM L-Glutamine 
(Invitrogen), heat-inactivated 10% fetal bovine serum (FBS HI, Gibco), 100 U/ml 
penicillin and 100 g/ml streptomycin (Gibco). Cell cultures were maintained in an 
incubator with 5% CO2 (Forma Series II Water Jacket CO2 Incubator, Thermo Scientific) 
at 37 ºC. Both the WT and P301L tau inter-molecular FRET biosensor were generated 
by transiently transfecting HEK293 cells using Lipofectamine 3000 (Invitrogen) with WT 
or P301L tau-GFP and tau-RFP (1:20 DNA plasmid concentration ratio). The 
effectiveness of HEK293 cells transfected with FRET constructs as a HTS platform has 
been demonstrated in our previous work (190, 226). P301L tau inter-molecular FRET 
biosensor was also transiently expressed in SH-SY5Y cells using Lipofectamine 3000 
(Invitrogen). To generate stable cell lines expressing GFP-tau-RFP or tau-GFP only, 
HEK293 cells were transiently transfected using Lipofectamine 3000 with GFP-tau-RFP 
or tau-GFP DNA plasmids. Transiently transfected cells were treated with G418 (Enzo 
Life Sciences, Farmingdale, NY) to eliminate non-expressing cells. Stable cell lines 
expressing GFP-tau-RFP or tau-GFP with the largest population of expressing cells 
were selected by fluorescence microscopy. The GFP-linker-RFP (linker contains 32 
amino acids, GFP-32AA-RFP) control stable cell line was generated as described 
previously (289). The control cells expressing only free soluble fluorophores (GFP or 
RFP only) were generated by transiently transfecting HEK293 cells using Lipofectamine 
3000 with plasmids containing GFP or RFP DNAs at the same plasmid concentration as 
the inter-molecular tau FRET biosensor. 
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7.3.3. Pilot screening with NIH clinical collection (NCC) library 
The NIH Clinical Collection (NCC) library, containing 727 compounds, was 
purchased from Evotec (Hamburg, Germany), formatted into 96-well mother plates using 
an FX liquid dispenser, and formatted across three 384-well plates at 50 nL (10 μM final 
concentration/well) using an Echo liquid dispenser. DMSO (matching %v/v) was loaded 
as in-plate no-compound negative controls to make a total of 960 wells. The 384-well 
flat, black-bottom polypropylene plates (PN 781209, Greiner Bio-One) were selected as 
the assay plates for their low autofluorescence and low interwell cross talk. The plates 
were sealed and stored at −20 °C until use. Two days prior to screening, HEK293 cells 
were transfected using Lipofectamine 3000 with WT tau-GFP/RFP (WT tau FRET 
biosensor) in 15 x 100 mm plates (5 x 106 cells/plate) and the stable tau-GFP cell line 
(donor-only control) was expanded in five 225 cm2 flasks. On each day of screening, the 
compound plates were equilibrated to room temperature (25 °C). The cells were 
harvested from the 100 mm plates by incubating with TrypLE (Invitrogen) for 5 min, 
washed three times in PBS by centrifugation at 300 g and filtered using 70 μm cell 
strainers (BD Falcon). Cell viability, assessed using a trypan blue assay, was >95%. 
Cells were diluted to 1 million cells/ml using an automated cell counter (Countess, 
Invitrogen). Expression of tau-GFP and tau-GFP/RFP (tau FRET biosensor) was 
confirmed by fluorescence microscopy prior to each screen. After resuspension and 
dilution in PBS, the biosensor cells were constantly and gently stirred using a magnetic 
stir bar at room temperature, keeping the cells in suspension and evenly distributed to 
avoid clumping. During screening, cells (50 μl/well) were dispensed by a Multidrop 
Combi Reagent Dispenser (Thermo Fisher Scientific) into the 384-well assay plates 
containing the compounds and allowed to incubate at room temperature for 2 hours 
before readings were taken by the fluorescence lifetime plate reader (Fluorescence 
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Innovations, Inc) as described previously (190, 226).  
7.3.4. HTS and fluorescence lifetime data analysis 
As described previously (190, 226), time-resolved fluorescence waveforms for 
each well were fit with single-exponential decays using least-squares minimization global 
analysis software to give donor-acceptor lifetime (τDA) and donor-only lifetime (τD). FRET 
efficiency (E) was then calculated based on Equation 1. 
𝐸 = 1 − (
𝜏𝐷𝐴
𝜏𝐷
)  𝐸𝑞. 1 
Assay quality was determined with the lead compound (MK-886) as positive control 
and DMSO as a negative control and calculated based on Equation 2 (192), 
𝑍′ =  1 −
3(𝜎𝑝 + 𝜎𝑛)
|𝜇𝑝 − 𝜇𝑛|
 𝐸𝑞. 2 
where σp and σn are the standard deviations (SD) of the observed τDA values, and µp and 
µn are the mean τDA values of the positive and negative controls. To make this metric 
less sensitive to strong outliers, we utilized the normalized median absolute deviation 
(1.4826*MAD) and median in place of the standard deviation and mean, respectively 
(193). 
Fluorescent compounds were flagged as potential false positives due to interference 
from compound fluorescence by a set of stringent fluorescent compound filters based on 
analysis of the spectral waveforms of each well from the NCC screen (190, 226). After 
removal of fluorescent compounds, a histogram of the FRET distribution from all 
compounds in the screen was plotted and fit to a Gaussian curve to obtain the mean (µ) 
and standard deviation (σ, SD). A hit was defined as a compound that decreased the 
FRET efficiency by more than five times the standard deviation (5SD) relative to the 
mean µ. Five reproducible hits, MK-886 (Cayman Chemical), Benzbromarone (Millipore 
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Sigma), Bumetanide (Millipore Sigma), Torsemide (Millipore Sigma) and Triclosan 
(Millipore Sigma) were purchased. 
7.3.5. Protein purification 
Full-length 2N4R WT tau proteins were purified from E. coli using previously 
published protocols (290). Full-length tau was expressed with a cleavable His-tag. After 
elution from a nickel column, cleavage of the His-tag was achieved by incubation with 
tobacco etch virus (TEV) protease at room temperature for at least 4 hours, followed by 
passing through the His-tag column again to separate cleaved and uncleaved protein 
and remove the TEV. Final purification was performed by size-exclusion 
chromatography and the purity of the proteins was assessed by 4%–15% SDS-PAGE 
gels (Bio-Rad) under reducing conditions, followed by Coomassie staining. Fractions of 
pure proteins from the gels were pooled together and the protein stock concentrations 
were measured using the BCA assay (Thermo Fisher Scientific). Full-length 2N4R 
P301L tau protein was purchased (rPeptide). 
7.3.6. Surface plasmon resonance (SPR) binding assay 
Binding affinity between full-length 2N4R WT or P301L tau and the hit 
compounds were determined by SPR analysis using BIAcore S200. Recombinant tau 
proteins were immobilized on the CM5 sensor chip (Biacore, GE Healthcare) via amine 
coupling. Briefly, the dextran surface was activated with a 1:1 mixture of 0.4 M 1-ethyl-3-
(3-dimethylaminopropyl)carbodiimide hydrochloride and 0.1 M N-hydroxysuccinimide. 
WT or P301L tau proteins (20 μg/ml) in 10 mM sodium acetate at pH 3.5-4.0 were 
flowed past a working surface before blocking the remaining activated carboxymethyl 
groups with 1 M ethanolamine at pH 8.5 to achieve a level of 1200 RU suitable for 




For direct binding assays to the tau proteins, hit compounds at eight different 
concentrations (1 nM to 5 μM), as well as DMSO-only controls, were prepared in 
HEPES-EP containing a total of 2% DMSO. The samples were injected over both the 
reference and tau immobilized surfaces at 10 μl/min for 180 seconds and dissociated in 
glycine-HCl pH 2.5. All the samples, along with blanks from buffer and DMSO-only 
controls, were measured on a 96-well microplate (Biacore, GE Healthcare) at 25 °C. 
Reflectivity response data points were extracted from response curves at 5 seconds 
prior to the end of the injection to determine steady-state binding. All the data were 
double referenced with blanks using standard procedures with Biacore S200 Evaluation 
Software v1.0.  
7.3.7. FRET dose-response assay 
MK-886, which shows direct binding to tau proteins and the strongest change in 
FRET, was tested in a FRET dose-response assay. The compound was dissolved in 
DMSO to make a 10 mM stock solution, which was serially diluted in 96-well mother 
plates. MK-886 was screened at  different concentrations (1 nM to 10 μM). Compound (1 
μl) was transferred from the mother plates into assay plates using a Mosquito HV liquid 
handler (TTP Labtech Ltd, UK). Three days prior to conducting the assays, the stable 
GFP-tau-RFP cells and GFP-32AA-RFP control cells were expanded in two 225 cm2 
flasks (Corning). The preparations for WT or P301L tau-GFP/RFP FRET biosensors and 
the soluble GFP/RFP controls cells were carried out similar as above. 
7.3.8. Cell cytotoxicity assay 
Cell cytotoxicity was measured using the CytoTox-Glo (Promega Corporation) 
luminescence assay kit. SH-SY5Y human neuroblastoma cells were plated at a density 
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of 1 x 106 cells/well in a 6-well plate (Corning) and transfected with unlabeled full-length 
2N4R P301L tau or equivalent vector-only control for 24 hours. The transfected cells 
were then plated at a density of 10000 cells/well in white solid 96-well plate (Corning) 
with a total volume of 100 l, followed by treatment with MK-886 at eight different 
concentrations (1 nM to 2 μM), as well as DMSO-only controls, for another 72 hours. 
After incubation, 50 μl of CytoTox-Glo Cytotoxicity Assay Reagent was added to all wells 
followed by mixing by orbital shaking and incubation for 15 minutes at room temperature. 
The first luminescence reading was measured using a Cytation3 Cell Imaging Multi-
Mode Reader luminometer (BioTek). 50 l of Lysis Reagent with 1% Triton X-100 was 
then added, followed by incubation at room temperature for 15 min, and luminescence 
was measured again using the luminometer. Cell cytotoxicity was calculated following 
the manufacturer protocol. Effect of MK-886 on the suppressors of inhibitors of apoptosis 
(IAPs) (YM-155 and UC-112) was tested with untransfected SH-SY5Y cells plated in 
white solid 96-well plate with treatment of YM-155 (1 μM) or UC-112 (1 μM) in the 
absence or presence of MK-886 (0.5, 1 or 2 μM).  
7.3.9. Western blot analysis 
To test the expression of tau FRET biosensors, HEK293 cells were plated in a 
100 mm plate at a density of 5 x 106 cells/plate and transfected with tau-GFP/RFP (tau 
FRET biosensor) plasmid. To test the clearance and phosphorylation state of tau in the 
cytotoxicity assay, SH-SY5Y cells were plated in a six-well plate at a density of 1 x 106 
cells/well and transfected with unlabeled P301L tau plasmid for 24 hours followed by 
treatment of MK-886 (2 µM) for 72 hours. In both cases, cells were lysed for 30 minutes 
on ice with radioimmunoprecipitation assay (RIPA) lysis buffer (Pierce RIPA buffer, 
Thermo Fisher Scientific) containing 1% protease inhibitor (Clontech, Mountain View, 
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CA) and 1% phosphatase inhibitors (Millipore Sigma), and centrifuged at 15,000 g at 4 
°C for 15 min. The total protein concentration of lysates was determined by bicinchoninic 
acid (BCA) assay (Pierce), and equal amounts of total protein (60 μg) were mixed with 
4× Bio-Rad sample buffer and loaded onto 4%–15% Trisglycine sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS-PAGE) gels (Bio-Rad, Hercules, CA). Proteins 
were transferred to polyvinylidene fluoride (PVDF) membrane (Immobilon-FL, EMD 
Millipore, Billerica, MA) and probed using antibodies against tau (Tau-5, Thermo Fisher 
Scientific) or antibody specific to Serine 396 of tau (Phospho-Tau S396, Thermo Fisher 
Scientific) with β-actin (ab8227, Abcam, Cambridge, MA) used as loading control. Blots 
were quantified on the Odyssey scanner (LI-COR Biosciences, Lincoln, NE). 
7.3.10. Protein labelling and single-molecule FRET (smFRET) measurements 
For site-specific labeling with maleimide-reactive fluorophores, cysteine residues 
were introduced using QuikChange Site-Directed Mutagenesis (Stratagene). Naturally 
occurring cysteines were mutated to serines. Labelling positions were selected to 
roughly mark the boundaries of the N-terminal domain or the proline-rich and 
microtubule-binding region of tau. Tau protein was purified as described above and 
labeled immediately following purification following published protocols (290). Briefly, the 
protein (typically 200 μL of ~100 μM protein) was incubated with 1 mM DTT for 30 
minutes at room temperature followed by exchange into labeling buffer (20 mM Tris pH 
7.4, 50 mM NaCl, and 6 M guanidine HCl) to remove DTT. The protein was incubated 
with the donor fluorophore, Alexa Fluor 488 maleimide (Invitrogen), at a protein to dye 
ratio of 2:1 at room temperature for one hour with stirring. The acceptor dye, Alexa Fluor 
594 maleimide (Invitrogen), was added at a 5-fold molar excess and incubated overnight 
at 4°C with stirring. Excess dye was then removed by buffer-exchanging the labeled 
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solution into 20 mM Tris (pH 7.4) and 50 mM NaCl buffer using Amicon concentrators 
(Millipore) and then passed over two coupled HiTrap Desalting Columns (GE Life 
Sciences).  
Single-molecule FRET measurements were carried out using ~30 pM of labelled 
tau in phosphate buffer (40 mM potassium phosphate, 50 mM KCl, pH 7.4) in 8-
chambered Nunc coverslips (ThermoFisher) passivated with poly(ethylene glycol) 
poly(L-lysine) (PEG-PLL) to reduce protein adsorption to the chambers. Control 
measurements included DMSO to match the concentration in samples containing MK-
886. Measurements were made on a MicroTime 200 time-resolved confocal microscope 
(Picoquant) in pulsed interleaved excitation FRET (PIE-FRET) mode. Laser power from 
485 and 561 nm lasers, operated at 40 MHz pulse rate, was adjusted to ~30 µW before 
sample illumination. Fluorescence emission was collected through the objective and 
passed through a 150 µm diameter pinhole. Photons were separated by an HQ585LP 
dichroic in combination with ET525/50M and HQ600LP filters and detected by avalanche 
photodiodes. Photon traces were collected in 1 ms time bins for one hour. A cutoff of 25 
counts/ms was applied to discriminate between bursts arising from fluorescently labeled 
protein and background noise. No bursts were identified in photon traces with DMSO 
only and MK-886 only when this criterion was applied. The FRET efficiency (ETeff) was 
calculated using SymphoTime 64 software. SmFRET histograms were fit with Gaussian 
distributions to determine the peak ETeff values. Alignment of instrument and analysis 
were verified using 10 base pair, 14 base pair and 18 base pair dsDNA standards. 
7.3.11. Thioflavin-S (ThS) assay 
HEK293 cells were transfected with tau-RFP (at equivalent DNA concentration 
as used in the tau FRET biosensor) for 48 hours prior to the addition of tau preformed 
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fibrils (PFF). Tau-GFP was not used as it would interfere with the thioflavin-S (ThS) 
signal. To make the PFF, 100 µl of purified tau proteins (10 µM) with DTT (5 mM) and 
heparin (0.4mg/ml) were first incubated for 120 hours at 37°C and shook at 1000 rpm in 
a thermal shaker (Thermo Fisher Scientific). After incubation, the sample was subjected 
to ultracentrifugation at 80,000 rpm for 30 minutes. The pellet was collected and 
sonicated to break up the fibrils into smaller pieces. The concentration of the fibrils was 
then measured by BCA. The sonicated fibrils were then treated to the transfected cells at 
a concentration of 40 µg/ml for 24 hours before conducting the ThS assay. Thioflavin-S 
(ThS, Millipore Sigma, product no. T1892) was dissolved in PBS buffer and was filtered 
through a 0.2 µm syringe filter to make a stock solution of 2.5 mM. For the ThS assay, 
cells were fixed with 1 ml of 4% paraformaldehyde in TBS for 15 minutes followed by 
washing with 1 ml of TBS for 5 minutes twice. After fixing, cells were permeabilized with 
1ml of 1% Triton in TBS for 5 minutes, followed by washing with 1ml of TBS for 5 
minutes twice. After permeabilization, cells were then treated with 0.002% ThS in TBS 
and incubate in the dark for 20 minutes. Cells were then washed twice with 50% ethanol 
for 10 minutes each and finally washed twice with TBS for 5 minutes each. Cells were 
then imaged with a fluorescence microscope using EVOS-FL cell imaging systems at 
20X magnification. Mean fluorescence intensity for each image was quantified using 
ImageJ and values were normalized to untransfected controls. 
7.3.12. Thioflavin-T (ThT) assay 
Thioflavin-T (ThT, Sigma, product no. T3516) was dissolved in PBS buffer and 
was filtered through a 0.2 µm syringe filter to make a stock solution of 2.5 mM. ThT was 
then diluted to 20 µM prior to addition to the tau proteins. The samples for ThT 
measurements were prepared by mixing 25 µl of 20 µM tau proteins with 25 µl of 20 µM 
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of ThT, resulting in final concentrations of 10 µM tau proteins and 10 µM ThT. DTT (5 
mM) and heparin (0.4 mg/ml) were then added to the samples; a control sample lacked 
addition of heparin. Lastly, the samples were treated with MK-886 (0.5 µM or 5 µM) and 
gossypetin (50 µM) with DMSO added to the no-compound controls. The ThT samples 
(50 µl each) were transferred to a black 96-well non-binding surface microplate with 
clear bottom (Corning product no. 3655) and incubated at 37°C with mild shaking (200 
rpm) in the Cytation 3 plate reader. The ThT fluorescence was measured by the Cytation 
3 plate reader through the bottom of the plate with excitation filter of 440 nm and 
emission filter of 480 nm. Readings were acquired every 20 minutes for a total of 120 
hours. 
7.3.13. Statistical analysis 
Data are shown as mean ± standard deviation unless stated otherwise. Statistical 
analysis was performed by a two-tailed unpaired t test (Student’s t test) using GraphPad 
Software to determine statistical significance for all experiments. Values of P <0.05 were 
considered statistically significant. GraphPad style in using asterisks to denote P values 
in figures was used (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 and n.s. 
indicates not significant). 
7.4. Results 
7.4.1. Inter-molecular FRET biosensor directly monitors structural changes in tau 
oligomers in cells  
To develop an in-cell HTS platform that can detect small-molecule modulation of 
tau oligomerization and/or perturbation of tau conformational states, we engineered two 
cellular tau FRET biosensors. We used human embryonic kidney 293 cells (HEK293) 
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expressing full-length 2N4R WT tau fused to green (GFP) or red (RFP) fluorescent 
proteins (tau-GFP/RFP or “tau FRET biosensor”) (Fig. 7.2A). Expression and 
homogeneity of the FRET biosensor were determined by fluorescence microscopy and 
immunoblotting. Fluorescence microscopy images showed that the tau proteins were 
evenly distributed in the cytosol of the cells, with no discernable puncta (which would 
have indicated more progressive aggregation, e.g. fibril formation) or other non-
uniformities (Fig. 7.2B). Western blot analysis of the tau biosensor cell lysates confirmed 
the expression of fluorophore-tagged tau (Supplementary Fig. 7.1A).  
We next tested the functionality of the tau FRET biosensor by measuring FRET 
efficiency using the FLT-PR (283). The value of FRET efficiency reflects the ensemble-
averaged inter-molecular proximity between tau molecules, which is derived from the 
distance between the donor and acceptor fluorophore fused to the tau proteins. FRET 
between tau-GFP (donor) and tau-RFP (acceptor) in live cells showed hyperbolic 
dependence on acceptor concentration (Fig. 7.2C), with a maximum energy transfer 
efficiency (E) of 0.086±0.002, illustrated through a substantial decrease in the donor FLT 
in the presence of the acceptor (Fig. 7.2D), indicating the formation of tau oligomers in 
cells. The kinetics of formation of the tau-tau assemblies was also measured by FRET, 
showing that the WT tau biosensor has an optimal FRET after 48 hours of expression 
(Supplementary Fig. 7.1B). We confirmed that the FRET observed from cells 
expressing tau biosensor arises from specific tau-tau interactions and not from non-
specific interactions between the free fluorophores (Supplementary Fig. 7.1C-D). 
Furthermore, we showed that the FRET biosensor is sensitive to the addition of 
forskolin, a small molecule known to induce tau hyperphosphorylation and self-
association, but not to gossypetin, a small molecule known to inhibit or remodel of tau 
fibrils (Supplementary Fig. 7.1E) (291). To confirm that only oligomeric species of tau, 
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but not fibrils, were present in the tau biosensor cells, we performed a thioflavin-S (ThS) 
assay in cells expressing tau-RFP at the same concentration of tau-GFP/RFP dual 
transfected cells (tau-GFP was not used as it will interfere with the ThS signal), with 
treatment of exogenous tau preformed fibril (PFF) as a positive control. Results from the 
ThS assay illustrate that only cells treated with PFF have a positive ThS signal (Fig. 
7.2E) with a significant increase in the ThS intensity (Supplementary Fig. 7.1F), 
confirming that no fibrils (e.g. β-sheet tau assemblies) are present in the biosensor cells, 

































































Figure 7. 2. The tau inter-molecular FRET biosensor and fluorescence lifetime technology 
enable direct monitoring of tau oligomerization in cells.  
(A) Schematic representation of live-cell based tau inter-molecular FRET biosensor. FRET signal 
is observed when tau oligomers form, which can be modulated by small-molecule inhibitors. Tau 
oligomer is drawn as a dimer for illustration but it can be any species more than a dimer (≥2-
mers). (B) Fluorescence microscopy images of (i) GFP channel, (ii) RFP channel and (iii) merged 
channel of HEK293 cells expressing tau-GFP/RFP (tau FRET biosensor). (C) Titration of tau-RFP 
(acceptor) to tau-GFP (donor) illustrates that the FRET efficiency of the biosensor follows a 
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hyperbolic dependence on acceptor concentration. (D) Fluorescence lifetime measurements of 
the tau biosensor show efficient FRET, indicating tau self-association. (E) Thioflavin-S (ThS) 
staining of HEK293 cells expressing tau-RFP (in same total DNA concentration as used in the 
FRET biosensor) in the presence and absence of the positive control of tau preformed fibrils 
(PFF). Data are means ± SD of three independent experiments. ****P < 0.0001 by two-tailed 
unpaired t test. 
7.4.2. Identification of novel small molecules from HTS of the NCC library that 
perturb the conformational ensembles of tau oligomers 
Using our cellular tau FRET biosensor, we performed a HTS of the NCC library 
(727 bioactive compounds) to identify compounds that perturb the conformational 
ensembles of tau oligomers. The NCC library is a collection of small molecules that have 
been previously tested in clinical trials, and have known safety profiles and details on 
potential MOA.  
After an initial quality control check of the tau FRET biosensor on each day of 
screening (fluorescent waveform signal level and coefficient of variance), the cells were 
dispensed into drug plates and incubated with the compounds (10 µM) or DMSO control 
wells for 2 hours. FLT measurements were acquired with the FLT-PR. A single-
exponential fit was used to determine the FLT from cells expressing the tau FRET 
biosensor (τDA) or expressing a tau-GFP donor-only control (τD) to determine FRET 
efficiency (Eq. 1). As FLT measurements are prone to interference from fluorescent 
compounds, a stringent fluorescent compound filter was used to flag 30 such 
compounds as potential false-positives (190, 226). FRET efficiency from all compounds 
that passed the fluorescent compound filter are plotted (Fig. 7.3A) and a histogram of 
the FRET distribution from these compounds was fit to a Gaussian curve to obtain a 
mean and standard deviation (SD) for the screen (Supplementary Fig. 7.2A).  
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Our initial goal was to discover compounds that alter the conformational 
ensembles of tau oligomers with the potential of disrupting tau-tau interactions, leading 
us to focus our search to compounds that reduce FRET (though other compounds 
that increase FRET could potentially remodel toxic oligomers and be of interest in 
future studies). Five reproducible hits from the library were shown to decrease FRET 
by more than 5SD below the mean of all wells (Fig. 7.3A, highlighted in red) while not 
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Figure 7. 3. Identification of MK-886 as a small molecule that directly perturbs 
conformational ensemble of tau oligomers.  
(A) Representative pilot screening with NCC library containing 727 compounds. A FRET 
efficiency cutoff threshold was applied at a change in FRET efficiency of 5SD (black lines). Five 
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reproducible hits decreased FRET by more than 5SD below the mean of all cells (red) and MK-
886 induced the largest FRET change (arrow). Surface plasmon resonance (SPR) binding curve 
for MK-886 to purified recombinant full-length 2N4R (B) wild-type (WT) and (C) P301L tau 
proteins.  (D) FRET analysis of the dose response of MK-886 in both WT and P301L tau inter-
molecular biosensors indicates EC50 values of 1.40 and 1.84 μM respectively. Data are means ± 
SD of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001 by 
two-tailed unpaired t test. 
7.4.3. Binding of hit compounds to purified tau proteins 
We next used surface plasmon resonance (SPR) to determine if these five hit 
compounds bind tau, delineating a potential direct or indirect MOA with tau. Of the five 
hits that reduced FRET with our tau biosensor, MK-886 was the only hit to demonstrate 
dose-dependent binding to purified WT tau protein with Kd = 0.178 μM (Fig. 7.3B and 
Supplementary Fig. 7.2D). MK-886 also showed binding to purified P301L tau protein, 
a more aggregation prone mutant of tau (292), with Kd = 0.375 μM (Fig. 7.3C and 
Supplementary Fig. 7.2E). Interestingly, MK-886 also had the strongest change in 
FRET (Fig. 7.3A, highlighted in arrow). The other four hit compounds did not show direct 
binding to immobilized tau protein (Supplementary Fig. 7.2F) and therefore most likely 
attenuate tau FRET through an indirect MOA. All subsequent analysis in this study is 
focused on MK-866. The indirect MOA compounds, although outside the scope of this 
study, are potentially useful and are briefly discussed below. 
7.4.4. FRET dose-response of MK-886 with cellular tau inter-molecular FRET 
biosensors 
The relative effective concentration (EC50) of MK-886 was determined by in-cell 
FRET measurements using the WT tau biosensor. The compound decreased FRET 
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efficiency in a dose-dependent manner with an EC50 value of 1.40 μM (Fig. 7.3D). We 
also performed a FRET dose response using P301L tau FRET biosensor. The FRET 
efficiency of this biosensor was found to be higher than that of WT tau biosensor 
(Supplementary Fig. 7.3A) which is consistent with the known tendency of P301L tau to 
be hyperphosphorylated and hence more oligomeric (292). Similar to WT, we observed 
a dose-dependent decrease in the FRET efficiency of the P301L tau biosensor with MK-
886 with an EC50 value of 1.84 μM (Fig. 7.3D), confirming that the hit compound also 
remodels tau oligomers in a disease-relevant model. Interestingly, we observed that MK-
886 lowered the FRET level of P301L biosensor to the basal FRET level of WT tau 
biosensor. This may suggest that MK-886 disrupts the toxic oligomers of P301L tau and 
converts them to less toxic conformations that are similar to the conformations adopted 
by the WT tau. In addition, we confirmed that the small molecule was acting specifically 
on tau and was not acting on the cytosolic fluorophores (Supplementary Fig. 7.3B-D). 
Assay quality (Z´) was determined using MK-886 (Eq. 2). The Z´ value of 0.720.02 
indicates excellent assay quality, validating MK-886 as a positive control tool-compound 
for targeting tau oligomers. 
We also expressed the P301L tau FRET biosensor in the SH-SY5Y neuronal cell 
model, and similar FRET was observed as in the HEK293 cells (Supplementary Fig. 
7.4A). This FRET again reflects the formation of oligomers, as it is known that -sheet 
fibrils do not spontaneously form in SH-SY5Y overexpressing P301L tau unless 
aggregation inducers are used (288). MK-886 reduced FRET from P301L tau biosensor 
in the SH-SY5Y cells with an EC50 of 1.06 µM (Supplementary Fig. 7.4B). Importantly, 
as will now be shown, if toxicity is observed when P301L tau is overexpressed in SH-
SY5Y cells, and the toxicity is rescued by MK-886, it will further support the conclusion 
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that the small molecule converts toxic tau oligomers into a non-toxic conformational 
state. 
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Figure 7. 4. Rescue of tau induced cell cytotoxicity in SH-SY5Y human neuroblastoma 
cells by MK-886.  
(A) SH-SY5Y cells were transfected with vector control and P301L tau. Significant cell death is 
observed in cells transfected with P301L tau as compared to the vector control. (B) MK-886 
rescued P301L tau induced cytotoxicity in SH-SY5Y cells with an IC50 of 0.523 M. Data are 
means ± SD of three independent experiments. *P < 0.05, **P < 0.01, and ***P < 0.001 by two-
tailed unpaired t test. 
7.4.5. MK-886 reduces tau induced cell cytotoxicity in SH-SY5Y cells with 
nanomolar potency 
We next tested the effect of MK-886 on P301L tau induced cytotoxicity in the SH-
SY5Y neuroblastoma cell model of tauopathy (81, 137, 293, 294). Overexpression of 
P301L tau showed significantly greater cell death (37%) when compared to the vector-
only control (23%) after 96 hours of expression (Fig. 7.4A and Supplementary Fig. 
7.5A). Treatment with MK-886 (1 nM to 2 μM) to cells overexpressing P301L tau showed 
significant rescue of P301L tau induced cytotoxicity in a dose-dependent manner, with 
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an IC50 of 0.523 μM (Fig. 7.4B), the same order of magnitude as MK-886’s binding 
affinity for recombinant P301L tau protein. The two-fold difference in IC50 of MK-886 in 
the cell cytotoxicity assay (0.523 μM) and the EC50 from the FRET assay (1.06 µM) may 
be due to the different treatment conditions as well as the expression of unlabeled vs. 
fluorophore-tagged P301L tau in each assay respectively.  
We note that MK-886—which was blindly identified in our HTS—has been shown 
to play a role in modulating AD-related amyloid and tau pathology through inhibition of 5-
lipoxygenase (5-LOX)-activating protein (FLAP) (295), potentially altering the clearance 
and phosphorylation state of tau (296, 297). Our observations suggest that MK-886 
rescues tau induced cytotoxicity through direct binding to tau protein and not by 
modulating FLAP, a previously undescribed mechanism of action. SH-SY5Y cells do not 
express 5-LOX or FLAP and therefore are a particularly well suited model to evaluate 
alternative MOA for MK-886 rescue of tau induced cytotoxicity (298). We also confirmed 
that there were no changes in the relative levels of expressed tau (Supplementary Fig. 
7.5B) or the phosphorylation state (Supplementary Fig. 7.5C) due to MK-886 treatment 
in the SH-SY5Y cell model, although it remains possible that MK-886 may be altering 
other PTMs such as acetylation or oxidation.  
In addition, it has been shown that expression of P301L tau may also result in 
cell death through down-regulating the expression of survivin, inhibitor of apoptosis 
proteins (IAPs) or X-linked inhibitor of apoptosis proteins (XIAPs)  (293). Thus, we 
needed to rule out the possibility that MK-886 rescues P301L tau induced cell 
cytotoxicity by modulating the expression of these genes, rather than by directly altering 
tau conformations. To do so, we used two small molecules (YM-155 and UC-112) that 
are potent suppressors of the expression of survivin, IAPs and XIAPs, thus mimicking 
the effect of P301L tau on this pathway. This allowed us to test whether MK-886 can 
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rescue cell cytotoxicity in the absence of P301L tau, simply by upregulating these 
survival genes (299). Our results showed that MK-886 did not rescue the cell cytotoxicity 
induced by YM-155 (1 μM) or UC-112 (1 μM) (Supplementary Fig. 7.6A-B). Thus, 
these important control experiments strongly suggest that MK-886 rescues P301L tau 
induced cell cytotoxicity by directly perturbing the conformations of the toxic tau 
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Figure 7. 5. MK-886 binds and perturbs tau monomer conformation.  
(A) Single-molecule FRET (smFRET) measurements in the absence and presence of MK-886 
with WT 2N4R tau double labeled at the proline-rich region/microtubule binding region 
(PRR/MTBR, left) or at the N-terminal domain (right). Tau schematic represents the labelling 
position for each construct. The black line is drawn from the peak of the histogram in buffer for 
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comparison with DMSO and MK-886 samples. Representative histograms are shown. (B) 
Quantification of the smFRET measurements indicates that the PRR/MTBR becomes 
substantially more compact (increase in FRET) upon binding MK-886 (5 µM) (A, bottom left) 
when compared to tau in buffer (A, top left) or DMSO (A, middle left) while the N-terminal domain 
(C) shows only minor differences in the presence of MK-886 (5 µM) (A, right). (D) FRET analysis 
of the dose response of MK-886 in the cellular tau intra-molecular biosensor indicates an EC50 
value of 2.12 M, similar to that of oligomer modulation, suggesting that the change in 
conformational states of oligomers is due in part to conformational changes of tau monomer. Data 
are means ± SD of three independent experiments. *P < 0.05, ***P < 0.001 and n.s. indicates not 
significant by two-tailed unpaired t test. 
7.4.6. MK-886 specifically perturbs the PRR/MTBR of tau monomer and induces 
conformational changes of the cellular tau intra-molecular biosensor  
 To further investigate the MOA of MK-886, we used single-molecule FRET 
(smFRET) to examine the effect of MK-886 on monomeric tau. Using two different 
doubly fluorescent-labeled tau constructs (labeled at the proline rich region/microtubule 
binding region (PRR/MTBR) or at the N-terminal domain) (290), we monitored the 
conformation of two distinct regions of tau (Fig. 7.5A). The smFRET shows that MK-886 
causes a substantial increase in FRET for the PRR/MTBR targeted construct (Fig. 7.5B) 
but only a minor decrease in FRET for the N-terminal domain construct (Fig. 7.5C). This 
suggests that MK-886 specifically binds and induces a conformational change in tau 
monomer at the PRR/MTBR region, resulting in a subsequent loss of interactions 
between the N-terminal domain and the PRR/MTBR. To determine whether MK-886 also 
perturbs the monomer conformation of tau in cells, we tested the compound with a 
cellular tau intra-molecular FRET biosensor (GFP-tau-RFP). The intra-molecular FRET 
biosensor has a basal 6% FRET signal (Supplementary Fig. 7.7), illustrating the intra-
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molecular interactions arising from the paper-clip monomeric structure in which the N- 
and C-terminus of tau are folded to close proximity (300). Treatment with MK-886 
reduced intra-molecular FRET with an EC50 of 2.12 M, similar to that of oligomer 
modulation, suggesting that the change in conformational states of oligomers is due in 
part to perturbation of the tau monomer (Fig. 7.5D).  
 It has been suggested that the folding over of tau’s two termini to form the classic 
“paper-clip” structure is due to electrostatic interactions that arise from the opposite net 
charges of the N-terminal and MTBR domains (300). While this global folding is specific, 
it has been shown to be a rather weak interaction (300). We speculate that the binding of 
MK-886 to the PRR/MTBR of tau may shield these interactions and lead to an opening 
of the two termini, resulting in the observed decrease in FRET of the intra-molecular 
FRET biosensor. From our previous observations with smFRET on tau constructs, this 
type of conformational change is often accompanied by the PRR/MTBR becoming 
substantially more compact (increase in FRET) in recombinant protein systems (290). 
7.4.7. MK-886 stabilizes tau conformations that promote the formation of -sheet-
positive fibrils in the presence of aggregation inducer 
We have shown that MK-886 directly binds to immobilized tau, modulates tau 
oligomer and monomer conformation (both in cells and purified proteins), and rescues 
tau induced cytotoxicity. To further explore MK-886’s MOA and identify whether MK-886 
targets on- or off-pathway oligomers, we performed a heparin induced thioflavin-T (ThT) 
aggregation assay in the absence and presence of MK-886. MK-886 shortens the lag 
phase of tau -sheet fibril formation in a dose-dependent manner (Fig. 7.6A), suggesting 
that it induces or stabilizes on-pathway, early-stage species in the amyloidogenic 
cascade. We confirmed that MK-886 did not have a direct effect on ThT fluorescence 
212 
 
(Supplementary Fig. 7.8A) and did not act to nucleate for fibril formation 
(Supplementary Fig. 7.8B). In addition, we tested if MK-886 disrupts tau preformed 
fibrils (PFF). Comparison of MK-886 to gossypetin (a known remodeler of tau fibrils) 
illustrates that MK-886 did not reduce the ThT signal from tau PFF, whereas gossypetin 
showed a significant decrease, indicating the disruption of -sheet fibril structure (Fig. 
7.6B). These results, in combination with the changes in FRET and reduction of tau 
induced cytotoxicity, suggest that MK-886 alters the conformational ensemble of tau 
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Figure 7. 6. MK-886 alters the ensemble of conformational states of tau oligomers by 
stabilizing a fibrillization promoting conformation.  
(A) Effect of MK-886 on the tau fibrillization cascade as characterizaed by thioflavin-T (ThT) 
assay with purified WT tau proteins. Fibrillization was induced by heparin (0.4 mg/ml) in the 
presence of DMSO control, MK-886 (0.5 and 5M) and gossypetin (50 M, a known small-
molecule inhibitor or remodeler of tau fibrils as positive control). (B) Effect of MK-886 on tau 
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preformed fibrils (PFF) with gossypetin as a positive control. All samples were treated with DTT (5 
mM). Data are means ± SD of three independent experiments. ***P < 0.001, ****P < 0.0001 and 
n.s. indicates not significant by two-tailed unpaired t test. 
7.5. Discussion 
The identity of a specific, toxic tau oligomeric species remains elusive. Indeed, it 
is unlikely that a single, unique toxic conformation exists. It is far more likely that an 
ensemble of toxic oligomers (differing in size, conformation, and even molecular 
constituency) populates the fibrillogenesis cascade (87-93). This heterogeneity in tau 
oligomer targets highlights the need for an ultra-sensitive screening platform capable of 
monitoring structural changes within the ensemble of tau assemblies. Our FRET-based 
platform for monitoring full-length tau oligomerization in cells is a new technology that is 
capable of doing this, as well as elucidating novel compounds which alter conformation 
and oligomerization, thereby providing a new pipeline of therapeutic discovery for 
tauopathies.  
With this technology in hand, we and others are in a position to explore multiple 
important issues. First, screens will now be done of larger libraries and of libraries built 
specifically for targeting the central nervous system (CNS) (i.e. favorable blood-brain 
barrier permeability). These screens will dramatically increase the statistical sampling of 
small-molecule induced changes in time-resolved FRET (TR-FRET) signatures. With a 
larger sample, the high information content of TR-FRET can, when complemented with 
other structural tools (discussed below), be used to cluster compounds into distinct 
classes based on their myriad of structural effects on the targets (226). To more 
adequately generalize the patho-physiological relevance of these clustered structural 
motifs, we will move to inducible cell lines (282), as well as alternate cell lines including 
eventually patient-derived induced pluripotent stem cells (iPSC) neurons (301) and 
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iPSC-derived spheroids (302, 303). Additional extensions of this technology for small 
molecule discovery should include using different cellular models of tau pathology 
including, among others, modification of the oligomerization trigger through the addition 
of tau seeds (fibrils, oligomers, or monomer), upregulation of specific kinases or 
chaperone proteins (e.g. GSK3β or HSP70), and treatment with environmental toxins 
(83). This will allow us to examine multiple proposed mechanisms of induced 
tauopathies, providing key insight into differences between on- and off-pathway 
oligomerization (304). Each of these steps will be critical to building a more complete 
and useful correlation between structural heterogeneity and toxicity.  
  Additionally, as we have shown that full-length tau can be engineered as a cell-
based, FRET-biosensor of oligomerization (here using the 2N4R isoform), we should 
now explore potential nuances in how oligomerization depends on tau isoform. Not only 
will we be able to explore the propensity of different isoforms to oligomerize, but should 
also test the likelihood that different isoforms co-mingle in heterogenous oligomers. It will 
be of great interest to ascertain whether lead compounds are isoform specific or can 
target multiple distinct isoforms. Broadly speaking, information on isoform-specific 
oligomerization could be useful in designing more effective, patient-stratified design of 
clinical trials (305). The Diamond group pioneered the tau cellular biomarker field with 
their tau repeat domain (tau-RD) FRET biosensor cells (282). Use of full-length tau thus 
expands on the existing technology and should facilitate additional stratification of 
potential biomarkers present in AD versus other tauopathies. Following Diamond, 
experiments that compare the sensitivity and relative reactivity of each biosensor to 
different tauopathy associated biofluids will provide new insight into heterogeneity in tau 
assemblies inherent in these distinct diseases.  
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 Ultimately, determining and validating the specific MOA by which lead 
compounds act—be they through direct binding to tau monomers/oligomers or indirectly 
by altering cellular processes that lead to alterations in oligomers—will require 
comprehensive approaches to link biophysical experiments with cell biological 
observables. One set of immediately accessible questions is how the compounds’ 
impact on monomer folding and/or oligomerization relates to tau localization in cells, 
most obviously on microtubule binding. Here, future work will further probe post-
translational modifications (including hyperphosphorylation, which we started here using 
forskolin) and acetylation, specifically testing how compounds alter the relationship 
between microtubule unbinding and tau folding/aggregation. As another example, tau 
has recently been shown to mislocalize to dendritic spines, disrupting synaptic 
transmission in primary neurons (306). Whether these or numerous other mechanisms 
related to mislocalization can explain the cytoprotective effects of lead compounds will 
require additional experiments. For example, nano-imaging modalities like fluorescence-
lifetime imaging microscopy (FLIM) and time-correlated single photon counting (TCSPC) 
can provide the necessary spatial resolution to correlate subcellular localization (e.g. 
microtubules, cytosol, mitochondria, etc.) and distinct tau conformations (307).  
Major challenges for the hypothesis 
The technology described here is based on the hypothesis that tau biosensors 
expressed in cells can be used to accomplish two complementary, but distinct goals: 1) 
they can be used to find small molecules that modulate tau toxicity; and 2) they can 
provide a direct, albeit low-resolution reporting of the structures and conformations of a 
heterogeneous ensemble of toxic and non-toxic states. For the first part of this 
hypothesis, namely modulation of toxicity, we have demonstrated the power of our 
approach with MK-886. The second part is more of a challenge. This broader and 
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longer-term hypothesis is built on the idea that biophysical tools, such as TR-FRET, can 
provide key insight into the unique structural fingerprints of heterogeneous toxic tau 
oligomers, and that this detail can be exploited in drug discovery. This is a far more 
nuanced and difficult bar for the field to meet, but is nonetheless a goal that should and, 
we believe, can be tackled. Why is this difficult? On the one hand, unlike fibrils, 
oligomers are highly heterogeneous (number of monomers per aggregate, local or 
transient structural motifs/folds, molecular constituency, etc...), making it improbable that 
high-resolution structural biology tools are or ever will be applicable to their study (they 
simply lack well-defined secondary or tertiary structural elements). On the other hand, 
the field currently relies only on low-resolution techniques that provide little to no 
structural information (e.g. antibody recognition, protease protection, detergent 
resistance). Finding a middle ground requires a set of structural techniques that can 
adequately and accurately interrogate oligomers, but more crucially can stratify structural 
fingerprints at a quantitatively useful and reproducible resolution. Absent high-resolution 
structures, we should nonetheless be able to ask: what are the critical amino acids that 
dictate oligomer-prone monomer folds and what are the deleterious inter-monomeric 
amino acid motifs that dictate toxicity? As an example of how this can begin to happen, 
we complemented our TR-FRET with smFRET, and were able to isolate the region of 
tau impacted by MK-886 binding. But this is just a start, as far more detailed information 
should be obtainable using a set of creative and state-of-the-art experimental and 
computational approaches to interrogate these structures (308-310).  
In theory, TR-FRET waveforms contain high-content information that can resolve 
relative species populations and protein-protein distance distributions (311). 
Unfortunately, TR-FRET alone does not provide atomic structural resolution to uniquely 
identify specific species. The process of extracting this structural data from TR-FRET 
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requires model fitting. The challenge is that the model must be constrained by 
information we do not yet have, including constraints on the stoichiometry of the tau 
oligomer. This highlights a current limitation in analyzing tau-tau TR-FRET as there are 
no well-defined structural states and the exact toxic species, including the number of 
interacting tau monomers, is unknown. To begin to make progress in this regard will 
require additional biophysical tools. These will include, among others, analytical 
ultracentrifugation (AUC) and analytical gel filtration for oligomer size. Despite the 
promise of these techniques for grouping oligomeric species into meaningful clusters, 
doing so in cells will be the greatest challenge moving forward. Higher resolution 
structural information for stratifying oligomeric species can be obtained in purified, in 
vitro assemblies using other spectroscopic techniques such as nuclear magnetic 
resonance (NMR) and electron paramagnetic resonance (EPR). However, because tau 
oligomers in cells likely consist of other molecular constituents and are folded with the 
help of chaperones, there is a real danger in relying too heavily on the folding of these 
assemblies outside of the native cellular environment. There have been recent advances 
that allow for the use of high-resolution techniques, such as NMR, in cells (312-314). 
These and other advances in biophysical tools will be of critical importance in the coming 
years. 
Linkage to other major theories 
  Tauopathies have a vast heterogeneity in their clinical presentations (e.g. AD, 
fronto-temporal dementia and movement disorders, amongst others) (315) which is one 
of the major challenges that plagues current clinical trials (316). This heterogeneity may 
be explained in part by strong histopathologic differences and differential laminar and 
regional brain distributions. For therapeutic intervention, an equally important potential 
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source of this heterogeneity is molecular variations such as isoform composition and 
post-translational modifications (315, 317). Hence, there is a need for robust tools and/or 
biomarkers to stage and delineate (particularly, at the molecular level) the numerous 
different tauopathies.  
Although our biosensors and HTS technology are focused on the oligomer 
hypothesis of tauopathy, they are directly translatable into other areas of tauopathy 
research and therapeutic discovery. The presence of misfolded tau and the formation of 
the tau oligomers can be attributed to upstream dysfunctions in neurophysiology and 
axonal transport. For example, mitochondrial dysfunction and oxidative stress are 
believed to be a prominent early event in the pathogenesis of AD, contributing to tau 
phosphorylation and the formation of neurofibrillary tangles (318). In particular, 
deterioration of mitochondrial functions such as impairments in the activity of Krebs cycle 
enzymes and electron transport machineries (e.g. cytochrome c oxidase (COX)) have 
been correlated with severity in the clinical state of tauopathies and AD (71, 72). 
Importantly, impaired COX activity can potentiate the generation of mitochondrial-
derived reactive oxidative species (ROS), suggesting that defective mitochondrial 
bioenergetics and oxidative stress are coupled in a vicious cycle (72). It has also been 
shown in that in familial AD, tau and amyloid-beta (A) can augment the pathological 
deterioration of mitochondrial function (319). In addition, there is compelling evidence 
that tau can play a role in controlling motor protein–driven vesicle transport along 
microtubules (320). Furthermore, there is an age-dependent decline in axonal transport 
rates which correlates with increases in hyperphosphorylated tau (73). Our FRET 
biosensors can be used to study these effects. For example, we can use the intra-
molecular biosensor to study the global tau folding when it is bound to microtubules 
versus when it is detached from microtubules. Our inter-molecular biosensor can also be 
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used to monitor the kinetics and the extent of free soluble tau that are detached from 
microtubules and start to form oligomers, providing important fundamental information in 
understanding early stage events underlying tau pathology.  
Misfolded or oligomerized tau can be a symptom, as much as a cause, of an 
underlying pathology. Despite our focus on disrupting oligomers, using the cellular tau 
biosensors to modulate upstream effectors of tau dysfunction may actually hold the most 
promise. The TR-FRET screen in cells does not discriminate between compounds that 
act directly on tau folding/oligomerization and those that operate indirectly by binding to 
other upstream targets. Coupling secondary biophysical assays to the screen allows us 
to elucidate direct versus indirect MOA. Compounds that act through an indirect MOA—
e.g. those that rescue dysfunctional autophagy or mitochondrial functions, endoplasmic 
reticulum or oxidative stress—can provide insight into specific pathways that are 
disrupted in tauopathy, giving rise to novel therapeutic targets and strategies. Upon 
inspection, this appears likely the case for several of the compounds we identified in our 
screen but whose MOA we have not yet elucidated. Two of these compounds 
(bumetanide and torsemide) are both loop diuretics which inhibit the sodium-potassium-
chloride cotransporter (NKCC1) in vascular smooth muscle and have been shown to 
reduce the risk of AD dementia in both adults with normal cognition or with mild cognitive 
impairments (321). The other two hits (benzbromarone and triclosan) have been shown 
to attenuate oxidative stress (322) and induce autophagy (323) (respectively), both 
known cellular dysfunctions in AD.  
Our biosensors should be useful in a variety of other contexts being pursued 
aggressively in the field. One example is the prion-like propagation of tau pathology 
(282). We plan to use the technology in an HTS campaign targeting the uptake and 
propagation of toxic tau species. We have already begun to see the power of the 
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technology in this way, observing increased FRET due to uptake of WT and truncated 
tau protein by our biosensor (data not shown). A second example builds on mounting 
evidence of cross-reactivity and comorbidity amongst misfolded proteins in numerous 
neurodegenerative diseases. These players include other IDPs, A and α-synuclein 
(324). Our biosensors can directly probe these types of interactions via co-expression of 
these constructs into the tau biosensor cells, and/or treating the tau biosensor with A or 
α-synuclein fibrils/oligomers and monitoring FRET, cytotoxicity, and uptake. Different 
donor and acceptor labelled proteins (e.g. tau-GFP/A-RFP etc.) can also be developed 
and utilized to study potential direct protein-protein interactions. Our strategy, combining 
cellular fluorescent biosensor and TR-FRET measurement in a HTS platform, is broadly 
applicable to other drug discovery efforts targeting IDPs involved in numerous 
neurodegenerative diseases. 
7.6. Supplemental figures 

















































































 Tau FRET Biosensor (FB)
 FB + Forskolin (20 M)
 FB + Gossypetin (10 M










































Supplemental Figure 7. 1. Characterization of tau inter-molecular FRET biosensor and 
soluble free GFP/RFP expressed in HEK293 cells.  
(A) Expression of tau-GFP and tau-RFP expressed in HEK293 cells stained with Tau-5 antibody. 
(B) Kinetic of the FRET measurements for WT tau FRET biosensor expressed in HEK293 cells. 
(C) Fluorescent microscopy images of soluble free GFP/RFP-only (fluorophore-only control) 
expressed in HEK293 cells at the same donor-to-acceptor ratio as the FRET biosensor. (D) 
Fluorescence lifetime measurement of the GFP/RFP-only control indicates the basal FRET from 
free soluble fluorophore. (E) Confirmation of the functionality of the tau FRET biosensor with  
addition of forskolin (a known small molecule that induces tau hyperphosphorylation and self-
association) and gossypetin (a known inhibitor or remodeler of fibril formation). (F) Quantification 
of in-cell thioflavin-S (ThS) staining with tau preformed fibril (PFF) used as a positive control. Data 
are means ± SD of three independent experiments. ****P < 0.0001 and n.s. indicates not 
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Supplemental Figure 7. 2. Donor-only control screen and surface plasmon resonance 
(SPR) characterization of hit compounds in binding to purified tau protein.  
(A) Histogram plot of all compounds from the NCC screen with the tau inter-molecular FRET 
biosensors after removal of fluorescent compounds to obtain the average FRET efficiency and 
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the standard deviation (SD) of the screen. (B) Representative donor-only control screen with NCC 
library using cells expressing only tau-GFP which do not show FRET signal so the lifetime plot is 
shown. Applied threshold at a change in lifetime of 5SD is shown by the black lines. There is no 
reproducible hit from the donor-screen indicating that the hits observed are due to random 
occurrence. In addition, the hit compounds obtained from the FRET screen do not appear as hits 
in any of the donor-only control screens. (C) Histogram plot of all compounds from the NCC 
donor-only screen after removal of fluorescent compounds to obtain the average lifetime and the 
SD of the screen. SPR raw binding curves for MK-886 on (D) purified WT tau protein and (E) 
purified P301L tau protein. (F) SPR characterization of other four hit compounds show no direct 
binding or interaction between the compounds and the tau protein. Data are means ± SD of three 






































































Supplemental Figure 7. 3. Characterization of P301L tau FRET biosensor and the effect of 
MK-886 on control FRET biosensors.  
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(A) Kinetic of the FRET measurements for P301L tau FRET biosensor expressed in HEK293 
cells. (B) Characterization of the GFP-32AA-RFP (fluorophores-only FRET control) expressing 
cells indicates FRET. The control FRET biosensor was used to test compound interference with 
GFP or RFP fluorophores, eliminating non-specific compounds that cause a FRET change in the 
screen. (C) MK-886 does not cause any significant FRET change in the GFP-32AA-RFP 
expressing control cells. (D) MK-886 does not cause any significant FRET change in the soluble 
free GFP/RFP-only expressing control cells. Data are means ± SD of three independent 
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Supplemental Figure 7. 4. Effect of MK-886 on P301L tau FRET biosensor expressed in SH-
SY5Y cells.  
(A) Kinetic of the FRET measurements for P301L tau FRET biosensor expressed in SH-SY5Y 
cells. (B) FRET analysis of the dose response of MK-886 in the P301L tau FRET biosensors 
expressed in SH-SY5Y cells (for 96 hrs) indicates an EC50 value of 1.06 M. Data are means ± 
















































Supplemental Figure 7. 5. Characterization and controls for P301L tau induced cell 
cytotoxicity assay in SH-SY5Y cells.  
(A) Kinetic of the P301L tau induced cell cytotoxicity in SH-SY5Y cells. (B) Effect of MK-886 on 
the total amount of tau expressed is shown by the Tau-5 antibody staining. (C) Effect of MK-886 
on the phosphorylation state Serine 396 of P301L tau expressed in SH-SY5Y cells is shown by 
the Phospho-Tau S396 antibody. -actin was used as loading control. Both controls indicate that 
the rescue of cell death by MK-886 is not due to an indirect mechanism. Data are means ± SD of 




























































































Supplemental Figure 7. 6. Effect of MK-886 on cell cytotoxicity induced by suppressors of 
survivin, inhibitor of apoptosis proteins (IAPs) or X-linked inhibitor of apoptosis proteins 
(XIAP).  
Both (A) YM-155 and (B) UC-112 induced cell cytotoxicity in SH-SY5Y cells and MK-886 does not 
rescue any cell death caused by these compounds. Data are means ± SD of three independent 





















Supplemental Figure 7. 7. Lifetime measurements of the basal FRET of the cellular tau 
intra-molecular biosensor.  
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The cellular tau intra-molecular FRET biosensor shows an efficient basal FRET, illustrating intra-
molecular interactions arising from the paper-clip monomeric structure where the N and C 
terminus of tau fold in on each other, bringing the GFP and RFP into close proximity. Data are 
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Supplemental Figure 7. 8. Controls for thioflavin-T (ThT) assay with purified WT tau 
proteins.  
(A) MK-886 and gossypetin do not interfere with ThT fluorescence after 72 hours of incubation. 
(B) MK-886 does not act as a nucleation center for fibril formation after 72 hours of incubation. 
Only the positive control of heparin shows a significant ThT positive signal. Data are means ± SD 
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of three independent experiments. ****P < 0.0001 and n.s. indicates not significant by two-tailed 
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8.1. Summary 
Huntington’s disease (HD) is the most common inherited neurodegenerative 
disorder and one of the nine polyglutamine (polyQ) diseases characterized by the 
pathological aggregation of the misfolded huntingtin protein with abnormally long polyQ 
expansion due to genetic mutation. Recent studies suggest that HD is a conformational 
disease and perturbing huntingtin protein conformations may be more effective in 
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targeting the toxic aggregates. To exploit this new therapeutic window, we engineered 
three FRET based biosensors that monitor the conformations of huntingtin (HTT) exon 1 
with different polyQ lengths (Q16, Q39 and Q72) in living cells. These FRET biosensors, 
together with a high-precision fluorescence lifetime detection platform, enable high-
throughput screening of small molecules that target HTT conformations. We found seven 
small molecules that perturbed HTT conformations and reduced HTT-induced neuronal 
cell cytotoxicity with submicromolar potency. In addition, these compounds altered FRET 
in HTT biosensors of shorter polyQ lengths, suggesting that they were acting through 
perturbing the protein conformations rather than directly binding to the -sheet 
aggregates. Using SPR and an advanced EPR technique, we confirmed that the 
compounds directly bind to both monomeric HTT proteins as well as HTT fibrils and 
disrupt the protein aggregation. This strategy in targeting the HTT conformations can be 
applicable to other proteins involved in polyQ diseases. 
8.2. Introduction 
Huntington’s disease (HD) is an inherited neurodegenerative disorder caused by 
expansion of a CAG repeat in the exon 1 of huntingtin (HTT) gene, which translates into 
an abnormal polyglutamine (polyQ) in HTT protein (102, 103). Despite the past few 
decades of rigorous and focused research, there are currently no cures or significant 
disease modifying therapies currently available for Huntington disease (HD) (103). Even 
though clinical trials of potential compounds acting through indirect mechanism (not 
directly targeting HTT) are imminent, there is currently no ongoing clinical trial of small 
molecules acting through direct disruption of HTT aggregation, which is still an important 
area for targeting (134-136). In addition, two pivotal trials of potential disease‐modifying 
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agents, coenzyme Q10 and creatine, recently met untimely ends (136). Hence, there is a 
need to discover treatments focusing on targeting HTT aggregation (325). 
HTT is an intrinsically disordered proteins that regulates fast axonal trafficking, 
vesicle transport (including transport of brain-derived neurotrophic factor (BDNF)) and 
synaptic transmission (105). It also plays an important role in neurons in the brain and is 
essential for normal development before birth (106). HD is one of the nine 
neuropathologies caused by an abnormal expansion of CAG repeats, encoding a polyQ 
stretch in various proteins (107). In HD, the expansion occurs at the exon 1 of the IT15 
gene of HTT protein. The wild type (WT) protein contains 35 glutamine repeats or less 
(≤Q35, no pathology) while in the mutant forms the expanded glutamines are more than 
35 repeats (Q36-39, late onset; ≥Q40, observed pathology) (108). Importantly, the length 
of the polyQ stretch and the age of disease onset are inversely correlated, with longer 
stretches resulting in earlier onset and increased severity of the disease (108-110). In 
addition, it has been shown that N-terminal HTT with polyQ tracts in the pathological 
range (>Q35), but not with polyQ tracts in the normal range (≤Q35), form high molecular 
weight protein aggregates with a -sheet fibril morphology(111). Mutant HTT protein 
disrupts many normal physiological processes and leads to unbalanced homeostasis of 
apoptotic molecules, deficits in autophagy, axonal transport impairment, transcriptional 
dysregulation, reduced cellular BDNF support, mitochondrial abnormalities, and 
glutamate excitotoxicity (116). 
While aggregate formation is the hallmark of HD (111, 118), its significance in 
regard to toxicity remains controversial. It has been suggested that large contained 
aggregates may form in neurons as a protective response. These prominent inclusion 
bodies (IBs) have been shown to decrease mutant HTT levels elsewhere in the neuron, 
prolonging cell survival (119). Recently, strong evidence for the toxicity of monomeric 
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and small oligomeric species of mutant HTT that have adopted specific conformational 
states has also emerged (120-130), but the great majority of cellular studies report on 
IBs alone and the true toxic species is still unknown (121, 131-133). 
The molecular details of protein misfolding and aggregation in neurodegenerative 
disorders may hold the key to therapeutic intervention (326). Previous drug discovery 
effort targeting HTT aggregation has been focusing on direct disruption of the high 
molecular weight species formed by HTT protein with >Q35 without taking into account 
HTT conformations (327). Recent evidences on small molecules or antibodies 
modulation of HTT conformations and hence aggregation have suggested a shift in 
paradigm to target HTT conformations for disruption of aggregates in drug discovery 
(152, 328-337). Specifically, it has been shown in vitro that monomeric HTTex1 proteins 
adopt similar structural features for both WT and mutant HTT proteins (335). In addition, 
anti-polyQ antibodies have been shown to be able to recognize a common polyQ region 
in both WT and mutant HTT proteins regardless of the polyQ lengths (336, 337). 
Furthermore, polyQ dependent structuring and rigidification of HTT proteins could be 
mimicked in HTT with shorter polyQ by a decrease in temperature (332). These suggest 
that besides targeting mutant HTT proteins with pathological polyQ lengths, it may be 
important to take into account HTT proteins with various polyQ lengths, including WT 
polyQ lengths, to have a more effective therapeutic targeting strategy. One commonality 
of the studies above are that they have mostly been done in vitro using purified proteins 
which do not recapitulate the cellular environment, lacking the numerous chaperone 
proteins that may be required to produce the ensemble of HTT monomers, oligomers or 
aggregates. Additionally, purified protein assays are only capable of identifying hits that 
directly perturb HTT and are wholly naive against indirect mechanism of action. 
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Here, we shift the HTT aggregation process into the cellular environment, where 
the ensemble of HTT conformations should more closely recapitulate the distribution of 
different monomeric, oligomeric or aggregated assemblies. To monitor HTT 
conformations and discover small molecules that disrupt toxic HTT aggregates, we 
engineered three distinct fluorescence resonance energy transfer (FRET) biosensors of 
HTT exon 1 (HTTex1) with different polyQ lengths (Q16, Q39 and Q72) to monitor HTT 
conformational changes and aggregation. We note that HTT cellular FRET biosensors 
(Q72 and Q79) have been previously developed and used to measure the extent of HTT 
aggregation. In this study, we have included both HTTex1 Q16 and Q39 biosensors to 
study how the conformations of HTTex1 with different polyQ lengths can be perturbed 
and targeted in different structural states. We used these biosensors in conjunction with 
a state-of-the-art fluorescence lifetime plate reader (FLT-PR) as a high-throughput 
screening (HTS) platform for drug discovery (283). Fluorescence lifetime detection 
increases the precision of FRET-based screening by a factor of 30 compared with 
conventional fluorescence intensity detection (284), and provides exquisite sensitivity to 
resolve minute structural changes within protein ensembles. This sensitivity allows direct 
detection of conformation changes within an ensemble of oligomers (e.g. conversion 
from toxic to non-toxic oligomer conformation), the dissociation of oligomers or 
aggregates, or changes in the ensemble of monomer conformations (190, 199, 226, 
270). In addition, expression of these biosensors in cells has the added advantage of 
identifying compounds that act both directly (by binding HTT) and indirectly (through 
orthogonal biochemical pathways) to modify toxic aggregates.  
In this study, we show for the first time that small molecules can target both WT 
and mutant HTTex1 with different polyQ lengths (Q16, Q39 and Q72) in cells to disrupt 
toxic HTT aggregate formation and rescue HTT induced cell death. After first 
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characterizing the expression and FRET signals of the biosensors with different 
structural states, we performed HTS of the library of pharmacologically active 
compounds (LOPAC) and identified seven small molecules that directly binds HTT and 
strongly attenuates FRET with EC50 values at a range of 0.040-5 µM. All compounds 
rescue HTTex1-Q72 induced cell cytotoxicity with the most potent compound having an 
IC50 of 0.25 M. To elucidate the mechanism of action, we tested the effects of 
compounds in the all HTTex1 FRET biosensors of different polyQ lengths to see if they 
perturb the biosensors differently. In addition, we also tested the binding affinity of the 
compounds to both monomers and -sheet fibrils using SPR and we observed that some 
compounds preferentially bound to purified monomeric HTTex1 proteins while some 
bound preferentially to -sheet fibrils. Furthermore, we used an advanced electron 
paramagnetic resonance (EPR) technique to show that all compounds, except one, 
disrupted HTT aggregation in both unseeded and seeded fibrillization. All these data 
imply that the compounds are perturbing a common region of the HTTex1 proteins but 
with different binding affinity to the monomeric or -sheet conformations of HTTex1, 
leading to structural changes and disruption of aggregates, hence defining a new 
therapeutic approach to targeting toxic HTT aggregates. 
 
8.3. Materials and methods 
8.3.1. Molecular biology 
To generate HTTex1-polyQ-GFP and HTTex1-polyQ-RFP with polyQ of Q16, 
Q39 and Q72, cDNA encoding the conserved region of the human HTT protein N-
terminus (17 amino acids before polyQ and 50 amino acids after polyQ) with different 
polyQ lengths fused to the N-terminus of EGFP and TagRFP vectors. The unlabeled 
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HTTex1-Q72 was generated without the fusion fluorescent proteins. All constructs 
contain the monomeric mutation A206K to prevent constitutive fluorophore clustering 
(204).  
8.3.2. Cell culture and generation of cellular FRET biosensors 
HEK293 and N2a cells (ATCC) were cultured in phenol red-free Dulbecco's 
Modified Eagle Medium (DMEM, Gibco) supplemented with 2 mM L-Glutamine 
(Invitrogen), heat-inactivated 10% fetal bovine serum (FBS HI, Gibco), 100 U/ml 
penicillin and 100 g/ml streptomycin (Gibco). Cell cultures were maintained in an 
incubator with 5% CO2 (Forma Series II Water Jacket CO2 Incubator, Thermo Scientific) 
at 37 ºC. The intermolecular HTTex1 FRET biosensors were generated by transiently 
transfecting HEK293 cells using Lipofectamine 3000 (Invitrogen) with HTTex1-polyQ-
GFP and HTTex1-polyQ-RFP (polyQ = Q16, Q39 or Q72; 1:20 DNA plasmid 
concentration ratio). The effectiveness of HEK293 cells transfected with FRET 
constructs as a HTS platform has been demonstrated in our previous work (190, 226). 
The HTTex1-Q72 FRET biosensor expressed in N2a cells was generated by transiently 
transfecting N2a cells using Lipofectamine 3000 (Invitrogen) with HTTex1-Q72-GFP and 
HTTex1-Q72-RFP (1:20 DNA plasmid concentration ratio). 
8.3.3. Pilot screening with LOPAC library 
The library of pharmaceutically active compounds (LOPAC), containing 1280 
compounds, was purchased from Evotec (Hamburg, Germany), formatted into 96-well 
mother plates using an FX liquid dispenser, and formatted across three 384-well plates 
at 50 nL (10 μM final concentration/well) using an Echo liquid dispenser. DMSO 
(matching %v/v) was loaded as in-plate no-compound negative controls. The 384-well 
flat, black-bottom polypropylene plates (PN 781209, Greiner Bio-One) were selected as 
the assay plates for their low autofluorescence and low interwell cross talk. The plates 
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were sealed and stored at −20 °C until use. Two days prior to screening, HEK293 cells 
were transfected using Lipofectamine 3000 with HTTex1-polyQ-GFP/RFP (HTTex1-
polyQ FRET biosensor) in 15 x 100 mm plates (5 x 106 cells/plate). On each day of 
screening, the compound plates were equilibrated to room temperature (25 °C). The 
cells were harvested from the 100 mm plates by incubating with TrypLE (Invitrogen) for 5 
min, washed three times in PBS by centrifugation at 300 g and filtered using 70 μm cell 
strainers (BD Falcon). Cell viability, assessed using a trypan blue assay, was >95%. 
Cells were diluted to 1 million cells/ml using an automated cell counter (Countess, 
Invitrogen). Expression of HTTex1-polyQ-GFP/RFP (HTTex1-polyQ FRET biosensor) 
was confirmed by fluorescence microscopy prior to each screen. After resuspension and 
dilution in PBS, the biosensor cells were constantly and gently stirred using a magnetic 
stir bar at room temperature, keeping the cells in suspension and evenly distributed to 
avoid clumping. During screening, cells (50 μl/well) were dispensed by a Multidrop 
Combi Reagent Dispenser (Thermo Fisher Scientific) into the 384-well assay plates 
containing the compounds and allowed to incubate at room temperature for 2 hours 
before readings were taken by the fluorescence lifetime plate reader (FLT-PR, 
Fluorescence Innovations, Inc) as described previously (190, 226).  
8.3.4. HTS data analysis 
As described previously (190, 226), time-resolved fluorescence waveforms for 
each well were fit with single-exponential decays using least-squares minimization global 
analysis software to give donor-acceptor lifetime (τDA) and donor-only lifetime (τD). FRET 
efficiency (E) was then calculated based on Equation 1. 
𝐸 = 1 − (
𝜏𝐷𝐴
𝜏𝐷
)  𝐸𝑞. 1 
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Assay quality was determined with the lead compound (niclosamide) as positive control 
and DMSO as a negative control and calculated based on Equation 2 (192), 
𝑍′ =  1 −
3(𝜎𝑝 + 𝜎𝑛)
|𝜇𝑝 − 𝜇𝑛|
 𝐸𝑞. 2 
where σp and σn are the standard deviations (SD) of the observed τDA values, and µp and 
µn are the mean τDA values of the positive and negative controls. To make this metric 
less sensitive to strong outliers, we utilized the normalized median absolute deviation 
(1.4826*MAD) and median in place of the standard deviation and mean, respectively 
(193). 
Fluorescent compounds were flagged as potential false positives due to 
interference from compound fluorescence by a set of stringent fluorescent compound 
filters based on analysis of the spectral waveforms of each well from the NCC screen 
(190, 226). After removal of fluorescent compounds, a histogram of the FRET 
distribution from all compounds in the screen was plotted and fit to a Gaussian curve to 
obtain the mean (µ) and standard deviation (σ, SD). A hit was defined as a compound 
that decreased the FRET efficiency by more than five times the standard deviation (5σ 
or 5SD) relative to the mean µ. Seven reproducible hits from all screens, niclosamide, 
10058-F4, AMG9810, TNP, rottlerin, TBB and dihydroergotamine mesylate (DMS) were 
purchased (Millipore Sigma). 
8.3.5. FRET dose-response assay 
The reproducible hit compounds from all screens were dissolved in DMSO to 
make a 10 mM stock solution, which was serially diluted in 96-well mother plates. The hit 
compounds were screened at nine different concentrations (1 nM to 10 μM). Compound 
(1 μl) was transferred from the mother plates into assay plates using a Mosquito HV 
liquid handler (TTP Labtech Ltd, UK). The preparations for HTTex1-polyQ-GFP/RFP 
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FRET biosensors (polyQ = Q16, Q39 or Q72) and FRET measurements were carried out 
similar as above. 
8.3.6. Cell cytotoxicity assay 
Cell cytotoxicity was measured using the CytoTox-Glo (Promega Corporation) 
luminescence assay kit. N2a mouse neuroblastoma cells were plated at a density of 5 x 
106 cells/plate in 100 mm plate (Corning) and transfected with unlabeled HTTex1-Q72 or 
equivalent vector-only control for 24 hours. The transfected cells were then plated at a 
density of 5000 cells/well in white solid 96-well plate (Corning) with a total volume of 100 
l, followed by treatment with hit compounds at a dose dependent manner of seven 
different concentrations (1 nM to 1 μM) or single dose at 0.2 M, as well as DMSO-only 
controls, for another 72 hours. After incubation, 50 μl of CytoTox-Glo Cytotoxicity Assay 
Reagent was added to all wells followed by mixing by orbital shaking and incubation for 
15 minutes at room temperature. The first luminescence reading was measured using a 
Cytation3 Cell Imaging Multi-Mode Reader luminometer (BioTek). 50 l of Lysis Reagent 
was then added, followed by incubation at room temperature for 15 min, and 
luminescence was measured again using the luminometer. Cell cytotoxicity was 
calculated following the manufacturer protocol. 
8.3.7. Thioflavin-S (ThS) assay 
HEK293 cells were transfected with HTTex1-polyQ-RFP (polyQ = Q16, Q39 or 
Q72 at equivalent DNA concentration as used in the HTTex1 FRET biosensor) for 48 
hours. HTTex1-polyQ-GFP was not used, as it would interfere with the ThS signal. 
Thioflavin-S (ThS, Millipore Sigma, product no. T1892) was dissolved in PBS buffer and 
was filtered through a 0.2 µm syringe filter to make a stock solution of 2.5 mM. For the 
ThS assay, cells were fixed with 1 ml of 4% paraformaldehyde in TBS for 15 minutes 
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followed by washing with 1 ml of TBS for 5 minutes twice. After fixing, cells were 
permeabilized with 1ml of 1% Triton in TBS for 5 minutes, followed by washing with 1ml 
of TBS for 5 minutes twice. After permeabilization, cells were then treated with 0.002% 
ThS in TBS and incubate in the dark for 20 minutes. Cells were then washed twice with 
50% ethanol for 10 minutes each and finally washed twice with TBS for 5 minutes each. 
Cells were then imaged with a fluorescence microscope using EVOS-FL cell imaging 
systems at 20X magnification. Mean fluorescence intensity for each image was 
quantified using ImageJ and values were normalized to untransfected controls. 
8.3.8. Expression, purification of Httex1-Q46 monomer and fibril preparation 
The thioredoxin (Trx) fused HTTex1-Q46 protein was expressed and purified as 
described previously (Pandey et al., JBC, 2018; Isas et al., Biochemistry, 2015). Briefly 
the cultures of pET32a-Httex1 (Q46) transformed BL21 cells were grown at 37 °C for 4h 
hour and were further inoculated in a 50-fold access of LB Media and allowed to grow to 
A600nm=0.7-0.8 at 37 °C. The expression was induced overnight using 1 mM isopropyl1-
thio-β-D-galactopyranoside (IPTG) at 18 °C. The successive protein purification was 
achieved using Nickel affinity chromatography followed by ion exchange 
chromatography. The biotinylation/spin labeling was achieved by reacting the protein 
harboring desired cysteine mutation with maleimide-PEG11-biotin (Thermo Fisher) / 
MTSL spin label (Toronto Research Chemicals) post Ni affinity step and excess spin 
label was removed using ion exchange chromatography. 
Fibrils were prepared by overnight incubation of HTTex1-Q46 fusion protein at 
25µM concentration (with desired percentage of biotin label) with EKMax (Invitrogen) to 
remove fusion tag (Trx) at 4 °C, in the presence of 1% molar ratio of (Q46) seeds. The 
fibrils were harvested by using bench top centrifuge (Eppendorf) at 15000 rpm. The 
quality of fibrils was confirmed using JEOL JEM-1400 transmission electron microscope. 
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8.3.9. Surface plasmon resonance (SPR) binding assay 
Binding affinity between HTTex1-Q46 monomer or -sheet fibril and the hit 
compounds was determined by SPR analysis using BIAcore S200. Recombinant 
HTTex1-Q46 monomer or -sheet fibril was immobilized on the CM5 sensor chip 
(Biacore, GE Healthcare) via amine coupling. Briefly, the dextran surface was activated 
with a 1:1 mixture of 0.4 M 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
and 0.1 M N-hydroxysuccinimide. HTTex1-Q46 proteins (20 μg/ml) in 10 mM sodium 
acetate at pH 5.0 was flowed past a working surface before blocking the remaining 
activated carboxymethyl groups with 1 M ethanolamine at pH 8.5 to achieve a level of 
1200 RU suitable for binding analysis. The reference surface was activated and reacted 
with only ethanolamine. 
For direct binding assays to the HTTex1-Q46 protein, hit compounds at eight 
different concentrations (0.1 μM to 200 μM), as well as DMSO-only controls, were 
prepared in HEPES-EP containing a total of 2% DMSO. The samples were injected over 
both the reference and HTTex1-Q46 monomer or -sheet fibril immobilized surfaces at 
10 μl/min for 180 seconds and dissociated in glycine-HCl pH 2.5. All the samples, along 
with blanks from buffer and DMSO-only controls, were measured on a 96-well microplate 
(Biacore, GE Healthcare) at 25 °C. Reflectivity response data points were extracted from 
response curves at 5 seconds prior to the end of the injection to determine steady-state 
binding. All the data were double referenced with blanks using standard procedures with 
Biacore S200 Evaluation Software v1.0.  
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8.3.10. Continuous Wave (CW)-electron paramagnetic resonance (EPR) 
measurements 
The R1 spin labeled HTTex1-Q46 at 35 position (reporter for structural changes 
in polyQ site) was prepared by following the previously established protocol ((Pandey et 
al., JBC, 2018).  Briefly the fusion tag (Trx) was removed using EKMax (Invitrogen) and 
the clean seed-free 35R1 derivative of HTTex1-Q46 was purified using reversed phase 
chromatography (Phenomenex, C4 column). The lyophilized powder was treated with 
0.5% TFA (v/v) in methanol to disaggregate any pre-existing oligomers and the organic 
was removed under the gentle stream of N2 gas. The resultant film was reconstituted in 
the 20 mM phosphate, 150 mM NaCl pH 7.4 buffer (with desired percentage of DMSO)  
in the absence and presence of compounds. 
The resulting samples were loaded into boro glass tubing and the EPR spectra 
were acquired using a X-band Bruker EMX spectrometer attached with a Bruker 
ER4119HS resonator. The scan width and the incident power for all the measurements 
were fixed to 100 Gauss and 12.7 milliwatts, respectively.  
The percentage of inhibition was estimated by comparing the change in EPR 
signal amplitude of R1 spin labeled HTTex1-Q46 in the presence of small molecules to 
that of protein alone at the desired time point during the HTTex1-Q46 misfolding kinetic 
study. 
8.3.11. Statistical analysis 
Data are shown as mean ± standard deviation unless stated otherwise. Statistical 
analysis was performed by a two-tailed unpaired t test (Student’s t test) using GraphPad 
Software to determine statistical significance for all experiments. Values of P <0.05 were 
considered statistically significant. GraphPad style in using asterisks to denote P values 
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in figures was used (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 and n.s. 
indicates not significant). 
8.4. Results 
8.4.1. Intermolecular FRET biosensor directly monitors conformational changes in 
huntingtin (HTT) oligomers and aggregates in cells  
To develop a cell-based HTS platform that can detect small-molecule 
perturbation of HTT conformational states or disruption of HTT aggregates, we 
engineered three HTT FRET biosensors expressed in living cells (Fig. 7.1A). We used 
HEK293 cells expressing HTTex1 with different polyglutamine (polyQ) lengths of Q16, 
Q39 or Q72 fused to green (GFP) or red fluorescent proteins (RFP) (HTTex1-(polyQ)-
GFP/RFP or HTTex1-(polyQ) FRET biosensors). The three different polyQ lengths were 
used as HTTex1-Q16, which is typically the non-mutant form of the protein, is known to 
form mostly monomers or oligomers and not the -sheet aggregates(338, 339). On the 
other hand, HTTex1-Q39 and -Q72 are known to form -sheet aggregates with 
increasing propensity of aggregation with longer polyQ length(339). While three different 
polyQ lengths were used in this study, we want to be clear that our primary goal was to 
focus on discovering small molecules that target the diseased states caused by HTTex1 
aggregation of polyQ length >Q35, with main focus on the HTTex1-Q72 FRET 
biosensor. Expression and homogeneity of the FRET biosensor were determined by 
fluorescence microscopy. Fluorescence microscopy images showed that the HTTex1-
Q16 proteins were evenly distributed in the cytosol of the cells, with no discernable 
puncta or other non-uniformities while more distinct puncta was formed in both HTTex1-
Q39 and -Q72 which indicated more progressive aggregation and -sheet aggregate 













































































Figure 8. 1. The huntingtin (HTT) intermolecular FRET biosensor and fluorescence lifetime 
technology enables direct monitoring of HTT aggregation in cells.  
(A) Schematic representation of live-cell based HTT intermolecular FRET biosensor. FRET signal 
is observed when HTT aggregates form, which is modulated by small-molecule inhibitors. HTT 
aggregate is drawn as a dimer for illustration but it can be more than a dimer (≥2-mers). (B) 
Fluorescence microscopy images of HEK293 cells expressing HTTex1-Q72-GFP/RFP (HTTex1-
Q72 FRET biosensor). (i) GFP channel, (ii) RFP channel, (iii) merged channel showing the 
presence of both HTTex1-Q72-GFP and HTTex1-Q72-RFP colocalized in the cells. (C) 
Fluorescence lifetime measurements of the HTTex1-Q72 biosensor show efficient FRET, 
indicating HTTex1-Q72 aggregation. (D) Titration of HTTex1-Q72-RFP (acceptor) to HTTex1-
Q72-GFP (donor) illustrates that the FRET efficiency of the biosensor follows a hyperbolic 
dependence on acceptor concentration. (E) Quantification of thioflavin-S (ThS) staining of 
HEK293 cells expressing HTTex1-RFP of various polyglutamine length (Q16, Q39 and Q72) in 
same total DNA concentration as used in the FRET biosensor (Supplementary Fig. 2). Data are 
means ± SD of three independent experiments. ****P < 0.0001 by two-tailed unpaired t test. 
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We next tested the functionality of the HTTex1 biosensors by measuring FRET 
efficiency using the fluorescence lifetime plate reader (FLT-PR)(283). The FRET 
efficiency reflects the average of the ensemble intermolecular proximity between 
HTTex1 molecules, which is derived from the distance between the donor and acceptor 
fluorophore fused to the proteins. Lifetime measurements between HTTex1-GFP (donor) 
and HTTex1-RFP (acceptor) for all Q16, Q39 and Q72 in live cells showed a substantial 
decrease in the donor fluorescence lifetime in the presence of the acceptor, indicating 
efficient FRET which increased with longer polyQ length and recapitulating the increased 
propensity of aggregation (Fig. 8.1C and Supplementary Fig. 8.1B). In addition, FRET 
observed illustrated a hyperbolic dependence on acceptor concentration with a 
maximum energy transfer efficiency (E) of 0.261±0.008 (Fig. 8.1D) in HTTex1-Q72 
FRET biosensor. Furthermore, our previous study showed that a negative control of 
expression of free soluble GFP and RFP in cells at the same DNA concentrations as the 
HTTex1 FRET biosensor showed a very low FRET efficiency of 0.019±0.004 between 
free soluble GFP and RFP(199). This indicated that FRET observed from cells 
expressing HTTex1 FRET biosensor arises from specific HTTex1 self interactions and 
not from nonspecific interactions between the free fluorophores.  
To further confirm the species of HTTex1 (oligomers or -sheet aggregates) 
present in the HTTex1 biosensor cells, we performed a thioflavin-S (ThS) assay in cells 
expressing HTTex1-RFP at the same concentration of HTTex1-GFP/RFP dual 
transfected cells (HTTex1-GFP was not used as it will interfere with the ThS signal which 
is green in fluorescence). Results from the ThS assay illustrate that the cells expressing 
HTTex1-Q16 did not show a ThS signal, similar to that of the untransfected cells, while 
cells expressing HTTex1-Q39 and -Q72 illustrated increasing ThS positive ThS signal 
(Fig. 8.1E and Supplementary Fig. 8.2). This confirms that the observed FRET from 
245 
 
HTTex1-Q16 FRET biosensor is mainly the result of oligomers formation and the 
observed FRET from HTTex1-Q39 and -Q72 are from -sheet aggregates formation. 
The combination of these cellular FRET biosensors and time-resolved FRET detection 
provides a powerful platform that is sensitive to identify novel compounds that modulate 
the ensemble of conformationally distinct HTTex1 species (monomers, oligomers or -
sheet aggregates). 
8.4.2. Identification of novel small molecules from HTS of the LOPAC library that 
perturb the conformational ensembles of HTTex1 oligomers and aggregates 
Using our cellular HTTex1 FRET biosensors, we performed a HTS of the library 
of the pharmaceutically active compounds (LOPAC: 1280 bioactive compounds) to 
identify compounds that perturb the conformational ensembles of HTTex1 oligomers or 
disrupt the -sheet fibril aggregates. After an initial quality control check of the cells 
expressing the HTTex1 FRET biosensors (Q16, Q39, Q72) on each day of screening 
(fluorescent waveform signal level and coefficient of variance), the cells were dispensed 
into drug plates and incubated with the compounds (10 µM) or DMSO control wells for 2 
hours. Lifetime measurements were acquired with the FLT-PR. A single-exponential fit 
was used to determine the lifetime from cells expressing the HTTex1 FRET biosensors 
(τDA) or expressing a HTTex1-GFP donor-only control (τD) to determine FRET efficiency 
(Eq. 1). As fluorescence lifetime measurements are prone to interference from 
fluorescent compounds, a stringent fluorescent compound filter was used to flag 
fluorescent compounds as potential false-positives in all screens due to interference 
from compound fluorescence (190, 226). FRET efficiency from all compounds that 
passed the fluorescent compound filter are plotted and a histogram of the FRET 
246 
 
distribution from these compounds was fit to a Gaussian curve to obtain a mean and 
standard deviation (SD) for all the three screens (Supplementary Fig. 8.3A-F). 
Our initial goal was to discover compounds that both directly disrupt HTTex1 
aggregates or alter the conformational ensembles of HTTex1 oligomers with the 
potential of disrupting HTTex1 aggregation, leading us to focus our search to 
compounds that reduce FRET (though other compounds that increase FRET could 
potentially remodel toxic oligomers and be of interest in future studies). Seven 
reproducible hits from the library were obtained from the separate screens with the three 
different FRET biosensors that decreased FRET by more than 3SD below the mean of 




Hits that illustrate dose-dependent FRET reduction
Q72–Hits Q39–Hits Q16–Hits Cpd name
1171 1171 1171 Niclosamide
- 331 331 10058-F4
796 796 796 AMG 9810
495 - - TNP
- - 744 Rottlerin
1090 1090 1090 TBB
- 273 273 DMS
 Niclosamide (EC50 = 0.06 M)
 10058-F4 (EC50 = 0.55 M)
 AMG 9810 (EC50 = 1.18 M)
 TNP (EC50 = 1.98 M)
 Rottlerin (EC50 = 0.63 M)
 TBB (EC50 = 0.46 M)
 DMS (EC50 = 5.12 M)


























 Niclosamide (EC50 = 0.05 M)
 10058-F4 (EC50 = 0.42 M)
 AMG 9810 (EC50 = 1.56 M)
 TNP (EC50 = 3.42 M)
 Rottlerin (EC50 = 0.59 M)
 TBB (EC50 = 0.57 M)
 DMS (EC50 = 4.51 M)













































 Niclosamide (EC50 =0.04 M)
 10058-F4 (EC50 =0.27 M)
 AMG 9810 (EC50 =2.01 M)
 TNP (EC50 =N/A)
 Rottlerin (EC50 =0.48 M)
 TBB (EC50 =0.73 M)
 DMS (EC50 =4.92 M)
 
 Figure 8. 2. Small-molecule inhibitors of HTTex1 aggregation obtained from high-
throughput screening (HTS) of LOPAC library using HTTex1 FRET biosensors (Q16, Q39 
and Q72).  
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(A) Hit compounds obtained from all screens using FRET biosenors with different polyQ lengths 
(Q16, Q39 and Q72). (B-D) FRET dose-response assays with hit compounds which produced a 
dose-dependent FRET reduction in (B) HTTex1-Q72, (C) HTTex1-Q39 and (D) HTTex1-Q16 
FRET biosensors. Data are means ± SD of three independent experiments. 
8.4.3. FRET dose-response of hit compounds with HTTex1 FRET biosensors 
Since the hits compounds were selected from different FRET biosensors, we 
wanted to test their effects in all three biosensors. The relative effective concentration 
(EC50) of the hit compounds was determined by in-cell FRET measurements using the 
HTTex1 FRET biosensors with Q16, Q39 and Q72. Surprisingly, all compounds 
decreased FRET efficiency in all biosensors in a dose-dependent manner (Fig. 8.2B-D), 
with EC50 range from of 0.040 to 5 μM. Since the compounds reduced FRET in all 
biosensors, this suggests that the hit compounds may be targeting common structures 
or regions that have high homology in all polyQ lengths (335, 340).  
Assay quality (Z´) was determined using niclosamide the best hit compound (Eq. 
2). The Z´ values for different FRET biosensors were 0.710.03 (HTTex1-Q72), 
0.660.02 (HTTex1-Q39), 0.520.02 (HTTex1-Q16) which indicate excellent assay 
quality, validating niclosamide as a positive control tool-compound for targeting HTTex1 
oligomers and aggregates. 
8.4.4. Hit compounds rescue HTTex1-Q72 induced cell cytotoxicity in N2a cells 
with nanomolar potency 
We next tested the effect of hit compounds on HTT induced cytotoxicity in the 
N2a cell model which was known to cause cell death(341). Overexpression of unlabeled 
HTTex1-Q72 showed significantly greater cell death when compared to the vector 
control (Fig. 7.3A). Five compounds rescued cell death in a dose-dependent manner 
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with IC50 values ranging from 0.2-0.5 μM (Fig. 8.3B) while other two compounds 
exhibited toxicity at concentration above 0.2 M. We then tested all compounds at a 
single dose of 0.2 M for comparison of their relative potency. All compounds, except 
TNP and DMS, rescued of HTTex1-Q72 induced cytotoxicity at 0.2 M (Fig. 8.3C). We 
note that our best compound, niclosamide, again has one of the largest rescue of cell 
cytotoxicity at 0.2 μM of concentration, comparable to 10058-F4 and rottlerin. To confirm 
that the rescue of cytotoxicity arises from disruption of HTTex1-Q72 aggregates, we then 
moved on to test the effects of all the compounds in the HTTex1-Q72 FRET biosensors 
expressed in N2a cells (Supplementary Fig. 8.4A). Treatment of all the hit compounds 
at their maximum effective doses illustrated significant FRET reduction of the HTTex1-
Q72 biosensor (Supplementary Fig. 8.4B), supporting that the observed rescue of 
cytotoxicity was from the disruption of HTTex1-Q72 aggregates. The IC50 values of hit 
compounds in the cell cytotoxicity assay were at similar magnitude as the EC50 observed 
from the FRET assays. The slight differences are likely due to the different treatment 
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Figure 8. 3.  Inhibition of HTTex1-Q72 induced cell cytotoxicity in N2a cells by hit 
compounds.  
(A) N2a cells were transfected with vector control and unlabeled HTTex1-Q72. Significant cell 
death is observed in cells transfected with HTTex1-Q72 as compared to the vector control. (B) Hit 
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compounds (10058-F4, AMG9810, TNP, rottlerin and DMS) rescued HTTex1-Q72 induced 
cytotoxicity in N2a cells in a dose-dependent manner with submicromolar potency. (C) 
Comparison of the functional effects of all the hit compounds at 0.2 M. Data are means ± SD of 
three independent experiments. *P < 0.05, **P < 0.01, and ***P < 0.001 by two-tailed unpaired t 
test. 
8.4.5. Binding of hit compounds to purified HTTex1-Q46 monomers or fibrils 
To determine if these seven hit compounds directly act on HTTex1 or modulate 
HTTex1 FRET by acting through an indirect pathway, we measured the binding affinity 
for each of the seven hit compounds to purified recombinant HTTex1-Q46 proteins as 
monomers or fibrils using surface plasmon resonance (SPR). SPR measurements were 
carried out by immobilizing purified HTTex1-Q46 monomers or fibrils onto the SPR chip 
followed by compounds flowing through the chip to allow for binding. All the seven hits 
demonstrated dose-dependent binding to purified HTTex1-Q46 monomers (Fig. 8.4A 
and Supplementary Fig. 8.5A-G) and fibrils (Fig. 8.5B and Supplementary Fig. 8.6A-
G). Interestingly, five of the seven compounds illustrated significantly different binding 
affinity to monomers or fibrils, indicating their preferential binding to a particular species. 
In particular, this is consistent with how the hits were selected from the screens. Hits that 
showed better binding affinity to monomers were primarily discovered by HTTex1-Q16 
and -Q39 FRET biosensors while hits that illustrated better binding affinity to fibrils were 
discovered by HTTex1-Q72 FRET biosensors. Even though all compounds showed a 
common outcome of dose-dependent FRET decrease in the biosensors, it is important 
to note that they may be perturbing the biosensors through interacting with different 
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Figure 8. 4. Binding of hit compounds to purified HTTex1-Q46 monomer or fibril.  
Surface plasmon resonance (SPR) characterization of binding of hit compounds to (A) HTTex1-
Q46 monomer or (B) HTTex1-Q46 fibril. Data are means ± SD of three independent experiments. 
8.4.6. The small-molecule inhibitors disrupt both unseeded and seeded 
aggregation of HTTex1-Q46 protein through EPR 
To further investigate if the hit compounds inhibited HTT aggregation, we used 
electron paramagnetic resonance (EPR) to examine the effect of hit compounds on both 
unseeded and seeded aggregation of HTTex1-Q46 protein. Using HTTex1-Q46 spin 
labeled at position 35, we monitored the misfolding of HTTex1-Q46 in the absence and 
presence of hit compounds and in both unseeded (Supplementary Fig. 8.7A-B) and 
seeded conditions (Supplementary Fig. 8.7C-D). The EPR results showed that the 
addition of hit compounds (20 μM), except TBB, led to inhibition of HTTex1-Q46 
misfolding or aggregation in both unseeded (Fig. 8.5A) and seeded (Fig. 8.5B) 
conditions. Since the binding affinity of TBB was shown by SPR to be ~130 M, it is 
consistent that we did not observe disruption of HTT aggregation at 20 M of the 
compound. These results, in combination with the changes in FRET and reduction of 
HTTex1-Q72 induced cytotoxicity, suggest that the hit compounds alter the 
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conformational ensemble of HTT monomers, oligomers or aggregates, hence leading to 














































































































































Figure 8. 5. Disruption of HTTex1-Q46 aggregation by hit compounds.  
Electron paramagnetic resonance (EPR) characterization of disruption of HTex1-Q46 aggregation 
of hit compounds in (A) unseeded and (B) seeded conditions. HTTex1-Q46 was spin labeled at 
position 35 and the aggregation assays, both unseeded and seeded, were tested in the absence 
(DMSO-only controls) and presence of hit compounds (20 M) for 20 hours. Data shown are 
quantification from the EPR raw curves using the relative change in the central line amplitude 
when treated with hit compounds as compared to the DMSO-only controls. Data are means ± SD 
of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001 by two-
tailed unpaired t test. 
8.5. Discussion 
There are three major classes of screening campaigns targeting HTT including 
targeted phenotype of aggregation, enhanced clearance and inhibition of cell death 
(145). These include recent efforts in preclinical targeting of HTT through indirect 
targeting mechanisms (146) including antisense oligonucleotides (148), antibodies 
fragments (147) and small molecules (149). In terms of direct targeting of the 
aggregation, several recent efforts have screened and discovered small molecules that 
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target toxic HTT aggregates that yielded efficacious, cytoprotective compounds. These 
small molecules include methylene blue (MB) (inhibition of protein aggregation by 
targeting monomer, oligomer and aggregates tested at 1-100 M; inhibition of cell 
cytotoxicity tested at 100 nM) (150), C2-8 (inhibition of protein aggregation IC50=25 M; 
inhibition of cell cytotoxicity tested with IC50=50 nM) (151), epigallocatechin gallate 
(EGCG) inhibition of protein aggregation (perturb oligomer conformation with IC50=~1 
M; inhibition of toxicity tested in yeast model of HD (at 500 M) and HD transgenic flies 
(at 0.1–100 M)) (152, 153), leflunomide and teriflunomide (inhibition of HTT-Q72-Luc 
protein aggregation reporter assay with IC50=1–3 M; inhibition of HTT protein 
aggregation tested at 100 M) (154), PGL-135 and PGL-137 (inhibition of HTT 
aggregation with IC50=40 M (PGL-135) and IC50=100 M (PGL-137); reduction of 
inclusion bodies in cells tested at 25 M (PGL-135) and 50 M (PGL-137)) (155), congo 
red (inhibition of HTT aggregation with IC50=0.3 M)(129, 156), thioflavin-S (inhibition of 
HTT aggregation with IC50=20 M) (156), and xyloketal derivatives (inhibition of HTT 
aggregation tested in Caenorhabditis elegans model of HD at 100 M) (157). However, 
none of these compounds has successfully advanced to become an effective 
therapeutic.  
One commonality among these molecules is that they were initially identified 
through direct measurements of HTT aggregation and disaggregation, without 
monitoring and providing information on the conformational changes or dynamics of the 
protein. Although small molecules that inhibit or disrupt HTT aggregation have been 
studied for decades, the targeting of HTT conformations has only recently been 
proposed, with the majority of efforts being focused on repurposing some of the 
previously identified small molecules such as MB (150), EGCG (152) and congo red 
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(129). In addition, with the exception of a few studies, most of them were performed 
using in vitro purified protein assays, which do not reliably represent the cellular 
environment as these assays lack numerous chaperone proteins that may contribute to 
the formation of oligomers and aggregates. Inherently, these purified protein assays are 
only capable of identifying hits that directly perturb HTT protein and are wholly naive 
against indirect mechanisms of action, affecting other pathologically relevant cellular 
processes. Hence, a cellular approach that monitors HTT aggregation holds promise as 
a novel HTS platform to discover more effective therapeutics. 
The most potent small-molecule hit compound from the HTS and the FRET 
assays (EC50 = 0.04-0.06 M) was niclosamide which also showed the strongest binding 
affinity for recombinant HTTex1-Q46 (Kd = 0.843 M for monomer and Kd = 3.45 M for 
fibril) and the largest effect in inhibition of HTTex1-Q46 aggregation as well as a strong 
rescue in HTTex1-Q72 induced cytotoxicity at 0.2 M, comparable to other known HTT 
aggregation inhibitors. Two other most potent inhibitors in the cytotoxicity assay were 
rottlerin (IC50 = 0.25 M) and 10058-F4 (IC50 = 0.27 M), which were also relatively 
potent in the FRET assays (EC50 of rottlerin = 0.48-0.63 M; EC50 of 10058-F4 = 0.27-
0.55 M) and were the top binders (Kd of rottlerin = 1.50 M; Kd of 10058-F4 = 5.12 M) 
to HTTex1-Q46 monomer next to niclosamide. This difference in the half maximal 
effective concentration could be due to different cell types used as well as the presence 
of the fluorophores in FRET assay that may result in less aggregation as compared to 
unlabeled HTTex1, hence smaller drug concentration may be sufficient to perturb the 
conformations. On the other hand, the difference between the cellular assays and the 
SPR binding assay could be due to the amount of proteins present for compound 
interactions, though the trend, in terms of potency, remains similar.  
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Niclosamide, together with rottlerin, were known to be effective mTOR inhibitors 
that lead to enhanced autophagy (342, 343). Since mTOR was present in HEK293 cells, 
we cannot eliminate that these compounds were also acting through inhibiting mTOR, 
resulting in the clearance of HTT proteins and hence leading to the rescue of HTT 
induced cytotoxicity. However, rottlerin has been shown to be inhibitor of huntingtin and 
prion aggregation (344, 345). On the other hand, 10058-F4 and AMG 9810 are known c-
Myc inhibitor and TRPV1 receptor antagonist respectively (346, 347). Interestingly, we 
found that HEK293 cells do not express these proteins and hence suggesting that the 
FRET change was specific to perturbation of HTTex1 conformations (348). Other 
compounds, TNP, TBB and DMS, were known inositol hexakisphosphate kinases 
inhibitor, casein kinase 2 inhibitor and serotonin receptor agonists respectively which 
were known to play a role in HD (349-351) so we also could not eliminate their effects on 
acting through these mechanisms. In addition, compounds like TBB, though showing 
binding to HTT proteins at high concentration through SPR, did not disrupt HTT 
aggregation through EPR, suggesting that it could be acting through the indirect 
mechanism of inhibiting CK2 which was shown to potentially rescuing cytotoxicity in 
HD(350). Furthermore, all of the compounds did not completely abolish the FRET 
signals in the intermolecular FRET biosensors, suggesting that HTT-HTT interactions 
were not completely disrupted but may have undergone a conformational change from 
an oligomer or aggregated species with closer proximity between the fluorophores to 
one with a more open conformation.  
Interestingly, our observations in that all small molecules caused perturbation of 
HTT cellular FRET biosensors with different polyQ lengths (Q16, Q39 and Q72) support 
the previous postulated model suggesting that both normal and expanded polyQ tracts 
(polyQ lengths below and above the pathological threshold) in the preaggregation state 
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share similar structures (335-337, 352, 353), rather than a specific toxic structure(354). 
This suggests that HTT proteins with polyQ lengths below and above the pathological 
threshold may adopt similar oligomeric conformations with the longer polyQ lengths 
having higher tendency to form -sheet aggregates. In addition, in the -sheet 
aggregates, these proteins may still uphold some of the common conformations 
originated from oligomers that could be targeted by the small molecules. This might also 
be inferred that there might be a prefibrillar structure that is capable of forming the toxic 
oligomers present in polyQ lengths less than the pathological threshold but they do not 
have the propensity or high enough local concentration to form the actual toxic 
aggregates. This suggests that the small molecules could potentially stabilize these pre-
toxic structures to prevent them from further aggregating into the toxic species. On the 
other hand, it is possible that these small molecules target another common feature 
rather than the polyQ tracts of the HTT proteins which made it possible that the 
molecules affect all polyQ lengths. 
The identity of a specific, toxic HTT aggregate remains elusive. Indeed, it is 
unlikely that a single, unique toxic conformation exists. It is far more likely that an 
ensemble of toxic oligomers and aggregates (differing in size, conformation and even 
molecular constituency) populate the amylogenic cascade(333). This heterogeneity in 
potential HTT aggregate targets highlights the need for an ultra-sensitive screening 
platform capable of monitoring structural changes within the ensemble of HTT 
assemblies. Our FRET-based platform for monitoring HTT aggregation in cells is a new 
technology that is capable of elucidating novel compounds which alter conformation and 
aggregation states of HTT proteins, thereby providing a new pipeline of therapeutic 
discovery for HD. This strategy, combining fluorescent biosensor and time-resolved 
FRET measurement in a HTS platform, should be generally applicable to other drug 
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discovery efforts targeting intrinsically disordered proteins involved in numerous 
polyglutamine diseases. 
8.6. Supplemental figures 
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Supplemental Figure 8. 1. Characterization of huntingtin exon 1 (HTTex1) intermolecular 
FRET biosensors.  
(A) Fluorescent microscopy images of GFP and RFP-tagged HTTex1 of various polyglutamine 
length, (i) Q16, (ii) Q39 and (iii) Q72, expressed in HEK293 cells. (B) Fluorescence lifetime 
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Supplemental Figure 8. 2. Thioflavin-S (ThS) staining of HEK293 cells expressing HTTex1-
RFP of various polyglutamine lengths.  
Fluorescence images of ThS staining of HEK293 cells being (i) untransfected or transfected with 
(ii) HTTex1-Q16-RFP, (iii) HTTex1-Q39-RFP and (iv) HTTex1-Q72-RFP. The amount of HTTex1-
RFP plasmids transfected for ThS assay is equal to the amount of HTTex1-GFP and HTTex1-
RFP plasmids used in the FRET biosensors. HTTex1-GFP is not used because it will interfere 
with the ThS signal which is green in fluorescence. Images are representative of three 
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Supplemental Figure 8. 3. High-throughput screening (HTS) of LOPAC library using 
HTTex1 FRET biosensors and hits identification.  
Representative pilot screening plots and Gaussian fits of the LOPAC library containing 1280 
compounds screened using (A-B) HTTex1-Q72, (C-D) HTTex1-Q39 and (E-F) HTTex1-Q72 
FRET biosensors. A FRET efficiency cutoff threshold was applied at a change in FRET efficiency 
of 3SD (black lines). Reproducible hits that decreased FRET by more than 3SD below the mean 
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of all cells were highlighted in red. Gaussian fits were performed by plotting histograms of all 
compounds from the LOPAC screens with the HTTex1 FRET biosensors after removal of 
fluorescent compounds to obtain the average FRET efficiency and the standard deviation (SD) of 
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N2a cells  
Supplemental Figure 8. 4. Hit compounds reduced FRET in the HTTex1-Q72 biosensor in 
N2a cells.  
(A) Fluorescence lifetime measurements of the HTTex1-Q72 FRET biosensor in N2a cells. (B) Hit 
compounds reduced FRET in the HTTex1-Q72 biosensor expressed in N2a cells. Data are 
means ± SD of three independent experiments. *P < 0.05, **P < 0.01, and ***P < 0.001 by two-
tailed unpaired t test. 






































































































































































































































































































Supplemental Figure 8. 5. Binding of the hit compounds to HTTex1-Q46 monomer as 
characterized by SPR measurements.  
SPR raw binding curves for (A) niclosamide, (B) 10058-F4, (C) AMG9810, (D) TNP, (E) rottlerin, 
(F) TBB, and (G) DMS. Bind curves are representative of three independent experiments. 




























































































































































































































































































Time (s)  
Supplemental Figure 8. 6. Binding of the hit compounds to HTTex1-Q46 fibril as 
characterized by SPR measurements.  
SPR raw binding curves for (A) niclosamide, (B) 10058-F4, (C) AMG9810, (D) TNP, (E) rottlerin, 














Supplemental Figure 8. 7. Disruption of HTTex1-Q46 aggregation by hit compounds as 
characterized by Continuous wave (CW)-electron paramagnetic resonance (EPR) 
measurements.  
(A-B) EPR characterization of disruption of HTTex1-Q46 aggregation by in the absence of seed 
(unseeded) and treated with (A) DMSO only as control or (B) hit compounds (20 M). Disruption 
of HTTex1-Q46 aggregation by hit compounds with 2% seed and treated with (C) DMSO only as 
control or (D) hit compounds (20 M). EPR raw curves were shown with treatment of niclosamide 
as a representative compound. HTTex1-Q46 was spin labeled at position 35 and the hit 
compounds were treated for 20 and/or 40 hours. Aggregation or misfolding causes line 
broadening and a concomitant reduction in amplitude. EPR raw curves are representative of 




CHAPTER 9: CONCLUDING REMARKS AND FUTURE 
DIRECTIONS 
This thesis research adopts a small molecule drug discovery approach through 
HTS with FRET biosensors to probe for conformational states of TNFR1 and 
conformational ensembles of tau oligomers or HTT aggregates. Specifically, we made 
use of a fluorescence lifetime detection method, which offers high-throughput and high-
precision measurements, in conjunction with fluorescent biosensor engineering to create 
novel screening platforms for targeting TNFR1 and IDPs.  
 We first performed extensive literature reviews to identify the gaps in the 
targeting mechanisms of TNFR1 and IDPs. It is clear from the existing studies that 
targeting receptor-receptor interactions and the conformational dynamics of TNFR1 as 
well as targeting the heterogeneity of ensembles of tau oligomers or HTT aggregates 
appear to present the most novel and effective approaches in mediating autoimmune 
diseases (e.g. rheumatoid arthritis) and neurodegenerative diseases (e.g. AD and HD). 
To test these hypotheses, engineered TNFR1, tau and HTT FRET biosensors and 
launched a series of HTS campaigns screening multiple libraries to discover small 
molecules that potentially work through these novel mechanisms.  
First, I discovered a small molecule, zafirlukast, which disrupts the TNFR1 
receptor-receptor interactions without disrupting ligand binding. I then discovered two 
small molecules, DS42 and SB200646 hydrochloride, that alter the conformational states 
of TNFR1 leading to receptor inhibition and activation respectively. These findings 
revolutionized the field in that TNFR1 conformational states, which can be altered by 
small molecule perturbation of the long-range structural couplings, between TNFR1 
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membrane distal and proximal domains, mediated through the ligand-binding domain, 
are acting as molecular switch in determining receptor functions. In addition, we 
conducted preliminary SAR on DS42 and in depth SAR analysis of zafirlukast through 
medicinal chemistry and showed that their potency and specificity were greatly improved 
with the newly synthesized analogues that represent promising candidates for 
therapeutic developments.  
Following the TNFR1 work, I extended the investigations on small molecule 
targeting of PPTs to IDPs including tau and huntingtin proteins, which are implicated in 
AD and HD. In these works, we found that the conformational ensembles of tau 
oligomers or HTT aggregates can be perturbed by small molecules. In addition, we 
discovered small molecule inhibitors that disrupt the oligomerization or aggregation of 
these proteins and rescue cell cytotoxicity with nanomolar potency.  
Future directions 
For the TNFR1 studies, immediate future work includes applying similar 
screening strategies to other TNF receptors such as Death Receptor 5 (currently 
ongoing) or neurotrophin receptor, which are important targets for cancer and 
neurodegenerative diseases. In addition, current small molecules that target TNFR1 
should be further optimized by medicinal chemistry to obtain more potent molecules, 
followed by testing the compound pharmacokinetics and pharmacodynamics as well as 
their functional effect in animal studies. Furthermore, to confirm the structural 
observations as determined by FRET, higher resolution structural studies, such as X-ray 
crystallography, NMR or cryo-EM, should be performed to validate the exact receptor 
structure perturbation by the small molecule effectors.  
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In terms of a broader picture of receptor activation in general, following the 
previous studies by our lab suggesting that TNFR1 dimers are a functional subunit of the 
receptor complex and receptor conformational changes are crucial to its function, my 
recent results suggest that direct measurement of the receptor monomer spacing may 
not be the most accurate measure of the structure-function relationship of TNFR1. 
Instead, we may have to take into account the three-dimensional orientation of the 
receptor, in addition to the spacing between monomers, to determine the functional 
states of the receptor. This includes the consideration of receptor conformation in 
interacting with the downstream signaling molecules such as TRADD. If this hypothesis 
holds true, new targeting strategies focusing on monitoring the receptor orientation, as 
well as its interactions with the downstream signaling molecules, will be important in 
discovering better therapeutics.  
For the tau studies, a straightforward improvement will be to express tau in a 
stable or inducible cell line as well as in human iPSCs for physiological relevance. This 
will further improve conditions for screening in a native environment. In addition, we will 
launch further HTS campaigns using the most optimized tau FRET biosensors to screen 
CNS-focused libraries such as the CNS-MPO or CNS-Set library to ensure that small 
molecules have a high probability of crossing the blood-brain barrier. In conjunction with 
smFRET and other techniques such as AUC, the biosensors can be used to develop a 
clearer picture of how mutations (e.g. P301L), different tau isoforms and post-translation 
modifications alter the conformations of oligomers, and what determines toxicity. 
Ultimately, we will need to test the functional effects of the hit compounds in animal 
models with tau oligomer induced pathology to see if they rescue the pathology. If the 
compounds are functional in the animal models, they will be poised to be tested in 
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clinical trials. As for biomarker development, an immediate next step is to compare our 
biosensor with the existing tau-RD FRET biosensor developed by the Diamond group, to 
test their sensitivity in cerebrospinal fluid (CSF) from AD patients. If our biosensor is 
sensitive to these patient samples, we can further investigate how different groups of 
patient samples may have different effects on our FRET biosensor. This will act as an 
initial step in potentially stratifying the patients into different groups to be tested in clinical 
trials for more effective targeting and drug discovery. 
In terms of targeting neurodegenerative diseases in general, different FRET-
based targeting strategies can be adopted to test other hypothesis in the field. For 
example, we will be able to test comorbidity among misfolded proteins such as tau, HTT, 
A and α-synuclein. In addition, we will also be able to study the seeding, uptake and 
propagation of IDPs. Furthermore, as our biosensors are expressed in cells, we will be 
able to investigate the roles of cellular components such as kinases or chaperone 
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11.1. Summary 
Dysregulation of tumor necrosis factor receptor (TNFR) signaling is a key feature 
of various inflammatory disorders. Current treatments for TNF-related diseases function 
either by sequestering ligand or blocking ligand-receptor interactions, which can cause 
dangerous side effects by inhibiting the receptors that are not involved in the disease 
condition. Thus, alternate strategies that target receptor-receptor interactions are 
needed. We hypothesized that the soluble extracellular domain (ECD) of long isoform of 
Death Receptor 5 (DR5) could block endogenous receptor assembly, mimicking the 
biological effect of decoy receptors that lack the death domain to trigger apoptosis. 
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Using live-cell FRET studies, we demonstrated that soluble ECD disrupts endogenous 
DR5-DR5 interactions. Cell viability assays were used to demonstrate the complete 
inhibition of TRAIL-induced apoptosis by the ECD, even though TRAIL is still able to 
bind to the receptor. Importantly, we used mutagenesis to prove that the inhibition of 
TRAIL-induced apoptosis by the ECD predominantly comes from the disruption of DR5 
oligomerization, and not ligand-sequestration. Inhibition of death receptor activation 
should have important therapeutic applications in diseases such as non-alcoholic fatty 
liver disease. More generally, this approach should be generalized to enable the 
inhibition of other TNF receptor signaling mechanisms that are associated in a wide 
range of clinical conditions.  
11.2. Introduction 
Members of the tumor necrosis factor receptor (TNFR) and tumor necrosis factor 
(TNF) superfamilies (TNFRSF/TNFSF) play a vital role in the homeostasis of the 
immune system (4, 355). However, increased expression of TNFR/TNF cytokines can 
cause severe inflammatory reactions and tissue injury (12, 356). For example, 
overexpression of death receptor 5 (DR5/TNRSF10B), a member of TNFR superfamily, 
in hepatocytes results in non-alcoholic fatty liver disease (357, 358); likewise, 
accumulation of excess TNF-α in joints results in arthritis (359). Current treatments for 
TNF-related ailments function either by sequestering ligand or blocking ligand-receptor 
interactions that activate TNFR signaling (16, 29-31, 33-36, 360). Unfortunately, these 
anti-TNF drugs cause significant side effects due to their interference with the host 
immune system. Furthermore, because members of the TNF family of ligands can bind 
to several related receptors, sequestration of ligands can cause adverse effects by 
inhibiting the receptors that are not involved in the disease condition (24, 361, 362). As 
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such, for the improved management of TNFR signaling diseases, there is a pressing 
need to develop receptor-specific therapies that do not interfere with ligand binding.  
Recently, pre-ligand assembly of TNF receptors has been acknowledged as an 
essential precursor to activation (49, 202, 203, 363). Hence, targeting the pre-assembled 
TNFR structures (e.g. receptor dimers and/or trimers) has been considered a potential 
therapeutic target (52, 364). DR5 is an excellent case study for this approach. This is 
because, unlike other members of the TNFR superfamily, the death receptors and 
related decoys receptors—which lack a complete functional cytoplasmic death domain 
and inhibit signaling—are capable of forming heterophilic complexes in a ligand-
independent manner (181, 365-367). Originally, decoy receptors were thought to inhibit 
apoptosis by sequestering ligand from the death receptors (368). However, recent 
studies have suggested that ligand-independent heteromeric complex formation 
between decoy receptors and death receptors, as opposed to ligand sequestration, may 
be the primary mechanism of signal inhibition (365-367). As a consequence, mimicking 
the biological action of decoy receptors with soluble proteins or small peptides should, in 
principle, serve as a receptor-specific approach to inhibition.  
Here, we show that it is possible to inhibit TNFR signaling by perturbing native, 
pre-assembled receptor-receptor complexes. Specifically, we targeted the pre-ligand 
assembly of DR5 to inhibit the apoptosis induced by TNF-related apoptosis inducing 
ligand (TRAIL/TNFSF10/Apo2L). DR5 is a pro-apoptotic TNF-receptor with an N-
terminal extracellular domain (ECD) made up of three cysteine-rich domains (CRD1-3), 
a transmembrane domain, and a cytoplasmic death domain, which is crucial for initiation 
of death signaling upon binding of TRAIL. We aimed to control TRAIL-induced apoptosis 
by using the isolated, soluble ECD of DR5, which lacks the functional death domain. 
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Soluble ECD, which contains both the presumed pre-ligand assembly domain (PLAD, 
CRD1) and ligand-binding domains (CRD2 and CRD3), could form both ECD-DR5 and 
ECD-TRAIL complexes (Fig. 10.1). We hypothesized that soluble ECD might act as a 
competitive inhibitor, which we anticipated in our experimental design, by masking the 
endogenous DR5 interaction site and making it inaccessible for its binding partner. Using 
a combination of biophysical, biochemical and cell-based techniques, we show that the 
soluble ECD binds directly to endogenous DR5 and effectively inhibits activation. 
Importantly, we prove that this mode of inhibitory action of ECD is at the receptor-
receptor interface, and thus provide the first direct demonstration that this approach is 
viable even while ligand is still able to bind (52). This strategy may be applicable to all 
the members of clinically important TNFR superfamily. 
11.3. Materials and methods 
11.3.1 Cell Cultures and Reagents 
HEK293 cells were cultured in phenol red-free DMEM (Gibco) and Jurkat cells 
were cultured in RPMI 1640 medium (ATCC). All media were supplemented with 2 mM 
L-Glutamine (Invitrogen), heat-inactivated 10% fetal bovine serum (FBS HI, Gibco), 100 
U/mL penicillin and 100 g/mL streptomycin (HyClone). Cell cultures were maintained in 
an incubator with 5% CO2 (Forma Series II Water Jacket CO2 Incubator, Thermo 
Scientific) at 37 ºC. Antibodies for Western blots, DR5 antibodies (mAb6313) and 
fluorescent secondary antibody (NL637) were purchased from R&D systems. DR5 
(D4E9) XP, Flag-tag (2044S) and FADD (2782S) antibodies were purchased from Cell 
Signaling Technology. β-actin (ab8227) was purchased from Abcam. His-tagged ECD 
protein was purchased from Origene.  
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11.3.2 Molecular Biology 
EGFP and TagRFP vectors were a kind gift from David D Thomas. cDNAs 
encoding DR5ΔCD (1-240) was inserted at the N-terminus of the EGFP and TagRFP 
vectors using standard cloning techniques. To prevent the dimerization and aggregation 
of EGFP, we mutated alanine 206 to lysine (A206K). All mutations were introduced by 
Quikchange mutagenesis and sequenced for confirmation. 
11.3.3 Overexpression and Purification of Recombinant proteins 
Extracellular domain of DR5 (residues 1–148) was overexpressed using the 
champion pET SUMO expression system in E.coli and purified according to the 
manufacturer's instructions. The N-terminal FLAG-tagged TRAIL (residues 114–281) 
was overexpressed using the pT7-FLAG-1 inducible expression system in E.coli and 
purified by anti-FLAG-affinity column (M2 anti- FLAG-agarose resin). Purity of the 
proteins was assessed by 4-15% SDS-PAGE gels (Bio-Rad) under reducing conditions 
followed by Coomassie staining. Protein concentrations were estimated using BCA 
assay (369). 
11.3.4 Spectral Characterization 
Secondary structure of ECD was determined by using circular dichroism (CD) 
spectroscopy. Spectral data were collected using a Jasco J-815 Circular Dichroism (CD) 
spectropolarimiter. Wavelength scans were recorded at 25 °C at a total protein 
concentration of 100 μM in 140 mM NaCl and 10 mM HEPES (pH 7.4) using a 0.5 mm 
path length cuvette. Spectral data were corrected for buffer signal and analyzed with 
Jasco secondary structure estimator. 
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11.3.5 Generation of Stable Cell Line 
HEK293 cells were transiently transfected (Lipofectamine 3000 (Invitrogen)) with 
DR5ΔCD-GFP only or both DR5ΔCD-GFP and DR5ΔCD-RFP (1:5 ratio) plasmids. Two 
days later, cells were plated in limiting dilution into 10 cm tissue culture plates and 
selected with 500 μg/mL G418 (Enzo Life Sciences).  
11.3.6 Fluorescence Lifetime Measurements 
HEK293 cells with a stable expression of DR5ΔCD/GFP and DR5ΔCD/GFP/RFP 
were grown to 80-90% confluence in a 10 cm plate. For lifetime measurements, stable 
cells were lifted with trypsin, washed three times with PBS and resuspended in ~4 ml of 
PBS at a concentration of 1 million cells/ml and dispensed (50 μL/well) into a 384-well 
glass-bottom plate by using multidrop combi reagent dispenser (Thermo Scientific). 
Donor lifetime in the presence and absence of acceptor with +/- ECD/M99A was 
measured by using fluorescence lifetime plate reader (Fluorescence Innovations, Inc., 
Minneapolis, MN). GFP fluorescence was excited with a 473 nm microchip laser and 
emission was filtered with 488 nm long pass and 517/20 nm band pass filters. Time-
resolved fluorescence waveforms for each well were fitted to single-exponential decays 
using least-squares minimization global analysis software (Fluorescence Innovations, 
Inc.) to give donor lifetime (τD) and donor-acceptor lifetime (τDA). FRET efficiency (E) was 
then calculated based on the equation 1 
 
11.3.7 Colocalization  
To test the colocalization of soluble-ECDs with DR5, ECD and M99A proteins 
were labeled with Alexa Fluor 555 (Molecular probes by Life Technologies) according to 
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the manufacturer's instructions. Next, HEK293 cells with a stable expression of 
DR5ΔCD/GFP were grown on 35 mm glass bottom MatTek culture dishes (MatTek 
Corporation) and treated with Alexa-555 labeled soluble ECD proteins and incubated for 
2-4 hours at 37 °C. Next, cells were gently washed two times with PBS to remove the 
unbound soluble proteins and fixed with 2% formaldehyde. Slides were then mounted 
with ProLong diamond antifade reagent (Molecular probes by Life technology) and 
images were acquired using an Olympus FluoView FV1000 IX2 Inverted Confocal 
microscopy equipped with a FluoView FV1000 laser scanning confocal head and 60× 
(1.42NA) oil immersion objective lenses.  
11.3.8 Western Blotting 
Cells were pelleted by centrifugation, washed with cold PBS and lysed in RIPA 
buffer (50mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5% Sodium deoxycholate, 1% NP-40) 
supplemented with protease inhibitors for 30-60 minutes at 4 °C. Total protein 
concentration of lysates was determined by BCA assay (369) and equal amounts of total 
protein (~60 μg) were mixed with 4X Biorad sample buffer and boiled for 3-5 minutes, 
and loaded on 4-15% Tris-glycine SDS-PAGE gels (Bio-rad). Proteins were transferred 
to a PVDF transfer membrane (EMD Millipore) and probed using antibodies against 
DR5, FLAG-tag, FADD and β-Actin.  
11.3.9 Pull-down Assay 
ECD-DR5 complex formation was tested by a pull-down assay with His-tagged 
ECD. His-tagged ECD protein (0.1 mg/ml) was mixed with Cobalt-conjugated magnetic 
beads (Clontech Talcon beads) and incubated at 4 °C for 2 hours. The beads were then 
washed three times with wash buffer (50 mM NaH2PO4, 300 mM NaCl, and 5 mM 
imidazole) to remove the unbound His-tagged ECD protein. Jurkat cell pellet was 
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washed three times with ice-cold PBS and lysed with native lysis buffer (Abcam) 
containing complete protease inhibitor cocktail (Clontech). Cells were then sonicated for 
30 seconds, incubated for 30 minutes on ice, and centrifuged at 16,000 g at 4 °C for 30 
minutes. Supernatant was transferred to tube containing His-tagged ECD protein bound 
to cobalt-conjugated magnetic beads and rotated at 4 °C for 2-4 hours. Then beads were 
washed three times with wash buffer. Finally, proteins were eluted with elution buffer (50 
mM NaH2PO4, 300 mM NaCl, and 250 mM imidazole). Eluted proteins were resolved by 
4-20% SDS-PAGE under reducing condition and then immunoblotted with MAB6313 
antibody.  
11.3.10 Co-immunoprecipitation 
Soluble FLAG-tagged proteins were (FLAG-TRAIL) mixed with Anti-FLAG 
magnetic beads and incubated at 4 °C for 2-4 hours. Then beads were washed three 
times with wash buffer (150 mM NaCl, 50 mM Tris, 10% Glycerol, pH 7.5) to remove the 
unbound FLAG-tagged protein. Jurkat cells were washed three times with ice-cold PBS 
and lysed with IP buffer (20 mM Tris-HCl, 1 mM EDTA, 100 mM NaCl, pH 7.5 and 0.5% 
NP- 40) containing complete protease inhibitor cocktail (Clontech). Cells were then 
sonicated for 30 seconds, incubated for 30 minutes on ice, and centrifuged at 16,000 g 
at 4 °C for 30 minutes. Supernatant was transferred to tube containing FLAG-tagged 
protein bound anti-FLAG antibody coated magnetic beads (Sigma-Aldrich) and rotated at 
4 °C for 4 hours, followed by three washes with IP buffer. Whole-cell lysates and 
Immunoprecipitate samples were resolved using 4-15% SDS-PAGE gels and subjected 
to western blotting using anti-DR5 antibody (DR5 (D4E9) XP). 
11.3.11 MTT Assay 
The effect of ECD on TRAIL-induced apoptosis was determined using MTT 
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assay. Jurkat cells were seeded in 96-well plates at 15,000 cells/well and incubated for 
24 hours at 37 °C, 5% CO2. Cell were treated with ECD and incubated for 1-2 hours and 
then treated with TRAIL (0.001-16 μg/ml) and incubated further for 24 hours at 37 °C. 
Cell proliferation was assessed by MTT assay according to the manufacturer's 
instructions (Sigma-Aldrich). Experiments were repeated three times, and data 
represented as the mean of six wells ± SD. 
11.3.12 Caspase-Glo 8 Assay 
Jurkat cells were seeded in 96-well plates at 15,000 cells/well and incubated for 
24 hours at 37 °C. Cell were treated with ECD and incubated for 1-2 hours and then 
treated with TRAIL (0.5 μg/ml), followed by 24 hours of incubation at 37 °C. An equal 
volume of Caspase-Glo 8 reagent (Promega) was added to each well, and the 
luminescence was measured after 30 minutes using a Cytation 3 Cell Imaging Multi-
Mode Reader luminometer (BioTek). Experiments were repeated three times, and data 
represented as the mean of six wells ± SD. 
11.3.13 Analysis of TRAIL-induced recruitment of FADD to DR5 
Jurkat cells were treated with soluble ECD proteins (200 μg/ml) and incubated for 
2-4 hours at 37 °C and then stimulated with TRAIL (1 μg/ml) for 2-4 hours. Post 
stimulation cells were washed with cold PBS and lysed in RIPA buffer (50mM Tris-HCl 
pH 7.5, 150 mM NaCl, 0.5% Sodium deoxycholate, 1% NP-40) supplemented with 
protease inhibitors for 30 minutes at 4 °C and centrifuged at 16000 g for 30 minutes at 4 
°C. Supernatants were transferred to tube containing FLAG-tagged protein bound anti-
FLAG antibody coated magnetic beads and rotated at 4 °C for 12-16 hours, followed by 
three washes with IP buffer. Immunoprecipitate samples were resolved using 4-15% 




11.4. Results  
11.4.1. Biochemical characterization of soluble ECD and recombinant FLAG-
tagged TRAIL proteins 
We postulated that soluble ECD could inhibit TRAIL-induced apoptosis by 
forming both ECD-DR5 and ECD-TRAIL complexes, which lack the functional death 
domain complexes (Fig. 11.1).  
 
Figure 11. 1. Viable strategy for inhibition of DR5 signaling.  
Isolated ECD protein could prevent ligand-induced apoptosis by complexing with DR5 and 
preventing the formation of the requisite cytosolic death domain dimer. 
To test this hypothesis, we produced soluble ECD and FLAG-tagged TRAIL 
using the champion pET-SUMO and pT7-FLAG-1 expression systems, respectively. 
Purified proteins were characterized by electrophoresis under denaturing and reducing 
conditions. ECD appeared as a single band at 17 kDa and Flag-tagged TRAIL at 22 
kDa, which are similar to their theoretical molecular weights based on the amino acid 
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sequences (Fig. 11.2a). Soluble ECD was further confirmed by immunoblotting (Fig. 
11.2b). The secondary structure of soluble ECD was determined by using circular 
dichroism (CD) spectroscopy. CD spectral data showed a weak shoulder peak at 220 
nm and a negative peak at 210 nm (Fig. 11.2c), which suggest that the ECD construct is 
primarily composed of random coil, turns, and a very small percent of ordered structures 
like β-sheets and α-helix. These results are in agreement with computationally (ExPAsy 
and STRIDE) predicted secondary structure based on the amino acid sequence of ECD 
and also with crystal structure of ECD-TRAIL complex (PDB: 1D0G) (370). Thus, the 
spectral data confirm that ECD is folded correctly. We further tested the ligand binding 
ability of the soluble-ECD by native gel electrophoresis. To confirm the ligand-binding 
property of soluble-ECD, we analyzed the ECD, TRAIL, and the mixture of ECD/TRAIL 
by a native-PAGE gel followed by Coomassie blue staining. A new higher molecular 
weight band was found in the ECD/TRAIL mixture (Fig. 11.2d), which suggests that 











Figure 11. 2. Characterization of recombinant proteins.  
(A) Coomassie-stained SDS-PAGE gel of ECD and TRAIL. Equal amounts of ECD and TRAIL 






































ECD was confirmed by western blot using antibody against DR5. (C) CD spectrum of ECD in the 
Apo-state (10 mM HEPES, 140 mM NaCl, pH 7.4). (D) Coomassie-stained native-PAGE gel of 
ECD, TRAIL and ECD/TRAIL mixture. 
11.4.2. Soluble ECD interacts with DR5 and disrupts the endogenous DR5-DR5 
interactions 
   It has been shown previously that several members of the TNF receptor 
superfamily exist as ligand-independent, homophilic and heterophilic oligomers. Here, 
we determined the interaction between endogenous DR5s by measuring live-cell time-
resolved fluorescence resonance energy transfer (TR-FRET) with green and red 
fluorescent-tagged receptors (GFP and RFP). Experiments were carried out in HEK293 
cells stably expressing DR5ΔCD fused to GFP and coexpressing DR5ΔCD fused to GFP 
and RFP just downstream of the transmembrane (TM) domain of the receptors (Fig. 
11.3a). Measurements showed a substantial decrease in the fluorescence lifetime of the 
donor in presence of the acceptor compared with the donor only (Fig. 11.3b), which 
confirms efficient energy transfer between the FRET pairs (Fig. 11.3c). These data show 
that DR5ΔCD receptors are capable of homophilic interactions in the absence of TRAIL 
(confirming the existence of a pre-assembled oligomeric form) and cytoplasmic death 
domain. These results are in good agreement with previously published data (181, 365-
367). Although ligand-independent oligomerization of DR5 has been recognized as an 
integral component of receptor signaling, the binding affinity of DR5-DR5 interaction in 
the context of the cell membrane is still an open question. Quantification of DR5-DR5 
interactions in the live cell plasma membrane is important for a complete understanding 
of DR5 signaling function and drug design.  Methodologies to quantify membrane 
protein-protein interactions have been slow to develop. Recently, Kalina et al. developed 
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a new quantitative fluorescence imaging technique that yields apparent FRET 
efficiencies and the binding affinities of fluorescently labeled receptors in the plasma 
membrane (371). We will use this method to determine the binding affinity of DR5-DR5 
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Figure 11. 3. Ligand-independent interaction between soluble ECD and endogenous DR5. 
 (A) Schematic of GFP or RFP fused DR5ΔCD construct. (B) Lifetime measurements of donor 
(DR5ΔCD/GFP) - in the presence and absence of acceptor molecule (DR5ΔCD/RFP) with +/- 


























ECD. Results are mean ± SD of triplicate determinations. (D) HEK293 cell lines stably expressing 
DR5ΔCD/GFP/RFP receptors were treated with indicated amount of soluble ECD. Dose-
dependent FRET changes in response to soluble-ECD was determined by TR-FRET assay (n=6). 
(E) ECD-DR5 complex formation was determined by a pull-down assay with His-tagged ECD. 
Eluted protein sample was analyzed by electrophoresis, followed by western blotting with 
antibody against DR5. Open arrowheads, bait; filled arrowhead, prey; open circles, nonspecific 
signals. 
   Next, we evaluated the effect of ECD on endogenous DR5 interactions. We 
speculated that, given sufficient self-affinity of the DR5 PLAD, the ECD should form a 
ligand-independent complex with DR5 receptors pre-assembled in the plasma 
membrane. We therefore tested the disruption of endogenous DR5-DR5 interactions by 
measuring TR-FRET before and after ECD treatment. Strikingly, cells treated with 
soluble ECD showed significantly lower FRET compared with untreated cells (Fig. 
11.3c). These results suggest that ECD is forming heterophilic complex with DR5 and 
hence increasing the distance between donor-acceptor pairs on pre-assembled 
receptors. Cells treated with soluble Bovine serum albumin (negative control) caused no 
significant FRET change compared with untreated cells (Fig. 11.3c), which suggests 
that the decrease in FRET in the presence of ECD is originating from ECD-DR5 complex 
formation. Next, we determined the effective concentration of ECD for disruption of 
membrane bound DR5-DR5 interactions by measuring a soluble ECD concentration-
depended FRET efficiency change in HEK293 cells expressing DR5ΔCD/GFP/RFP. 
Soluble-ECD decreased FRET efficiency in a dose-dependent manner (Fig. 11.3d), with 
half-maximal effective concentration of ~4.6 μM. To further confirm the interaction 
between ECD and DR5, a pull-down experiment was conducted with His-tagged ECD. 
Western blot analysis showed both ECD and DR5 bands in the pull-down sample, which 
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suggests that His-tagged ECD is complexing with endogenous DR5 (Fig. 11.3e). Next, 
we sought to directly observe the interaction between soluble-ECD and membrane 
bound DR5 by confocal microscopy. To do so, we labeled the soluble ECD with Alexa 
fluor 555 and observed its interaction with DR5ΔCD/GFP on the cell surface. Confocal 
images showed a certain degree of colocalization of fluorescently labeled ECD and 
DR5ΔCD/GFP on the surface of HEK293 stable cells (Fig. 11.4). However, some stable 
cells were only stained with Alexa fluor labeled ECD, which might be due to a slight 
variability in DR5ΔCD-GFP expression. Moreover, fluorescently labeled ECD may also 
be binding to HEK293 cells, which have very low levels of endogenous DR5 expression 
(372, 373), that are resistant to the G418, but are not expressing DR5ΔCD-GFP. In 
summary, these results confirm that ECD is interacting with DR5 by disrupting 
endogenous DR5-DR5 interactions in the plasma membrane.  
     DR5ΔCD-GFP 
 
Alexa 555-labeled ECD 
 
             Merged 
 
Figure 11. 4. Interaction between soluble-ECD and membrane bound DR5 on the cell 
surface.  
DR5ΔCD-GFP and Alexa Fluor 555-labled ECD co-localized at the surface of HEK293 cells. 
Scale bars correspond to 50 μm. 
11.4.3. ECD is a functional inhibitor of TRAIL-induced apoptosis 
To determine whether soluble ECD inhibits TRAIL-induced apoptosis, we treated 
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Jurkat cells with ECD and compared to untreated cells. Cell proliferation assay (MTT) 
showed that cells treated with ECD were significantly protected against TRAIL-induced 
apoptosis compared with untreated cells (Fig. 11.5a) and increased the effective 
concentration of TRAIL. We further determined the IC50 of ECD by measuring TRAIL-
induced cell death at different doses of ECD (0.01-200 μg/ml) (Fig. 11.5b). We then 
specifically tested whether the effect of ECD was on the DR5 apoptotic pathway, which 
can be determined by monitoring caspase-8 activity (374). First we tested the 
cytotoxicity of ECD by measuring the caspase-8 activity before and after ECD treatment. 
Cells treated with ECD showed a very low luminescence signal, which indicates that the 
ECD cannot induce caspase-8 activity and therefore not toxic to cells. Next, we 
determined the TRAIL-induced caspase-8 activity in the presence and absence of ECD. 
We observed a significant decrease in caspase-8 activity in ECD-treated cell compared 
with untreated cells in presence of TRAIL (Fig. 11.5c). Taken together, these results 
confirm that the soluble ECD is a functional inhibitor of TRAIL-induced apoptosis. Since, 
ECD contains both PLAD and ligand-binding pockets, the antiapoptotic effect of ECD 
might be due to disruption of pre-ligand assembly of DR5 receptors and/or sequestration 
of TRAIL. We therefore investigated the effect of ECD on TRAIL-DR5 interactions by 
coimmunoprecipitation. Western blot results show that ECD does not block ligand 
binding: TRAIL and DR5 interact similarly in the presence and absence of ECD (Fig. 
11.5d), thus confirming our model (Fig. 11.1). This result also implies that TRAIL is not 















Figure 11. 5. Effect of ECD on TRAIL-induced apoptosis.  
(A) Cell viability assay in the presence and absence of ECD. Jurkat cells were plated on a 96-well 
plate and treated with TRAIL (0.001-16 μg/ml) in the presence (100 μg/ml) and absence of ECD 
protein. After 24 hours of incubation, the percentage of cell survival was determined by MTT 
assay. (B) ECD median inhibitory concentration (IC50) was determined by MTT assay. (C) 
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μg/ml), and TRAIL+ECD. Results are mean ± SD. (D) TRAIL-DR5 complex formation was 
determined by coimmunoprecipitation with anti-FLAG–conjugated magnetic beads, followed by 
Western blot analysis. 
11.4.4. ECD inhibits ligand-induced apoptosis through ligand-independent 
association with DR5 
To further control against the potential effects of ligand sequestration and prove 
that the ECD bound to cell-surface DR5 is causing the inhibition, we created a known 
binding mutation (181, 365, 375) in the ligand-binding pocket of ECD (ECD/M99A) and 
examined its effect on TRAIL-induced apoptosis. Quantification of ligand binding affinity 
of M99A is critical to prove that the inhibitory effect of soluble ECD is due to the 
disruption of endogenous DR5-DR5 interactions rather than sequestration of TRAIL. We 
tested the ligand binding properties of soluble ECD and M99A by a pull-down assay. 
These results show that ECD/M99A mutation significantly reduced the TRAIL-binding 
affinity to soluble ECD (Supplementary Fig. 11.1A and B). Our qualitative pull-down 
assay results are consistent with that of Benedict et al., who showed that M99A binds 







Figure 11. 6. Ligand-independent interaction between soluble M99A and endogenous DR5.  
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(A) Lifetime measurements of donor (DR5ΔCD /GFP) - in the presence and absence of acceptor 
molecule (DR5ΔCD /RFP) with +/- ECD and M99A (n=16). (B) FRET efficiency in the presence 
and absence of ECD/M99A and BSA as a negative control. Results are mean ± SD of triplicate 
determinations. (C) HEK293 cell lines stably expressing DR5ΔCD/GFP/RFP receptors were 
treated with indicated amount of soluble ECD/M99A. Dose-dependent FRET changes in 
response to soluble-ECD/M99A was determined by TR-FRET assay (n=6).  
 
Next, we tested whether the ECD/M99A mutant disrupts the endogenous DR5-
DR5 interactions. We evaluated the effect of ECD/M99A mutation on endogenous DR5-
DR5 interactions by measuring TR-FRET before and after M99A treatment. Interestingly, 
cells treated with soluble ECD/M99A showed a longer lifetime compared with untreated 
cells (Fig. 11.6a), which confirms lower energy transfer between the FRET pair (Fig. 
11.6b). These results suggest that ECD/M99A is forming heterophilic complex with DR5 
and hence increasing the distance between donor-acceptor pairs on pre-assembled 
receptors. Subsequently, we determined the effective concentration of M99A for 
disruption of membrane bound DR5-DR5 interactions by measuring a soluble M99A 
concentration-dependent FRET efficiency change in HEK293 cells expressing 
DR5ΔCD/GFP/RFP. Soluble-ECD/M99A decreased FRET efficiency in a dose-
dependent manner (Fig. 11.6c), with half-maximal effective concentration of ~4.8 μM. In 
order to directly observe the interaction between soluble-ECD/M99A and DR5, we 
labeled the soluble ECD/M99A with Alexa fluor 555 and looked at its interaction with 
DR5ΔCD/GFP on the surface of HEK293 stable cells. Confocal images showed the co-
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Figure 11. 7. Interaction between soluble-ECD and membrane bound DR5 on the cell 
surface.  
DR5ΔCD-GFP and Alexa Fluor 555-labled ECD/M99A co-localized at the surface of HEK293 
cells. Scale bars correspond to 50 μm. 
 
These results confirm that the M99A mutation did not affect the receptor-receptor 
interaction. We then tested whether the ECD/M99A mutant protects the cells from 
TRAIL-induced apoptosis. Cells treated with ECD and ECD/M99A functioned similarly, 
with both proteins significantly protecting the cells against TRAIL-induced apoptosis 
compared with untreated cells (Fig. 11.8a). Next, we tested the effect of soluble-ECD 
and M99A on TRAIL-induced recruitment of Fas-associated protein with death domain 
(FADD) to DR5 by Co-immunoprecipitation assay with anti-FLAG M2 antibody and Flag-
tagged TRAIL (Fig. 11.8b). It has been previously shown that TRAIL induces recruitment 
of endogenous FADD to DR5 (376). To determine whether soluble ECD and M99A 
inhibit TRAIL-induced recruitment of FADD to DR5, we treated Jurkat cells with these 
soluble ECD proteins and compared to untreated cells. Co-immunoprecipitation assay 
showed that cells treated with ECD and M99A significantly inhibited TRAIL-induced 
recruitment of FADD to DR5 compared with untreated cells (Fig. 11.8b). These results 
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suggest that the soluble ECD of DR5, which lacks the functional death domain, might act 
as a competitive inhibitor by masking the endogenous DR5 interaction site and making it 
inaccessible to its binding partner, which is important for DISC formation. This 
observation, thus, further support our hypothesis. Taken together, these data clearly 
show that inhibition of TRAIL-induced apoptosis by ECD predominantly emanates from 





Figure 11. 8. Inhibition of TRAIL-induced apoptosis by ECD predominantly comes from the 
disruption of DR5 oligomerization on the cell surface.   
(A) Jurkat cells treated with TRAIL (0.5μg/ml) in the presence (0.01-200 μg/ml) and absence of 
ECD proteins. Cell viability was determined by MTT assay. Results are mean ± SD of triplicate 
determinations. (B) Jurkat cells were treated with soluble ECD and M99A proteins, and then 
stimulated with Flag-tagged Apo2L/TRAIL-Flag for 2-4 hours and analyzed for FADD recruitment. 
Lysates were subjected to IP with anti-FLAG–conjugated magnetic beads, followed by western 
blot analysis.  
11.5. Discussion 
Several of the most heavily studied and targeted members of the TNFR 





















Protein Concentration (µg/ml) 
TRAIL/+ECD 
TRAIL/+M99A 
TRAIL Only WB: Anti-DR5 
WB: Anti-FADD 
TRAIL         +                   +                      + 
ECD             −                   +                     − 
M99A           −                   −                      + 
IP: Flag-tagged TRAIL + Anti Flag M2 Beads   
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oligomers (49, 202, 363, 365-367, 377) on the cell surface. These oligomers are 
stabilized by the extracellular pre-ligand assembly domain (PLAD), which exists within 
the amino-terminal side of the cysteine-rich domains (CRDs) of the receptors. Mutations 
in the PLAD regions of FAS and TNFR1 have been found to participate in pathogenesis 
of autoimmune lymphoproliferative syndrome and TNFR-associated periodic syndrome, 
respectively (202, 203, 377). As a consequence, competitively blocking pre-ligand 
assembly via the PLAD has been considered as a potential therapeutic target. Over a 
decade ago, it was famously proposed that soluble-PLAD could inhibit TNFR1 assembly 
and prevent TNF-α induced TNFR1 signaling. Using a soluble GST-tagged PLAD 
protein, the authors showed inhibition of TNF-α induced TNFR1 signaling in vitro and 
subsequent amelioration of arthritis in animal models. Unfortunately, however, the GST-
tagged PLAD interfered with ligand binding (52).  
Therefore, it remained unproven until now that disruption of TNF receptor-
receptor interactions by soluble proteins, without inhibiting ligand binding, is a viable 
therapeutic strategy. We demonstrated here that soluble ECD inhibits TRAIL-induced 
apoptosis via forming heteromeric complexes with endogenous DR5. Deficiency of death 
domains in the ECD-DR5 complex significantly reduces the signal transduction pathway 
that induces apoptosis. Our data clearly show that soluble ECD does not block ligand 
binding. In fact, our mutational studies (ECD/M99A) ruled out the alternate explanation, 
sequestration of ligand, for the anti-apoptotic effect of soluble ECD. Thus, we can 
definitively conclude that the inhibitory effect of ECD predominantly originates from the 
disruption of DR5-DR5 interactions on the cell surface. We should note here that we 
attempted to perform this study with just the CRD1 domain of DR5 (in attempt to mirror 
the TNFR1 mouse study (52)). In our case, because we wanted to avoid any chance of 
interfering with ligand binding, we did not include a GST-tag. Interestingly, we found that 
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the isolated CRD1 domain was insoluble. Rather than pursuing strategies to increase 
the solubility of CRD1, we instead decided to work with the entire ECD, which has no 
solubility issues.  
DR5 was an ideal system in which to test this targeting strategy because it is 
already known that a similar biological mechanism exists (the decoy receptors). In 
particular, it is known that TRAIL can bind to heterophilic complexes of DR5 and decoy 
receptors (378). DR5 is most well-known as an anti-cancer target, because it is 
overexpressed in cancer cells (379, 380). In that case, TRAIL or antibody agonists have 
been used to overactivate, not inhibit, the receptor. Progress in this therapeutic effort 
has been slowed by TRAIL resistance mechanisms. In the context of the current study, 
there are alternative diseases in which inhibition of DR5 is a sought after strategy. In 
particular, DR5 signaling plays a major role in progression of nonalcoholic fatty liver 
disease and nonalcoholic steatohepatitis (NASH). Recent studies have shown that 
ligand independent DR5 signaling promotes hepatocyte lipoapotosis (357), which is a 
clinical hallmark of NASH. Hence, inhibition of ligand independent assembly of DR5 and 
signaling may have a therapeutic value in NASH.  
In general, soluble peptides that mimic the protein-protein interaction interfaces 
should bind targets with greater specificity than small molecules. Consequently, peptides 
should show negligible off-target effects, which might help to overcome the dangerous 
side effects of conventional anti-TNF therapeutics. Additionally, rapid clearance of 
soluble peptides prevents the accumulation of harmful metabolites and decreases the 
risk of toxicity. Thus, it is tempting to suggest that small peptides engineered to mimic 
the essential binding residues in the PLAD may be even more effective than the full-
length ECD or isolated PLAD. To conclude, our therapeutic approach using a soluble 
protein that targets receptor-receptor interactions shows great promise for ongoing 
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efforts to develop more effective receptor-specific drugs. 







Supplemental Figure 11. 1. Effect of M99A mutation on TRAIL binding affinity.  
(A) TRAIL-ECD and TRAIL-ECD/M99A (B) complex formation was determined by pull-down 
assay with anti FLAG–conjugated magnetic beads. Eluted protein samples were analyzed by 4-
20% Tris-glycine SDS-PAGE gels. Open arrowheads, bait (TRAIL); filled arrowhead, prey (ECD); 
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